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Abstract 
Cystic fibrosis (CF) is the most common genetic life-limiting disease in the UK. 
Strategies to correct dysfunctional CF transmembrane conductance regulator 
(CFTR) will not benefit all people with CF and alternative approaches are required. 
Transmembrane protein 16A (TMEM16A) was recently identified as an essential 
component of the epithelial calcium activated chloride channel (CaCC) and has 
potential to bypass effects of faulty CFTR. TMEM16A expression is confirmed in the 
adult airway, however, its presence in the paediatric airway was previously unknown. 
Robust experimental models are required to investigate such therapeutic avenues in 
children. Primary bronchial epithelial cells (PBECs) have been pivotal through their 
role in CFTR modulator development. Although primary nasal epithelial cells 
(PNECs) provide a more accessible paediatric model, their characterisation was 
previously undetermined. 
To investigate the role of paediatric PNECs as a substitute for PBECs, I established 
a programme to sample both nasal and bronchial mucosal brushings from children 
with and without CF. These were used to develop differentiated paediatric cultures 
using strategies to optimise culture success by improving cell yield, promoting cell 
attachment and minimising infection. Epithelial properties of paediatric PNECs were 
confirmed in relation to tight junctional integrity and muco-ciliary differentiation. Ion 
transport assessment revealed that CFTR and CaCC expression were not different 
in PNECs versus PBECs in both non-CF and CF cultures. Low levels of TMEM16A 
expression were identified in the paediatric nasal and bronchial epithelium. Finally, 
application of a novel TMEM16A activating compound to the PNEC model 
demonstrated potential to enhance TMEM16A-mediated airway epithelial chloride 
transport. 
This characterisation of ex vivo paediatric PNECs has provided evidence to support 
their role as a tool to investigate the CF airway. Inter-donor variability of PNEC ion 
transport properties is an important consideration for future investigation of novel 
therapeutic modulators of CFTR and alternative ‘non-CFTR’ airway epithelial 
channels. 
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1 Chapter 1. Introduction 
1.1 Cystic fibrosis 
1.1.1 Overview: the significance of cystic fibrosis  
Cystic Fibrosis (CF) is the most common life-limiting autosomal recessive disease 
affecting North Western European populations. Approximately 1 in 2500 newborns 
and over 10000 children and adults are affected in the United Kingdom (UK) (Cystic 
Fibrosis Trust, 2011). CF is increasingly recognised to occur in other populations 
worldwide, albeit at a much lower incidence (O'Sullivan and Freedman, 2009, 
Elborn, 2016).  
The underlying defect in CF arises from mutations in the CF transmembrane 
conductance regulator (CFTR) gene (Riordan et al., 1989) . This encodes for a 
chloride channel predominantly expressed in epithelia, including the sweat gland, 
airway, gastrointestinal tract, pancreas and vas deferens. Although this gives rise to 
multisystem disease, morbidity and mortality is predominantly secondary to 
progressive respiratory pathology.  
Significant advances in the understanding of CF pathophysiology and 
multidisciplinary clinical care have greatly contributed to improved survival outcomes.  
The current median age of survival is 45.1 years and the proportion of adults with CF 
is likely to increase over time (Elborn et al., 1991, Burgel et al., 2015). CF is 
managed nationally by specialist regional centres comprised of experienced 
clinicians, nurses, physiotherapists, dieticians and other relevant allied health 
professionals to provide high quality multidisciplinary treatment in accordance with 
CF Trust Standards of Care (Cystic Fibrosis Trust, 2011).  
The CF national Newborn Screening Programme (NBS) was introduced in the UK in 
2007 and has enabled early identification of disease and optimisation of clinical 
management. Nevertheless, the burden of care remains significant, comprising of 
intensive daily treatment regimens to improve quality of life and survival. Despite 
these efforts, progressive respiratory disease leads to eventual respiratory failure 
and either consideration for lung transplantation where feasible, or unfortunately 
death.  
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1.1.2 The genetic defect in cystic fibrosis 
The CFTR gene was first cloned in 1989 (Riordan et al., 1989). It is located at 
position q31.2 on the long arm of chromosome 7 and encodes the transmembrane 
CFTR protein. CFTR is a member of the adenosine triphosphate (ATP)-binding 
cassette (ABC) transporter superfamily, which are characterised by direct ATP 
binding to enable cell membrane molecular transport.  
CFTR is constructed from two homologous units and in total consists of five 
membrane domains (Figure 1). Each homologous unit has a membrane spanning 
domain (MSD), which forms the transmembrane ion channel pore. Unique to other 
ABC proteins which are active transporters, the CFTR pore is  anion selective. Each 
MSD is connected to a cytoplasmic nucleotide binding domain (NBD). The two 
homologous units are linked by a regulatory (R) domain, which is phosphorylated by 
cyclic adenosine monophosphate (cAMP)-dependent activation of protein kinase A 
(PKA) (Hwang and Sheppard, 2009). R domain phosphorylation together with NBD-
ATP binding and subsequent MSD conformational change results in CFTR activation 
and gating of chloride secretion (Vergani et al., 2005). However, the activation and 
regulation of CFTR is complex, with additional involvement of other factors including 
signalling proteins and protein kinases. These form large macromolecular complexes 
with CFTR and are involved in CFTR trafficking and function (Guggino and Stanton, 
2006).  
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Figure 1: Structure of CFTR 
Two MSDs form the ion channel pore across the membrane. These are each 
connected to an NBD (NBD1 and NBD2) within the cytoplasm. ATP binding to the 
NBDs coupled with R domain phosphorylation by cAMP-mediated PKA activation 
results in CFTR channel opening and chloride and bicarbonate secretion. Adapted 
from (Ratjen et al., 2015).  
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1.1.3 Classification of cystic fibrosis transmembrane conductance regulator 
(CFTR) mutations 
Approximately 2000 CFTR mutations have been identified of which 200 have been 
confirmed as disease causing. The F508del (c.1521_1523delCTT) mutation is the 
most common in European populations with around 90 % of patients having at least 
one affected allele and 50 % of patients with two affected alleles in the UK (Zolin et 
al., 2017). CFTR mutations have been classified into six classes according to the 
underlying mechanisms involved in CFTR synthesis, trafficking and function, as 
demonstrated in Figure 2 and summarised in Table 1. Class I mutations arise from 
nonsense, frameshift or messenger ribonucleic acid (mRNA) splicing mutations. This 
produces premature termination signals resulting in absent protein production. Class 
II mutations occur as a result of dysfunctional CFTR processing and trafficking to the 
cell surface. In class III mutations, although CFTR is expressed at the cell surface, 
there is impaired channel gating due to defective NBD binding. Class IV mutations 
are a result of abnormalities in the channel pore, resulting in restricted ion transport 
and conductance defects. Low CFTR levels arise from splicing defects in class V 
mutations. With class VI mutations, there is instability of functional CFTR at the cell 
surface resulting in high turnover and reduced levels of CFTR. Despite this 
classification, some mutations are not confined to an individual class as exemplified 
by F508del. Here, phenylanine deletion at position 508 results in abnormal protein 
folding due to impaired NBD1 stability, giving rise to a class II mutation. However, 
this mutation also results in a gating defect as present in class III mutations 
(Okiyoneda et al., 2010). Furthermore, mutation classification is complicated by the 
existence of considerable phenotypic heterogeneity within individual mutation types 
and classes, suggesting a potential impact of other genotypic-phenotypic interactions 
arising from environmental, microbiological and non-CFTR effects. 
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Mutation 
Class 
Nature of 
CFTR defect 
Functional 
consequence 
Example Therapeutic 
Strategy 
I Protein 
synthesis 
Reduced 
CFTR 
expression  
Gly542X Production 
correctors 
(ataluren) 
II Protein 
processing 
Misfolded 
protein 
degraded in 
proteasome 
and not 
transported to 
cell surface  
F508del Corrector 
plus 
potentiator 
(lumacaftor 
plus 
ivacaftor) 
III Channel 
gating 
Reduced/lack 
of channel 
opening 
Gly551Asp Potentiator 
(ivacaftor) 
IV Channel 
conductance 
Misshaped 
CFTR pore 
restricts 
chloride 
movement 
Arg551Asp Potentiator 
(ivacaftor) 
V Reduced 
protein 
production 
Very low 
levels of CFTR 
protein 
3849 + 10kb 
C®T 
No data 
available 
VI Increased cell 
surface 
turnover 
Functional but 
unstable 
protein at cell 
surface 
120del23 No data 
available 
Table 1: CFTR mutation classes 
Classification of CFTR mutations with implicated functional consequences. 
Adapted from (Brodlie et al., 2015) 
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Figure 2: Schematic representation of CFTR mutation class 
Class I mutations are caused by nonsense, frameshift or mRNA splicing mutations 
and produce premature termination signals resulting in absent CFTR production. 
Class II mutations arise from dysfunctional CFTR processing and failure of CFTR 
trafficking to the cell surface. CFTR is expressed at the cell surface in class III 
mutations, but impaired channel gating secondary to defective nucleotide binding 
leads to abnormal chloride epithelial transport. The CFTR channel pore is abnormal 
in class IV mutations leading to restricted chloride transport and conductance 
defects. Splicing defects in class V mutations lead to low CFTR levels. In class VI 
mutations, functional CFTR is unstable at the plasma membrane resulting in high 
CFTR turnover at the cell surface and reduced levels.  Adapted from (Brodlie et al., 
2015). 
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1.1.4 Pulmonary manifestations of cystic fibrosis 
CFTR is expressed in multiple organs, giving rise to multisystem disease. Extra-
pulmonary manifestations of CF are described in Table 2. Despite this multisystem 
pathology, progressive pulmonary disease is responsible for 95 % of all morbidity 
and mortality (Döring et al., 2007). Chronic endobronchial infection, neutrophilic 
inflammation, and retention of mucopurulent secretions lead to progressive 
bronchiectasis and eventual irreversible respiratory failure and death. Figure 3 
shows radiographic features evident in CF lung disease.  
Mainstays of CF therapy have targeted symptomatic relief by provision of stringent 
regimens of life-long courses of antibiotics, inhaled mucolytic agents and intensive 
chest physiotherapy. Despite these interventions, eventual respiratory failure results 
in early mortality unless lung transplantation is available as a feasible option. This 
has demonstrated survival of 50 % at 10 years post transplantation (Stephenson et 
al., 2015) . However, after transplantation, long term respiratory morbidity can occur 
and the burden associated with the extra-pulmonary features persists (Meachery et 
al., 2008, Stephenson et al., 2015). 
Early respiratory infection is typically characterised by Haemophilus influenza and 
Staphylococcus aureus bacteria and associated with neutrophilic inflammation 
(O'Sullivan and Freedman, 2009). This progresses to infection dominated by 
Pseudomonas aeruginosa, which increases in prevalence with age. Initial non-
mucoid P. aeruginosa strains can be eradicated with targeted aggressive treatment. 
However, with chronic infections, strains produce biofilms resistant to standard 
antibiotic therapy (Mathee et al., 1999, Pedersen et al., 1992, Pier et al., 1991). CF 
airways are susceptible to P. aeruginosa growth due to mucus stasis, impaired 
bacterial clearance, enhanced bacterial-epithelial attachment and the hypoxic 
microenvironment created by mucus plaques  (Smith et al., 1996, Matsui et al., 2006, 
Worlitzsch et al., 2002). Chronic infection and colonisation is apparent in 
approximately 80 % of CF patients and causes significant morbidity and mortality 
(O'Sullivan and Freedman, 2009, Cystic Fibrosis Trust, 2004). Acquisition of 
resistant strains leads to ongoing neutrophilic inflammation, severe bronchiectasis, 
decline in lung function and eventual mortality (O'Sullivan and Freedman, 2009).  
Eradiation is of paramount importance and measures are required to specifically 
prevent the perpetual pulmonary decline associated with P. aeruginosa.  
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System Disease Manifestation Treatment 
Gastrointestinal Meconium ileus  
(15 % newborns) 
Gastrograffin enema, surgery 
 Distal intestinal 
obstruction syndrome 
(15 % adults affected) 
As for meconium ileus 
 Gastro-oesophageal 
reflux 
Proton pump inhibitors, pro-
kinetics, surgery (fundoplication) 
 Rectal prolapse Pancreatic enzyme supplements, 
surgery 
 Increased malignancy  
 
Pancreatic exocrine 
insufficiency  
(90-95 % children 
affected) 
Tumour-specific management  
 
Pancreatic enzyme supplements, 
fat soluble vitamins (A, D, E, K), 
dietary intervention  
 CF related diabetes 
(50 % adults affected) 
Insulin 
 Pancreatitis Supportive management 
(intravenous fluids, analgesia) 
 CF related liver disease Vitamin K, ursodeoxycholic acid, 
transplantation 
Upper 
respiratory tract 
Chronic rhinosinusitis +/- 
nasal polyps  
Topical steroids, surgery 
Bones Osteoporosis Vitamin D, calcium, exercise 
Reproductive Congenital bilateral 
absence of vas deferens 
and azoospermia 
Fertility counselling and treatment 
where applicable 
 Reduced fertility in 
females 
As above 
Table 2: Extra-pulmonary manifestations of CF disease 
(Houwen et al., 2010, Moran et al., 2009, Alexander et al., 2008) 
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Figure 3: Radiographic features of CF lung disease 
Chest x-ray (A) of a 10-year-old child showing evidence of bronchiectasis with 
collapse and consolidation affecting the right upper lobe. High resolution 
computerised tomography scan (B) of a teenager with end-stage CF demonstrating 
extensive severe bronchiectasis with bronchial wall thickening and dilatation. The 
characteristic “tree-in bud” sign (arrow) is a feature of bronchial luminal mucus 
plugging and impaction (Rossi and Owens, 2005). 
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1.1.5 Early lung disease in cystic fibrosis   
The lungs of newborn babies are thought to be free of respiratory damage or 
infection with rapid progression to pulmonary inflammation evident early in infancy. 
An American study of 16 CF infants (aged 12 months and younger) showed 
evidence of neutrophil accumulation, detectable free neutrophil elastase activity and 
increased levels of interleukin (IL)-8 in bronchoalveolar lavage (BAL) fluid compared 
to control infants (Khan et al., 1995b). Interestingly this inflammatory response was 
also evident in BAL sampled from infants free of both common and CF-related 
respiratory pathogens, suggesting evidence of respiratory inflammation before 
infectious insult. A more recent study carried out by the Australian Respiratory Early 
Surveillance Team for CF of 125 children in Perth and Melbourne showed that 8.5 % 
of infants had radiographic evidence of bronchiectasis on computerised tomography 
(CT) scan in the first year of life with an increased prevalence of 36 % by 4 years of 
age (Stick et al., 2009). This prevalence increased with age, where 56 % of children 
had features of bronchiectasis by their fifth year of life. Although this latter study is 
may have covered a wide geographic area and treatment practices could vary to 
those in the UK, the represented demographic and patient management are likely to 
be characteristic of the developed world.    
Recent animal studies have challenged the idea that the CF lung is normal at birth. 
The development of a CF piglet model has enabled investigation of disease in 
newborn piglets, which share similarities with human babies including meconium 
ileus, exocrine pancreatic dysfunction and progression to CF pulmonary 
inflammation and infection in the first few weeks to months of life (Adam et al., 2013). 
Using this model, CF piglets displayed radiographic evidence of air trapping and 
airflow obstruction before the onset of infection, inflammation and mucus obstruction. 
Structural airway abnormalities, relating to the tracheal and carina, have been found 
in newborn CF piglets, with potential implications on increased deposition of 
particulate matter and bacteria together with exacerbation of airway mucus 
obstruction (Awadalla et al., 2014). However, the piglets investigated in these studies 
were CFTR-/- and likely to represent a more severe pathology to that seen in humans 
with a small degree of residual CFTR function, as is seen with the most common 
F508del mutation. 
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1.2 The airway epithelium in cystic fibrosis 
1.2.1  The healthy airway epithelium 
The airway epithelium plays an essential role in lung host defence through mucus 
secretion and clearance of unwanted inhaled pathogens and particulate matter. It is 
largely comprised of basal, secretory and ciliated cells. Airway composition varies 
with distal progression towards the lung alveolar surface. Early bronchi are 
cartilaginous, contrary to narrower bronchioles originating from the 10th airway 
generation that contain smooth muscle (Fischer and Widdicombe, 2006). Large 
airways are characterised by a pseudostratified columnar epithelium, whereas lower 
respiratory bronchioles are cuboidal. 
Basal cells are attached to the basement membrane and predominate in larger 
conducting airways. They serve as progenitors for mucous and ciliated cells and 
provide attachment via hemidesmosomes of other columnar epithelial cells to the 
basement membrane (Evans et al., 1989). In lower respiratory bronchioles, club cells 
(previously referred to as Clara cells) provide this stem cell function.  
There is a predominance of submucosal glands in large airways, goblet cells in lower 
airways and club cells in respiratory bronchioles (Verkman et al., 2003). This 
anatomical location reflects underlying roles in airway defence, where goblet cells 
protect against large particulate matter and club cells against toxic gases 
(Widdicombe and Wine, 2015, Fischer and Widdicombe, 2006). Ciliated cells 
account for around half of all airway epithelial types and are essential for airway 
mucus clearance along the mucociliary escalator from the airways to the throat 
where mucus is swallowed or expectorated (Knight and Holgate, 2003). 
1.2.2 The airway surface liquid 
The airway surface liquid (ASL) is a thin layer of fluid above the apical (luminal) 
surface of airway epithelial cells. It contains water, inorganic ions, proteins, lipids and 
mucins and provides a barrier between inspired and expired air. ASL volume, pH, 
ionic and nutrient composition are tightly controlled by the airway epithelium and 
regulation of its composition is important for mucociliary clearance (MCC) and 
antimicrobial function (Haq et al., 2015). Antimicrobial factors including b-defensins, 
lactoferrin and lysozymes contained within the ASL are involved in innate and 
 12 
adaptive host mechanisms that protect the airways from inhaled pathogens (Pezzulo 
et al., 2012).  
ASL hydration is regulated predominantly by CFTR-mediated chloride secretion, 
which provides the net driving force and generation of an osmotic gradient for water 
movement towards the airway lumen (Figure 4). The epithelial sodium channel 
(ENaC) is also important in regulating ASL volume through its role in sodium 
absorption (Randell et al., 2006).  
There are two distinct layers within the ASL as shown in Figure 5 (Widdicombe and 
Wine, 2015). The 7 µm periciliary layer (PCL) lies adjacent to the airway epithelial 
cell and surrounds the extended cilial length (Widdicombe and Widdicombe, 1995). 
An adequate PCL volume is required for efficient ciliary beat and MCC. Above this 
sits the mucus layer (MCL) which contains large gel-forming mucins, including 
MUC5B and MUC5AC, produced by secretory submucosal glands and goblet cells 
respectively (Groneberg et al., 2002).  
Until recently, the ‘gel-on-liquid’ ASL model was proposed, describing these large 
gel-forming mucins contained within the MCL sitting above an aqueous PCL 
(Widdicombe and Widdicombe, 1995). However, this concept did not explain the 
distinct PCL and MCL layers. Recent investigation using PBECs has described an 
alternative ‘gel-on-brush’ model  (Button et al., 2012). Here, the PCL contains large 
macromolecular mucins, including MUC1 and MUC4, adhered to cilia, microvilli and 
the epithelial surface (Button et al., 2012). This dense meshwork increases with 
proximity to the epithelial surface, preventing penetration of larger MCL 
macromolecules and certain infectious agents from entering the PCL. These 
tethered macromolecules regulate PCL hydration by generating an osmotic pressure 
and modulus. In a healthy airway, the MCL has a lower osmotic modulus, enabling 
water entry into the MCL, preserving PCL hydration. 
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Figure 4: Airway epithelial ion transport mechanisms  
Chloride (Cl-) enters and accumulates in the airway epithelial cell via the basolateral 
Na/K/2Cl co-transporter. Sodium (Na+) entering via the Na/K/2Cl cotransporter is 
removed by the Na/K-ATPase pump. Basolateral potassium (K+) channels recycle 
K+, which hyperpolarises the basolateral membrane and provides the 
electrochemical driving force for chloride exit into the ASL. Apical chloride exit 
generates an electrical gradient for paracellular sodium secretion. Together with 
chloride secretion, this creates an osmotic gradient leading to paracellular and 
transcellular water (H2O) secretion.  
ENaC absorbs sodium from the ASL. Sodium is actively exchanged for potassium by 
the basolateral Na/K/ATPase pump. The secretory effect of CFTR together with 
ENaC-mediated sodium absorption maintain overall ASL hydration.  
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Figure 5: Schematic representation of the healthy airway epithelium  
In the healthy airway the airway surface liquid (ASL) consists of the periciliary and 
mucus layers (PCL and MCL). The tight meshwork of mucins within the PCL 
prevents entry of the large macromolecular mucins from the MCL. The greater 
osmotic modulus created by this meshwork also preserves PCL hydration status. 
The ASL also contains antimicrobial factors important for airway innate host defence. 
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1.2.3 The airway surface liquid in cystic fibrosis 
Dysfunctional CFTR reduces chloride and bicarbonate transport into the lumen. This 
leads to sodium and water compartmental shifts, producing a dehydrated airway 
surface and thick mucopurulent secretions. In this dehydrated ASL, water 
preferentially leaves the MCL, which increases its concentration and osmotic 
modulus. Eventually, in a severely dehydrated CF airway, the MCL osmotic modulus 
exceeds that of the PCL (Button et al., 2012). Preservation of PCL hydration is 
compromised, resulting in its dehydration and compression by the MCL. PCL 
dehydration leads to cilial compression, reduced ciliary beat frequency, impaired 
MCC and progressive airway infection and inflammation (Figure 6).  
Given CFTR’s role in bicarbonate transport, it has been hypothesised that the CF 
ASL is acidic, which in turn contributes to respiratory bacterial infection. Many ASL 
antimicrobial factors are pH sensitive and their function is impaired at an acidic pH 
(Nakayama et al., 2002). Bacterial killing has been reduced in the acidic ASL of the 
transgenic CF pig model, which can be restored to wild type function by increasing 
the pH from 6.9 to 7.4 using aerosolised sodium bicarbonate (Pezzulo et al., 2012).  
Assessment of ASL pH in cultured primary airway epithelial cells using pH-sensitive 
electrodes showed an increased rate of ASL acidification over time in CF cultures, 
with differences in pH maintained after 24 hours (Coakley et al., 2003). Interestingly, 
although the cultures were studied after 14 days of confluence and time in culture, 
the initial pH values were similar in both CF and non-CF cultures.  
In vivo nasal pH assessment in neonates using nasal pH probes demonstrated a 
more acidic pH in CF versus non-CF babies (pH 5.2 ± 0.3 versus 6.4 ± 0.2)  (Abou 
Alaiwa et al., 2014). Although a relative difference in pH was found between both 
groups, it is interesting to note that the absolute values found using this technique 
were both acidic. Using the same method, no differences were found in children or 
adults with or without CF. The authors suggested that early changes in ASL pH 
could trigger airway disease and that ongoing disease airway remodelling may 
reduce these pH differences over time, accounting for the lack of acidic pH seen in 
older populations (Abou Alaiwa et al., 2014).  
Further in vivo studies, including recent investigation using pH-sensitive fibre-optic 
probes and earlier studies utilising pH probes (used for the diagnosis of gastro-
 16 
oesophageal reflux) have not found any differences in ASL pH between children with 
and without CF (Schultz et al., 2017, McShane et al., 2003).  
These findings are contrary to those using exhaled breath condensate and the CF 
pig model, where ASL acidification was significant in CF subjects (Tate et al., 2002, 
Pezzulo et al., 2012). A key challenge in addressing the question of potential ASL 
acidification has been largely accounted for by variations in detection methods, 
species variability and practical difficulties involved in maintaining accurate pH 
assessment both in vivo and in ex vivo systems. Furthermore, there is notable 
variation in the absolute pH values determined in different studies, perhaps 
warranting appreciation of relative rather than absolute pH changes in CF versus 
non-CF comparisons. However, given these recent findings, it is possible that CFTR 
dysfunction does not result in ASL acidification.  
In addition to its potential effect on ASL pH, bicarbonate is also required for mucus 
secretion and clearance. Lack of CFTR-dependent bicarbonate transport increases 
mucus viscosity, leading to dysfunctional MCC without affecting ASL hydration 
(Birket et al., 2014). In CF murine intestinal tissue depleted of bicarbonate, mucus is 
denser and more impenetrable compared to wild-type controls, requiring more 
rigorous methods for epithelial removal (Gustafsson et al., 2012). Lack of 
bicarbonate secretion may reduce calcium chelation, which is required for the 
unfolding of mucin aggregates secreted from goblet cells and expansion and 
formation of a mucus gel (Gustafsson et al., 2012). Given similarities with the 
properties of key mucins in the respiratory and intestinal environments, these 
principles could apply to the CF respiratory epithelium.  
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Figure 6: Schematic representation of the CF airway epithelium  
Normal airway (A) as previously described. In the dehydrated CF airway (B), water 
leaves the MCL, eventually increasing its osmotic modulus. In a severely dehydrated 
airway, such as in CF, water eventually leaves the PCL, causing cilial compression 
and dysfunction. The acidic environment impairs antimicrobial function and increases 
mucus viscosity. These processes lead to MCC impairment and subsequent 
bacterial inflammation and infection. Adapted from (Haq et al., 2015) 
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1.3 Recent advances in cystic fibrosis therapy 
1.3.1 Overview 
The mainstays of CF treatment include stringent treatment regimens of chest 
physiotherapy, life-long courses of antibiotics, pancreatic enzyme supplements, 
inhaled mucolytic agents and intensive chest physiotherapy. However, such 
strategies have not corrected the underlying defect and eventual respiratory failure is 
characteristic of the disease.  
The well-recognised phenotypic heterogeneity in CF, even amongst individuals with 
identical CFTR genotypes, has greatly challenged traditional strategies for therapy, 
with significant variations in disease progression and treatment response. However, 
greater understanding of CFTR mutation classes has driven the investigation and 
development of small molecule targeted therapy, which has revolutionised the 
approach for CF therapeutics in the last ten years.   
1.3.2 Gene therapy 
Since the cloning of CFTR in 1989, direct targeting of defective CFTR with gene 
therapy has remained an attractive option. Direct introduction of wild-type CFTR into 
CF airway epithelial cells has the potential to increase functional CFTR expression 
(Alton et al., 2015). Recent developments led by the UK CF Gene Therapy 
Consortium (UKCFGTC) focused on a non-viral vector approach using a 
deoxyribonucleic acid (DNA)-liposome complex for wild-type CFTR airway delivery. 
In a phase IIb randomised double-blind placebo-controlled trial, this approach 
revealed modest improvements in lung function, as measured by percentage 
predicted forced expiratory volume in 1 second (FEV1), of 3.7 % (p=0.046), similar to 
responses seen with lumacaftor/ivacaftor therapy (Alton et al., 2015). However, 
considerable heterogeneity was evident amongst responders in the UK multi-centre 
gene therapy trial highlighting potential challenges with the development of agents 
that adequately penetrate the airway surface in a range of disease severities (Alton 
et al., 2015). Phenotypic variation may account for these differences, raising the 
possibility that a combination of strategies involving targeted precision medicine with 
gene therapy may be required to produce adequate treatment effects. Early phase 
clinical trials led by the UKCFGTC are currently underway to investigate a novel viral 
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vector based on in vitro work in murine and human airway liquid interface (ALI) 
cultures and results are awaited (Alton et al., 2017). This approach hopes to 
overcome recognised limitations of standard viral vector approaches, which include 
the need to damage the epithelium to enable transduction and inducing a host 
immune response resulting in subsequent loss of activity and expression (Alton et 
al., 2017).  
1.3.3 Targeted small molecule therapy 
Targeted small molecule therapy for specific mutation classes has been a major 
advancement in CF therapy, most notably with the development of a small molecule 
CFTR potentiator, ivacaftor, targeting the Gly551Asp CFTR mutation. (Figure 7). In 
vitro investigation of airway epithelia expressing this mutation revealed 
improvements in chloride transport, ASL height (and therefore hydration) and cilial 
function (Van Goor et al., 2009a). Phase III clinical trials showed significant 
improvements in lung function accompanied by benefits in sweat chloride, 
respiratory symptoms, reduced pulmonary exacerbations and hospital stay (Ramsey 
et al., 2011, Davies et al., 2013, McKone et al.). Ivacaftor was commissioned for UK 
use in 2012 in patients aged over 6 years with at least one Gly551Asp allele and the 
European Union has approved usage with a rarer Class III mutation.  
Phase III trials investigating combination therapy of ivacaftor with the CFTR 
corrector, lumacaftor, for patients with the most common CFTR mutation, F508del, 
aged 12 years and over and also in younger patients aged 6 to 11 years showed 
statistically significant improvements in lung function (Wainwright et al., 2015, Ratjen 
et al., 2017) .  This received US Food and Drug Administration (FDA) approval in 
2015. However, improvements in FEV1 of around 2 % were modest in comparison to 
ivacaftor for patients with Gly551Asp where the mean improvement was 10 % 
(Wainwright et al., 2015).  
More recently, the EVOLVE phase III trial of a novel small molecule corrector, 
tezacaftor, in combination with ivacaftor demonstrated an increase in percentage 
predicted FEV1 of 4 % from baseline versus placebo in F508del homozygous 
patients, thereby providing improved benefit and fewer adverse events compared to 
the lumacaftor/ivacaftor combination (Taylor-Cousar et al., 2017). Furthermore, a 6.8 
% improvement was evident in heterozygote subjects with one F508del mutation and 
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a residual function mutation (Rowe et al., 2017). This combination therapy has now 
achieved US FDA approval. Investigations involving triple therapy of ivacaftor, 
tezacaftor and a third novel compound are underway for patients with one copy of 
F508del and one copy of a Class I-III ‘minimal function’ mutation (Vertex 
Pharamceuticals Incorporated, 2018).  
Despite its benefits of targeted small molecule therapy, ivacaftor does not benefit 
approximately 90 % of people with CF. The lumacaftor/ivacaftor combination 
(Orkambiä) for patients with at least one F508del copy was granted UK licence in 
2015, but has not achieved approval by the National Institute for Health and Care 
and Excellence (NICE), on the grounds of cost-effectiveness and lack of long-term 
data. Future approaches are likely to involve a combination of small molecules 
tailored towards restoring specific aspects of CFTR function. Employment of small 
molecule precision therapy is likely to be an expensive option, exemplified by 
ivacaftor which costs £180,000 per patient annually (Brodlie et al., 2015, Whiting et 
al., 2014). 
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Figure 7: Small molecule targeted treatment strategies for CFTR mutation 
classes 
The potentiator, ivacaftor increases CFTR function at the airway epithelial surface by 
increasing the opening probability of Gly551Asp-CFTR channel. Correctors, such as 
lumacaftor and tezacaftor, enhance intracellular processing and delivery of mutant 
CFTR to the cell surface. The production corrector, ataluren, promotes read-through 
of premature mRNA termination codons and increases CFTR production. However, 
ataluren failed to show significant improvements in FEV1 in a Phase III trial (Kerem 
et al., 2014). Adapted from Brodlie et al. (Brodlie et al., 2015). 
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1.4 Experimental models in cystic fibrosis 
1.4.1 Overview  
Valid experimental models are required to help further our understanding of early CF 
pathophysiology and potential therapeutic options. Early investigation of disease 
processes is of paramount importance, particularly in the context of research 
involving children. With the recent recognition of ‘theraptyping’ as a strategy to 
characterise responses to current and emerging CFTR modulator compounds in 
individuals with CF, there is a significant need to develop reliable patient-derived 
models (Clancy et al., 2018). 
Identification of the underlying genetic defect has enabled the development of 
knockout animal models to help develop understanding of in vivo disease 
pathogenesis and investigate the effects of novel therapies. Cellular based in vitro 
models have provided an insight into distinct epithelial functions particularly in the 
context of CF airway disease.  Strategies for utilisation of specific research models 
largely depend on resource availability and the specific focus of CF research.  
1.4.2 Animal models  
Huge efforts have been made to produce CF mouse models to investigate 
pathophysiology, variations in genetic defects and new therapeutic strategies. 
Several loss of function CF knockout mice models were initially generated using 
homologous recombination of CFTR in mouse embryonic stem cells (Snouwaert et 
al., 1992, Ratcliff et al., 1993, Rozmahe et al., 1996). Later murine models employed 
the introduction of specific CF causing mutations, including F508del and Gly551Asp, 
thus providing more focussed in vivo phenotypic disease profiling compared with 
CFTR-null mice models. (Colledge et al., 1995, Zeiher et al., 1995, Delaney et al., 
1996).  
Despite the significant contribution of murine models to CF research over the last 20 
years, differences between mice and humans greatly limits their translation and 
application into human disease (Table 3). Similarities exist with intestinal pathology, 
whereby CF mice display obstruction, malabsorption, cryptal mucus and chronic gut 
inflammation. However, the majority of CF mouse models do not show signs of 
spontaneous bacterial lung infection, inflammation or lower airway disease 
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(Snouwaert et al., 1992, Ratcliff et al., 1993, Delaney et al., 1996, Kent et al., 1996). 
Mice lack respiratory bronchioles and therefore small airway pathology (Pack et al., 
1981). In humans, trachea and major bronchi are characterised by submucosal 
glands and goblet cells predominate proximal airways. In mice, however, there is 
relative paucity of mucus producing epithelial cells (Pack et al., 1981). Submucosal 
glands are confined to the trachea and proximal airways are comprised of club cells 
(Rosen et al., 2018). Intrinsic differences in airway composition, respiratory 
physiology, innate immune response and alternative chloride channel expression are 
all possible explanations for differences seen (Grubb et al., 1994, Scholte et al., 
2004).  
An alternative CF mouse model has been genetically engineered to overexpress the 
b-ENaC subunit. These mice display a phenotype more in keeping with human CF 
respiratory disease, with evidence of impaired mucociliary clearance, airway mucus 
obstruction, neutrophilic inflammation and bacterial infection (Mall et al., 2004) . 
Although this has helped overcome some challenges faced with CF mouse models, 
it remains limited by intrinsic species differences and retention of normal CFTR 
provides limited translation to human CF disease. Chronic sodium hyperabsorption 
and ASL depletion has led to the development of pulmonary emphysema and 
eosinophilic inflammation in b-ENaC mice, suggesting that this model may be more 
applicable for the investigation of chronic obstructive pulmonary disease (Mall et al., 
2008). 
Pigs and ferrets have more recently been employed in CF research, largely due to 
closer similarities in respiratory anatomy and disease phenotype compared with 
humans as described in Table 3 (Rogers et al., 2008, Sun et al., 2010). Furthermore, 
these models display extra-pulmonary manifestations of CF including hepatic 
disease and pancreatic exocrine insufficiency. Although valuable in complementing 
and increasing our understanding of CF pathophysiology, particularly in early CF 
lung disease, maintenance and application of these models requires immense 
resource and expertise.  
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CF disease 
phenotype  
Human Mouse Rat Pig Ferret Rabbit 
Spontaneous 
respiratory 
infections 
Present Absent Absent Present  Present Unknown 
Growth 
impairment 
Present Present Present Present  Present Present 
Intestinal 
manifestations 
Present Present Present Present Present Present 
Pancreatic 
dysfunction:  
      
Exocrine  
Endocrine 
Present 
Present 
 
Absent 
Absent 
Absent 
Unknown 
Present 
Present 
Present 
Present 
Unknown 
Unknown 
Hepatic disease Present Absent Unknown Present Present Unknown 
Biliary disease Present Absent - Present Present Unknown 
Table 3: Comparable CF disease phenotypes in experimental animal models 
CF disease phenotypes in different animal models. Rats do not possess a gall 
bladder and many phenotypes in the rat and rabbit are currently unknown.  
Adapted from (Rosen et al., 2018) 
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1.4.3 Cellular models  
More accessible in vitro models have been developed to complement understanding 
of CF pathophysiology and aid development of targeted CF therapy. Immortalised 
cell lines are generated from epithelial carcinomas or transformation of epithelial 
cells with viral, chemical or physical agents. Their extended lifespan, enhanced 
proliferation and relative homogeneity have helped to overcome some of the 
limitations of primary airway epithelial cells and proved beneficial with the 
investigation of inflammatory processes, mucus phenotypes and therapeutic 
responses in epithelial diseases such as CF (Gruenert et al., 1995). A large number 
of immortalised cell lines have been developed which vary in their epithelial 
characteristics (Gruenert et al., 2004). However, limitations of this model include 
associated karyotype instability, which can generate subpopulations of cells that do 
not retain the phenotype of interest (Gruenert et al., 2004). The process of 
transformation and multiple passages also affects expression and differentiation of 
key epithelial characteristics including cell polarity, cilia formation and tight junctions 
(Gruenert et al., 2004).  
1.4.4 Gene-editing and induced pluripotent stem cells 
Gene editing techniques are being developed with the aim of repairing individual 
CFTR mutations using a number of systems. One system utilises the Cas9 protein 
derived from clustered regularly interspaced short palindromic repeats (CRISPR) 
bacterial adaptive immune systems (Wang et al., 2016). Cas9 is used as an RNA-
guided endonuclease to create a double strand break in close proximity to the DNA 
site to be repaired (Harrison et al., 2018). Other systems use other nucleases 
including zinc-finger and transcription activator-like effector nucleases (Wang et al., 
2016).  
Once the double stranded break is made, the cell’s endogenous homology-directed 
repair pathways are exploited to replace the mutant sequence with a donor corrected 
molecule containing the desired DNA sequence. The breaks are repaired by non-
homologous end joining whereby DNA is joined by creating small insertions or 
deletions. However, this technique is limited by its relatively low level of precision.  
To optimise technique efficiency and broaden gene-editing application to all CFTR 
mutations, homology-independent targeted integration (HITI) methods are currently 
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being investigated to incorporate larger segments of DNA into the CFTR sequence 
with improved efficiency (Harrison et al., 2018). These technologies also carry a risk 
of  inserting a double stranded break into similar DNA sequences within the genome 
(Harrison et al., 2018). However, these “off target” effects may be reduced by 
optimising guide RNA design and Cas9 modification (Chen et al., 2017, Fu et al., 
2014). 
Although these techniques are very much still in the experimental stage, translation 
into human cells will have potential to repair CFTR in disease-affected cells. Gene 
editing technologies can also be applied to induced pluripotent stem cells (IPSCs). 
IPSCs have been genetically engineered from patient-derived samples, including 
hair, blood and mucus and clonally expanded in high numbers to produce 
differentiated cells of CF-affected tissues, including the respiratory epithelia (Huang 
et al., 2014). Incorporation of gene editing into IPSCs can be used to investigate CF 
disease modelling and enable high throughout assessment of novel therapies. 
1.4.5 The role of primary airway epithelial cells in cystic fibrosis research 
Ex vivo culture of primary airway epithelial cells has improved our understanding of 
respiratory diseases, airway inflammatory mechanisms and neoplastic processes. 
They have been pivotal in CF research, where they provide a physiologically relevant 
model to study treatment responses such as ivacaftor and gene therapy (Van Goor 
et al., 2009a).  Application of the air liquid interface (ALI) model has enabled ex vivo 
development of a muco-ciliary phenotype that is more representative of the in vivo 
pseudostratified columnar airway epithelium compared to submerged, 
undifferentiated cultures and allows comprehensive investigation of airway epithelial 
function (Fulcher et al., 2005).  
Primary bronchial epithelial cells (PBECs) can be isolated from explanted CF lung 
tissue. Although transplantation may be performed in children, it is more common in 
adolescents or adults with end-stage disease. PBECs can also be harvested from 
bronchial brushings and tissue collected during bronchoscopic procedures 
(McNamara et al., 2008, Brodlie et al., 2010). In paediatric research, this requires a 
general anaesthetic and often the clinical need for bronchoscopy to avoid 
unnecessary procedures in this young patient group.  
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1.4.6 Primary nasal epithelial cells in cystic fibrosis research 
The necessity for paediatric CF research is increasingly recognised and has 
previously been challenged by methods that are invasive and limited by experimental 
material. Given the possibility of early pathological changes, a robust strategy for 
timely investigation of disease processes and potential treatments is of paramount 
importance. In contrast to the invasive procedures required for PBEC collection, 
primary nasal epithelial cells (PNECs) can be cultured from nasal mucosal 
brushings. Clinical PNEC collection for congenital ciliary disorder diagnosis is a well-
established procedure and generally well tolerated by awake children. PNECs would 
therefore be hugely beneficial in facilitating longitudinal sampling from children of 
different ages, CF genotypes and disease severity in multiple settings.  
The nose forms part of the conducting component of the respiratory tract, which is 
also comprised of the mouth, pharynx, larynx, trachea, bronchi and respiratory 
bronchioles. The gas exchanging component of the respiratory system is 
represented by the terminal respiratory bronchioles and corresponding alveoli. The 
larynx traditionally forms the physical barrier between the upper and lower 
respiratory tracts (Gaga et al., 2001). Within the nose, the internal cavity is separated 
by the nasal septum. Three bony ridges, or turbinates, project from the lateral wall of 
each side of the internal cavities. These increase the surface area of the narrow 
interior cavity to promote warming and humidification of inspired air. Turbulent flow 
within this component enables filtration and trapping of large inhaled particulate 
matter. Nasal mucosal brushings for PNEC culture are generally sampled from the 
inferior nasal turbinate surface (de Courcey et al., 2012). Methods of acquisition for 
both PBECs and PNECs are shown in Figure 8.  
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Figure 8: Methods for the acquisition of bronchial and nasal epithelial cells 
Bronchial epithelial cells can be acquired by brushing the bronchial mucosal surface 
from explanted CF lung tissue (A)  or during flexible bronchoscopy (B) using a 
cytology brush (Brodlie et al., 2010, Olympus, 2017) Alternatively, nasal epithelial 
cells can sampled from nasal mucosal brushings taken from the inferior nasal 
turbinate surface (C ); image adapted from (Sahin-Yilmaz and Naclerio, 2011).  
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Primary bronchial epithelial cell culture from CF lungs 105
was then stored at −80◦C for 24 hours. At this point
the tubes were transferred to a liquid nitrogen cell
freezer for long-term storage.
Cryotubes containing 1 mL cell suspensions were
removed from a liquid nitrogen cell freezer and
rapidly rewarmed in a 37◦C water bath. Once de-
frosted the suspension was centrifuged at 1000 rpm
for 5 minutes. The supernatant was discarded and
5mL of BEGMprewarmed to 37◦Cwas slowly added
and the cells resuspended. The resultant cell suspen-
sion was then seeded in a 25-cm2 tissue culture flask
and cultured as previously described.
Histology and immunohistochemistry
Specimens of explanted lung were fixed in 10%
buffered formaldehyde (Genta Medical, York, UK),
dehydrated through graded alcohols, and embedded
in paraffin wax. Sections of 5 µm thickness were
prepared and stained with hematoxylin and eosin
and alcian blue/periodic acid–Schiff by standard tech-
nique. First-passage PBECs were grown on collagen
(Vitrogen 100) coated on 8-chamber slides (Thermo
Fisher) and stained for cytokeratin as previously de-
scribed, and with hematoxylin and eosin [31].
Electrophysiology studies
First passage PBECs from patient 9 (see Table 2)
were grown on collagen (Vitrogen 100)–coated glass
coverslips. The PBECs were transferred to a tissue
chamber and mounted on the stage of an inverted mi-
croscope. Whole-cell currents were recorded with an
EPC-7 patch clamp amplifier (List Electronic, Darm-
stadt, Germany). Currents were elicited using a step
voltage protocol over the range ±100 mV and ana-
lyzsed as described previously [32].
The pipette solution for experiments involving ion-
omycin contained (mM): 120.0 CsC1, 2.0 MgCl2,
0.2 EGTA, 1.0 ATP, and 10.0 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES) (pH 7.2
with CsOH). Pipette solution for experiments us-
ing forskolin had EGTA adjusted to 5 mM and the
addition of 2.12 mM CaCl2 (calculated free Ca2+
concentration 100 nM). The standard bath solution
contained (mM): 145 NaCl, 4.5 KCl, 2.0 CaCl2,
1.0 MgCl2, 10.0 HEPES, and 5.0 glucose (pH 7.4).
Cl− selectivity of whole-cell current was confirmed by
measuring the change in reversal potential (Erev) fol-
lowing the replacement of 100 mMNaCl in the stan-
dard bath solution with 100 mM sodium aspartate.
Stock solutions of 100 mM forskolin (Tocris, Bris-
tol, UK) and 10 mM ionomycin (Calbiochem, San
Diego, USA) were prepared in DMSO.
FIGURE 1 Explanted lung from a person with
CF and representative histology of airway
inflammation and mucus in end-stage CF lung
disease. (a) Explanted lung from a person with
CF (measuring 230 mm superior-inferior, 155
mm anterior-posterior, and 60 mm
medial-lateral). (b) Hematoxylin and eosin stain
of section of an airway from an explanted CF
lung demonstrating intense neutrophilic
inflammation and a plug of inflammatory debris.
(c) Alcian blue/periodic acid–Schiff stain of
explanted lung from a person with CF.
RESULTS
Patient Details, antimicrobials used, and
outcome of cultures
A total of 22 lung transplants were performed
over 18 months. The patient demographics and
C⃝ 2010 Informa Healthcare USA, Inc.
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The nasal epithelium composition reflects its underlying role in conditioning air 
together with providing a barrier against infective and noxious substances. The 
epithelium begins as stratified, keratinised, and squamous with gradual transition into 
a pseudostratified, ciliated columnar epithelium (Gaga et al., 2001). It shares 
histological similarities with the bronchial epithelium including the presence of goblet 
cells, ciliated cells, non-ciliated cells, basal cells, connective tissue and inflammatory 
cells (Serrano et al., 2005). However, despite the concept of a “united airway”, it is 
important to consider the distinct functions of the nose and bronchi (Gaga et al., 
2001). In contrast to the nose, the bronchial epithelium plays a key role in MCC and 
filters smaller particulate matter, and unlike the nasal epithelium also contains serous 
and club cells.  
Studies directly comparing PNECs with PBECs have been performed in a range of 
respiratory disorders, however studies are limited in CF. A comparison of ALI PNECs 
and PBECs isolated from 21 adult patients with chronic obstructive pulmonary 
disease demonstrated greater levels of basal and stimulated IL-8 release, but IL-8 
levels were positively correlated in both groups (Comer et al., 2012). With respect to 
the culture process, PBECs reached confluence after a longer period of time. This 
latter finding was also apparent in a further study comparing inflammatory responses 
between submerged PBECs and PNECs isolated from adults with respiratory 
tumours, interstitial lung disease, sarcoidosis and children with persistent chest x-ray 
changes, recurrent stridor, wheeze or cough, asthma and bronchopulmonary 
dysplasia (McDougall et al., 2008). Investigation of a combination of paired and 
unpaired PBECs and PNECs in this study showed similar morphology with 
analogous levels of stimulated inflammatory mediator release including IL-8, IL-6, 
granulocyte colony-stimulating factor and vascular endothelial growth factor 
(McDougall et al., 2008). Paired analysis of PBEC and PNEC ALI cultures from 9 
children with asthma and atopy and 6 healthy children have shown lower proportions 
of ciliated cells in PNECs but similar stimulated inflammatory responses  (Guo-Parke 
et al., 2013, Pringle et al., 2012). Inflammatory responses following respiratory 
syncytial virus exposure were similar in bronchial and nasal cultures.  
Micro-array global gene expression analysis of CF and non-CF nasal and bronchial 
epithelia revealed similar proportions of differentially expressed genes between the 
tissue types in each group (Ogilvie et al., 2011). However, patterns of differential 
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gene expression were different in bronchial versus nasal cultures (Ogilvie et al., 
2011). This was attributed to potential lower levels of chronic disease and airway 
remodelling seen in the CF nose compared with the lungs. The differentially 
expressed genes in the CF nasal and bronchial epithelium included those involved in 
cellular movement and signalling. This differed to the non-CF group, where cell 
growth, proliferation and tissue maintenance were of higher relevance (Ogilvie et al., 
2011). These findings suggest that the nose and lower airways have varying roles in 
disease and in CF.  However, although the non-CF nasal and bronchial epithelia 
were paired from the same participants, the CF group were mostly unpaired and 
therefore susceptible to inter-donor variability. Furthermore, non-epithelial 
inflammatory cells isolated from the bronchial cultures, particularly in the CF group, 
may have accounted for some of the differences seen.  
Interestingly in the same study, 863 genes were differentially expressed between CF 
and non-CF bronchial epithelia, with predominance evident in inflammatory 
pathways, cell signalling and cellular movement (Ogilvie et al., 2011). This was in 
contrast to the CF and non-CF nasal epithelium, where only 15 genes were 
differentially expressed, with enriched expression in amino acid metabolism and cell 
morphology. Another large-scale analysis found only 26 genes to be differentially 
expressed in well differentiated CF versus non-CF tracheal and bronchial cultures  
(Zabner et al., 2005). Despite the functional crossover, differentially expressed 
genes were not identical in both studies. Methodological variations could account for 
this difference, including airway epithelial cell collection technique, culture conditions, 
RNA sequencing and threshold setting for selecting ‘significant’ genes.  
PNECs are increasingly being employed in respiratory research and nasal cells have 
predicted electrophysiological and ion transport properties (de Courcey et al., 2012). 
Nevertheless, there are no direct comparisons of PBECs and PNECs from paired 
participants and comprehensive analysis of paediatric cultures remains limited. This 
knowledge would be hugely beneficial in determining the role of PNECs in 
translational research and personalised paediatric treatment, which is likely to 
predominate future CF therapy. 
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1.5 Alternative ‘non CFTR’ targets in cystic fibrosis lung disease 
1.5.1 Overview 
Although measures are underway to improve upon existing corrector therapy for 
rescue the F508del mutation, alternative strategies are required to benefit all people 
with CF, regardless of CFTR mutation type. One potential option is to correct ASL 
abnormalities that play a key role in CF pathogenesis. In addition to CFTR there are 
other plasma membrane channels and transporters including ENaC, alternative 
chloride channels, anion exchangers, potassium channels and aquaporins. Targeting 
these “by-pass” channels could compensate for abnormalities seen in the CF ASL 
with ion transport, solute trafficking, pH and volume and may provide potential 
therapeutic strategies for all people with CF. 
1.5.2 The epithelial sodium channel 
ENaC is expressed in the apical aspect of absorptive epithelia including the 
conducting airways, distal nephron, sweat gland and distal colon (Canessa et al., 
1994). It is a transmembrane protein consisting of three homologous subunits, α, b 
and ɣ, which form the channel pore for the amiloride-sensitive low conductance 
sodium channel (Canessa et al., 1994). An additional fourth subunit, δ, expressed in 
the brain, pancreas and urogenital tract, can replace the α subunit to enhance ENaC 
activity (Waldmann et al., 1995, Wichmann et al., 2018).  
In respiratory epithelia, ENaC-mediated sodium absorption generates a 
transepithelial potential difference providing the driving force for water and chloride 
absorption via a paracellular shunt pathway (Mall and Galietta, 2015). The 
basolateral Na/K/ATPase channel (Figure 4) actively pumps sodium out of the 
epithelial cell in exchange for potassium. The balance between ENaC’s absorptive 
function together with CFTR-mediated chloride secretion maintains ASL hydration.  
In addition to the absence of CFTR’s secretory function in CF, ASL dehydration is 
thought to be further confounded by ENaC upregulation in the absence of CFTR. 
This results in sodium hyper-absorption and further ASL dehydration. There are 
several lines of evidence to suggest this including cAMP-dependent CFTR ENaC 
regulation (Stutts et al., 1995). In vitro assessment of short circuit current (Isc) in 
response to amiloride, an ENaC inhibitor, in nasal tissue has shown a larger 
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decrease in Isc in CF versus non CF subjects suggesting a greater ENaC presence in 
CF (Boucher et al., 1986). Furthermore, a greater amiloride-sensitive nasal potential 
difference (PD) is evident in CF subjects versus healthy controls  (Knowles et al., 
1983). Interestingly, transgenic mice over-expressing the b-ENaC subunit display a 
CF phenotype with ASL dehydration, impaired MCC and neutrophilic lung 
inflammation (Mall et al., 2004). However, transgenic human-CFTR expression in 
these mice has not corrected airway disease (Grubb et al., 2012).  
Endogenous serine proteases such as neutrophil elastase, which is abundant in CF, 
may contribute to ENaC upregulation in disease (Gaillard et al., 2010). Importantly, 
ENaC dysfunction has not been demonstrated in all experimental models of CF 
leaving the CFTR/ENaC relationship under ongoing debate (Gentzsch et al., 2010).  
Several strategies have been employed to target ENaC inhibition for CF therapy as a 
means to restoring ASL hydration. A double-blinded crossover trial involving aerosol 
delivery of an ENaC inhibitor, amiloride, did not show significant improvements in 
lung function due to its relative low potency and rapid airway absorption (Knowles et 
al., 1990). More potent derivatives of amiloride were also rapidly cleared or absorbed 
from the airway both in vitro and in in vivo sheep models (Hirsh et al., 2004). Further 
clinical trials are underway for alternative ENaC inhibitors developed via high 
throughput screening approaches and the results of these are currently awaited.  
Protease inhibitors have also been employed to downregulate ENaC. More recently, 
early phase clinical trials have commenced to investigate the effects of a Spx-101, a 
peptide mimetic of the endogenous protease inhibitor short palate lung and nasal 
clone 1 (SPLUNC1). By direct binding with ENaC, SPLUNC1 prevents ENaC 
proteolytic cleavage and activation by serine proteases (Garcia-Caballero et al., 
2009). Spx-101 promoted ENaC internalisation in bronchial cell culture models and 
improved MCC in the b-ENaC mouse and sheep models (Walker et al., 2017). Gene 
silencing by the introduction of small interfering RNA (siRNA) could be an alternative 
method for ENaC inhibition. Indeed nanoparticle formulations for siRNA delivery 
targeting the α-ENaC subunit have been investigated in primary airway epithelial 
cells and shown effective silencing (Manunta et al., 2017). This airway focussed 
approach would reduce systemic effects of ENaC inhibition and provides an 
attractive therapeutic option. However, it is in the very early stages of development 
and will require careful consideration of optimum dose and delivery. 
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1.5.3 Calcium activated chloride channels 
Correction of chloride (and bicarbonate) transport may provide a superior approach 
to truly compensate for defective ion transport in CF. Calcium activated chloride 
channels (CaCCs) were described as an alternative CFTR-independent route for 
epithelial chloride secretion in the early 1990s.  Stimulation with nucleotide 
triphosphates, including ATP and uridine triphosphate (UTP), both in PNECs and by 
in vivo nasal PD measurement, revealed large increases in chloride secretion 
(Knowles  et al., 1991, Mason et al., 1991). Nasal PD measurement is non-invasive 
and reflects transepithelial ion transport. It involves sequential perfusion of 
compounds across the nasal epithelial surface. Amiloride is initially applied to block 
the absorptive effect of ENaC prior to perfusion with compounds targeting the 
channel of interest. In this case, amiloride-containing solutions of ATP, UTP, 
adenosine and uridine were added to activate CaCCs and the resultant increase in 
PD was calculated (Knowles  et al., 1991).  Interestingly nasal PD elevation following 
nucleotide addition was greater in CF versus non-CF participants. This finding has 
been complemented by the relatively mild murine CF lung phenotype and attributed 
to the presence of non CFTR-dependent calcium regulated chloride transport (Clarke 
et al., 1994).  
CaCCs were first described in Xenopus oocytes where fertilisation caused CaCC 
opening and subsequent membrane depolarisation (Miledi, 1982). In humans, 
CaCCs are required for epithelial secretion, smooth muscle contraction and sensory 
transduction (Hartzell et al., 2004). Increases in cytosolic calcium concentration by 
physiological ligands including ATP, UTP, acetylcholine, histamine, endothelin I and 
angiotensin II, results in halide secretion, with relative permeability as follows: iodide 
> bromide > chloride > fluoride (Hartzell et al., 2004, Qu and Hartzell, 2000). 
Although CaCC function has been well characterised for many years, the molecular 
identity was only recently described. A number of candidates including integral 
membrane bestrophin proteins and the calcium-sensitive chloride accessory protein 
family (CLCA) did not satisfy the hallmark criteria of CaCCs including activation by 
micromolar intracellular calcium concentrations and voltage-dependent modulation of 
channel activity.  
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1.6 Transmembrane protein 16A (TMEM16A)  
1.6.1 TMEM16A: a component of the calcium activated chloride channel  
Transmembrane protein 16A (TMEM16A) was recently discovered as an essential 
component of CaCC by three independent research groups in 2008 (Yang et al., 
2008, Caputo et al., 2008, Schroeder et al., 2008). Endogenous CaCCs are required 
to generate a fertilisation potential that prevents polyspermia in Xenopus oocytes. 
However, this is not the case in the polyspermic Axolotl salamander oocytes. Using 
this knowledge, Schroeder et al. injected mRNA extracted from Xenopus oocytes 
into Axolotl oocytes resulting in the generation of large CaCC currents and eventual 
identification of a single complementary deoxyribonucleic acid (cDNA) clone bearing 
the TMEM16A coding sequence (Schroeder et al., 2008).  
Th-2 cytokines such as IL-4 and IL-13 have been shown to upregulate calcium 
dependent chloride secretion in PBECs (Danahay et al., 2002, Galietta et al., 2002). 
Utilising this concept, Caputo et al. performed a microarray-based gene approach in 
IL-4 treated and untreated PBECs to identify proteins with corresponding mRNA 
upregulation. Subsequent siRNA gene silencing in relevant pancreatic and bronchial 
derived cell lines and PBECs revealed TMEM16A to be responsible for calcium 
mediated chloride secretion (Caputo et al., 2008).  
In the same year, after performing a search of public domain databases for putative 
transmembrane proteins, Yang et al. identified TMEM16A as a potential candidate 
for CaCC in view of its multiple MSDs and ten human homologues (Yang et al., 
2008).  Expression of mouse TMEM16A (which shares homology with human 
TMEM16A) in the human embryonic kidney 293T (HEK293T) cell line demonstrated 
TMEM16A-mediated chloride currents similar to endogenously activated CaCCs. 
These results were confirmed by siRNA knockdown in mouse salivary glands (Yang 
et al., 2008). In this study, TMEM16A was activated by increases in intracellular 
calcium and its anion permeability was consistent with endogenous CaCCs (Yang et 
al., 2008).  
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1.6.2 Structure and function of TMEM16A 
TMEM16A is a member of the TMEM16 family, which is comprised of ten proteins, 
otherwise known as the anoctamins. These proteins typically have between 800 and 
1000 amino acid residues and are predominantly scramblases involved in membrane 
lipid movement. However, a smaller number, including the closely related TMEM16A 
and TMEM16B, proteins, function as CaCC ion channels (Schroeder et al., 2008). 
TMEM16A is widely expressed in secretory epithelial cells, including the airway, 
pancreas, kidney, retina, salivary glands and gastrointestinal tract (Yang et al., 2008, 
Ousingsawat et al., 2009). TMEM16B is expressed in neuronal cells including 
olfactory neurons and photoreceptors (Stephan et al., 2009, Stöhr et al., 2009). 
TMEM16A consists of eight transmembrane domains with intracellularly located 
amino and carboxyl termini (Figure 9A). Of its ten family members, TMEM16A is 
closely related to TMEM16B as evident in the phylogenetic tree in Figure 9B. As 
characteristic of CaCCs, TMEM16A is activated by G protein coupled receptor 
(GPCR) purinergic P2Y stimulation, via ligands such as ATP and UTP. This 
increases inositol-1,4,5-triphosphate (IP3) production by phospholipase C, resulting 
in calcium release from intracellular stores (Figure 10A). Activation occurs with 
cytosolic free calcium concentrations of 0.2 – 1.0 µM and channel activity is further 
modulated by membrane potential (Hartzell et al., 2004). At this concentration range, 
the resultant stimulated current is outwardly rectifying and time-dependent.  
Mutational studies involving the replacement of three highly conserved positively 
charged amino acid residues with negatively charged glutamate residues have 
confirmed the region spanning the re-entrant loop between the fifth and sixth 
transmembrane domains to be the pore-forming region (Yang et al., 2008). Recent 
work investigating the transmembrane domains of mouse TMEM16A using cryo-
electron microscopy has identified ten highly conserved pore-lining residues that 
affect anion selectivity in addition to a cluster of seven residues that regulate channel 
gating and stability in open and closed states (Dang et al., 2017). 
The exact mechanism for calcium binding in TMEM16A remains unclear. A highly 
conserved region within the first intracellular loop (ICL1) of five negatively charged 
glutamic acid residues resembling the ‘calcium bowl’ in large conductance calcium 
activated potassium (BK) channels was initially proposed as a calcium binding site 
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(Schreiber and Salkoff, 1997). Although ablation of this region has not shown 
significant effects on channel sensitivity, this region may be important for channel 
and voltage modulation (Xiao et al., 2011).   
The third intracellular loop (ICL3) has since been suggested to be essential for 
calcium activation. Replacement of this region in a chimera containing the ICL3 of 
TMEM16B has reduced calcium affinity by almost 8-fold compared to wild-type 
TMEM16A (Scudieri et al., 2013). This has been confirmed by calcium insensitivity in 
a mutant form of TMEM16A whereby ICL3 was deleted (Lee et al., 2015b). Further 
investigation based on homology modelling has shown ICL3 to be comprised of two 
oppositely charged parallel helices that interact with each other in a calcium 
dependent manner (Lee et al., 2015b). These studies have suggested that under 
resting conditions, the positively charged helix holds the negatively charged calcium-
sensor helix in place, which is pushed away from the positive helix upon calcium ion 
attachment (Figure 10B). Mutations in both helices has reduced TMEM16A calcium 
sensitivity with no apparent effect on channel voltage sensitivity (Lee et al., 2015b). 
The proposed putative calcium binding site is comprised of two glutamic acid 
residues at positions 702 and 705, with alterations in calcium sensitivity evident in 
mutagenesis of these residues (Yu et al., 2012).  
Four splicing variants of TMEM16A have been identified. Activation of an alternative 
promoter in variant a results in missing transcripts in the first 116 amino acids 
(Ferrera et al., 2009). Variants b, c and d can arise from exon inclusion or skipping 
involving exons 6b, 13 and 15 which code for short protein regions of 22, 4 and 26 
amino acids respectively (Ferrera et al., 2009). Variants a and b are localised on the 
N-terminus; c and d are located within ICL1 (Caputo et al., 2008). The isoform, 
TMEM16A(0) lacks all splice variants and is significantly shorter than 
TMEM16A(abcd), with 840 amino acids compared with 1008 (Caputo et al., 2008).  
Splicing variants may arise from cell proliferation, differentiation or pathological 
processes and play a functional role in regulating calcium transport in dependent 
tissues (Ferrera et al., 2009). Implications of these variants have been investigated 
using the halide sensitive yellow fluorescence protein (YFP) assay. This can be used 
as a measure of CaCC sensitivity and works on the above-mentioned principle of 
CaCC anion selectivity (iodide > bromide > chloride). Cells loaded with YFP are 
placed into an iodide rich solution and challenged with a calcium agonist. 
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Subsequent iodide influx results in rapid YFP fluorescence, the rate of which is 
proportional to CaCC activity.  Using this assay in human embryonic kidney cells 
together with whole cell patch clamp analysis of ion transport, functional variability is 
evident with splicing variants. The ac variant has a four-fold higher affinity for calcium 
compared to abc, indicating that the b segment has a higher threshold for calcium 
sensitivity. The ab variant significantly reduces CaCC activity, while the d segment 
has no effect on CaCC variability (Ferrera et al., 2009). Importantly, splicing variants 
can either exhibit tissue specificity of be co-expressed within the same tissues. 
Alternative splicing bears important physiological relevance in regulating CaCC 
sensitivity and voltage dependence, which may explain variations seen in different 
cell and tissue types.  
TMEM16A channel gating by direct calcium binding has been challenged by the 
possibility that additional accessory CaCC sensors, such as calmodulin, may be 
involved in channel function. Specific calmodulin inhibitors have decreased 
TMEM16A(abc) activation and the b segment has been put forward as a calmodulin 
binding site (Tian et al., 2011). Investigation in human embryonic kidney (HEK) 293T 
cells has shown that the calcium dependent calmodulin-TMEM16A interaction 
increases relative bicarbonate channel permeability (Jung et al., 2013). However, 
calcium dependent TMEM16A activation remains strongly present in absence of the 
b variant and opposing results are evident with calmodulin inhibition (Xiao et al., 
2011). More recent work has shown that although calmodulin may be involved in 
channel modulation, it is not required for TMEM16A activation and that gating occurs 
with direct calcium-TMEM16A binding (Yu et al., 2014). In view of these conflicting 
findings, further investigation is clearly required to ascertain the precise TMEM16A 
mechanisms involved in calcium binding, channel gating and modulation.  
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Figure 9: TMEM16A structure 
Predicted topology for TMEM16A is shown in A consisting of eight transmembrane 
domains with intracellular C and N termini and a re-entrant loop between the fifth and 
sixth domains. A region in the ICL3 contains two glutamic acid residues E702 and 
E705 which may be involved in calcium binding. The EAVK sequence in ICL1 at 
positions 448-551 may be important for modulation of channel opening (Scudieri and 
Galietta, 2016). Phylogenetic tree of TMEM16A proteins is shown in B. TMEM16A 
and TMEM16B are close paralogues (Scudieri et al., 2012b). 
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Figure 10: Mechanisms for TMEM16A activation 
A: Stimulation of luminal G protein coupled receptor (GPCR) receptors by ligands 
such as ATP and UTP causes an increase in IP3 production by phospholipase C and 
subsequent release of calcium from intracellular stores, such as the endoplasmic 
reticulum (ER). This increase in intracellular calcium activates TMEM16A and 
resultant chloride (and bicarbonate) secretion.  
B: The two helices in third intracellular loop are oppositely charged. In the resting 
state (A), the positively charged reference helix holds the negatively charged 
calcium-sensor helix in place. Upon calcium ion attachment (B), the calcium-sensor 
helix is pushed away. Mutations in these regions result in reduced overall calcium ion 
sensitivity (Lee et al., 2015b) 
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1.6.3 TMEM16A relevance in the airway epithelium 
In the adult human airway, TMEM16A is expressed in the apical bronchial epithelium 
and in submucosal glands as shown in Figure 11 (Ousingsawat et al., 2009). 
TMEM16A knockout mice have demonstrated defective tracheal airway calcium 
dependent chloride transport and a CF-like phenotype with impaired MCC and 
suggestions of inadequate airway hydration (Rock et al., 2009, Ousingsawat et al., 
2009). siRNA-knockdown in PBECs has shown TMEM16A to be a major component 
of calcium activated chloride transport in the airway (Ousingsawat et al., 2009). 
In addition to the upregulation of CaCC and TMEM16A, IL-4 and IL-13 increase the 
abundance of mucus-secreting goblet cells (Scudieri et al., 2012a, Zhang et al., 
2013, Gorrieri et al., 2016). In the context of a ‘pro-inflammatory’ CF airway, this has 
significance for anion secretion, ASL regulation, mucus secretion and MCC (Caputo 
et al., 2008, Scudieri et al., 2012a, Lin et al., 2015). Studies investigating epithelial 
repair in CF PBECs have also shown that TMEM16A is required for cell proliferation 
and migration (Ruffin et al., 2013). In this study, a reduction in chloride activity was 
evident in CF versus wild type PBECs, which was attributed to reduced levels of 
TMEM16A mRNA and protein expression in CF PBECs.  
TMEM16A displays permeability to bicarbonate in addition to chloride, and like 
CFTR, this is less than the channel’s permeability to chloride (Jung et al., 2013, Ni et 
al., 2014, Tang et al., 2009). This function could be of relevance in correcting pH 
abnormalities in the CF airway, if indeed the CF airway is acidic (Jung et al., 2013). 
Bicarbonate is also required for the expansion of mucus granules and mucin 
secretion (Garcia et al., 2009, Gustafsson et al., 2012). TMEM16A-mediated 
bicarbonate secretion may be of physiological relevance in promoting MCC via 
enhancing mucin release from goblet cells.   
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Figure 11: Expression of TMEM16A in human adult airways 
Apical expression of TMEM16A in the epithelium of a mid-size bronchus (A) and in 
the serous submucosal glands (C). Lack of expression noted in larger mucus ducts 
(E). Negative controls demonstrated in B, D and F (Ousingsawat et al., 2009) 
 
 
 
 
 
 
 
 
 
 42 
1.6.4 Airway interactions of TMEM16A and CFTR 
CFTR has numerous stimulatory and inhibitory interactions with other cellular 
proteins involved in receptor or cell signalling. It is possible that CFTR interacts with 
TMEM16A to regulate secretory processes in the CF airway. CFTR has inhibited 
endogenous CaCC activity in Xenopus oocytes and bovine pulmonary artery 
endothelium (Kunzelmann et al., 1997, Wei et al., 1999). The purinergic CaCC 
response is enhanced in CF airway tissue and epithelial cells from both mice and 
humans (Knowles  et al., 1991, Clarke et al., 1994, Mall et al., 2003, Ousingsawat et 
al., 2011). Basal and increased expression of CFTR has inhibited TMEM16A-
mediated chloride secretion in a human bronchial epithelial cell line, with complete 
abolishment of TMEM16A activity following CFTR activation (Ousingsawat et al., 
2011). Notably, in this study, TMEM16A over-expression has reduced CFTR-induced 
currents (Ousingsawat et al., 2011).   
There are several explanations for the interactions between CFTR and TMEM16A. 
These include i) recognised effects of intracellular calcium on the enzymatic 
regulation of intracellular cAMP; ii) purinergic receptor-mediated increase in cAMP 
and calcium; iii) regulation of intracellular calcium by cAMP-affected proteins; and iv) 
CFTR-mediated GPCR translocation to the plasma membrane leading to an 
increase in calcium and subsequent TMEM16A activation (Namkung et al., 2010b, 
Kunzelmann et al., 2012). 
1.6.5 Exploring TMEM16A modulation as a target for CF therapy 
Despite the increase in CaCC activity noted in CF experimental models, it is clear 
from the presence of severe lung disease in CF that physiological activity alone is 
not sufficient to compensate for dysfunctional CFTR. This may be explained by the 
transient nature of CaCC activation and its relatively minor contributory role in 
chloride secretion relative to CFTR. However, modification of TMEM16A activity is 
an attractive target to bypass dysfunctional CFTR and correct chloride and 
bicarbonate transport, with potential to improve the underlying ASL pH and volume 
abnormalities evident in CF.   
Clinical trials have investigated the effects of the investigational compound 
denufusol, a P2Y receptor agonist that stimulates CaCC-mediated chloride 
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secretion. Early phase trials revealed significantly improved lung function in patients 
with mild impairments in lung function after nebulised denufusol treatment for 28 
days. In a subsequent phase III placebo controlled double blinded trial (TIGER-1) 
there was a 2 % improvement in percentage predicted FEV1 after denufusol 
treatment for 28 weeks, but this effect was modest and no improvements in 
secondary outcomes of pulmonary exacerbations, quality of life scores and 
hospitalisation were seen (Deterding et al., 2005). A further clinical trial was carried 
out to assess the efficacy of denufusol over a longer treatment period (Ratjen et al., 
2012). No significant benefits in lung function were seen following a 48-week 
treatment period. This lack of clinical efficacy was attributed to the possibility that 
denufusol has a relatively short half-life in pulmonary tissue compared with in vitro 
assessment, despite nebulised administration three times daily. Furthermore, the 
study was performed in patients with relatively mild lung function, and benefits may 
not have been apparent in this patient population.  
Targeting TMEM16A is likely to be challenging in view of its wide expression and risk 
of off-target effects. In addition to the epithelia, TMEM16A is expressed in smooth 
muscle cells in the airway, reproductive and gastrointestinal tracts (Huang et al., 
2009, Gallos et al., 2013). Furthermore, TMEM16A overexpression has been shown 
in certain human cancers including gastrointestinal stromal tumours and head and 
neck cancers, and it may be of relevance in tumour metastasis (Wang et al., 2017).  
This effect varies in different cell types, potentially due to distinct differences in 
activation of cell signalling pathways by TMEM16A, which has been extensively 
described in the review by Wang et al.  
Although some of these more widespread effects of TMEM16A activation could in 
some part be limited by direct airway delivery of a CF therapeutic compound, the 
potential effects on smooth muscle and airway hyper-responsiveness are of serious 
relevance (Zhang et al., 2013). A greater understanding of precise channel function 
and gating mechanisms will be essential to enable targeted modulation of TMEM16A 
to prevent this significant off-target effect. An additional layer of complexity also lies 
with the variation in TMEM16A tissue expression and varying levels of CaCC activity 
described in different cells. However, alternative ANO1 splicing may be relevant for 
the investigation of pharmacological agents to modify physiological processes and 
off-target effects that arise from these variations.  
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1.7 Research aims and objectives 
1.7.1 Hypotheses 
There is limited evidence directly comparing the functional characteristics of PBECs 
and PNECs isolated from children with and without CF. If their properties are similar, 
PNEC use in paediatric CF research will be hugely beneficial.  
Although TMEM16A expression has been investigated in adult cultured epithelial 
cells, lung tissue and other models, it’s relevance in children is yet to be determined. 
Given the role of TMEM16A in epithelial chloride and bicarbonate transport, 
modification of TMEM16A function may be a potential therapeutic strategy in CF.  
The work carried out in this PhD has aimed to address the following hypotheses: 
1. PNECs can be used as a suitable drug discovery tool in CF. 
2. TMEM16A is expressed in paediatric PNECs and PBECs, where it is involved in 
calcium activated chloride transport. 
3. Paediatric PNECs can be used to investigate the effects of novel TMEM16A 
activators including their potential to compensate for defective CFTR-mediated 
ion transport that is evident in CF. 
1.7.2 Aims and objectives 
The specific aims of this work were to: 
1. Sample PNECs and PBECs from children with and without CF who are attending 
the Great North Children’s Hospital to establish paediatric ALI culture models. 
2. Characterise and compare the epithelial and electrophysiological profiles of fully 
differentiated PBECs and PNECs derived from children with and without CF to 
further validate PNEC suitability as a paediatric drug discovery tool. 
3. Investigate TMEM16A expression and its involvement in endogenous CaCC 
function in paediatric CF PNECs and PBECs. 
4. Comparatively assess novel small molecule TMEM16A activator effects on ion 
transport in these cellular models as a potential therapeutic avenue to bypass 
dysfunctional CFTR. 
 45 
2 Chapter 2 Materials and Methods 
2.1 Research ethics and consent  
Ethical approval was granted by the Newcastle and North Tyneside 1 Research 
Ethics Committee on 8th September 2015 (reference: 15/NE/0215) following an 
application by myself with Drs Malcolm Brodlie, Chris Ward and Mike Gray. 
Research and Development Department approval was granted by the Newcastle 
upon Tyne NHS Foundations Trust (reference: 7494).  
Written consent was obtained by myself from parents of children with and without CF 
undergoing clinical bronchoscopy at the Great North Children’s Hospital (GNCH) in 
Newcastle upon Tyne. Parent and age appropriate participant information leaflets 
were designed by myself for participants with and without CF and are shown in 
Appendix A.  
2.2 Air liquid interface culture of paediatric primary nasal and bronchial 
epithelial cells 
2.2.1 Collection of paediatric nasal brushings 
Children with CF undergoing clinical bronchoscopy under the care of the paediatric 
respiratory team at GNCH were recruited into the study. Children without a clinical 
diagnosis of CF and, where performed a negative CF NBS, undergoing clinical 
bronchoscopy for the investigation of other respiratory indications were recruited as 
non-CF controls.  
After administration of general anaesthesia, nasal brushings were collected by 
brushing the inferior nasal turbinate of each nostril with a 2 mm disposable cytology 
brushes (Conmed 129R) using a rotary and linear movement for 10 seconds. The 
brushes were placed into 10 mL of Roswell Park Memorial Institute (RPMI) 1640 
medium (Sigma-Aldrich) for transfer to the laboratory for processing. This was 
performed prior to flexible bronchoscopy.  
2.2.2 Collection of paediatric bronchial brushings 
Bronchial brushings were collected during flexible bronchoscopy after the performing 
clinician had visualised the airways and obtained all clinically indicated samples. A 
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sheathed bronchial cytology brush was inserted into the channel port and carefully 
advanced. Upon direct visualisation of the brush tip at a 2nd or 3rd generation 
bronchus, the brush was unsheathed, and the bronchial surface was carefully 
brushed using a similar rotary and linear movement to that used for the acquisition of 
nasal brushings. The size of bronchoscopic brush (2 mm brush as above, or 1.2 mm, 
Olympus BC-203D-2006) was determined by the internal channel diameter of the 
flexible bronchoscope (Table 4), which had been selected at the discretion of the 
performing physician and dependent upon the age and size of the child. After 
brushing, the cytology brush was re-sheathed and the bronchoscope was withdrawn 
with the brush in situ, cut and placed into 10ml of RPMI 1640 medium for transfer to 
the laboratory for processing.  
 
Flexible bronchoscope outer diameter 
(mm) 
Compatible cytology brush  
(mm) 
2.2 (Neonates and infants) 1.2 
2.8 (Infants) 1.2 
3.5 (Young children) 1.2 
4.4 (Older children) 2.0 
Table 4: Compatibility of paediatric flexible bronchoscope with bronchoscopic 
cytology brush size  
Neonates are defined as children under 1 month of age; infants are children under 
the age of 1 year.  
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2.2.3 Harvesting of paediatric primary nasal and bronchial epithelial cells   
Tissue culture was performed using a Class II biological safety cabinet. Methods 
were based on those previously described (Fulcher et al., 2005, Forrest et al., 2005, 
Brodlie et al., 2010). Brushings were gently agitated in collection medium, ensuring 
complete removal of epithelial cells, which were centrifuged in collection medium at 
200 x g for 7 minutes at 10 °C. The supernatant was discarded and the remaining 
cell pellet re-suspended in 1 mL of Bronchial Epithelial Growth Medium (BEGM) 
(Lonza) supplemented with single quots (Lonza) and antimicrobials (Table 5).  
The combined nasal cell suspension was seeded into a 25 cm2 tissue culture flask 
(Corning), pre-coated with 30 µg/mL collagen (Purecol, Advanced Biomatrix) and 
primed with 4 mL of BEGM.  
The bronchial cell suspension isolated from the single brushing was seeded into a 
12.5 cm2 tissue culture flask (Corning), pre-coated with a mix of 30 µg/mL collagen 
(Purecol), 10 µg/mL bovine serum albumin (BSA) (Sigma-Aldrich) and 10 µg/mL 
fibronectin (Sigma-Aldrich) and primed with 1.5 mL of BEGM.  
Flasks were incubated at 37 °C, in 5 % carbon dioxide (CO2) and cells were 
monitored daily for growth and infection. BEGM media was supplemented with 100 
µg/mL Primocin (Invivogen) to provide additional antimicrobial cover for the first 72 to 
96 hours. Media was replaced with standard antimicrobials (Table 5) and exchanged 
every 48 hours.  
Cells were passaged at 80 – 90 % confluency and processed as previously 
described (Brodlie et al., 2010). BEGM was removed from the flasks and either 2.5 
mL or 5 mL of 0.05 % trypsin/0.02 % ethylene diamine tetracetic acid (EDTA) 
(Sigma-Aldrich) added to the 12.5 or 25 cm2 flask respectively and incubated at 37 
°C. After cell detachment, an equal volume of RPMI containing 10 % fetal calf serum 
(FCS, Sigma-Aldrich) was added to neutralise the trypsin and centrifuged at 200 x g 
for 7 minutes at 10 °C. The resultant supernatant was discarded and the pellet re-
suspended in BEGM. Cells were seeded onto the apical compartment of pre-
collagen coated and medium-primed Transwell (Corning) semipermeable clear 
polyester membranes (6.5 mm diameter, 0.4 µm pore size) in 100 µL BEGM aiming 
for a density of 60,000-80,000 cells per membrane (180,000 – 240,000 cells/cm2). 
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600 µL of BEGM was added to the Transwell basolateral compartments. The apical 
medium was exchanged the following day to remove unattached epithelial cells and 
both the apical and basolateral medium was exchanged every 48 hours. Cells were 
visualised daily and air lifted after attaining confluence at 48 to 72 hours. 
 
Component Volume 
Bronchial Epithelium Basal Medium 500 mL 
Bovine pituitary extract 2 mL 
Retinoic acid 500 µL 
Insulin 500 µL 
Hydrocortisone 500 µL 
Transferrin 500 µL 
Epinephrine 500 µL 
Human epidermal growth factor 500 µL 
Tri-iodothyronine 500 µL 
Gentamicin/amphotericin 500 µL 
Penicillin/Streptomycin * 5 mL (final concentration Penicillin 100U/mL, Streptomycin 100 µg/mL 
Table 5: Components of BEGM medium 
Components supplied by Lonza (concentrations not published). 
 * Supplied by Sigma-Aldrich 
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2.2.4 Air liquid interface culture  
The apical medium was removed and basolateral BEGM medium replaced with 
differentiation medium. This consisted of a 50:50 mix of BEGM basal medium with 
Dulbecco’s Modified Eagle’s Medium (DMEM-high glucose) (Lonza) supplemented 
with single quots as described in Table 5, with the exception of retinoic acid, added 
at 100 ng/ml, human epidermal growth factor, added at 0.5 ng/mL and 
gentamicin/amphotericin which was omitted. Calcium chloride was supplemented 
with 500 µL of 1 M solution in 500 mL of DMEM. Cells were regularly visualised 
using light microscopy for leakage and membrane integrity. Basolateral medium was 
exchanged every 48 hours. The apical surface was washed weekly using phosphate 
buffered saline (PBS) (Sigma). Resultant washings were stored at -80 °C for future 
analysis. Figure 12 provides a summary of the ALI culture process. 
 
Figure 12: Air liquid interface culture methods 
Sampled nasal and bronchial brushings were collected into RPMI medium and 
transported to the laboratory. After processing, the resultant cell pellets were re-
suspended into tissue culture flasks. After attaining 80-90 % confluency, cells were 
seeded onto semipermeable membrane supports and initially submerged with 
BEGM. Cells were air lifted when confluent to enable differentiation to a 
pseudostratified, ciliated columnar airway epithelium. 
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2.3 Characterisation of differentiated paediatric nasal and bronchial epithelial 
cultures 
2.3.1 Transepithelial electrical resistance  
Weekly serial transepithelial resistance (TEER) measurements were performed to 
assess tight junction integrity according to the manufacturer’s instructions (STX2 
electrodes, EVOM2TM Epithelial Voltohmmeter, World Precision Instruments (WPI)) 
Pre-warmed PBS (100 µL) was added to the apical compartment of each membrane 
and cultures were incubated and allowed to equilibrate at 37 ºC for 20 minutes. 
TEER measurement was also performed on a ‘blank’ membrane without seeded 
cells in each plate to provide the background level of resistance and this value was 
subtracted from each measurement. The final calculation of TEER was performed as 
follows: 
TEER (W.cm2) = (TEER value – blank value) x culture insert surface area 
2.3.2 Electron microscopy  
Electron microscopy (EM) was performed by the EM Research Service, Newcastle 
University. After fixation, nasal and bronchial ALI cultures were prepared as below by 
the EM Research Service. For scanning electron microscopy (SEM) differentiated 
ALI cultures were fixed with glutaraldehyde in Sorenson’s Phosphate Buffer 
(overnight minimum) and rinsed several times in the buffer. Fixed cultures were 
dehydrated through graded alcohols in ethanol as follows: 25 %, 50 %, 75 %, 100 % 
and 100 % ethanol and dried. Cultures were mounted on an aluminium stub and gold 
coated. SEM was performed by the EM Research Service using a Tescan Vega 
LMU scanning electron microscope and digital images collected with Tescan 
supplied software.  
For transmission electron microscopy (TEM), differentiated cultures were fixed firstly 
with glutaraldehyde in sodium cacodylate buffer, followed by osmium tetroxide. Fixed 
cultures were dehydrated through graded acetone as follows: 25 %, 50 %, 75 %, 100 
% and 100 % acetone and embedded in resin. Sections of 0.5 µm were cut using an 
ultramicrotome, stretched with chloroform and mounted on copper grids. The grids 
were examined by the EM Research Service using a Philips CM100 Compustage 
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(FE1) transmission electron microscope and digital images were collected using an 
AMT CCD camera (Deben).  
2.3.3 Fixation of air liquid interface cultures in paraformaldehyde 
Differentiated cultures at 28d ALI were washed with 100 µL PBS and fixed in 4 % 
paraformaldehyde (PFA, Sigma-Aldrich) for 20 minutes. PBS was applied to the 
surface of fixed cultures, which were maintained at 2-4 °C until ready for paraffin 
embedding and histological assessment.  
2.3.4 Preparation of paraffin-embedded sections  
Paraffin-embedded sections were prepared by a HCPC registered biomedical 
scientist (Kasim Jiwa, Sir William Leech laboratory, Freeman hospital) as follows: 
PFA-fixed ALI cultured membranes were cut away and detached from their inserts 
using a scalpel. The membranes were divided into 2 semi-circles and placed into 
labelled cassettes for histology processing.  Membranes were dehydrated by 
immersing the cassette through graded alcohols, with a 20-minute interval for each 
concentration of alcohol (70 %, 80 %, 95 % and 99 %). The membranes were 
submerged twice in xylene solvent for 20 minutes and infiltrated using a molten 
paraffin wax bath for 2 hours at 60 ºC.  
Processed membranes were externally embedded into paraffin blocks and cross 
sections were cut at 5 µm using a microtome. Sections were dewaxed in xylene for 
10 minutes and dehydrated in graded alcohol (99 %, 99 % and 95 %).  
2.3.5 Haematoxylin and eosin staining 
This was performed on paraffin embedded sections of ALI cultures to enable 
histological assessment of epithelial morphology. Sections were dewaxed in xylene 
twice for 5 minutes and rehydrated in 99% and 95% alcohol for 1 minute each. After 
washing in distilled water, freshly filtered Harris Haemaotoxylin (Thermofisher) was 
applied to the sections for 2 minutes. Sections were washed in tap water for 3 min 
and checked microscopically for nuclear staining. A counterstain with Eosin Y 
(Thermofisher) was applied for 2 minutes. Sections were washed well and 
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dehydrated through graded alcohols using 95 %, 99 % and 99 % ethanol for 30 
seconds each. Pertex (Leica Biosystems) was used to mount the slides.  
2.3.6 Periodic acid-Schiff staining  
This was performed to stain for mucin glycoproteins within the epithelium of paraffin 
embedded sections of ALI cultures. Sections were dewaxed, rehydrated and washed 
as described in section 2.3.5. 1 % Periodic Acid (Sigma-Aldrich) was applied to 
sections for 10 minutes. Sections were rinsed in distilled water before applying 
Schiff’s reagent (Sigma-Aldrich) for 10 minutes. After rinsing in tap water, Harris 
Haematoxylin (Thermofisher) was applied for 1 minute. Sections were washed, 
dehydrated and mounted.  
2.3.7 Alcian blue/periodic acid-Schiff staining 
This staining was performed to differentiate between acidic and neutral mucin 
glycoproteins within the epithelium of paraffin embedded sections of ALI cultures. 
Sections were dewaxed, rehydrated and washed as described in section 2.3.5. 
Sections were incubated with 0.1 % diastase (VWR) for 30 minutes and washed with 
tap water. PAS staining was then performed as above.  
2.3.8 Zona-occludins immunofluorescence  
This was performed to assess for the presence of tight junctions in PFA-fixed ALI 
cultures. Cultured cells were rinsed in PBS and blocked with 3 % BSA for 1 hour. 
Cells were washed in PBS and 0.05 % Tween 20 (Sigma-Aldrich) (PBST) and the 
mouse monoclonal zona-occludins antibody (ZO-1A12, Thermofisher,) was applied 
at 1:100 dilution in 3 % BSA overnight at 4 °C. Cells were washed in PBST before 
applying the secondary goat ant-mouse antibody (Alexa Fluor 488 A-11001, 
Thermofisher) at a 1:1000 dilution in 1 % BSA for 60 minutes at room temperature. 
Cells were light protected from this stage. Cells were washed in PBST and DAPI was 
applied for nuclear staining at 1:1000 dilution in PBS for 5 minutes. Cells were 
washed in PBS and mounted with Mowiol for assessment by confocal microscopy. 
Control experiments were also performed in the absence of primary and secondary 
antibodies. 
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2.3.9 Alpha-acetylated tubulin immunofluorescence  
This was performed to assess for the presence of cilia in PFA-fixed ALI cultures. 
Cultured cells were rinsed in PBS and blocked with 2 % BSA/0.04 % Triton X 
(Sigma-Aldrich) for 1 hour. Cells were washed in PBST and the mouse monoclonal 
alpha (a)-acetylated tubulin antibody (T7451, Sigma-Aldrich,) was applied at 1:500 
dilution in 2 % BSA/0.04 % Triton X (Sigma-Aldrich) overnight at 4 °C. Cells were 
then washed in PBST before applying the secondary goat anti-mouse antibody 
(Alexa Fluor 594 A-11032, Thermofisher) at a 1:1000 dilution in 1 % BSA for 60 
minutes at room temperature. Cells were light protected from this stage. Cells were 
washed in PBST and DAPI (Sigma-Aldrich) was applied for nuclear staining at 
1:1000 dilution in PBS for 5 minutes. Cells were washed in PBS and mounted with 
Mowiol (Sigma-Aldrich) for assessment by confocal microscopy. Control experiments 
were also performed in the absence of primary and secondary antibodies.  
2.3.10 TMEM16A immunofluorescence  
This was performed to assess for the presence of TMEM16A in PFA-fixed ALI 
cultures and based on methods described by Benedetto et al (Benedetto et al., 
2017). Cultured cells were rinsed in PBS and blocked with 2 % BSA/0.04 % Triton X 
for 1 hour. Cells were washed in PBST and the rabbit polyclonal TMEM16A antibody 
(GWB-MP178G, Genway Biotech) was applied at 1:100 dilution in 2 % BSA/0.04 % 
Triton X overnight at 4 °C. Cells were washed in PBST before applying the 
secondary goat ant-rabbit antibody (Alexa Fluor 488 A-11034, Thermofisher) at a 
1:1000 dilution in 1 % BSA for 60 minutes at room temperature. Cells were light 
protected from this stage. Cells were washed in PBST and DAPI was applied for 
nuclear staining at 1:1000 dilution in PBS for 5 minutes. Cells were washed in PBS 
and mounted with Mowiol for assessment by confocal microscopy. Control 
experiments were also performed in the absence of primary and secondary 
antibodies. 
All antibody characteristics used for the above immunofluorescent techniques are 
summarised in Table 6. 
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Primary 
antibody 
Target Type Host  Dilution Secondary 
antibody 
T7451 a-acetylated tubulin 
Monoclonal Mouse 1:500 A-11032 
(AF 594) 
ZO-1A12 Zona occludins 
Monoclonal Mouse 1:100 A-11001 
(AF 488) 
GWB-
MP178G 
TMEM16A 
 
Polyclonal Rabbit 1:100 A-11034 
(AF 488) 
Table 6: Primary antibodies used in immunofluorescent work 
Abbreviations: AF Alexa Fluor 
 
2.3.11 Confocal microscopy  
ALI cultures stained with the above immunofluorescence methods were visualised 
using a Nikon A1 plus confocal microscope at either 20x or 40x magnification 
utilising a numerical aperture of 0.75 mm or 1.3 mm respectively. Scanning speed 
was consistent, with typically 40 optical x-y sections for all images acquired. Pre-set 
lasers and filters were used to assess the fluorescence for DAPI-stained nuclei at an 
excitation wavelength of 405 nm. To visualise the specific targets, pre-set lasers and 
filters were used to excite at either 488 or 594 nm depending upon the secondary 
antibody used (Table 6).  
2.3.12 Quantification of TMEM16A positive immunofluorescence  
This was performed using ImageJ software using a two-step process. Quantification 
of immunofluorescence was first determined using ImageJ to calculate the area of 
fluorescence intensity as shown in Figure 13. The number of cells were then 
calculated by identification of the number of DAPI stained nuclei. This enabled the 
assessment of area of fluorescence intensity per cell for each ALI culture.  
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Figure 13: Quantification of TMEM16A immunofluorescence 
Air liquid interface PNEC cultures derived from a CF donor were treated with IL-4 (to 
upregulate TMEM16A expression) and were fixed in 4 % paraformaldehyde and 
assessed for the presence of TMEM16A with immunofluorescence techniques as 
described above. Images were obtained using confocal microscopy, with positive 
TMEM16A staining (green) and nuclei stained with DAPI (blue) as shown in A. 
ImageJ software was used to select out and quantify the area of positive TMEM16A 
staining or the area of fluorescence (A.U) as shown in B (red). The number of cells 
were quantified, as shown in C, and used to calculate the final A.U per cell.  
 
 
A B 
C 
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2.4 Enzyme linked immunosorbent assays of bronchoalveolar lavage and air 
liquid interface cell culture supernatants 
2.4.1 Bronchoalveolar lavage collection and processing 
Bronchoalveolar lavage (BAL) was collected from children at the time of clinical 
bronchoscopy. The volume of 0.9 % saline instilled and choice of BAL site was 
determined by the performing clinician and based on European Respiratory Society 
taskforce guidelines (de Blic et al., 2000). BAL was performed by gently positioning 
the tip of the bronchoscope in the selected position and instilling the designated 
volume of saline. Fluid was aspirated into a sterile suction trap and transported to the 
laboratory for immediate processing.  
The BAL sample was centrifuged at 1250 rpm (183 x g) for 6 minutes at 4 ºC (Mistral 
3000i). The supernatant decanted and centrifuged at 2500 rpm (743 x g) for 6 
minutes at 4 ºC. The final supernatant was divided into 500 µL aliquots and stored at 
-80 ºC for later analysis. 
2.4.2 Mucin 5AC assessment  
An indirect enzyme linked immunosorbent assay (ELISA) was used for the detection 
of MUC5AC in supernatants harvested from ALI cell cultures at 28d ALI. MUC5AC 
standard (harvested from purified pig gastric mucin) was diluted in PBS and applied 
at 100 µL in duplicate into standard wells of a 96 well microtitre plate (Thermofisher) 
in the range of 0 -10 µg/ml. Cell culture supernatants were diluted in PBS using a 
1:2, 1:5 or 1:10 dilution or applied neat at 100 µL into wells in duplicate. Samples 
and standards were allowed to develop overnight. Plates were emptied and washed 
three times in 400 µL of PBST (Sigma-Aldrich). Wash steps were repeated after 
each ELISA protocol step. Unoccupied binding sites were blocked with 300 µL 1 % 
casein (Sigma-Aldrich) in PBS for 2 hours. The primary antibody (45M1 mouse anti-
human MUC5AC, Thermofisher) was diluted 1:1000 in 0.1 % casein/PBST and 
added at 100 µl for 2 hours. The secondary antibody (horseradish peroxidase-
conjugated polyclonal goat anti-mouse antibody; Dako) was diluted 1:5000 and 
added at 100 µL for 2 hours. Finally, peroxidase substrate ABTS (2,2’-azino-bis(3-
ethylbenzthiazoline-6-sulphonic acid; Sigma-Aldrich) was added at 100 µL and left to 
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develop for 30 minutes. Absorbance at 405 nm was measured using a plate reader 
(M200, Infinite, Männendorf). The lower limit of detection was 0.156 µg/mL.  
2.4.3 Mesoscale Discovery multiplex cytokine analysis  
Meso Scale Discovery (MSD) technology was used to quantify cytokines in ALI cell 
culture and BAL supernatants using the validated human V-PLEX platform 
(K15067L-1 kit, Meso Scale Diagnostics), specifically measuring interleukin (IL)-17A, 
IL-6, IL-1b, tumour necrosis factor (TNF)-a, interferon (IFN)-g, IL-14 and IL-13 
according to the manufacturer’s instructions. Quantification of IL-8 was performed of 
ALI culture and BAL supernatants diluted at 1:100 using a U-PLEX human IL-8 kit 
(K151RAD-1m, Meso Scale Diagnostics) according to the manufacturer’s 
instructions. The lower limits of detection for each cytokine were as follows: IL-4 0.06 
pg/mL, IL-6 0.33 pg/mL, IL-17A 2.1 pg/mL, IL-1b 0.15 pg/mL, IFN-g 1.7 pg/mL, TNF-
a 0.54 pg/mL and IL-8 0.15 pg/mL.  
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2.5 Ussing chamber short circuit current measurement 
The Ussing chamber was developed by Hans Ussing in the 1940s as a technique to 
measure short circuit current (Isc) as an indicator of net transepithelial ion transport 
(Ussing and Zerahn, 1951).  
Experiments were performed using non-perfused Ussing chambers controlled by the 
VCC MC8 (Voltage Current Clamp MultiChannel, Physiologic Instruments, Inc.). A 
schematic representation of an Ussing chamber system is shown in Figure 14. Prior 
to each experiment, ‘blank’ semi-permeable supports, without cultured cells, were 
mounted into the system to offset the potential difference and fluid resistance 
between the two chambers. Semi-permeable supports of differentiated ALI cultures 
were then mounted into the chambers and bathed both apically and basolaterally in 
5mL of Krebs solution. Experiments were performed in a 125 mM chloride containing 
Krebs solution unless otherwise specified, whereby either 40 mM or 0 mM chloride 
Krebs solutions were used. The composition of these solutions are shown below in 
Table 7. Chambers were gassed with 5 % CO2/95 % O2 and maintained at pH 7.4 
and 37ºC. Each chamber was connected to an Ag/AgCl pellet voltage sensing 
electrode and an Ag wire current passing electrode. These were connected to the 
chamber by agar bridges in 3 M KCl.  
To measure Isc, transepithelial voltage (Vte) was clamped to 0 mV and the injected 
current, required to maintain Vte to 0 mV, was continuously measured and recorded 
using the Acquire and Analyze software (Harvard Apparatus). Under these 
conditions, the injected Isc was a direct measure of net ion transport across the 
epithelial monolayer. The transepithelial electrical resistance (TEER) was also 
continuously recorded using the same software by intermittently clamping the Vte to 
5 mV and TEER calculated using Ohm’s law.  
After a 20-minute period of stabilisation, pharmacological reagents of interest were 
added to either the apical or basolateral compartments (depending upon individual 
mechanisms of action) and the resultant effect on Isc was assessed. For all 
experiments, the protocol consisted of initial apical amiloride addition (100 µM, 
Tocris) to inhibit ENaC. This was followed by apical addition of forskolin (10 µM, 
Tocris) as a cAMP activator of CFTR, which was subsequently inhibited with apical 
CFTRinh-172 (20 µM, Tocris). Finally, UTP (100 µM, Sigma-Aldrich) was apically 
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added as a purinergic agonist for CaCC activation. A representative Ussing chamber 
trace derived from a non-CF ALI culture is shown in Figure 15A.  
The resultant amiloride-sensitive Isc was calculated as shown in Figure 15B. This 
was performed by first determining the baseline Isc by calculating the mean Isc values 
for 1 minute prior to amiloride addition. The minimum Isc value after amiloride 
addition was next determined using GraphPad Prism software and subtracted from 
the calculated baseline to obtain the resultant amiloride-sensitive Isc. Responses to 
forskolin, CFTRinh-172 and UTP were calculated using a similar approach as shown 
also in Figure 15B. In addition, the total current calculated from the area under the 
curve (AUC) using GraphPad Prism software, was used to assess the total UTP-
induced Isc response (Figure 15C). 
Figure 14: Schematic representation of Ussing chamber  
PNEC and PBEC ALI differentiated cultures grown on semi-permeable supports 
were mounted in the Ussing chamber. The epithelial monolayer was bathed apically 
and basolaterally with 5 mL of Krebs solution. Each chamber was connected to 
voltage and current sensing electrodes. The Isc required to clamp the Vte to 0 mV 
was recorded. Pharmacological reagents were added to the apical or basolateral 
compartments and resultant changes in Isc and RT were assessed. 
mV
µA
Gas
Basolateral Apical
Voltage sensing electrode
Current sensing electrode
Krebs Krebs
Epithelial monolayer
Pharmacological reagent
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125 mM chloride 40 mM chloride 0 mM chloride 
25 mM NaHCO3 25 mM NaHCO3 25 mM NaHCO3 
115 mM NaCl 31 mM NaCl 115 mM Na gluconate 
5 mM KCl 84 mM Na gluconate 2.5 mM K2SO4 
1 mM CaCl2 5 mM KCl 6 mM Ca gluconate 
1 mM MgCl2 1 mM CaCl2 1 mM Mg gluconate 
 1 mM MgCl2  
Table 7: Composition of Krebs solutions used for Ussing chamber 
experiments 
10 mM D-glucose was added to all solutions on the day of experiments.  
Abbreviations: CaCl2: calcium chloride; KCl: potassium chloride; K2SO4 potassium 
sulphate; MgCl2: magnesium chloride; NaCl: sodium chloride; NaHCO3: sodium 
bicarbonate. 
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Figure 15: Representative short circuit current responses to amiloride, 
forskolin and CFTRinh-172 and calculated changes in responses in ALI cultures 
derived from a non-CF donor 
Representative short circuit current (Isc) trace showing responses to amiloride, 
forskolin, CFTRinh-172 and UTP are shown in A. The minimum Isc value after 
amiloride addition (determined with GraphPad Prism software) was subtracted from 
the calculated baseline 1 minute prior to amiloride addition to obtain the resultant 
amiloride-sensitive Isc (red). Similarly, the forskolin-induced Isc was obtained by 
subtracting the mean baseline Isc 1 minute prior to forskolin addition from the 
maximum peak response to forskolin (blue). Isc responses to CFTRinh-172 (green) 
and UTP (purple) were calculated using the same approach. The area under the 
curve (AUC) was analysed using GraphPad Prism software and used to assess the 
total UTP-induced Isc response (C).  
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2.6 Intracellular calcium assessment 
Nasal epithelial cells were submerged and cultured on 25 mm glass coverslips 
(VWR) at a seeding density of 6 x 105 per coverslip and investigated after achieving 
80-90 % confluence.  
All intracellular calcium measurements were performed by JinHeng Lin (PhD 
student, Newcastle University). Cells were washed in NaHEPES buffered solution 
(containing in mM: 130 NaCl, 5 KCl, 1 CaCl2, 1 MgCl2, 10 NaHEPES and 10 D-
glucose, pH 7.4) and incubated with 5 µM Fura-2 AM for 1 hour. The dye was 
removed and cells were incubated in NaHEPES for a further 15 minutes to enable 
dye de-esterification. Cells were then mounted onto a Nikon microscope at room 
temperature and imaged with a Nikon fluor x 40 oil immersion objective with a 
numerical aperture of 1.3. A NaHEPES solution was perfused across the cells at a 
rate of 3 mL/min. Cells were alternately excited at 340 nm and 380 nm for 0.25 s 
each continuously, and emitted light was collected at 510 nm and recorded using 
InCyt PM-2 software (Biopress Online). The changes in the ratio of 340 nm:380 nm 
emission were proportional to changes in intracellular calcium ([Ca2+]I).  
2.7 Quantitative real time polymerase chain reaction  
2.7.1 Extraction of RNA and cDNA synthesis 
Quantitative real-time polymerase chain reaction (RT-qPCR) was used as a 
technique to investigate the expression of genes of interest. This was performed by 
first extracting total RNA from paediatric differentiated non-CF and CF PNEC and 
PBEC ALI cultures using the standard protocol of the AllPrep RNA/Protein kit 
(Qiagen) as shown below in Figure 16. After extraction, RNA was eluted in 20 µL of 
RNAase-free water (Thermofisher). The NanoDrop One UV-Vis spectrophotometer 
(Thermofisher)  was used to determine the concentration (by ultraviolet absorbance 
at 260 nm) and purity (ratio of 260:280 nm absorbance) of the extracted RNA. Total 
RNA was converted to cDNA using a random hexamer primer, dNTP mix, reverse 
transcriptase buffer, RiboLock RNAase inhibitor and maxima reverse transcriptase 
(Thermofisher) which were incubated with the RNA for 10 minutes at 25 °C followed 
by 30 minutes at 50 °C and terminated by heating at 85 °C for 5 minutes.  
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Figure 16: Protocol for RNA extraction from differentiated ALI cultures 
RNA was extracted from differentiated PNEC and PBEC ALI cultures using the 
AllPrep RNA/Protein kit (Qiagen) as highlighted within the blue circles. After 
extraction, the RNA was eluted into 20 µL of RNAase free water for subsequent 
conversion to cDNA. Image adapted from AllPrep RNA/Protein handbook (Qiagen, 
2014). 
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2.7.2 Quantitative real-time polymerase chain reaction (SYBRTM Green) 
RT-qPCR was performed using the QuantStudio 3 Real Time PCR machine 
(Thermofisher). A final reaction volume was produced containing 45 ng of cDNA, 0.3 
µL (200 µM) of each forward and reverse primers, 7.5 µL of PowerUpTM SYBRTM 
Green Master Mix (Thermofisher) and RNAase free water to make a final volume of 
15 µL. Primer sequences for all genes of interest are shown in Table 8 and Table 9. 
GAPDH was used as the reference house-keeping gene and cDNA derived from an 
internal reference control was used in each RT-qPCR plate to enable comparisons 
across different plate preparations.  
Amplifications were performed starting with an initial denaturation step at 95 °C for 
10 minutes followed by the PCR phase comprising of 40 cycles of denaturation at 95 
°C for 10 seconds and a combined primer annealing/extension at 60 °C and 72 °C 
for 20 seconds each. At the end of each PCR, a melting curve was generated with 
95 °C for 15 seconds followed by 60 °C for 1 minute and dissociation at 95 °C for 15 
seconds. This process has been summarised in Figure 17. Template negative 
controls and assessment of melt curve analysis (Figure 17) were used to determine 
the absence of DNA contamination.  
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Target Sequence Amplicon 
length (bp) 
GAPDH* F: 5'-TGCACCACCAACTGCTTAGC-3' 87 
 R: 5'-TGCACCACCAACTGCTTAGC-3'  
CFTR* F: 5'-CACTGCTGGTATGCTCTCCA-3’ 237 
 R: 5'-CACTGCTGGTATGCTCTCCA-3’  
TMEM16A* F: 5'-TGCATGGTCCCGTTCTTACT-3’ 376 
 R: 5'-TGCATGGTCCCGTTCTTACT-3’  
MUC5AC* F: 5'-CAGCCACGTCCCCTTCAATA-3’ 64 
 R: 5'-CAGCCACGTCCCCTTCAATA-3’  
MUC5B* F: 5′-GCAACACCCTCCTCTAGCAC-3′ 120 
 R: 5′-AGGTGTTGTCCCTGGAGTTG-3′  
a-ENaC† F: 5’-CAGCCCATACCAGGTCTCAT-3’ 221 
 R: 5’-ATGGTGGTGTTGTTGCAGAA-3’  
b-ENaC† F: 5’-TCCTACCCTCGTCCCTACCT-3’  151 
 R: 5’-CCAGGAAGGAGAAAACCACA-3’  
g-ENaC† F: 5’-ACCACCAGCCATGGTCTAAG-3’ 211 
 R: 5’-GTTCAGGTCCCGGGATTTAT-3’  
Table 8: Primer sequences for genes encoding epithelial channels of interest  
Abbreviations: F: forward; R: reverse.  
* In house primers designed in Dr Mike Gray’s lab using Primer3web 
(http://primer3.ut.ee/) and verified with Primer Blast 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/). † Sequences obtained from (Lee et 
al., 2015a) and verified with Primer Blast.  
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Target Sequence Amplicon 
length (bp) 
ZO-1 F: 5'-ACCAGTAAGTCGTCCTGATCC-3' 128 
 R: 5'-TCGGCCAAATCTTCTCACTCC -3'  
CDH1 F: 5'-ATTTTTCCCTCGACACCCGAT-3’ 109 
 R: 5'-TCCCAGGCGTAGACCAAGA-3’  
EpCAM F: 5’-AATCGTCAATGCCAGTGTACTT-3’ 178 
 R: 5’-TCTCATCGCAGTCAGGATCATAA-3’  
Foxj1 F: 5'-TCGTATGCCACGCTCATCTG-3’ 183 
 R: 5'-CTCCCGAGGCACTTTGATGA-3’  
TUBA1A F: 5'-CTATGTGCCGCAGGTTCTCT-3’ 119 
 R: 5'-CTCACGCATGGTTGCTGCTT-3’  
Table 9: Primer sequences for genes encoding epithelial markers of interest 
Abbreviations: F: forward; R: reverse.  
All primers were in house primers designed in Dr Brodlie’s lab using Primer3web 
(http://primer3.ut.ee/) and verified with Primer Blast 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/). 
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Figure 17: Process for real time quantitative polymerase chain reaction and 
melt curve analysis 
The protocol used for real time quantitative polymerase chain reaction (RT-qPCR) is 
shown in A, with the initial denaturation, followed by the PCR and melt curve stages. 
Representative melt curve analysis graph after RT-qPCR with primers for zona-
occludins 1 (ZO-1; pink) and GAPDH (red) is shown in B, showing single peaks for 
each gene indicating the production of pure DNA amplification products.  
 
 
A 
B 
ZO-1 
GAPDH 
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2.7.3 Analysis of real-time quantitative polymerase chain reaction 
The Design and Analysis Application Software (Thermofisher) was used to 
determine the threshold cycle (CT) for expression analysis of each gene of interest in 
samples investigated. This was used to determine the relative quantification of each 
gene, using the comparative CT method whereby the DCT (relative to GAPDH) was 
first calculated as follows: 
Equation 1:   DCT = CT gene of interest - CT GAPDH 
These DCT  values were normalised to the internal reference control sample to 
enable comparison across experimental plates. To determine the relative fold 
change for each gene between two different groups (e.g. non-CF PBECs  non-CF 
PBECs), the 2-DDCT  method was used, whereby the relative fold change was 
calculated as follows: 
Equation 2:   DDCT =  DCT non-CF PNECs - DCT non-CF PBECs 
Equation 3:   Relative fold change = 2-DDCT  
A challenge of using patient derived samples is the difficulty in justifying and 
assigning a particular sample from one group to compare with another (Schmittgen 
and Livak, 2008). To overcome this in relation to equation 2, the DCT for the first 
group (in this case non-CF PNECs) was determined by calculating the mean DCT for 
all non-CF PNECs. Individual DCT values for samples in the second group (in this 
case non-CF PBECs) were subtracted from this to ascertain the DDCT for each non-
CF PBEC sample. The mean of these values was determined, and applied to 
equation 3 to derive the relative fold change between the two groups. This approach 
is exemplified in Table 10 and was used for all grouped data analyses of mRNA 
expression in this PhD.  
Although this analysis determined the relative fold change between two groups, this 
calculation did not incorporate SD for the calculated DCT values for each individual 
sample. To overcome this, 2-DCT (i.e. relating to equation 1) values were also 
calculated for each sample to enable the calculation of the median ± IQR for each 
group from the individual patient sample values. This provided relative gene 
expression data and an alternative analysis of the spread of data (Schmittgen and 
Livak, 2008).  
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Non-CF 
PNECs 
DCT 
Non-CF 
PBECs 
DCT 
DDCT 
 
Relative fold change 
(2-DDCT) 
  (10.3 - non-CF PBECs DCT)  
10.1 9.1 -1.3 2.4 
9.5 8.0 -2.4 5.2 
10.7 15.8 5.4 0.0 
11.3 12.4 2.1 0.2 
8.4 11.3 0.9 0.5 
10.4 13.1 2.7 0.2 
12.4 14.7 4.4 0.1 
9.8 13.5 3.2 0.1 
Mean:  
10.3 
 
 Mean fold change:  
1.1 ± 1.9 
Table 10: Exemplification of relative fold change calculation for TMEM16A 
expression in non-CF PNECs versus PBECs 
Abbreviations: CT cycle threshold. 
DCT = CT TMEM16A - CT GAPDH.  
DDCT as described above i.e. mean DCT non-CF PNECs - DCT non-CF PBECs.  
Relative fold change is 2-DDCT. 
In this example, the mean relative fold change for TMEM16A in non-CF PBECs 
versus non-CF PNECs is 1.1 ± SD 1.9.  
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2.8 Statistical analysis  
Prism version 7.0 for Mac (GraphPad software, CA, USA) was used to perform all 
statistical analyses and prepare graphical representations of data. The Shapiro-Wilk 
test was applied to assess the normality of data. Normally distributed data is 
presented as the mean ± standard deviation (SD) in text and figures and analysed 
using the unpaired t test or one-way analysis of variance (ANOVA) with post hoc 
Bonferroni’s multiple comparison test in accordance with the data set. Non-normally 
distributed data is presented as the median ± interquartile range (IQR) in text and 
figures and analysed using the Mann Whitney test or Kruskal-Wallis analysis of 
variance with Dunn’s post hoc analysis of variance in accordance with the data set. 
Statistical tests used for data analysis are detailed in the figure legends. Data was 
considered to be statistically significant at p-values of less than 0.05.  
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3 Chapter 3 Development and characterisation of differentiated 
primary nasal and bronchial epithelial cell cultures derived from 
children with and without CF 
3.1 Introduction  
As discussed earlier in the thesis, primary airway epithelial cells have been pivotal to 
enable further investigation of pathological processes in CF in addition to facilitating 
drug discovery (Van Goor et al., 2009a). The culture of both primary bronchial and 
nasal epithelial cells are established techniques that are performed by many CF 
research groups. 
In children, bronchial epithelial cells are harvested either during a bronchoscopy, 
which requires a general anaesthetic, or at transplantation, which is an infrequent 
occurrence thereby limiting available samples for research. Nasal epithelial cells 
provide a more attractive experimental model, given the relative ease of sampling 
and potential for application in a range of CF disease severities, genotypes and 
clinical settings. Despite the uptake of nasal culture use in CF research, there are 
very few comparisons of nasal and bronchial epithelial characteristics. Indeed, it is 
still recognised amongst the CF research community that further comparative 
assessment with bronchial epithelial cells is very much needed (Clancy et al., 2018). 
Furthermore, with the evolution of ‘theratyping’ to investigate specific effects of 
CFTR variants on CFTR function and therapeutic response, there is considerable 
need for robust, reliable, patient-derived experimental models to deliver effective 
personalised CF care. 
Establishment of this resource in Newcastle will enable the investigation of the 
research aims and objectives outlined in this thesis. Furthermore, if successful, it will 
be valuable for the progression of paediatric CF research in Newcastle. With a 
regional CF paediatric patient population of around 180 children, the current 
infrastructure is well suited to facilitating this process.  
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3.2 Hypotheses 
This chapter will involve the investigation of the following hypothesis: 
• Paediatric PNECs will have similar epithelial characteristics to PBECs and are 
therefore a representative model for CF research. 
3.3 Aims  
The specific aims of the work detailed in this chapter were to: 
• establish a programme to enable the sampling of elective nasal and bronchial 
brushings from children already attending the GNCH for a clinically-indicated 
bronchoscopy 
• develop and optimise methods to obtain PNEC and PBEC ALI cultures from 
brushings isolated from children with and without CF and non-CF participants 
• assess the morphology of successfully established ALI cultures including 
investigation of epithelial integrity and mucociliary phenotypes 
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3.4 Results 
3.4.1 Establishment of a programme to harvest paediatric nasal and bronchial 
brushings  
To establish this programme at GNCH and Newcastle University, I coordinated the 
necessary ethical approval in accordance with the Integrated Research Application 
System and Research Ethics Committee review. I developed the research protocol 
together with parent and age-appropriate participant information sheets (see 
Appendix A for relevant ethical approval documentation, consent forms and parent 
and participant information literature). The value of public engagement in research 
was highlighted through my participation in activities with the North East’s Young 
People’s Advisory Group for paediatric research relating to protocol design and 
updates of research progress.  
Through my involvement in this research project, I obtained certification in Good 
Clinical Practice (GCP) relating to research in secondary care, issues relating to 
informed consent in paediatric research and the acquisition and use of human tissue. 
It was also necessary to acquire technical knowledge relating to the model and size 
of bronchoscopes used within the hospital and verify information regarding the 
compatibility of cytology brushes with existing equipment.  
Nasal brushings can be sampled from awake children and is current practice at 
GNCH for the clinical diagnosis of primary ciliary disorders. However, for the 
purposes of this research and to enable the acquisition of both nasal and bronchial 
epithelial cells, both sets of brushings were sampled during a clinically-indicated 
bronchoscopy to minimise invasive procedures in children. It was essential to ensure 
that members of the paediatric CF multi-disciplinary team, paediatric anaesthetists 
and surgical theatre staff were well-informed throughout. They were instrumental in 
facilitating sampling of brushings through their exceptional co-operation and 
assistance throughout the period of participant recruitment.  
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3.4.2 Development and optimisation of differentiated paediatric primary nasal 
and bronchial epithelial air liquid interface cultures 
Recruitment of paediatric participants for the work performed in this PhD took place 
between November 2015 until March 2018. Figures related to recruitment, brushings 
harvested and culture success are summarised in Figure 18. All parents and children 
with CF who were approached consented to their participation. For non-CF 
participants, parents and children declined on 5 occasions. A total of 29 CF and 20 
non-CF participants were recruited. Clinical information and success rates of PNEC 
and PBEC cultures are summarised in Table 11 and Table 12. The median age of 
the non-CF group was lower than the CF group as shown in Figure 19 (non-CF: 3.2 
years, range 0.8-15.7 versus CF: 5.4 years, 0.5-15.3) and there was a small 
preponderance for male children in both groups (CF: 55 %, non-CF 60 %). The 
majority (72 %) of CF participants were homozygous for the F508del mutation. The 
predominant indication for bronchoscopy in non-CF participants was for the 
investigation of recurrent chest infections, which occurred in 60% of cases.  
Nasal brushings were sampled from all recruited participants (n=29 CF and 20 non-
CF). Bronchial brushings were not sampled due to technical difficulties during the 
bronchoscopy in three cases and the procedure was not re-attempted (n=27 CF and 
19 non-CF bronchial brushings). All bronchial brushings were harvested from the 
same anatomical generation of lobar bronchi. Either a 1.2 mm or 2.0 mm bronchial 
brush was used to harvest bronchial epithelial cells. This selection was at the 
discretion of the performing clinician and dependent upon the size of the child and 
the internal bronchoscope working channel diameter. A smaller 1.2 mm brush was 
used in 60 % of non-CF participants, with a lower frequency in CF participants of 43 
%, in accordance with the increased age in this latter group. 
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Figure 18:  Participant recruitment and sampling of nasal and bronchial 
brushings from children with and without cystic fibrosis 
* Bronchial brushings not sampled for technical reasons from 1 non-cystic fibrosis 
(CF) and 2 CF participants. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Sa
m
pl
e 
G
en
ot
yp
e 
A
ge
 
(y
) 
Se
x 
Pa
nc
re
at
ic
 
fu
nc
tio
n 
Sw
ea
t t
es
t 
(m
m
ol
/L
) 
FE
V 1
   
   
   
   
   
   
   
 
(%
 p
re
d)
 
R
el
ev
an
t 
m
ic
ro
bi
ol
og
y 
PN
EC
 
su
cc
es
s 
PB
EC
 
su
cc
es
s 
PC
F1
 
F5
08
de
l/ 
G
55
1D
 
2.
9 
M
 
PI
 
11
4 
N
D
 
M
. c
at
ar
rh
al
is
 
N
o 
1  
N
o 
1  
PC
F2
 
F5
08
de
l/2
18
4d
el
A 
2.
5 
M
 
PI
 
11
7 
N
D
 
N
on
e 
N
o 
2  
N
o 
2  
PC
F3
 
F5
08
de
l/F
50
8d
el
 
9.
3 
M
 
PI
 
N
D
 
96
 
N
on
e 
Ye
s 
N
o 
3  
PC
F4
 
F5
08
de
l/F
50
8d
el
 
12
.5
 
F 
PI
 
10
6 
61
 
A.
 fu
m
ig
at
us
 
N
o 
1  
N
S 
PC
F5
 
F5
08
de
l/F
50
8d
el
 
1.
3 
F 
PI
 
10
3 
N
D
 
N
on
e 
Ye
s 
N
S 
PC
F6
 
F5
08
de
l/F
50
8d
el
 
0.
6 
M
 
PI
 
10
3 
N
D
 
N
on
e 
N
o 
3  
Ye
s 
PC
F7
 
F5
08
de
l/F
50
8d
el
 
12
.2
 
M
 
PI
 
N
D
 
80
 
N
on
e 
N
o 
4  
N
o 
4  
PC
F8
 
F5
08
de
l/F
50
8d
el
 
1.
2 
M
 
PI
 
In
su
ffi
ci
en
t 
N
D
 
N
on
e 
N
o 
4  
N
o 
4  
PC
F9
 
F5
08
de
l/F
50
8d
el
 
3.
9 
M
 
PI
 
98
 
11
7 
N
on
e 
Ye
s 
N
o 
3  
PC
F1
0 
F5
08
de
l/F
50
8d
el
 
5.
9 
F 
PI
 
11
2 
62
 
N
on
e 
Ye
s 
N
o 
3  
PC
F1
1 
F5
08
de
l/F
50
8d
el
 
0.
5 
F 
PI
 
93
 
N
D
 
R
hi
no
vi
ru
s 
Ye
s 
N
o 
1  
PC
F1
2 
F5
08
de
l/F
50
8d
el
 
5.
4 
F 
PI
 
N
D
 
71
 
N
on
e 
Ye
s 
N
o 
5  
PC
F1
3 
F5
08
de
l/Q
49
3X
 
10
.5
 
F 
PI
 
10
5 
95
 
E.
 c
ol
i 
Ye
s 
N
o 
1  
PC
F1
4 
F5
08
de
l/1
13
8i
ns
G
 
15
.3
 
M
 
PI
 
10
4 
87
 
N
on
e 
N
o 
1  
Ye
s 
PC
F1
5 
F5
08
de
l/F
50
8d
el
 
4.
3 
M
 
PI
 
N
D
 
81
 
H
. i
nf
lu
en
za
e,
  
A.
 fu
m
ig
at
us
 
Ye
s 
N
o 
5  
PC
F1
6 
F5
08
de
l/F
50
8d
el
 
3.
3 
M
 
PI
 
91
 
N
D
 
N
on
e 
N
o 
6  
N
o 
6  
 
 77 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
PC
F1
7 
F5
08
de
l/F
50
8d
el
 
10
.2
 
M
 
PI
 
11
8 
10
4 
N
on
e 
N
o 
6  
N
o 
6  
PC
F1
8 
F5
08
de
l/F
50
8d
el
 
2.
3 
F 
PI
 
10
6 
N
D
 
N
on
e 
N
o 
1  
Ye
s 
 
PC
F1
9 
F5
08
de
l/F
50
8d
el
 
10
.3
 
F 
PI
 
N
A 
66
 
Ac
hr
om
ob
ac
te
r  
Ye
s 
N
o 
5  
PC
F2
0 
F5
08
de
l/1
15
4i
ns
T 
14
.7
 
M
 
PI
 
N
A 
55
 
N
on
e 
N
o 
2  
N
o 
2  
PC
F2
1 
F5
08
de
l/F
50
8d
el
 
0.
9 
M
 
PI
 
N
D
 
N
D
 
N
on
e 
N
o 
1  
N
o 
1  
PC
F2
2 
F5
08
de
l/F
50
8d
el
 
11
.4
 
F 
PI
 
N
D
 
98
 
P.
 a
er
ug
in
os
a,
 
A.
 fu
m
ig
at
us
 
N
o 
1  
Ye
s 
PC
F2
3 
F5
08
de
l/2
89
6d
el
A 
5.
7 
F 
PI
 
11
2 
10
0 
M
yc
ob
ac
te
riu
m
 
m
ar
as
ce
ns
 
Ye
s 
Ye
s 
PC
F2
4 
F5
08
de
l/R
75
1L
 
6.
4 
M
 
PS
 
74
 
? 
B.
 c
ep
ac
ia
 
N
o 
1  
Ye
s 
PC
F2
5 
F5
08
de
l/F
50
8d
el
 
5.
7 
M
 
PI
 
10
3 
86
 
N
on
e 
Ye
s 
Ye
s 
PC
F2
6 
F5
08
de
l/G
54
2X
 
5.
3 
M
 
PI
 
99
 
67
 
N
on
e 
Ye
s 
N
o 
6  
PC
F2
7*
 
F5
08
de
l/F
50
8d
el
 
3.
2 
F 
PI
 
10
3 
N
D
 
N
on
e 
N
o 
1  
N
o 
1  
PC
F2
8†
 
F5
08
de
l/F
50
8d
el
 
5.
6 
M
 
PI
 
N
D
 
89
 
M
yc
ob
ac
te
riu
m
 
av
iu
m
 
Ye
s 
 
N
o 
3  
PC
F2
9 
F5
08
de
l/F
50
8d
el
 
4.
6 
F 
PI
 
10
4 
68
 
N
on
e 
N
o 
1  
N
o 
3  
 T
ab
le
 1
1:
 C
lin
ic
al
 d
et
ai
ls
 o
f C
F 
pa
rti
ci
pa
nt
s 
Ab
br
ev
ia
tio
ns
: y
: y
ea
rs
; M
: m
al
e;
 F
: f
em
al
e;
 P
I: 
pa
nc
re
at
ic
 in
su
ffi
ci
en
t; 
PS
: p
an
cr
ea
tic
 in
su
ffi
ci
en
t; 
pr
ed
: p
re
di
ct
ed
; N
A 
: 
no
t a
va
ila
bl
e;
 N
D
: n
ot
 d
on
e;
 N
S:
 n
ot
 s
am
pl
ed
 (t
ec
hn
ic
al
 re
as
on
s)
. R
el
ev
an
t m
ic
ro
bi
ol
og
y 
in
di
ca
te
s 
re
su
lts
 fr
om
 s
pu
tu
m
 
or
 c
ou
gh
 s
w
ab
s 
ta
ke
n 
be
fo
re
 b
ro
nc
ho
sc
op
y.
  *
 S
am
e 
do
no
r a
s 
PC
F5
. †
 S
am
e 
do
no
r a
s 
PC
F1
5.
 R
ea
so
ns
 fo
r c
ul
tu
re
 
fa
ilu
re
: 1
 fa
ilu
re
 d
ur
in
g 
AL
I p
ha
se
; 2
 lo
w
 b
ru
sh
in
g 
yi
el
d;
 3
 c
ul
tu
re
 in
fe
ct
io
n;
 4
 s
us
pe
ct
ed
 to
xi
ci
ty
; 5
 p
ro
bl
em
s 
w
ith
 c
el
l 
at
ta
ch
m
en
t; 
6 
un
de
te
rm
in
ed
 c
au
se
. 
 78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sa
m
pl
e 
D
ia
gn
os
is
 
A
ge
 
(y
) 
Se
x 
Sw
ea
t t
es
t 
(m
m
ol
/L
) 
FE
V 1
   
   
   
   
   
   
 
(%
 p
re
d)
 
R
el
ev
an
t 
m
ic
ro
bi
ol
og
y 
PN
EC
 
su
cc
es
s 
PB
EC
 
su
cc
es
s 
PW
T1
 
R
ec
ur
re
nt
 c
he
st
 in
fe
ct
io
ns
 
2.
0 
M
 
N
D
 
N
D
 
N
on
e 
Ye
s 
N
o 
1  
PW
T2
 
R
ec
ur
re
nt
 c
he
st
 in
fe
ct
io
ns
 
an
d 
w
he
ez
e 
1.
7 
F 
N
D
 
N
D
 
N
on
e 
Ye
s 
N
o 
1  
PW
T3
 
R
ec
ur
re
nt
 c
he
st
 in
fe
ct
io
ns
 
an
d 
tra
ch
ei
tis
 
7.
9 
M
 
N
D
 
11
0 
N
D
 
N
o 
2  
Ye
s 
 
PW
T4
 
R
ec
ur
re
nt
 c
he
st
 in
fe
ct
io
ns
 
5.
6 
F 
N
D
 
N
D
 
N
D
 
Ye
s 
N
S 
PW
T5
 
R
ec
ur
re
nt
 c
he
st
 in
fe
ct
io
ns
 
an
d 
w
he
ez
e 
3.
3 
F 
N
D
 
N
D
 
N
D
 
N
o 
1  
N
o 
1  
PW
T6
 
R
ec
ur
re
nt
 w
he
ez
e 
7.
5 
F 
N
D
 
N
D
 
N
D
 
Ye
s 
Ye
s 
PW
T7
 
R
ec
ur
re
nt
 c
he
st
 in
fe
ct
io
ns
 
1.
8 
M
 
N
or
m
al
 
N
D
 
N
on
e 
N
o 
2  
Ye
s 
PW
T8
 
R
ec
ur
re
nt
 w
he
ez
e 
an
d 
tra
ch
ei
tis
 
3.
1 
F 
N
or
m
al
 
N
D
 
N
D
 
Ye
s 
Ye
s 
 
PW
T9
 
R
ec
ur
re
nt
 w
he
ez
e 
0.
9 
M
 
N
or
m
al
 
N
D
 
N
on
e 
Ye
s 
Ye
s 
PW
T1
0 
R
ec
ur
re
nt
 c
he
st
 in
fe
ct
io
ns
 
an
d 
w
he
ez
e 
2.
8 
F 
N
or
m
al
 
N
D
 
N
on
e 
N
o 
3  
Ye
s 
PW
T1
1 
R
ec
ur
re
nt
 c
he
st
 in
fe
ct
io
ns
 
2.
3 
M
 
N
or
m
al
 
N
D
 
N
D
 
Ye
s 
Ye
s 
 
PW
T1
2 
R
ec
ur
re
nt
 c
he
st
 in
fe
ct
io
ns
 
0.
8 
M
 
N
D
 
N
D
 
R
SV
 
N
o 
6  
N
o 
6  
PW
T1
3 
R
ec
ur
re
nt
 c
he
st
 in
fe
ct
io
ns
 
3.
3 
M
 
N
or
m
al
 
N
D
 
N
D
 
Ye
s 
N
o 
1  
 79 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PW
T1
4 
R
ec
ur
re
nt
 c
he
st
 in
fe
ct
io
ns
 
an
d 
w
he
ez
e 
1.
3 
M
 
N
D
 
N
D
 
N
D
 
N
o 
1  
N
o 
1  
PW
T1
5 
R
ec
ur
re
nt
 c
he
st
 in
fe
ct
io
ns
 
1.
1 
M
 
N
D
 
N
D
 
M
. c
at
ar
rh
al
is
 
N
o 
1  
N
o 
1  
PW
T1
6 
Pe
rs
is
te
nt
 c
ou
gh
 
15
.7
 
F 
N
D
 
10
8 
N
D
 
Ye
s 
 
Ye
s 
PW
T1
7 
R
ec
ur
re
nt
 c
ro
up
 
13
.4
 
M
 
N
D
 
N
D
 
N
D
 
Ye
s 
Ye
s 
PW
T1
8 
Pe
rs
is
te
nt
 c
ou
gh
  
Pe
rs
is
te
nt
 C
XR
 
co
ns
ol
id
at
io
n 
 
3.
8 
F 
N
D
 
N
D
 
N
D
 
N
o 
1  
N
o 
1  
PC
F1
9 
As
th
m
a 
Pe
rs
is
te
nt
 c
ou
gh
  
8.
0 
M
 
N
D
 
11
5 
N
on
e 
N
o 
1  
N
o 
1  
PW
T2
0 
R
ec
ur
re
nt
 c
he
st
 in
fe
ct
io
ns
 
5.
8 
F 
N
or
m
al
 
N
D
 
H
. i
nf
lu
en
za
e 
N
o 
1  
Ye
s 
 
Ta
bl
e 
12
: C
lin
ic
al
 d
et
ai
ls
 o
f n
on
-C
F 
pa
rt
ic
ip
an
ts
  
Ab
br
ev
ia
tio
ns
: y
: y
ea
rs
; M
: m
al
e;
 F
: f
em
al
e;
 p
re
d:
 p
re
di
ct
ed
; N
D
: n
ot
 d
on
e;
 N
S:
 n
ot
 s
am
pl
ed
 (t
ec
hn
ic
al
 re
as
on
s)
. 
R
el
ev
an
t m
ic
ro
bi
ol
og
y 
in
di
ca
te
s 
re
su
lts
 fr
om
 s
pu
tu
m
 o
r c
ou
gh
 s
w
ab
s 
ta
ke
n 
be
fo
re
 b
ro
nc
ho
sc
op
y.
 R
ea
so
ns
 fo
r c
ul
tu
re
 
fa
ilu
re
: 1
 fa
ilu
re
 d
ur
in
g 
AL
I p
ha
se
; 2
 lo
w
 b
ru
sh
in
g 
yi
el
d;
 3  
cu
ltu
re
 in
fe
ct
io
n;
 4  
su
sp
ec
te
d 
to
xi
ci
ty
; 5
 p
ro
bl
em
s 
w
ith
 c
el
l 
at
ta
ch
m
en
t; 
6  u
nd
et
er
m
in
ed
 c
au
se
. 
PW
T1
9 
 80 
Figure 19: Participant demographics  
The age (A) of recruited participants is presented as box plots showing median age ± 
25th and 75th quartiles with whiskers indicating the maximum and minimum values. 
The sex (B) of recruited participants are presented in the bar graphs as percentage 
frequency.  
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3.5 Culture outcomes  
3.5.1 Cell yield from nasal and bronchial brushings 
Methods used for developing paediatric ALI cultures were derived from existing 
procedures within the research group for the culture of adult PBECs isolated from 
bronchoscopic brushings and explanted CF lung tissue (Fulcher et al., 2005, Brodlie 
et al., 2010, Forrest et al., 2005). Nasal cultures had not previously been developed. 
Published literature relating to methods described by other research groups was 
consulted to develop and optimise techniques for airway epithelial sampling in 
Newcastle (McDougall et al., 2008, McNamara et al., 2008, Guo-Parke et al., 2013).   
Cell yield was assessed in 4 CF PBEC and PNEC pairs after brushings were 
harvested. All brushes compared were 2.0 mm in size and calculations were 
corrected for number of brushes used to sample epithelial cells. No differences were 
found in the median cell yield between PNECs and PBECs with 4.5 x104, IQR 2.3 to 
6.7 x104  versus 3.5 x104, IQR 2.1 to 6.8 x104 cells respectively, p=0.89 (Figure 20). 
Figure 20: Cell yield isolated from nasal and bronchial brushings 
The number of cells isolated from 4 CF nasal and 4 bronchial brushings harvested 
from CF participants was assessed using a haemocytometer. All brushes were 2.0 
mm in size. Data is presented as median ±IQR and analysed using the Mann 
Whitney test, p=0.89. 
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3.5.2 Determinants of air liquid interface culture success 
ALI cultures were successful in 13 of 29 (45 %) CF PNECs, 7 of 27 (26 %) CF 
PBECs, 10 of 20 (50 %) non-CF PNECs and 10 of 19 (53 %) non-CF PBECs. Paired 
cultures from the same individual donors were possible in 2 CF donors and 6 non-CF 
donors.  
Culture outcomes and reasons for failure are summarised in Figure 21. Overall 
culture success rate was 42 %, with highest rates in non-CF PBECs of 53 %. During 
the initial stages of culture technique development, predominant reasons for failure 
were either technical or due to culture infection. Paediatric bronchial brushings to 
harvest PBECs had not previously been performed at GNCH. Technical reasons 
occurred early in recruitment (e.g. with donor PCF2) and included an inadequate 
brushing technique leading to low cell yield and subsequent problems with the initial 
expansion stage in tissue culture flasks.  
Culture infection, both from the donor source and environmental contamination, can 
be problematic in cultures derived from CF patients (Garratt et al., 2014). All 7 
incidences of culture infection occurred during the initial submerged expansion 
phase, of which 5 (71 %) occurred in CF PBECs with 1 infection in both CF PNEC 
and non-CF PNECs. Culture media was supplemented with penicillin/streptomycin 
with 18 PBEC and PNEC cultures isolated from the first 10 CF participants. Although 
bacterial infection was not an issue, all infected cultures displayed evidence of fungal 
infection on phase contrast microscopy (Figure 22). 
The source of these infections was most likely due to environmental contamination 
since BAL microbiology from these donors was either bacterial or normal. 
Antimicrobials as detailed in Table 13 were subsequently added to PCF7 and PCF8 
cultures to minimise infection. These antimicrobials are routinely used to culture CF 
PBECs isolated from end-stage diseased explanted lung tissue in the current lab 
environment (Brodlie et al., 2010). However, supplementation in paediatric cultures 
on this occasion resulted in universal cell death. The addition of a commercially 
available antimicrobial, Primocin, for the first 72 hours of culture significantly reduced 
infection rates from 22% prior to its application to 4 % in subsequent CF and non-CF 
cultures without detrimental effects on epithelial cell survival (p=0.01; Chi-squared 
test). 
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Problems with epithelial cell attachment were encountered with all bronchial cultures 
in the early phases of culture development affecting 15 % of CF PBECs overall. This 
difficulty was not evident with PNECs. Despite improvements with brushing 
technique and successful prevention of infection, cells failed to attach to the 
collagen-coated tissue culture flasks, leading to subsequent culture failure. Eventual 
modification of the substratum with the addition of fibronectin and 1 % BSA (as 
outlined in 2.2.3) improved cell attachment. Culture success rates for PBECs were 
re-calculated from the time of substratum modification and shown in Table 14. 
Evidently, there was a more pronounced improvement with CF PBEC culture 
success from 13 % to 42 % after the introduction of BSA/fibronectin. The success 
rate reduced for the non-CF PNECs, however this is likely to reflect the increase in 
culture numbers after this timepoint.  
After the above-mentioned modifications, successful expansion and growth was 
achieved under submerged conditions enabling progression to ALI culture. Failure 
during the ALI phase occurred in 30 – 42 % of all cultures with the greatest incidence 
in non-CF PBECs (Figure 21). 
Despite investigation for the presence of infection and maintenance of optimum 
culture conditions, no obvious explanations were apparent for the causes of ALI 
failure. However, cultures that took longer to reach confluence in the initial 
submerged expansion phase were more likely to fail at ALI as shown in Figure 23 A 
and B. This median time was significantly less in successful PNECs than those that 
failed at any stage of ALI (8.0d, IQR 7.0 to 8.0 versus 9.5d, IQR 8.3 to 12.0, 
p=0.0001) and was also apparent in PBECs (11.5d, IQR 10.0 to 13.3 versus 15.0d, 
IQR 12.3 to 18.6, p=0.008). This suggests that time to confluence is a useful marker 
of ALI culture success and therefore could help with early exclusion of cultures that 
are unlikely to progress during ALI.  
As shown in Figure 23C, median time to confluence in successful non-CF PNECs 
was 8.0d (IQR 7.0 to 9.0) and significantly shorter that non-CF PBECs (11.5d, IQR 
9.5 to 13.5, p=0.03). This difference was also apparent in successful CF cultures 
(PNECs: 7.0d, IQR 6.5 to 8.0 versus PBECs: 11.5d, IQR 10.3 to 135, p=0.01). No 
significant differences were found between cells harvested from the same 
anatomical sites.  
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Figure 21: Outcomes of PNEC and PBEC air liquid interface cultures 
Outcomes were compared in PNECs and PBECs cultures isolated from all non-CF 
and CF participants. These included ALI culture success, culture infection, failing to 
achieve confluence due to low cell yield, poor epithelial cell attachment during initial 
submerged expansion phase, failure during ALI culture, suspected toxicity from 
antimicrobials and finally reasons that were undetermined during the submerged 
expansion phase; n=20 non-CF PNECs, 19 non-CF PBECs, 29 CF PNECs and 27 
CF PBECs.  
 
 
 
 
 
 
 
No
n C
F P
NE
C
No
n C
F P
BE
C
CF
 PN
EC
CF
 PB
EC
0
20
40
60
80
100
Fr
eq
ue
nc
y 
of
 e
ve
nt
 (%
)
Infection 
Failure to achieve confluence
Poor cell attachment
Failure at ALI
Suspected toxicity
Undetermined cause
Successful
 85 
 
Figure 22: Fungal contamination of epithelial culture  
Evidence of fungal contamination of submerged CF PBEC culture during the initial 
expansion phase as visible by phase contrast microscopy. This contaminant has a 
typical fungal appearance with evidence of central spore and surrounding hyphae.  
 
 
Antimicrobial Concentration  
Ceftazidime 128 µg/mL 
Tobramycin 16 µg/mL 
Amphotericin B 4 µg/mL 
Vancomycin 10 µg/mL 
Voriconazole 10 µg/mL 
Table 13: Working concentrations of supplementary antimicrobials used in 
culture growth media 
 
 
 
Hyphae 
 Spore 
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 Non-CF  
n/N (%)  
CF 
n/N (%) 
Pre-modification 
PNEC 
 
2/3 (67) 
 
8/17 (47) 
PBEC 1/3 (33) 2/15 (13) 
Post modification   
PNEC 8/17 (47) 5/12 (42) 
PBEC 9/16 (56) 5/12 (42) 
Table 14: Culture success rates after timepoint of PBEC cell culture 
substratum modification  
Abbreviations: n: number of cultures; N: total number of cultures 
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 Figure 23: Time to reach confluence relative to culture success 
Median time to achieve 80-90 % confluence was assessed in PNEC (A) and PBEC 
(B) submerged cultures in relation to ALI success. Data is presented as median 
±IQR and analysed using the Mann-Whitney test; PNECs: p=0.0001; PBECs; 
p=0.0008); PNECs: n=23 successful; 16 unsuccessful; PBECs: n=14 successful, 12 
unsuccessful. Median time was also assessed according to cell culture type in ALI 
cultures that were successful (C). Data is presented as median ±IQR and analysed 
using the Kruskall Wallis with Dunn’s multiple comparison test; non-CF PNEC versus 
non-CF PBEC: p=0.03; CF PNECs versus CF PBECs: p=0.01; non-CF PNEC: n=10; 
non-CF PBEC: n=10; CF PNEC: n=13; CF PBEC: n=4. 
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3.6 Epithelial characteristics of differentiated paediatric primary nasal and 
bronchial epithelial cultures 
3.6.1 Morphology 
Immediately after brushing collection, clusters of epithelial cells were evident with 
active ciliary beating when viewed under phase contrast microscopy. Figure 24A 
demonstrates a representative image for a PNEC cell cluster the appearance of 
which was the same in harvested PBECs. 
Culture morphology was assessed at regular intervals using phase contrast 
microscopy from submerged to ALI culture to monitor the epithelial appearance. 
After 2 days of submerged growth, cell attachment and growth of epithelial colonies 
were evident in both PBEC and PNEC cultures with similar epithelial morphology 
(Figure 24B and C). 80-90 % confluent submerged PBEC and PNEC cultures shared 
the characteristic ‘cobblestone’ appearance (Figure 25).  
Assessment after 28d ALI revealed a tight epithelial monolayer that was ciliated and 
had evidence of mucus production at the culture surface (Figure 26). 
Ultrastructural assessment of differentiated first passage PBECs and PNECs at 28d 
ALI culture was performed using TEM and confirmed the presence of a 
pseudostratified columnar epithelium comprising of ciliated, mucus-producing and 
basal cells (Figure 27). 
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Figure 24: Phase contrast microscopy image of submerged epithelial cells 
immediately and 2 days after brushing  
Representative image of epithelial cells after brushing collection is shown in A. Small 
colonies of nasal (B) and bronchial (C) epithelial cells are adherent to the collagen 
matrix and undergoing division and formation of epithelial colonies 2 days after 
brushing collection.  
 
Epithelial colony 
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Figure 25: Morphology of confluent submerged airway epithelial cultures 
Representative images of confluent submerged nasal (A) and bronchial (B) epithelial 
monolayers. Epithelial cells were grown to 80-90 % confluency before passage. At 
this stage, the epithelial cells demonstrated the typical “cobblestone” appearance.  
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Figure 26: Representative phase contrast microscopy images of first passage 
PNEC and PBECs at 28d of ALI culture 
Phase contrast images taken of Transwell inserts of PNEC (A) and PBECs (B) at 
28d ALI to demonstrate the cellular morphology with tightly formed epithelial 
monolayers. There is a surface of mucus overlying the epithelia evident in both 
images and more prominent in the PBEC.  
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Figure 27: Assessment of epithelial differentiation of PNECs and PBECs using 
transmission electron microscopy 
The images demonstrate the presence of ciliated (c), mucus producing (m) and 
basal (b) cells in differentiated PNEC (A) and PBEC (B) ALI cultures harvested from 
the non-CF PWT17 donor.  
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3.6.2 Haematoxylin and eosin staining  
H&E tinctorial assessment of paraffin embedded sections of first passage PBEC and 
PNEC ALI cultures after 28d ALI demonstrated differentiated epithelial morphology 
(Figure 28). 
 
Figure 28: Haemaotoxylin and eosin tinctorial assessment of differentiated CF 
PNEC ALI culture 
Paraffin-embedded PNEC culture sections at 28d ALI were stained with H&E to 
demonstrate epithelial morphology and differentiation.  
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3.6.3 Transepithelial electrical resistance measurement 
TEER is the measurement of electrical resistance across a cellular monolayer and is 
a well-recognised technique to provide quantitative functional assessment of 
epithelial monolayer and tight junction integrity (Blume et al., 2010, Srinivasan et al., 
2015). Tight junctions provide adhesive contact between neighbouring epithelia and 
regulate epithelial permeability and polarity (Hartsock and Nelson, 2008). In the 
context of this PhD, it was especially important to monitor TEER in ALI cultures 
designated for the subsequent profiling of ion transport and investigation of 
TMEM16A (as discussed later). In primary airway epithelia, a TEER close to 500 
W.cm2  indicates suitability for in vitro assessment, however a lower limit of 150 
W.cm2  has been acknowledged for application in Ussing chamber experiments (Lin 
et al., 2007, Fulcher et al., 2005). On review of the literature, practically cultures are 
deemed suitable for use at values above 300 - 400 W.cm2 (Guo-Parke et al., 2013, 
Tosoni et al., 2016). 
TEER measurements of first passage PNEC and PBEC ALI cultures were made 
weekly (where possible) as previously described Chapter 2 section 2.3.1. All cultures 
demonstrated TEER increases over time, with peak values generally reached at 28d, 
(mean TEER of 459 – 1629 W.cm2). Significant changes were seen in all cultures at 
28d compared with 21d ALI (Figure 29). PNEC cultures also showed significant 
differences at 21d. As shown in Figure 30, the overall mean TEER measurement 
was higher in CF PNECs and significantly greater at 21 and 28 d ALI than in CF 
PBECs (21d ALI: 1514 W.cm2 ± SD 698 versus 766 W.cm2 ± SD 221, p=0.02; 28d 
ALI: 1629 W.cm2 ± SD 674 versus 896 W.cm2 ± SD 294, p=0.02) and non-CF PNECs 
(21d ALI: 738 W.cm2 ± SD 9, p=0.005; 28d ALI: 848 W.cm2 ± SD 276, p=0.005).  
Further comparisons were made between paired CF and non-CF cultures isolated 
from the same donor (Figure 31). In parallel with the grouped analysis, TEER in CF 
PNECs was significantly greater than the PBEC counterpart, but this significance 
was also apparent at 7 and 14d ALI. Furthermore, TEER was significantly greater in 
non-CF PNECs at all stages of ALI in comparison to their paired PBEC counterparts. 
The lack of significance in the grouped non-CF analysis may be attributable to the 
overall variability of TEER in these groups. 
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Figure 29: Transepithelial resistance measurement in differentiated paediatric 
PNEC and PBECs derived from non-CF and CF donors 
Chopstick electrode measurements of transepithelial resistance (TEER) using an 
epithelial voltohmmeter (WPI) in first passage ALI non-CF PNECs (A), non-CF 
PBECs (B), CF PNECs (C) and non-CF PBECs (D). Each point represents the mean 
TEER reading for each culture. Data is presented as mean ± SD and analysed with 
one-way ANOVA with post hoc Bonferroni’s multiple comparison test, non-CF PNEC: 
7d v 21d p=0.004, 7d v 28d p=0.0005; non-CF PBEC: 7d v 28d p=0.01; CF PNEC: 
7d v 21d p=0.004, 7d v 28d p=0.001; CF PBEC: 7d v 28d p=0.02. The range of n 
numbers at each timepoint are as follows: non-CF PNECs: 2-8; non-CF PBECs: 1-5; 
CF PNECs: 5-13; CF PBECs: 2-6.  
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Figure 30: Comparison of transepithelial resistance measurements 
Comparisons of TEER measurements were made at 7d (A), 14d (B), 21d (C) and 
28d (D) ALI. Each point represents the mean TEER reading for each culture. Data is 
presented as mean ±S.D and analysed using one-way ANOVA with post hoc 
Bonferroni’s multiple comparison test;  * p=0.02, ** p=0.005 for C and D.  
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Figure 31: Transepithelial resistance assessment in paired PNEC and PBEC 
cultures 
Weekly transepithelial resistance (TEER) measurements were compared in paired 
non-CF (A) and CF (B) PNECs and PBECs. Lines represent the mean TEER ± SD. 
Data analysed using unpaired t-test; ***p<0.001, ****p<0.0001.  
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3.6.4 Tight junctional proteins 
Tight junctions are comprised of transmembrane occludin and claudin proteins, and 
cytoplasmic scaffolding proteins such as ZO-1, which provide connections between 
transmembrane and cytoplasmic proteins (Hartsock and Nelson, 2008). To further 
investigate the localisation of tight junctions in first passage ALI cultures, the 
presence of ZO-1 was investigated by immunofluorescence as demonstrated in 
Figure 32. Further evidence of tight junctional formation was confirmed by SEM as 
shown in Figure 33.  
E-cadherin, a member of the cadherin transmembrane protein family, is required for 
the initiation and assembly of tight junction formation (Contreras et al., 2002). Tight 
junctional composition is regulated by the epithelial cell adhesion molecule (EpCAM) 
through its effects on claudin intra-cellular localisation and degradation (Wu et al., 
2013). To determine variations in epithelial integrity between CF and non-CF nasal 
and bronchial cultures, mRNA expression profiles for CDH1, the gene encoding E-
cadherin, ZO-1 and EpCAM were investigated in first passage cultures at 28d ALI 
using RT-qPCR. Calculated 2-ΔCT values were used to represent the relative fold 
change of gene expression for each group assessed as shown in Figure 34. No 
differences with ZO-1 and CDH1 expression were found in all 4 groups.  
EpCAM expression was increased in PBECs versus PNECs in both non-CF (7.4-
fold) and CF groups (3.6-fold). Furthermore, EpCAM expression was increased by 
12.6-fold in CF PBECs versus non-CF PBECs and by 8.4-fold in CF PNECs versus 
non-CF PNECs. However, no statistically significant differences were found between 
2-ΔCT values for each group (Figure 35).  
These results suggest that no differences in ZO-1 and CDH1 expression were 
evident at the mRNA level, between both non-CF and CF nasal and bronchial 
cultures. EpCAM expression was upregulated in PBECs versus PNECs in each 
disease group, but these changes were not significant. There was no correlation of 
gene expression with TEER (Figure 36), suggesting that they were not contributory 
to TEER variations evident in the cultures.  
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Figure 32: Assessment of ZO-1 by immunofluorescence in a PBEC derived 
from a CF donor at 28d of ALI culture 
PBEC cultures derived from the CF PCF22 donor were fixed in 4 % PFA and 
assessed for ZO-1 (green) using immunofluorescence; nuclei stained with DAPI 
(blue). Images below show no secondary and no primary antibody controls. 
No secondary antibody No primary antibody 
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Figure 33: Tight junctions demonstrated by scanning electron microscopy 
Scanning electron microscopy (SEM) image taken of a PNEC ALI culture derived 
from the non-CF PWT1 donor demonstrating location of tight junctions (TJ) and cilia 
(c).  
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Figure 34: Relative gene expression of ZO-1, CDH1 and EpCAM in first 
passage PNEC and PBEC ALI cultures 
ZO-1 (A), CDH (B) and EpCAM (C) expression were assessed in differentiated 
cultures at 28d ALI using RT-qPCR. 2-ΔCT values were calculated to determine 
relative gene expression and complement data for relative fold change. Data is 
displayed as the median ±IQR and analysed with Kruskal-Wallis and post hoc 
Dunn’s multiple comparison test with no statistical differences found; non-CF PNECs 
(n=8), non-CF PBECs (n=8); CF PNECs (n=8), CF PBECs (n=4 for ZO-1; n=3 for 
CDH1 and EpCAM).   
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Figure 35: Relative fold change of ZO-1, CDH1 and EpCAM in first passage 
PBEC and PNEC ALI cultures 
Relative fold changes of ZO-1, CDH1 and EpCAM were assessed in non-CF cultures 
(A), CF cultures (B), nasal cultures (C) and bronchial cultures (D) as assessed by 
RT-qPCR; non-CF PNECs (n=8), non-CF PBECs (n=8); CF PNECs (n=8), CF 
PBECs (n=4).
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Figure 36: Correlation of tight junctional gene expression with transepithelial 
resistance in differentiated PNEC and PBEC ALI cultures 
Spearman correlation analysis was performed for ZO-1 (A), CDH1 (B) and EpCAM 
(C) expression measured by 2-ΔCT with corresponding transepithelial (TEER) 
measurements of each culture taken at 28d ALI. Each point represents values for 
cultures derived from an individual donor. The correlation coefficient (r) was 
calculated whereby r of 1 indicated perfect correlation, 0 is no correlation and -1.0 
refers to perfect inverse correlation; corresponding p values are shown; n=19. 
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3.6.5 The cilial phenotype  
ALI cultures were monitored regularly for the presence of motile cilia by phase 
contrast microscopy. This occurred significantly earlier in PBECs than in PNECs as 
demonstrated in Figure 37 (mean 18d; ± SD 1.8 versus 23d ± SD 3.3, p=0.005).  
Ciliated epithelia were confirmed in PFA-fixed ALI cultures by immunofluorescence 
assessment of a-acetylated tubulin after 28 days of ALI culture.  a-tubulin is a major 
structural component of microtubules and its acetylation is required for microtubule 
stability (Rymut et al., 2013). Motile cilia express a-acetylated tubulin, which is 
widely used as a marker for cilial assessment in airway epithelial cultures (Jain et al., 
2010, Rymut et al., 2013) . The representative image of immunofluorescent staining 
in a non-CF PBEC ALI culture shown in Figure 38 shows evidence of cilia in the 
apical aspect of the differentiated culture in 52 % of surface epithelial cells.  
Cilia are typically membrane bound and contain the axoneme which forms the 
microtubule cytoskeleton (Satir and Christensen, 2007). Axonemes of multi-ciliated 
epithelial cells contain dynein arms whereby nine doublet microtubules surround a 
central pair of microtubules, known as the “9 + 2” dynein formation (Satir and 
Christensen, 2007). SEM and TEM images taken from ALI cultures demonstrate this 
dynein formation, providing further evidence for successful differentiation (Figure 39). 
Comparative assessment of relevant cilial gene expression was performed using RT-
qPCR of mRNA isolated from a cohort of differentiated PNECs and PBEC ALI 
cultures harvested from CF and non-CF donors at 28d ALI. Cilia are generally 
classified into two groups; primary cilia, which are solitary and non-motile, and motile 
cilia, which occur in clusters of 100 to 300 on the surface of apical epithelia (Jain et 
al., 2010). The cilial type changes with differentiation of ALI cultures with an 
abundance of primary cilia during early stages of ALI compared with a shift to a 
predominance of motile cilia in differentiated epithelia (Jain et al., 2010). Expression 
of TUBA1A, which encodes a-acetylated tubulin, was assessed to compliment the 
above immunofluorescence work. Expression of Foxj1, which encodes a 
transcription factor essential for motile ciliated cell differentiation, was also 
investigated in the same cohort of ALI cultures (Yu et al., 2008).   
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Comparative analysis of gene expression in PNECs and PBECs was performed to 
ascertain differences in relation to the nasal and bronchial airway epithelium. Despite 
the upregulation of TUBA1A expression by 6.6-fold and 4.1-fold in CF PBECs 
compared with CF PNECs and non-CF PBECs respectively, there was no significant 
increase in the corresponding 2-ΔCT analysis of relative gene expression (Figure 40 
and Figure 41). There was a 5-fold upregulation in TUBA1A in non-CF PBECs 
versus their PNEC counterparts, but this was not accompanied by a significant 
increase in the corresponding 2-ΔCT analysis of relative gene expression. Foxj1 
expression was increased in non-CF and CF PBECs of 19.8 and 25.3 times 
respectively versus their nasal counterparts. This was accompanied with a significant 
increase in 2-ΔCT in CF PBECs versus CF PNECs (median 0.216 ±IQR 0.19-0.25 
versus 0.013 ±IQR 0.002-0.05, p=0.05) and non-CF PNECs (0.003 ±IQR 0.001-0.01, 
p=0.006). Interestingly, there was a suggestion of Foxj1 upregulation in non-CF 
versus CF cultures in both nasal (5.8-fold) and bronchial (12.8-fold) groups, but 
these were not significant. These results suggest a predominance for Foxj1 
expression in PBECs. Given the role of Foxj1 for motile cilia development, this 
finding may reflect anatomical variations in cilial phenotypes and role in mucociliary 
clearance in the bronchial epithelium.  
No significant differences were found in TUBA1A expression in CF cultures 
compared with non-CF cultures. Interestingly Foxj1 was upregulated in CF PBECs 
compared with all PNECs. 
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Figure 37: Observed time for motile cilia in differentiated PNEC and PBEC ALI 
cultures 
Differentiated PNEC and PBEC ALI cultures were monitored daily for the detection of 
motile cilia with phase contrast microscopy. This occurred significantly earlier in non-
CF PBECs versus PNECs. Each point represents cultures derived from an individual 
donor. Data is presented as mean ± SD and analysed using the unpaired t test; 
**p<0.01, n=7 for each culture type.  
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Figure 38: Immunofluorescent detection of a-acetylated tubulin in non-CF 
PBEC ALI culture 
Representative image of a PBEC derived from a non-CF donor that was fixed in 4 % 
PFA after 28d ALI and assessed for a-acetylated tubulin (red) presence at the apical 
surface of epithelial cells. Nuclei are stained with DAPI (blue). The lower images 
represent no secondary and no primary antibody controls. 
 
No secondary antibody No primary antibody 
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Figure 39: Assessment of cilia ultra-structure in PNEC cultures using electron 
microscopy  
Transmission (A and B) and scanning (C) electron microscopy images demonstrate 
the presence of cilia (c) and structure at the apical surface of differentiated cultures 
at 28d ALI. There is evidence of the characteristic dynein microtubule (MT) formation 
as demonstrated in A and B.  
A 
C 
B 
MT 
c 
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Figure 40: Relative gene expression of TUBA1A and Foxj1 in PNEC and PBEC 
ALI cultures 
TUBA1A (A) and Foxj1 (B) expression were assessed in differentiated cultures at 
28d ALI using RT-qPCR. 2-ΔCT values were calculated to determine relative gene 
expression and complement the data for relative fold change and provide statistical 
comparisons. Each point represents cultures derived from individual donors. Data is 
displayed as the median ±IQR and analysed with Kruskal-Wallis with post hoc 
Dunn’s multiple comparison test; **p=0.005, *p=0.05; non-CF PNECs (n=8), non-CF 
PBECs (n=8); CF PNECs (n=8), CF PBECs (n=4).   
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Figure 41: Relative fold change of TUBA1A and Foxj1 in PNEC and PBEC ALI 
cultures 
Relative fold changes of TUBA1A and Foxj1 expression were compared in non-CF 
cultures (A), CF cultures (B), nasal cultures (C) and bronchial cultures (D) as 
assessed by RT-qPCR; non-CF PNECs (n=8), non-CF PBECs (n=8); CF PNECs 
(n=8), CF PBECs (n=4); *p=0.05 (refers to the corresponding 2-ΔCT analysis in Figure 
40). 
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3.6.6 The mucus phenotype  
It was possible to visualise mucus production on the surface of ALI cultures with the 
naked eye and on phase contrast microscopy (Figure 42A). To further confirm this, 
first passage ALI cultures were stained with Periodic acid-Schiff’s stain to 
demonstrate the presence of glycoproteins and with the addition of Alcian Blue to 
confirm this as acidic mucin glycoproteins (Figure 42B and C).  
MUC5AC and MUC5B are the predominant gel-forming mucins secreted in airway 
epithelial cells. Concentration of MUC5AC in apical washings harvested from 
differentiated ALI cultures at 28d ALI was investigated by indirect ELISA (Figure 43). 
Final concentrations were corrected for the dilutional factor taking into account the 
predicted volume of the ASL (10 µL) relative to the volume used for apical washing 
(Harvey et al., 2011). Concentrations were lowest in non-CF PNECs (median 65.1 
µg/mL, IQR 46.5 to 93.7) and although higher concentrations were evident in non-CF 
PBECs (165.9 µg/mL, IQR 127.4 to 172.3), this difference was not significant 
(p=0.23). The highest median concentration of MUC5AC was evident in CF PBECs 
(343.2 µg/mL, IQR 236.5 to 368.2), which was significantly greater than the 
concentration in CF PNECs (68.3 µg/mL, IQR 38.8 to 148.8, p=0.03). Comparisons 
in paired PBEC and PNECs isolated from the same donors suggested higher 
MUC5AC concentrations in PBECs in both CF and non-CF cultures (non-CF PBEC: 
155.2  ±24.3 versus non-CF PNEC: 46.0 µg/mL ± SD 12.1; CF PBEC 343.2 ± SD 
15.4 versus CF PNEC: 90.9 ± SD 75.4), however statistical analyses were not 
possible due to the low donor numbers (Figure 43). 
MUC5AC and MUC5B mRNA expression was also assessed in ALI cultures using 
RT-qPCR (Figure 44). No significant differences were found with either MUC5AC or 
MUC5B expression in CF and non-CF cultures in both PBECs and PNECs.  
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Figure 42: Mucus production by differentiated ALI cultures  
Phase contrast appearance of ALI cultures (A) with secretory droplets and mucus 
material overlying the surface of the epithelial monolayer. Paraffin-embedded ALI 
sections were stained with Periodic-acid Schiff’s (PAS) reagent (B) to demonstrate 
glycoprotein presence as shown by the magenta staining localised to the apical 
epithelium and mucus secreting cells. PAS staining with Alcian Blue (C) confirmed 
the presence of acidic mucin glycoproteins as shown by the blue staining. 
 
A 
B 
C 
  113 
Figure 43: Concentration of MUC5AC in PNEC and PBEC ALI cultures 
An indirect ELISA was performed to compare the concentration of MUC5AC in apical 
washings harvested from first passage ALI cultures at 28d ALI (A). Data is presented 
as mean ±S.D. and analysed using Kruskal-Wallis and Dunn’s multiple comparison 
test; *p=0.03; non-CF PNECs n=8, non-CF PBECs n=3, CF PNECs n=5, CF PBECs 
n=4. Measurement of MUC5AC concentration in paired PBECs and PNECs isolated 
from the same donor, which are colour matched (B); n=3 non-CF donors, n=2 CF 
donors (statistical analysis not performed). 
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Figure 44: Relative gene expression of MUC5AC and MUC5B in PBEC and 
PNEC ALI cultures 
MUC5AC (A) and MUC5B (B) expression were assessed in differentiated cultures at 
28d ALI using RT-qPCR. 2-ΔCT values were calculated to determine relative changes 
in gene expression. Data is displayed as the median ±IQR. and analysed with 
Kruskall Wallis and Dunn’s multiple comparison test with no statistical differences 
found; non-CF PNECs (n=7), non-CF PBECs (n=8); CF PNECs (n=8), CF PBECs 
(n=3).   
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3.6.7 The nasal and bronchial airway inflammatory profile  
The airway inflammatory environment of children with CF is abnormal with increasing 
levels of IL-8 found previously in infants and inflammation recognised to occur early 
in life (Khan et al., 1995a, Pillarisetti et al., 2011). Other cytokines including IL-17A, 
IL-6 and IL-4 have been elevated in BAL and serum isolated from CF patients (Tan et 
al., 2011, Nixon et al., 1998, Bergin et al., 2013). 
In this study, BAL samples were obtained from 16 non-CF and 12 CF participants. Of 
all 28 samples, 59 % BALs were obtained from the right middle lobe, 26 % the left 
lower lobe, 11 % the right lower lobe and 4 % from the left lingula. In all cases, 10mL 
of normal saline was instilled into the bronchoscope for lavage. The mean 
percentage return was 27 %, with a median return of 2.3mL (range 0.2 to 6.0mL). 
BAL supernatants were processed as described in Chapter 2 Methods section 2.4.3 
and utilised for the investigation of the inflammatory profile of recruited participants.  
As previously described in Chapter 2 section 2.4.3, MSD technology was used to 
investigate a panel of cytokines using the V-PLEX (IL-17A, IL-6, IL-1b, TNF-a, IFN-g,   
IL-14, IL-13) and U-PLEX (IL-8) ELISA-based assays.  
The results are shown below in Figure 45 and Table 15 and are presented as the 
concentration of mediator per mL of BAL aspirate. Where cytokine levels were below 
the lower limit of detection a value equating to 50 % of the lower limit of detection 
value was assigned. Significantly greater levels of the following cytokines were found 
in CF versus non-CF BAL: IL-1b (p=0.04), IL-17A (p=0.007), IFN-g (p=0.006), TNF-a 
(p=0.001), IL-6 (p=0.04); IL-4 (p=0.01) and IL-13 (p=0.001). No differences were 
evident with IL-8 (p=0.6) between the two groups.  
Further subgroup analysis was performed to determine any relationship between 
BAL culture status and cytokine concentration. BAL microbiology culture results are 
shown in Table 16 with 75 % and 69 % of CF and non-CF showing positive results 
respectively. BAL cultures in each non-CF and CF groups were assigned as either 
culture positive or negative and comparisons were made for each cytokine (Figure 46 
and Figure 47). Significant differences were found for IL-1b (p=0.003) and TNF-a 
(p=0.01) in the non-CF groups. Differences were not significant for any of the 
cytokines assessed in CF cultures between culture negative and positive samples. 
However, there was a suggested increase in IL-4, IL-13, IL-8, IL-17A and TNF-a in 
CF BAL culture positive samples.  
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This cytokine panel was also assessed in cell culture supernatants harvested from 
PNEC and PBEC cultures at 28d ALI to ascertain any relationship with the BAL data. 
ALI cell culture supernatants were harvested and the cytokine panel above was 
assessed as previously described. No significant differences were found with any of 
the cytokines assessed (Figure 48 and Table 17). Corresponding p values for 
statistical analyses performed are shown in Table 18. There was a suggested 
increase in levels of IL-17A and IL-1b in PBEC versus PNEC cultures in both non-CF 
and CF groups, however, these findings were not significant. Furthermore, the 
median IL-6 level was greatest in CF PBECs, but again this was not significant. 
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Figure 45: Inflammatory profile of bronchoalveolar lavage supernatants 
The Meso Scale Discovery U-Plex assay was used to analyse IL-17A, IL-6, IL-1b, 
TNF-a, IFN-g, IL-4 and IL-13 in BAL supernatants as described. The V-Plex assay 
was used to analyse IL-8. Points represents individual donors; red points are values 
< lower limit of detection. Bars represent median ± IQR. Data analysed with Mann-
Whitney test; p values are shown in Table 15; non-CF: n=16; CF: n=12. 
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Cytokine Non-CF BAL CF BAL p value 
IL-8 
 
3244 
(1232 - 7409) 
5073 
(1055 - 7571) 
0.6 
IL-17A 
 
1.1 
(1.1 - 4.8) 
8.5 
(3.3 - 19.3) 
0.002 
IL-6 3.2 
(1.7 - 9.6) 
9.9 
(5.2 - 27.7) 
0.04 
IL-1b 
 
4.8 
(0.5 - 37.2) 
59.6 
(3.4 - 19.3) 
0.04 
TNF-a 
 
1.3 
(0.2 - 9.5) 
23.5 
(5.0 -  79.4) 
0.002 
IFN-g 
 
2.5 
(1.3 - 8.2) 
11.8 
(5.1 - 80.3) 
0.006 
IL-4 0.2 
(0.06 - 0.4) 
0.8 
(0.4 - 1.4) 
0.003 
IL-13 1.6 
(1.6 - 4.8) 
7.1 
(3.7 - 9.2) 
0.001 
Table 15: Cytokine concentrations in bronchoalveolar lavage supernatants 
Abbreviations: BAL: bronchoalveolar lavage; IL interleukin; TNF tumour necrosis 
factor; IFN interferon. 
 Values are expressed as median ±IQR; units are pg/mL.  Data analysed using Mann 
Whitney test and corresponding p values are shown; non-CF: n=16; CF: n=12. 
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CF BAL Microbiology Non-CF 
BAL 
Microbiology 
PCF15 Mycobacterium spp. PWT1 E. coli 
PCF16 M. catarrhalis PWT2  
 
No growth 
PCF17 Achromobacter  PWT3 
 
H. influenza 
PCF18 
 
No growth PWT4 M. catarrhalis 
PCF19 
 
Mycobacterium spp. PWT5 No growth 
PCF20 
 
Proteus mirabilis  PWT6 No growth 
PCF21 No growth PWT7 H. influenza 
PCF22 A. fumigatus PWT8 H. influenza,        
M. catarrhalis 
PCF24 No growth PWT9 H. influenza 
PCF25  P. aeruginosa PWT10 No growth 
PCF26 H. influenza PWT11 M. catarrhalis, 
MRSA 
PCF27  Aspergillus fumigatus PWT12 K. pneumonaie 
  PWT13  H. influenza,        
K. pneumonaie 
  PWT14 H. influenza 
  PWT18 H. influenza 
  PWT19 No growth 
Table 16: Microbiology culture of bronchoalveolar lavage samples 
Microbiology culture results of bronchoalveolar lavage (BAL) samples harvested for 
cytokine analysis.  
  120 
Figure 46: Assessment of cytokine profiles in culture negative and positive 
non-CF bronchoalveolar lavage supernatants 
Concentrations of IL-8, IL-17A, IFN-g, TNF-a, IL-1b, I  L-6, IL-4 and IL-13 were 
compared in non-CF BAL supernatants as described to enable comparisons between 
culture negative and positive samples. Bars represent median ± IQR. Data analysed 
with Mann-Whitney test; p values: IL-8  0.7; IL-17A 0.06; IL-6 0.3, IL-1b 0.003; TNF-a 
0.01; IFN-g 0.07; IL-4 0.05; IL-13 0.3; n=16. 
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Figure 47: Assessment of cytokine profiles in culture negative and positive CF 
bronchoalveolar lavage supernatants 
Concentrations of IL-8, IL-17A, IFN-g, TNF-a, IL-1b, IL-6, IL-4 and IL-13 were 
compared in non-CF BAL supernatants as described to enable comparisons between 
culture negative and positive samples . Bars represent median ± IQR. Data analysed 
with Mann-Whitney test; p values: IL-8  0.3; IL-17A 0.2; IL-6 0.9, IL-1b 0.1; TNF-a 
0.06; IFN-g 0.5; IL-4 0.3; IL-13 0.3; n=12. 
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Figure 48: Inflammatory profile of cell culture supernatants 
ALI cell culture supernatants were harvested from non-CF PNECs (A), non-CF 
PBECs (B), CF PNECs (C) and CF PBECs (D) and IL,8, IL-17A, IL-6, IL-1b, TNF-a, 
IFN-g, IL-4 and IL-13 were assessed as described. Points represents individual 
donors; blue points are values > upper limit of detection. Bars represent median ± 
IQR. Data analysed with Kruskall-Wallis and Dunn’s multiple comparison test with no 
significant differences found; A: n=10; B: n=7; C: n=11; D: n=6. 
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Cytokine Non-CF  
PNEC  
Non-CF 
PBEC 
CF PNEC CF PBEC 
IL-8 
 
19522   
(14630 - 
39043) 
42813  
(10686 - 
48985) 
28181 
(7210 - 
41225) 
35836 
(18342 - 
101948) 
IL-17A 
 
13.1 
(10.2 -18.1) 
18.6 
(7.0 - 23.2) 
13.0 
(10.5 -14.9) 
19.8 
(15.1 - 23.6) 
IFN-g 
 
10.9 
(7.8 - 16.2) 
29.1 
(15.3 - 31.7) 
12.2 
(10.3 - 15.0) 
19.7 
(18.0 - 27.0) 
TNF-a 
 
12.5 
(8.5 - 18.1) 
14.3 
(6.1 - 18.3) 
17.0 
(12.7 - 20.8) 
14.2 
(10.9 - 21.8) 
IL-1b 
 
2.8 
(1.7 - 4.1) 
3.9 
(1.5 - 4.3) 
2.3 
(2.0 - 2.9) 
3.2 
(2.2 - 4.3) 
IL-6 122.4 
(38.8 - 753.1) 
452.8 
(66.8 - 730.1) 
87.6 
(63.6 - 467.5) 
1124 
(715.8 - 2808) 
IL-4 2.7 
(1.8 - 3.4) 
3.1 
(1.8 - 4.1) 
2.3 
(1.2 - 3.1) 
2.6 
(2.5 - 2.9) 
IL-13 14.9 
(12.6 - 15.7) 
16.5 
(7.4 - 17.1) 
14.9 
(11.3 -15.8) 
16.9 
(11.3 - 19.6) 
Table 17: Cytokine concentrations in cell culture supernatants 
Abbreviations: IL interleukin; TNF tumour necrosis factor; IFN interferon. 
Values are expressed as median ±IQR; units are pg/mL. Non-CF PNEC: n=10; non-
CF PBEC: n=7; CF PNEC: n=11; CF PBEC: n=6. 
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Cytokine Non-CF  
PNEC v PBEC 
CF 
PNEC v PBEC 
Nasal 
Non-CF v CF 
Bronchial 
Non-CF v CF 
IL-8 >0.99 >0.99 >0.99 >0.99 
IL-17A >0.99 0.2 >0.99 >0.99 
IFN-g 0.1 0.2 >0.99 >0.99 
TNF-a >0.99 >0.99 >0.99 >0.99 
IL-1b >0.99 0.6 >0.99 >0.99 
IL-6 >0.99 0.1 >0.99 0.9 
IL-4 >0.99 >0.99 >0.99 >0.99 
IL-13 >0.99 0.5 >0.99 >0.99 
Table 18: Statistical comparisons of cell culture supernatant cytokine profiles  
Abbreviations: v versus; IL interleukin; TNF tumour necrosis factor; IFN interferon. 
Data was analysed using the Kruskall-Wallis and Dunn’s multiple comparison test. 
Corresponding p values for each cytokine assessed in each culture group are shown. 
Non-CF PNEC: n=10; non-CF PBEC: n=7; CF PNEC: n=11; CF PBEC: n=6. 
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3.7 Discussion 
3.7.1 Feasibility of establishing a programme to harvest paediatric nasal and 
bronchial brushings 
It can be challenging to establish a new programme for the acquisition of research 
samples within a hospital institution. However, this was achieved through early 
discussions with the clinical paediatric respiratory and CF MDT, the anaesthetic team 
and surgical theatre staff, who were all incredibly supportive and receptive to the 
research process.  
Importantly, the research was discussed with parents and children with CF, to 
establish their overall perception and opinions of parent and participant information 
literature. For the majority of children without CF and some with CF, this has been 
their first exposure to flexible bronchoscopy and therefore a worrying and stressful 
time for parents. Sampling carries a relatively low risk of a small amount of bleeding 
from the brushing site in addition to the risks that are associated with the 
bronchoscopy itself. These are perceived as “low risk” interventions, however, it was 
important to respect parental perception of these associated risks and carefully 
adhere to GCP guidelines for research ethics and consent. Although it was explained 
that the children would not benefit directly from their participation, the parental 
response to their child’s involvement was incredibly receptive. Through this 
experience, I have been overwhelmed by the attitudes of parents and children 
towards this research from both the CF and non-CF groups. 
3.7.2 Challenges faced with the tissue culture process 
The success rates of establishing ALI cultures in this study are comparable to other 
similar studies involving children (Mosler et al., 2008, Garratt et al., 2014). Infection is 
a well-recognised complication of airway epithelial cell culture, particularly in the first 
72 hours (Garratt et al., 2014). In a previous study performed to investigate 
determinants of paediatric CF bronchial culture outcomes, 28.9 % of cultures isolated 
from 260 brushings were infected. 25 % of cultures infected with fungus had relevant 
organisms isolated in corresponding BAL samples (Garratt et al., 2014). In this PhD 
study, rates were appreciably lower with only 7 % of all brushings displaying 
evidence of infection. All infections occurred in the absence of associated BAL fungal 
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microbiology, suggesting environmental contamination as opposed to contaminating 
airway flora.  
The most significant challenges were faced with PBEC development, with lowest 
success rates in CF PBECs. Although type I collagen alone was appropriate for 
paediatric PNEC culture, PBECs required the addition of fibronectin and 1 % BSA to 
promote cell attachment after helpful discussion with colleagues in the tissue culture 
field. This approach was required only during the submerged expansion phase after 
which type I collagen alone was used in all culture inserts to maintain consistency 
with PNECs. Interestingly similar problems with cell attachment in CF culture using 
type 1 collagen alone have been previously reported by another group (Tosoni et al., 
2016).  
This problem was rectified prior to non-CF recruitment, and therefore it cannot be 
ascertained if this was limited specifically to bronchial culture. Type I collagen has 
been used for bronchial epithelial culture in the current lab setting and by other 
research groups (Fulcher et al., 2005, Brodlie et al., 2010, Yaghi et al., 2010, Comer 
et al., 2012). The basement membrane of airway epithelial cells contains type IV 
collagen and laminin in the lamina densa that are secreted by basal epithelial cells, 
below which lies the lamina reticularis composed of type III and IV collagen (Tam et 
al., 2011). Therefore, it is possible that PBECs may have attached better with the use 
of type IV collagen. Further investigation would be required to determine assessment 
of PBEC attachment to type IV collagen compared with type 1.  
Neutrophil elastase is a protease released by neutrophils in the lung and plays a key 
role in the pathogenesis of CF lung disease. It is also implicated in degradation of the 
extracellular matrix by causing specific damage to structural proteins including 
collagen and fibronectin (Janoff et al., 1979, Downey et al., 2009). It is possible that 
this could have hindered epithelial cell attachment in CF PBECs, and additional 
exogenous fibronectin was required to promote adherence. To investigate this 
further, levels of neutrophil elastase and fibronectin production could be investigated 
to determine differences in the effects on the extracellular matrix and epithelial 
attachment in freshly brushed CF and non-CF bronchial and nasal samples. 
Furthermore, although not directly measured, all PBECs were more motile after 
collection due to vigorous cilia activity compared with PNECs, which may have 
further hindered epithelial attachment.   
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There were no clear reasons for failure during the ALI stage of culture, particularly 
after techniques were well established and standardised methods were employed for 
brushing technique, tissue culture equipment, seeding density, culture media and 
substrate choice. Mycoplasma infection is often insidious and associated with culture 
failure but was not present in unsuccessful cultures. Regular monitoring of incubator 
CO2 levels was performed to ensure that incubation conditions were optimally 
maintained.  Although anecdotal, discussions with other research groups regularly 
involved in airway epithelial culture have revealed shared experiences of ALI culture 
failure without apparent reason or isolated cause. Furthermore, there was a distinct 
problem with culture failure associated with specific media batches, however, the 
cause for this problem remains unknown despite liaising with the manufacturer.  
The highest rates of failure at any stage of ALI were in non-CF PBECs. Around two 
thirds of these failed cultures were harvested with the smaller bronchial brush. Lower 
cell numbers require greater time for expansion and in view of the association 
between culture success and time to confluence, it is possible that the lower cell yield 
let to the development of poorer quality, senescent cells and subsequent culture 
failure. Furthermore, utilisation of larger brushes may have yielded more basal 
progenitor cells thereby facilitating subsequent differentiation. Detailed exploration 
into these potential causes would be time and resource intensive. Nevertheless, 
future sampling and culture success could be improved by sampling more than one 
bronchial brushing per participant.  
3.7.3 Epithelial characterisation 
In this chapter, differentiated ALI cultures have been characterised in terms of 
morphology and ability to form polarised epithelial monolayers that display ciliated 
and mucus phenotypes.  
TEER measurements were highest in CF PNECs and although not statistically 
significant and likely limited by sample size, values were almost 2-fold greater in CF 
PBECs compared with non-CF PBECs. However, no apparent differences or 
correlations were found with expression of ZO-1 and other genes involved in 
maintaining epithelial integrity between CF and non-CF cultures. This finding of 
increased CF-related TEER in conjunction with the absence of differences in ZO-1 
has previously been reported in ALI cultures (Sajjan et al., 2004). These authors 
concluded that the overlying mucus layer in CF ALI cultures contributed to higher 
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TEER measurements with reduction of TEER to “non-CF values” after mucus 
removal with 3 % xylitol, which is a mucolytic agent (Sajjan et al., 2004).  
TEER values were also greater in CF nasal cultures compared with their bronchial 
counterparts. There is little reported in the literature regarding direct TEER 
comparisons in CF PBECs and PNECs, however, comparatively high values have 
been reported in other studies involving PNECs (Tosoni et al., 2016).  
Despite maintenance of consistent culture conditions including seeding density of 
epithelial cells there was considerable inter-donor variability in TEER measurements 
at all stages of ALI culture, particularly notable in CF PNECs with over a 4-fold 
difference between minimum and maximum mean values at 28d ALI. TEER 
measurement is temperature dependent with lower values evident at reduced 
temperatures and 37 °C being optimal to closely representative of the in vivo 
environment  (Blume et al., 2010). To assess TEER, PBS was warmed to 37 °C, 
applied to the apical culture surface and incubated at 37 °C for 15 minutes before 
measurements were made. This approach was adopted for all TEER measurements 
to minimise temperature related variation and maintain consistency.  Inter-donor 
variations in TEER have been previously described (Stewart et al., 2012, Tosoni et 
al., 2016). Consideration of these variations will be essential in the interpretation of 
ion transport profiles of cultured cells and the relevant responses to ion channel 
activators and inhibitors.  
Successful ALI cultures were able to differentiate into ciliated epithelial cells. Foxj1 
expression was significantly greater in CF PBECs versus all PNECs. No differences 
were found with non-CF PBECs; however this could be accounted for by the greater 
variability in expression evident in this group. Foxj1 promotes differentiation during 
later stages of ciliagenesis in epithelial cells already committed to cilial phenotypes 
(You et al., 2004). It is possible that greater levels of expression seen in CF PBECs 
could reflect the underlying role of cilial function in lower airways for MCC. However, 
previous studies have shown that ciliary beat frequency is higher in CF nasal versus 
bronchial epithelia (Alikadic et al., 2011).  Furthermore, there is no evidence to 
suggest that there are differences in the percentage of ciliated cells in the two 
epithelial locations and this is supported by similar changes of TUBA1A expression in 
all ALI cultures. Foxj1 is a marker of motility with increased expression at later stages 
of ALI (Jain et al., 2010). In this current study, observed ciliagenesis was determined 
later in PNECs by a mean of 5 days at 23d ALI. Given that gene expression analysis 
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was performed close to this time at 28d ALI, this may have missed later increases in 
Foxj1 expression in PNECs. Analysis may have been better performed at a common 
time point after ciliagenesis as opposed to time in ALI culture to better differentiate 
between PNEC and PBEC expression. These findings could also be complemented 
by investigation of protein expression by immunofluorescence or Western blot 
techniques. 
Although ALI cultures produced mucus, the amount produced and consistency varied 
between cultures. In CF cultures, it was much more adherent to the epithelial surface 
and difficult to remove. This was in contrast to the mucus produced by non-CF 
cultures, which was much easier to harvest. Therefore, it was difficult to make 
accurate direct comparisons of mucus produced by CF and non-CF cultures.  
It has traditionally been challenging to investigate mucin concentrations in biological 
samples predominantly due to their large size and gel-forming characteristics 
(Henderson et al., 2014). As an alternative, apical washings were harvested from 
cultures and direct comparisons of mucin concentration were made using ELISA. 
This technique has previously been recommended for the investigation of mucins in 
airway epithelial cultures (Abdullah et al., 2012). Unfortunately, it was difficult to 
obtain reliable and consistent assessment of MUC5B concentration and this method 
does require further optimisation. MUC5AC was present in all ALI cultures with 
highest concentrations evident in washings harvested from CF PBECs. 
Hypersecretion of mucus is evident in CF lung disease secondary to goblet cell 
hyperplasia (Groneberg et al., 2002, Henderson et al., 2014). Although this was not 
formally assessed in these cultures, this could be a potential explanation for this 
finding.  
RT-qPCR analysis did not reveal any differences in gene expression in all ALI 
cultures. Prior investigation involving non-CF cultures has also shown similar levels 
of MUC5AC and MUC5B in nasal versus bronchial cells (Bernacki et al., 1999). 
However, these findings contradict previous evidence of increased expression in 
tissue harvested from explanted CF lungs (Henderson et al., 2014). Therefore, these 
findings may signify that investigation in ALI cultures does not truly represent 
transcriptional changes evident in vivo which are likely affected by inflammatory 
mediators and insults in the CF airway environment. Furthermore, mRNA expression 
may not truly predict mucus properties of the airway, requiring alternative methods 
for investigation.  
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3.7.4 Assessment of the airway inflammatory environment  
The inflammatory airway environment of non-CF and CF participants was 
investigated by assessing the cytokine profile of BAL supernatants.  Results showed 
significant elevations of IL-17A, IFN-g, TNF-a, IL-1b, IL-6, IL-4 and IL-13 in CF versus 
non-CF BAL supernatants. BAL neutrophil and IL-8 levels have previously been 
shown to be increased in asymptomatic children with CF, including in some children 
without positive respiratory cultures (Khan et al., 1995a). In this present study, IL-8 
levels were elevated in both groups with no significant differences found. An 
important consideration is that the non-CF participants were not a healthy group, with 
problems including recurrent respiratory infections and symptoms of persistent of 
persistent bacterial bronchitis (PBB). In this group 69 % of children had positive BAL 
microbiology (compared with 75 % in the CF group). Elevated IL-8 levels together 
with features of neutrophilic inflammation have been found in BAL isolated from 
children with PBB and non-CF bronchiectasis, indicating that IL-8 elevation is not 
exclusively elevated in the CF airway  (Marchant et al., 2008, Bergin et al., 2013).   
The results found in this present study are in keeping with previous investigation in 
children, which has shown significantly elevated levels of Th1 (IFN-g), Th2 (IL-13) 
and Th17 (IL-17A) and Th17 related cytokines (IL-6) in CF versus non-CF controls 
(Tiringer et al., 2013). These authors also found elevated levels of IL-5 and IL-1b and 
although they did not specifically investigate IL-4, levels of other Th2 cytokines were 
increased (Tiringer et al., 2013). In addition to IL-8, TNF-a, IL-6 and IL-17A are 
involved in modulation of the airway inflammatory response in CF (Taggart et al., 
2000, Bergin et al., 2013, Tiringer et al., 2013). Importantly, the findings by Tiringer et 
al found that of the cytokines investigated in this PhD, IL-17A, IL-6, IL-1b, IL-8 and IL-
13 significantly correlated with high resolution CT changes, with the additional finding 
of IL-17A and its correlation with relevant CF pathogens such as Aspergillus and P. 
aeruginosa (Tiringer et al., 2013). Furthermore, previous investigation in explanted 
CF lung tissue has demonstrated immunoreactivity for IL-17A in lavage specimens, 
with localisation to neutrophil and mononuclear cells, suggesting a role in neutrophil-
mediated inflammation in the CF airway (Brodlie et al., 2011). Although not acutely 
unwell, all CF children in this present study were undergoing clinical bronchoscopy 
for recurrent respiratory symptoms that were not responding to standard antibiotic 
therapy, therefore there was an element of intercurrent respiratory illness in addition 
to chronic inflammatory changes that were part of their disease progression. BAL 
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samples were not comprehensively assessed for cytology and this would have 
complemented the supernatant findings and provided more detail of the airway 
inflammatory environment.  
The same panel of cytokines were assessed in cell culture supernatants that were 
harvested from differentiated PNEC and PBECs at 28d ALI. No differences were 
apparent in all cytokines assessed in the non-CF and CF groups. Supernatants were 
harvested under unstimulated conditions, and the response to relevant stimuli, such 
as clinical P. aeruginosa isolates, was not assessed. This would have been useful to 
determine any parallels with the BAL data. Notably all cytokines measured were 
comparatively higher than the levels found in BAL and the exact cause for this is 
unclear. It is possible that the process of ALI culture or supernatant harvesting 
stimulated inflammatory responses in the epithelia. This could be investigated further 
with detailed exploration of cytokine expression and exploration of relative changes in 
cytokine concentrations to infective stimuli. 
Although BAL cytokine analysis can provide a useful insight into the airway 
inflammatory environment, it is important to acknowledge the challenges faced with 
quantifying solute concentrations in BAL. It may be over-simplistic to assume that the 
aspirated volume of saline provides a representation of the ‘whole’ airway 
environment, particularly in light of recent evidence to suggest that regions are 
differentially affected by disease in CF (Li et al., 2012, Gutierrez et al., 2001). It is 
also difficult to determine how much solute found within the BAL is contained within 
the airway epithelial lining fluid and although this can be overcome by measuring the 
ratio of BAL to plasma solute concentration of urea and albumin, there are limitations 
with these methods and ratios can vary between disease groups (Walters and 
Gardiner, 1991). In this PhD, cytokine concentrations were expressed per mL of BAL 
aspirate. This approach was taken in the absence of matched participant serum 
samples and in view of the consistent approach that was taken with volume of saline 
instilled and techniques used for BAL collection.  
 
 
 
 
 
  132 
3.8 Conclusion 
In this chapter, I have demonstrated the ability to successfully establish a programme 
to culture nasal and bronchial epithelial cells from children with and without CF using 
an ALI technique to produce differentiated epithelial cells. In order to achieve this, it 
was necessary to overcome initial challenges with culture infection, low brushing 
epithelial yield and bronchial attachment in CF PBECs. Future ALI PBEC success is 
likely to be improved by multiple bronchial brush sampling to increase cell yield and 
culture success. 
Although detailed assessment of cilial and mucus phenotypes were not performed in 
cultured cells, the above findings have confirmed the presence of differentiated 
ciliated and mucus producing PNEC and PBEC ALI cultures. These established 
techniques could be utilised to perform more extensive investigation of these 
parameters if required in the future.  
The notable inter-donor variability in TEER may have relevance for the future 
analysis of ion transport profiles in cultured cells and will require recognition and 
careful consideration in analyses performed. However, with these considerations and 
based on the above findings, paediatric PNECs are a suitable experimental model to 
investigate the remaining aims and objectives outlined for this PhD. 
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4 Chapter 4: Functional characterisation of ion transport profiles 
in differentiated paediatric primary nasal and bronchial epithelial 
cultures derived from children with and without cystic fibrosis 
4.1 Introduction 
After having successfully established paediatric PNEC and PBEC ALI cultures and 
verified their epithelial characteristics, the next focus of this PhD was to perform a 
detailed investigation of the ion transport properties of these fully differentiated cells. 
This was important to firstly demonstrate the feasibility of utilising these cultures in 
Ussing chamber experiments and subsequent TMEM16A characterisation, and 
secondly to determine potential differences between PNEC and PBEC cultures.  
Previous studies involving comparisons of PNEC and PBEC paediatric cultures have 
focussed on alternative functional measurements including stimulated cytokine 
responses and epithelial characteristics, however, these have not involved CF 
participants (McDougall et al., 2008, Thavagnanam et al., 2014). Studies assessing 
ion transport profiles in paediatric cultures are limited, with the publication of one 
paper during the compilation of this thesis (Brewington et al., 2018b). These authors 
concluded that paediatric CF PNEC cultures can be utilised in place of PBECs, with a 
particular focus on the utilisation of PNECs to investigate CFTR function and 
response to modulator therapy (Brewington et al., 2018b). Although there is now 
published data relating to this area of CF research, the findings in this PhD will help 
to build on this work. In view of early disease processes that are increasingly 
recognised in children with CF, research involving paediatric cultures is exceptionally 
valuable.  
This chapter will explore the feasibility of using epithelial cultures established in this 
PhD for Ussing chamber experiments and investigate ENaC-mediated sodium 
absorption and chloride secretion by CFTR using this experimental technique.  
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4.2 Hypotheses 
• Differentiated paediatric PNEC and PBEC ALI cultures can be used in Ussing 
chamber experiments to explore the function of ENaC and CFTR. 
• There are no differences in ENaC and CFTR function in paediatric PNEC and 
PBEC ALI cultures therefore validating PNECs as a representative CF research 
model. 
4.3 Aims 
The specific aims of this chapter were to: 
• assess the feasibility of using paediatric differentiated ALI PNEC and PBEC 
cultures in Ussing chamber experiments 
• investigate the function and expression of ENaC and CFTR in paediatric 
differentiated ALI cultures and determine any differences between PNECs and 
PBECs derived from non-CF and CF participants 
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4.4 Results 
4.4.1 Feasibility assessment of paediatric primary air liquid interface cultures 
for the profiling of ion transport  
To determine the suitability of paediatric ALI cultures for analysis of ion transport 
properties, Isc responses were investigated using Ussing chamber experiments as 
described in Chapter 2. Initial work was performed in PNECs due to early challenges 
faced with PBEC culture as described in Chapter 3.  
To ascertain Isc changes over time in ALI culture, responses were monitored from 
28d until 45d ALI in one CF PNEC ALI culture, PCF3N (Figure 49). Although 
performed only once in each monolayer, due to limited availability of culture inserts, 
responses to each reagent were as predicted. Amiloride addition resulted in a 
reduction in Isc due to ENaC inhibition. CFTR activation by forskolin was absent due 
to the isolation of these cultures from a homozygous F508del CF donor. A very small 
response to the CFTR inhibitor, CFTRinh-172, was evident at 27d and 34d ALI. 
Finally, purinergic activation of CaCC by ATP increased Isc. ATP was used in place of 
UTP during this early stage in the PhD. 
Resultant Isc responses to amiloride and ATP are shown in Figure 49. The amiloride-
sensitive Isc reduced over time in ALI culture with the peak response of -4.0 µA/cm2 at 
27d ALI, which had halved by 45d ALI. The ATP-induced Isc was greatest at 34d ALI 
at 16.9 µA/cm2, which reduced to 5.9 µA/cm2 by 45d ALI.  
These results demonstrated the feasibility of using paediatric PNECs to investigate 
Isc responses with expected responses to each reagent. However, there was an 
apparent change in Isc response over time in ALI culture, with peak responses seen 
at 27d and 34d to amiloride and ATP respectively. Responses to both reagents were 
reduced from 41d onwards. Therefore, these findings together with previous TEER 
assessment (as described in Chapter 3) informed the decision to make subsequent 
assessment of Isc responses close to 28d ALI. 
To maximise the usage of culture inserts available for experimental work, it was next 
determined whether repeated Ussing experiments could be performed on the same 
insert after a period of washing in between experiments. After performing the Ussing 
chamber experiment with the apical addition of amiloride, forskolin, CFTRinh-172 and 
UTP as described in Chapter 2, the culture insert was washed in the Ussing chamber 
using a protocol of two additions and removal of Krebs solution to the apical and 
  136 
basolateral compartments, a third addition of Krebs with a 30-minute period of 
gassing and final replacement of Krebs prior to repeating the experiment.  
The effects of this protocol on tight junction integrity were assessed by measuring 
initial TEER before and after washing, as well TEER changes in response to 
amiloride, forskolin, CFTRinh-172 and UTP on a CF PNEC (PCF5N) derived from a 
F508del homozygous participant at 14d and 21d ALI (Figure 50). The initial TEER at 
both 14d and 21d ALI in the first experimental run pre-washing was measured at 
1667 W.cm2. At the end of the first experiment after UTP addition, the TEER was 
recorded at 1250 W.cm2 and 1000 W.cm2 at 14d and 21d respectively. After the 
washing protocol in run 2, TEER was reduced to 625 W.cm2 at 14d ALI and remained 
at 1000 W.cm2 at 21d ALI. Amiloride addition increased TEER in all circumstances 
due to ENaC-mediated inhibition of sodium absorption and a resultant decrease in 
transcellular  conductance. However, the magnitude of this increase was reduced 
after washing at both 14d and 21d ALI, with an increase of 833 W.cm2 at both time 
points in run 1, versus an increase of 208 W.cm2 and 250 W.cm2 at 14d and 21d 
respectively. As predicted, there was no change in response to both forskolin and 
CFTRinh-172 due to a lack of chloride conductance by dysfunctional CFTR at both 
timepoints before and after washing. UTP addition decreased TEER by 1250 W.cm2 
and 1500 W.cm2 at 14d and 21d respectively during the first experimental run due to 
an increase in calcium-activated chloride conductance. However, this TEER 
reduction was less pronounced after washing at both timepoints with no change seen 
at 14d and a reduction of 200 W.cm2 at 21d ALI.  
Overall, these results demonstrated the negative effect of repeated experiments and 
washing on tight junction integrity and the ability to make reliable comparisons using 
the same culture insert. Subsequent Ussing chamber experiments were therefore 
performed at around 28d ALI using fresh culture inserts for each experiment. 
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Figure 49 : Ussing chamber assessment of short circuit current responses 
over time in a CF PNEC culture  
PNEC culture inserts derived from the CF PCF3 donor (F508del/F508del) were 
mounted in an Ussing chamber and bathed apically and basolaterally with a 125mM 
chloride Krebs solution. Short circuit current (Isc) responses to the apical addition of 
amiloride (10 µM), forskolin (10 µM), CFTRinh-172 (20 µM) and ATP (100 µM) were 
assessed at 27d (black), 34d (red), 41d (blue) and 45d (green) of ALI culture and 
shown in A. (There was a delay in amiloride addition at 27d ALI by 1 minute). Peak 
changes in short-circuit current (DIsc) after amiloride and ATP addition at 27d (black), 
34d (red), 41d (blue) and 45d (green) ALI were calculated and represented in B and 
C respectively; n=1 insert for each time point. 
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Figure 50: Effects of culture washing on TEER in Ussing chamber experiments 
in a CF PNEC culture  
PNEC culture inserts derived from the CF PCF5 donor (F508del/F508del) at 28d ALI 
was mounted in the Ussing chamber to assess TEER response to amiloride (10 µM), 
forskolin (10 µM), CFTRinh-172 (20 µM) and UTP (100 µM) at 14d ALI (Run 1) as 
shown in A. After washing the insert, the experiment was repeated to determine the 
effect of washing on TEER in response to individual reagents (Run 2). This was 
repeated at 21d ALI as demonstrated in B. 
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4.4.2 Investigation of epithelial sodium channel expression in differentiated 
paediatric primary airway epithelial cell cultures 
In the airway epithelium, fluid absorption from the ASL is primarily mediated by the 
transport of sodium ions by ENaC at the apical membrane. Amiloride is a potent 
inhibitor of ENaC and can be utilised in electrophysiological studies to investigate 
epithelial ENaC function (Canessa et al., 1994, Mall et al., 1998).  
Ussing chamber experiments were performed to investigate the functional expression 
of ENaC in paediatric differentiated PBEC and PNEC cultures from 25 to 33d ALI. A 
Krebs solution containing 125mM chloride was added to the apical and basolateral 
compartments and maintained at 5 % CO2 and 37°C. After a 15-20 min period to 
enable baseline Isc stabilisation, 10 µM amiloride was added to the apical 
compartment to inhibit ENaC activity. The resultant Isc and TEER were measured as 
described in Chapter 2 section 2.5. 
To exemplify the typical responses to amiloride in non-CF PNEC cultures, 
representative Ussing chamber traces for Isc and TEER responses in PNECs derived 
from a non-CF donor are shown below in Figure 51. The resultant amiloride-sensitive 
Isc and TEER were calculated as described in Chapter 2 section 2.5. In this non-CF 
PNEC culture, apical amiloride addition reduced the Isc by -28.1µA/cm2 due to 
inhibition of ENaC-mediated sodium absorption. As demonstrated in this figure, 
ENaC activity contributed to the majority of the initial resting Isc. This was 
accompanied by a TEER increase of 417 W.cm2 due to a reduction in sodium ion 
conductance.  
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Figure 51: Representative Ussing chamber traces of short circuit current and 
transepithelial electrical resistance in response to amiloride addition in a non-
CF PNEC culture  
A PNEC culture derived from the non-CF PWT17 donor was mounted in the Ussing 
chamber and bathed apically and basolaterally in a 125 mM chloride Krebs solution. 
After a 20-minute period of stabilisation, 10 µM amiloride was added to the apical 
compartment. Resultant short circuit current (Isc) and corresponding transepithelial 
electrical resistance (TEER) were recorded as shown in A and B respectively.  
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4.4.3 Assessment of epithelial sodium channel function  
To determine if there were any functional differences in the amiloride-sensitive Isc 
between PNEC and PBEC cultures isolated from non-CF and CF donors, Ussing 
chamber experiments were performed in 7 non-CF PNEC, 5 non-CF PBEC, 6 CF 
PNEC and 4 CF PBEC cultures from 25 to 33d ALI. Comparisons of the calculated 
amiloride-sensitive Isc obtained from these cultures are shown in Figure 52.  
In non-CF cultures, the amiloride-sensitive Isc was significantly greater in PNECs 
versus PBECs (non-CF PNEC: median -25.2 µA/cm2, IQR -17.1 to -44.9 versus non-
CF PBEC: -7.4 µA/cm2, IQR -4.4 to -9.6, p=0.008). In the non-CF PNEC group, 
cultures isolated from one particular donor demonstrated a large amiloride-sensitive 
current with a mean response of -115.4 µA/cm2 ± SD 2.7. This result likely 
contributed to overall significance seen in differences between these two groups. 
Although there was a 2-fold increase in the amiloride-sensitive Isc in CF nasal versus 
bronchial cultures, this was not statistically significant (CF PNEC: -16.9 µA/cm2, IQR 
-12.8 to -20.7 versus CF PBEC: -8.2, IQR -2.6 to -10.4, p=0.38). Importantly, no 
differences were found in the median amiloride-sensitive Isc in non-CF versus CF 
cultures in both PNEC and PBEC cultures (p>0.99 for both).  
In this PhD study, epithelial cells were harvested from participants with a range of 
CFTR mutations. These mutations are shown relative to the amiloride-sensitive Isc in 
Figure 52. G542X is a class 1 nonsense mutation that fails to produce full-length 
CFTR protein causing loss of channel function (Welsh and Smith, 1993). The 
2986delA mutation is rare and poorly described in the literature, but clinically 
associated with a severe phenotype and pancreatic insufficiency. Therefore, all 
mutations investigated, aside from F508del/R751L, are associated with severe 
effects on CFTR function. With this in mind, the distribution of Isc changes in response 
to amiloride were heterogeneous, with no obvious association with CF-disease 
severity and no effect of CF presence on ENaC expression.  
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Figure 52: Assessment of amiloride-sensitive short circuit current in non-CF 
and CF PNEC and PBEC cultures 
The amiloride-sensitive change in short circuit current (DIsc amiloride) was assessed 
in differentiated PNEC and PBECs at 25 to 33d ALI in Ussing chamber experiments. 
Each point represents the mean amiloride-sensitive Isc for each donor investigated. 
Data is presented as median ± IQR and analysed with Kruskal-Wallis and post hoc 
Dunn’s multiple comparison test; **p=0.009; non-CF PNECs (n=7 donors, 25 inserts), 
non-CF PBECs (n=5 donors, 21 inserts), CF PNECs (n=6 donors, 20 inserts), CF 
PBECs (n=4 donors, 17 inserts). CFTR mutations for each donor are colour-coded as 
shown in the legend. 
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4.4.4 Assessment of epithelial sodium channel subunit expression  
ENaC is composed of three homologous subunits, a, b and g which together form the 
functional channel pore in the apical airway epithelium (Canessa et al., 1994). RT-
qPCR analysis was performed in differentiated paediatric ALI cultures from 25 to 33d 
ALI to determine the relative mRNA expression of each subunit (Figure 53).  
In non-CF cultures, no differences in a-ENaC were apparent in PNECs versus 
PBECs (1.0-fold change ±0.7) as shown in Figure 53A. Overall there was a 2.3-fold 
±2.0 (mean ± SD) increase in b-ENaC expression in non-CF PBECs versus non-CF 
PNECs (Figure 53A). However, there was no significant increase in the 
corresponding 2-ΔCT analysis of relative gene expression (Figure 54B). There was a 
1.5-fold ±1.3 increase in g-ENaC expression in non-CF PBECs versus PBECs 
(Figure 53A), however, the corresponding analysis of 2-ΔCT was not significant Figure 
54C). 
In CF cultures, there was a 1.7-fold ±0.1 increase in a-ENaC expression in CF 
PBECs versus PNECs (Figure 53B). b-ENaC expression was similar in the two 
groups (1.1-fold ±0.2). g-ENaC expression was increased by 2.9-fold ±2.5 in CF 
PBECs versus PNECs. However, again, these were not accompanied by statistical 
changes in gene expression assessed by 2-ΔCT analysis (Figure 54). 
Gene expression and relative fold change analysis of each subunit was also 
performed to determine any differences between CF and non-CF cultures in the 
nasal and bronchial groups. In PNECs (Figure 53C), no differences were found in a-
ENaC expression between CF and non-CF cultures (fold change of 1.0 ±0.8). There 
was a 2.3-fold ±2.0 increase in b-ENaC expression in CF versus non-CF PNECs. g-
ENaC expression was reduced in CF PNECs by 0.6-fold ±0.3 relative to non-CF 
PNECs. There were no significant differences seen in 2-ΔCT analysis of gene 
expression for these comparisons (Figure 54). Assessment in bronchial cultures 
(Figure 53D) suggested increased expression of all three subunits in CF versus non-
CF PBECs: a-ENaC: 1.5 ±0.1, b-ENaC: 1.7 ±0.5 and g-ENaC: 1.6 ±1.4.  However, 
the 2-ΔCT analysis of gene expression for these analyses were not statistically 
significant, potentially attributable to the low sample numbers in the CF group (Figure 
54).  
Overall, the predominant subunit expressed by all ALI cultures was a-ENaC, with g-
ENaC expressed the least (Figure 55). However, there was considerable variability 
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evident in expression of all three subunits in all ALI cultures. To further highlight the 
evidence of this variability between disease and non-disease groups, the fold change 
of each subunit for each individual CF culture relative to the pooled expression for 
non-CF cultures has been presented below for PNECs (Figure 56A) and PBECs 
(Figure 56B).  In the PNEC group, all cultures except PCF15N, PCF23N and 
PCF28N displayed an increase in at least one ENaC subunit expression. Notably, 
there was no consistency in the specific subunit that was elevated amongst CF 
cultures. The cultures which showed either similar or reduced fold changes were all 
isolated from children with severe disease genotypes (F508del/F508del and 
F508del/2896delA). Interestingly, PCF15N and PCF28N were isolated from the same 
F508del/F508del donor but sampled 1 year apart. Although the CF PBEC samples 
available for RT-qPCR investigation were small, it is evident from these 2 cultures 
that there was an increase in ENaC subunit expression in CF versus non-CF PBECs, 
again with variability of specific subunits between the 2 samples.   
To determine any potential relationship of ENaC expression with functional activity, 
the correlation of each subunit with the amiloride-sensitive Isc was investigated in 
differentiated ALI cultures where both experimental techniques were performed.  
Spearman rank correlation assessment of all ALI cultures did not reveal any 
relationship between ENaC subunit expression and amiloride-sensitive Isc  as 
demonstrated in Figure 57 (a-ENaC: r=-0.03, p=0.9; b-ENaC: r=-0.13, p=0.6; g-
ENaC: r=-0.22, p=0.39). Further subgroup analysis of each culture group did not 
reveal any correlations of ENaC subunit mRNA expression with amiloride-sensitive 
Isc (not shown).  
These findings show that in this cohort of ALI cultures, there was no correlation of 
ENaC subunit mRNA expression with functional ENaC assessment as investigated 
by the amiloride-sensitive Isc.  
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Figure 53: Relative fold change of a-ENaC, b-ENaC an  d g-ENaC in all cultures 
Relative fold changes of a-ENaC, b-ENaC and g-ENaC expression were determined 
in PBECs relative to PBECs in non-CF (A) and CF (B) PNEC (black) and PBEC 
(grey) cultures (B) as assessed by RT-qPCR. Comparisons were also made between 
CF relative to non-CF cultures in PNECs (C) and PBECs (D); non-CF PNECs: n=8 
donors. Bars represent mean ± SD; non-CF PBECs: n=8 donors, CF PNECs: n=8 
donors; CF PBECs: n=2 donors.  
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Figure 54: Relative gene expression of a-ENaC, b-ENaC and g-ENaC in all non-
CF and CF PNEC and PBEC cultures 
a-ENaC (A), b-ENaC (B) and g-ENaC (C)  expression were assessed in differentiated 
cultures at around 28d ALI using RT-qPCR. 2-ΔCT values were calculated to 
determine relative gene expression and complement data for relative fold change. 
Data is displayed as the median ±IQR and analysed with Kruskal-Wallis and post hoc 
Dunn’s multiple comparison test; p>0.99 for all comparisons; non-CF PNECs (n=8), 
non-CF PBECs (n=8, n=7 for ENaC-g ); CF PNECs (n=8), CF PBECs (n=2).   
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Figure 55: Log2 fold change of b-ENaC and g-ENaC relative to a-ENaC 
expression in all non-CF and CF PNEC and PBEC cultures 
Relative fold change of b-ENaC and g-ENaC relative to a-ENaC is demonstrated 
above by calculating the log2 fold change of subunits in each culture group. Bars 
represent mean ± SD; non-CF PNECs (n=8), non-CF PBECs (n=8, n=7 for ENaC-g ); 
CF PNECs (n=8), CF PBECs (n=2).   
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Figure 56: Relative fold change of ENaC subunit expression in CF cultures 
Fold change of ENaC subunit expression in each CF PNEC culture was assessed 
relative to the pooled expression of non-CF PNECs as shown in A (n=8 non-CF 
PNECs, n=8 CF PNECs). Fold change of ENaC subunit expression in each CF 
PBEC culture was assessed relative to the pooled expression of non-CF PBECs as 
shown in B (n=8 non-CF PBECs, n=2 CF PBECs).  
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Figure 57 : Correlation of a-ENaC expression with the amiloride-sensitive short 
circuit current  
Spearman analysis of correlation was performed for expression of a-ENaC (A), b-
ENaC (B) and g-ENaC (C) as measured by 2-ΔCT with corresponding assessment of 
amiloride-sensitive short circuit current (Isc) in all CF and non-CF PNEC and PBEC 
cultures. The correlation coefficient (r) was calculated whereby r of 1.0 indicates 
perfect correlation, 0.0 is no correlation and -1.0 refers to perfect inverse correlation; 
n=18. 
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4.4.5 Assessment of epithelial sodium channel function and expression in 
paired primary nasal and bronchial epithelial cultures  
It is possible that the variability in ENaC subunit mRNA expression and function 
across all differentiated ALI cultures could account for the lack of correlation seen. 
Therefore, further detailed investigation of ENaC function and subunit mRNA 
expression was performed in 3 paired PNEC/PBEC cultures isolated from the same 
non-CF donors (Figure 58 to Figure 60) and 2 paired PNEC/PBEC cultures from the 
same CF donors (Figure 61 and Figure 62) to ascertain any potential relationships.  
In the 3 paired non-CF cultures, PWT8, PWT11 and PWT17, the amiloride-sensitive 
Isc was greater in all PNEC cultures versus their PBEC counterparts. This effect was 
greatest in the PWT11 cultures: PNEC: median -33.8 µA/cm2, IQR -29.5 to -36.4 
versus PBEC: -2.7, IQR -2.4 to -3.2; p=0.004 (Figure 59). Increased PNEC Isc 
responses were also statistically significant in PWT8 cultures (PNEC: -43.0 µA/cm2, 
IQR -39.1 to -52.7 versus PBEC: -8.3, IQR -7.5 to -10.1, p=0.03) and PWT17 
cultures (PNEC: -15.1, IQR -12.7 to -22.3 versus PBEC: -10.1, IQR -9.2 to -12.0, 
p=0.02) as shown in Figure 58 and Figure 60 below.  
These changes were accompanied by increased a-ENaC expression in PNECs 
relative to PBEC cultures in all non-CF cultures as demonstrated in Figure 58 
(PWT8), Figure 59 (PWT11) and Figure 60 (PWT17). The resultant percentage 
increase of a-ENaC expression in PNECs was +53 % in PWT8, +22 % in PWT11 
and +22 % in PWT17. In PWT8, this was accompanied by increases in b-ENaC and 
g-ENaC of +58 % and +77 % respectively in PNECs. Findings in all three subunits 
were less cohesive in PWT11 and 17, where expression of g-ENaC decreased in 
PNECs by 4-fold and 2-fold respectively.  
Comparative analysis of the amiloride-sensitive Isc and ENaC expression was also 
investigated in 2 CF paired cultures, PCF23 and PCF25. As evident with the non-CF 
cultures, the amiloride-sensitive Isc was increased in the PCF23 PNECs (Figure 61), 
but this difference was not statistically significant (PNEC: -13.8 µA/cm2, IQR -9.9 to -
19.5 versus PBEC: -10.6, IQR -9.5 to -12.0, p=0.06). Despite this increase in ENaC 
function in PNECs, there was a 1.5 to 3-fold decrease in expression of all three 
subunits. 
In contrast to all other paired cultures, there were no significant differences in the 
amiloride-sensitive Isc in PNECs and PBECs derived from the CF PCF25 donor as 
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shown in Figure 62 (PNEC: -6.4 µA/cm2, IQR -3.9 to -9.0 versus -9.5, IQR -8.4 to -
11.4, p=0.09). This was accompanied by a -76 % decrease in a-ENaC expression 
and increases in b-ENaC and g-ENaC of +25 % and +15 % respectively. 
Overall, these results suggest that in non-CF paired cultures, the amiloride-sensitive 
Isc was consistently significantly greater in PNECs, with a suggestion of increased a-
ENaC mRNA expression. These findings were not evident in all paired CF cultures, 
with variability in patterns of ENaC subunit expression. However, paired analysis was 
only possible in CF cultures derived from 2 donors, and warrants further investigation 
in more donors.    
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Figure 58: Paired assessment of amiloride-sensitive short circuit current and 
ENaC subunit expression in PNEC and PBEC cultures derived from the non-CF  
PWT8 donor  
Ussing chamber traces for PNEC and PBEC cultures at 28 to 30d ALI isolated from 
the non-CF PWT8 donor are shown in A. The lines represent the mean short circuit 
current (Isc) with error bars for the SD (PNEC in black, PBEC in blue). Corresponding 
amiloride-sensitive Isc responses (DIsc amiloride) are shown in B; data is presented as 
median ±IQR and analysed with Mann-Whitney test, *p=0.03; n=4 inserts for each 
culture type. mRNA expression of a (black), b (red) and g-ENaC (green) are shown in 
C.  
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Figure 59: Paired assessment of amiloride-sensitive short circuit current and 
ENaC subunit expression in PNEC and PBEC cultures derived from the non-CF 
PWT11 donor  
Ussing chamber traces for PNEC and PBEC cultures at 28 to 30d ALI isolated from 
the non-CF PWT11 donor are shown in A. The lines represent the mean short circuit 
current (Isc) with error bars for the SD (PNEC in black, PBEC in blue). Corresponding 
amiloride-sensitive Isc responses (DIsc amiloride) are shown in B; data is presented as 
median ±IQR and analysed with Mann-Whitney test, **p=0.004; PNEC: n=5 inserts; 
PBEC: n=6 inserts. mRNA expression of a (black), b (red) and g-ENaC (green) are 
shown in C.  
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Figure 60: Paired assessment of amiloride-sensitive short circuit current in 
PNEC and PBEC cultures derived from the non-CF PWT17 donor  
Ussing chamber traces for PNEC and PBEC cultures at 28 to 30d ALI isolated from 
the non-CF PWT17 donor are shown in A. The lines represent the mean short circuit 
current (Isc) with error bars for the SD (PNEC in black, PBEC in blue). Corresponding 
amiloride-sensitive Isc responses (DIsc amiloride) are shown in B; data is presented as 
median ±IQR and analysed with Mann-Whitney test, *p=0.02; PNEC: n=6 insert for 
each culture type. mRNA expression of a (black), b (red) and g-ENaC (green) are 
shown in C.  
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Figure 61: Paired assessment of amiloride-sensitive short circuit current in 
PNEC and PBEC cultures derived from the CF PCF23 donor  
Ussing chamber traces for PNEC and PBEC cultures at 28 to 30d ALI isolated from 
the CF PCF23 donor (F508del/2896delA) are shown in A. The lines represent the 
mean short circuit current (Isc) with error bars for the SD (PNEC in black, PBEC in 
blue). Corresponding amiloride-sensitive Isc responses (DIsc amiloride) are shown in 
B; data is presented as median ±IQR and analysed with Mann-Whitney test (no 
statistical differences found); n=6 inserts for each culture type. mRNA expression of 
a (black), b (red) and g-ENaC (green) are shown in C.  
0 5 10 15 20 25
0
5
10
15
20
Time (min)
I sc
 (µ
A
/c
m
2 )
Amiloride
PCF23 PNEC
PCF23 PBEC
A
PCF23 PNEC PCF23 PBEC
-25
-20
-15
-10
-5
0
Δ
 I s
c a
m
ilo
rid
e 
(µ
A
/c
m
2 )
B
PCF23 PNEC PCF23 PBEC
0.00
0.01
0.1
0.2
0.3
0.4
EN
aC
 s
ub
un
it 
ex
pr
es
si
on
 (2
- Δ
C
T )
 
α-ENaC
β-ENaC
γ-ENaC
C
  156 
Figure 62: Paired assessment of amiloride-sensitive short circuit current in 
PNEC and PBEC cultures derived from the CF PCF25 donor  
Ussing chamber traces for PNEC and PBEC cultures at 28 to 30d ALI isolated from 
the CF PCF25 donor (F508del/F508del) are shown in A. The lines represent the 
mean short circuit current (Isc) with error bars for the SD (PNEC in black, PBEC in 
blue). Corresponding amiloride-sensitive Isc responses (DIsc amiloride) are shown in 
B; data is presented as median ±IQR and analysed with Mann-Whitney test (no 
statistical differences found); n=6 inserts for each culture type. PBEC: n=6 inserts. 
mRNA expression of a (black), b (red) and g-ENaC (green) are shown in C.  
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4.4.6 Investigation of CFTR channel expression  
Given the importance of CFTR-mediated chloride secretion in the airways, CFTR 
channel function was investigated in paediatric differentiated ALI cultures. This was 
performed firstly to verify the presence and absence of CFTR function in non-CF and 
CF cultures respectively, and secondly to compare PNEC with PBEC responses and 
determine the suitability of PNECs for CF research.  
CFTR-mediated chloride secretion was assessed in paediatric differentiated ALI 
cultures from 25 to 33d ALI in Ussing chamber experiments as described in Chapter 
2. In view of the significant contribution of ENaC to the basal Isc, it was important to 
first inhibit ENaC before exploring CFTR function. Forskolin, an activator of cAMP, 
was applied to the apical compartment of the Ussing chamber to determine its effect 
on CFTR-mediated chloride secretion. After a period of 5 to 10 minutes to enable Isc 
stabilisation, CFTRinh-172 was applied apically for selective CFTR inhibition.  
To exemplify responses to forskolin and CFTRinh-172 on Isc and TEER in non-CF 
cultures, Ussing chamber traces of PBECs isolated from the non-CF PWT8 donor 
are shown in Figure 63. A 125mM chloride Krebs solution was added to the apical 
and basolateral compartments and maintained at 5 % CO2 and 37 °C. After a 20-
minute period to enable basal Isc stabilisation, 10 µM amiloride was added to the 
apical chamber to inhibit ENaC. This decreased Isc by -7.6 µA/cm2 and increased 
TEER by 189.7 W.cm2. Apical addition of 10 µM forskolin resulted in a robust and 
rapid Isc increase of 18.6 µA/cm2 (with an initial peak and eventual plateau) and 
TEER decrease of 174.0 W.cm2. CFTRinh-172 (20 µM) was added apically to inhibit 
CFTR activity, which decreased Isc by -15.6 µA/cm2 and increased TEER by 413.3 
W.cm2. This decline was initially rapid and followed by a more gradual response.  
Forskolin and CFTRinh-172 responses in CF cultures are shown in representative 
Ussing chamber traces from PBECs isolated from the CF PCF23 donor in Figure 64. 
This donor had the F508del/2896delA genotype, resulting in a severe clinical 
phenotype, pancreatic insufficiency and elevated diagnostic sweat chloride of 112 
mmol/L. The mean magnitude of the amiloride-sensitive Isc  was -12.2 µA/cm2 with an 
TEER increase of 148.9 W.cm2. As predicted, responses to CFTR activation and 
inhibition were minimal. Forskolin induced a very small increase in mean Isc of +0.24 
µA/cm2 and a reduction of TEER by 35.3 W.cm2. The response to CFTRinh-172 was 
small, with a change in mean Isc of -0.7 µA/cm2 and no change in TEER.  
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Figure 63: Representative Ussing chamber traces of short circuit current and 
transepithelial electrical resistance responses to forskolin and CFTRinh-172 in a 
non-CF PBEC culture  
A PBEC ALI culture insert derived from the non-CF PWT8 donor was mounted in the 
Ussing chamber and bathed apically and basolaterally in 125 mM chloride Krebs. 
After a 20-minute period of stabilisation, 10 µM amiloride was added to the apical 
compartment to inhibit ENaC. 10 µM forskolin and 20 µM CFTRinh-172 were added 
apically at 25 and 35 minutes respectively.  Resultant short circuit current (Isc) and 
corresponding transepithelial electrical resistance (TEER) were measured as shown 
in A and B respectively. Lines mean responses in 2 inserts with error bars for the SD.  
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Figure 64: Representative Ussing chamber traces of short circuit current and 
transepithelial electrical resistance responses to forskolin and CFTRinh-172 in a 
CF PBEC culture 
A CF PBEC ALI culture insert (PCF23B) was mounted in the Ussing chamber and 
bathed apically and basolaterally in 125 mM chloride Krebs. After a 25-minute period 
of stabilisation, 10 µM amiloride was added to the apical compartment to inhibit 
ENaC. 10 µM forskolin and 20 µM CFTRinh-172 were added apically at 30 and 40 
minutes respectively.  Resultant short circuit current (Isc) and corresponding 
transepithelial electrical resistance (TEER) were measured as shown in A and B 
respectively. Lines mean responses in 2 inserts with error bars for the SD. 
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4.4.7 Assessment of CFTR function  
To determine if there were any differences in Isc responses to forskolin and CFTRinh-
172 between PNEC and PBEC cultures isolated from non-CF and CF donors, Ussing 
chamber experiments were performed in 7 non-CF PNEC, 5 non-CF PBEC, 6 CF 
PNEC and 4 CF PBEC cultures at 25 to 33d ALI. The calculated changes in Isc in 
response to forskolin and CFTRinh-172 are shown in Figure 65. CF donor responses 
have been colour-coded according to genotype.  
In non-CF cultures, no significant differences were found with forskolin-induced Isc 
responses in PNECs versus PBECs (non-CF PNECs: median 14.3 µA/cm2, IQR  13.1 
to 22.1 versus non-CF PBECs: 11.5 µA/cm2, IQR 7.9 µA/cm2 to 23.3, p>0.999). As 
shown in Figure 65, there were no differences in the CFTRinh-172-sensitive Isc  in 
non-CF PNECs versus PBECs (non-CF PNECs: -12.6 µA/cm2, IQR -11.5 to -22.2 
versus -9.7 6 µA/cm2, IQR -7.3 to -15.9, p>0.999). As evident from these results, 
there was considerable inter-donor variability in forskolin and CFTRinh-172 responses 
in both groups.  
In the CF group, no significant differences were found in the forskolin-induced Isc (CF 
PNECs: median 0.05 µA/cm2, IQR 0 to 0.5 versus CF PBECs: median 0.3 µA/cm2, 
IQR 0.2 to 0.3, p>0.999) and CFTRinh-172-sensitive Isc (CF PNECs: median -0.2 
µA/cm2, IQR 0 to -0.3 versus CF PBECs: median -0.4 µA/cm2, IQR -0.2 to -0.5, 
p>0.999). These results indicated no differences between responses to forskolin and 
CFTRinh-172 in this cohort of PNECs and PBECs.  
As expected, comparative assessment in nasal cultures showed significantly greater 
responses to forskolin (p=0.002) and CFTRinh-172 (p=0.001) in non-CF PNECs 
compared with CF PNECs. Interestingly, these differences were not significant in 
non-CF versus CF PBECs (forskolin: p=0.2; CFTRinh-172: p=0.3). There was a 
distinct outlier in the CF PBEC group showing a mean forskolin-induced Isc of 4.4 
µA/cm2 (± SD 4.0) and a CFTRinh-172-sensitive Isc of -5.3 µA/cm2 (±4.8). These 
cultures were derived from a donor with the F508del/R751L genotype (PCF24). 
Removal of this donor from the analysis did not affect the significance when analysed 
with the same statistical test (forskolin: p=0.2; CFTRinh-172: 0.4). Lack of significance 
is most likely explained by the relatively small sample size of the CF PBEC group 
and highlights the need to explore this further in a larger number of donors.  
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Amongst CF PBEC cultures isolated from donors with severe mutations, a small-
forskolin induced Isc was evident ranging from 0.5 to 0.6 µA/cm2 in PNECs and 0.2 to 
0.3 µA/cm2 in PBECs. A small CFTRinh-172-sensitive Isc was also evident in 4 PNECs 
(range -0.2 to -0.4 µA/cm2) and 3 PBECs (-0.2 to -0.5 µA/cm2). A representative 
Ussing chamber trace from a CF PBEC culture (PCF25 donor, F508del/F508del) is 
shown in Figure 66 to exemplify these small responses. Despite these changes in Isc, 
the morphology of the waveform is clearly different to that seen in non-CF cultures 
(Figure 63) with a more gradual increase in forskolin-induced Isc that is rapidly 
inhibited by CFTRinh-172. Within this CF culture group, 4 cultures were isolated from 
F508del homozygous donors and 1 from the participant with F508/2896delA. These 
results suggest that cultures derived from participants harbouring severe disease-
causing mutations can demonstrate residual, albeit small, CFTR functional activity.  
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Figure 65: Assessment of short circuit current responses to forskolin and 
CFTRinh-172 in non-CF and CF PNEC and PBEC cultures 
The forskolin-induced (DIsc forskolin; A) and CFTRinh-172-sensitive (DIsc CFTRinh-172; 
B) changes in short circuit current were assessed in differentiated PNEC and PBECs 
at around 28d ALI culture using Ussing chamber experiments. Each point represents 
the mean DIsc for each donor investigated. Data is presented as median ± IQR and 
analysed with Kruskal-Wallis and post hoc Dunn’s multiple comparison test; A: 
**p=0.002; B: ***p=0.001. Non-CF PNECs (n=7 donors, 25 inserts), non-CF PBECs 
(n=5, 21 inserts), CF PNECs (n=6, 21 inserts), CF PBECs (n=4, 18 inserts). CF 
mutation types are colour coded as presented in the legend.  
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Figure 66: Representative Ussing chamber trace demonstrating residual CFTR 
activity in a CF PBEC culture 
A PBEC ALI culture insert derived from the CF PCF25 donor (F508del/F508del) was 
mounted in the Ussing chamber and the resultant short circuit current (Isc) was 
measured with cells bathed apically and basolaterally in 125 mM chloride Krebs. 
After a 20-minute period of stabilisation, 10 µM amiloride was added to the apical 
compartment to inhibit ENaC. 10 µM forskolin and 20 µM CFTRinh-172 were added 
apically at 25 and 35 minutes respectively.  
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4.4.8 Assessment of CFTR function in paired primary nasal and bronchial 
epithelial cultures  
To further investigate any potential differences in Isc responses to forskolin and 
CFTRinh-172 in PNEC and PBEC cultures, comparative assessments were made in 3 
paired non-CF and 2 paired CF cultures.  
Ussing chamber traces for cultures isolated from the non-CF PWT8 and PWT11 
donors with corresponding calculated Isc responses to forskolin and CFTRinh-172 are 
depicted in Figure 67 and Figure 68. Here the shape of the forskolin-induced Isc 
waveform differed consistently between PNEC and PBEC cultures. In both cases, 
PBECs demonstrated an initial peaked response, followed by a plateau. This peak 
was lacking in the PNEC counterparts and finding was not evident in PNEC/PBEC 
cultures isolated from PWT17 as shown in Figure 69, where the forskolin-induced Isc 
waveforms were similar. Despite these variations, there were no significant 
differences found in the magnitude of the median forskolin-induced Isc in paired 
cultures isolated from PWT8; PNEC median 23.6 µA/cm2, IQR 21.9 to 25.0 versus 
PBEC: 24.3 µA/cm2, IQR 20.4 to 27.9, p > 0.999 analysed by Mann-Whitney test), 
PWT11 (PNEC: median 14.6 µA/cm2, IQR 10.0 to 15.3 versus PBEC: 11.3 µA/cm2, 
IQR 4.8 to 18.6, p>0.999) and PWT17 (PNEC median 6.7 µA/cm2, IQR 4.0 to 15.2 
versus PBEC: 8.5 µA/cm2, IQR 7.0 to 13.8, p=0.39).  
Despite no differences in forskolin response, the CFTRinh-172-sensitive Isc was 
significantly greater in PNECs isolated from PWT8 compared with PBECs (PNEC: 
median -22.2 µA/cm2, IQR -21.5 to -23.0 versus PBEC: -19.2 µA/cm2, IQR -16.5 to -
20.1, p=0.03). No significant differences were evident in the CFTRinh-172-sensitive Isc 
in cultures derived from PWT11 (PNEC: median -11.6 µA/cm2, IQR -9.5 to -13.5 
versus PBEC: -12.6 µA/cm2, IQR -10.7 to -15.9, p=0.4) and PWT17 (PNEC: -6.0 
µA/cm2, IQR -3.8 to -12.5 versus PBEC: -6.2 µA/cm2, IQR -4.9 to -7.9, p > 0.999).  
Ussing chamber traces for paired Isc responses in PNECs and PBECs isolated from 
the PCF23 and PCF25 donors with the corresponding calculated Isc responses to 
forskolin and CFTRinh-172 are shown in Figure 70 and Figure 71, respectively. 
PCF23 cultures did not demonstrate differences in response to forskolin (PNEC: 
median 0.33 µA/cm2, IQR 0.15 to 0.44 versus PBEC: 0.21 µA/cm2, IQR 0.18 to 0.24, 
p=0.31) and CFTRinh-172 (PNEC: median -0.37 µA/cm2, IQR -0.19 to -0.54 versus 
PBEC: -0.51 µA/cm2, IQR -0.32 to -0.78, p=0.31).  
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This was in contrast to findings evident in cultures derived from PCF25, whereby the 
CFTRinh-172-sensitve Isc was significantly lower in PNECs (PNEC: -0.23 µA/cm2, IQR 
-0.15 to -0.24 versus PBEC: -0.44 µA/cm2, IQR -0.35 to -0.58, p=0.04). Although not 
significant, this was paralleled by a suggested smaller forskolin-induced Isc response 
in PNECs (PNEC: 0.0 µA/cm2, IQR 0 to 0.04 versus PBEC: 0.39 µA/cm2, IQR 0.0 to 
0.5, p=0.06). These differences are evident in the Ussing chamber traces 
demonstrated in Figure 71, whereby there is a small but present response to both 
forskolin and CFTRinh-172 in the PCF25 PBEC cultures. Overall, these findings 
suggest that in cultures derived from both non-CF and CF cultures, there are no 
significant differences evident in response to forskolin. However, variations in 
CFTRinh-172-senstive Isc responses were evident.  
 
  166 
Figure 67 : Paired assessment of forskolin-induced and CFTRinh-172-sensitive 
short circuit current in PNEC and PBEC cultures derived from the non-CF 
PWT8 donor  
Ussing chamber traces for PNEC and PBEC cultures isolated from the non-CF 
PWT8 donor are shown in A. The lines represents the mean short circuit current (Isc) 
with error bars for the SD (PNEC in black, PBEC in blue, n=2 inserts for each culture 
type). The change in Isc (DIsc) after forskolin (B) and CFTRinh-172 (C) addition was 
calculated for each experiment. Data is presented as median ±IQR and analysed 
with Mann-Whitney test, *p=0.03; PNEC: n=4 inserts, PBEC: n=4 inserts.  
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Figure 68: Paired assessment of forskolin-induced and CFTRinh-172-sensitive 
short circuit current in PNEC and PBEC cultures derived from the non-CF 
PWT11 donor  
Ussing chamber traces for PNEC and PBEC cultures isolated from the non-CF 
PWT11 donor are shown in A. The lines represents the mean short circuit current 
(Isc) with error bars for the SD (PNEC in black, PBEC in blue, n=5 PNEC inserts, n=3 
PBEC inserts). The change in Isc (DIsc) after forskolin (B) and CFTRinh-172 (C) 
addition was calculated for each experiment. Data is presented as median ±IQR and 
analysed with Mann-Whitney test with no statistical differences found; PNEC: n=5 
inserts, PBEC: n=6 inserts.  
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Figure 69: Paired assessment of short circuit current responses to forskolin 
and CFTRinh-172 in PNEC and PBEC cultures derived from the non-CF PWT17 
donor  
Ussing chamber traces for PNEC and PBEC cultures isolated from the non-CF 
PWT17 donor are shown in A. The lines represents the mean short circuit current 
(Isc) with error bars for the SD (PNEC in black, PBEC in blue, n=6 inserts for each 
culture type). The change in Isc (DIsc) after forskolin (B) and CFTRinh-172 (C) addition 
was calculated for each experiment. Data is presented as median ±IQR and 
analysed with Mann-Whitney test with no statistical differences found, PNEC: n=6 
inserts, PBEC: n=6 inserts. 
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Figure 70: Paired assessment of short circuit current responses to forskolin 
and CFTRinh-172 in PNEC and PBEC cultures derived from the CF PCF23 donor  
Ussing chamber traces for PNEC and PBEC cultures isolated from the CF PCF23 
donor (F508del/2896delA) are shown in A. The lines represents the mean short 
circuit current (Isc) with error bars for the SD (PNEC in black, PBEC in blue, n=6 
inserts for each culture type). The change in Isc (DIsc) after forskolin (B) and CFTRinh-
172 (C) addition was calculated for each experiment. Data is presented as median 
±IQR and analysed with Mann-Whitney test with no statistical differences found, 
PNEC: n=6 inserts, PBEC: n=6 inserts. 
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Figure 71: Paired assessment of short circuit current responses to forskolin 
and CFTRinh-172 in PNEC and PBEC cultures derived from the CF PCF25 donor  
Ussing chamber traces for PNEC and PBEC cultures isolated from the CF PCF25 
donor (F508del/F508del) are shown in A. The lines represents the mean short circuit 
current (Isc) with error bars for the SD (PNEC in black, PBEC in blue, n=6 inserts for 
each culture type). The change in Isc (DIsc) after forskolin (B) and CFTRinh-172 (C) 
addition was calculated for each experiment. Data is presented as median ±IQR and 
analysed with Mann-Whitney test, * p=0.04, PNEC: n=6 inserts, PBEC: n=6 inserts. 
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4.4.9 Assessing the relationship between short circuit current responses to 
forskolin and CFTRinh-172 
In these experiments, forskolin and CFTRinh-172 have been utilised as a measure of 
CFTR function. Given the different mechanisms of action of both reagents, it may be 
over simplistic to assume that responses are negatively correlated i.e. a positive Isc 
response to forskolin is related to a negative response of similar magnitude to 
CFTRinh-172. To further explore the relationship between the two reagents in PNEC 
and PBECs, linear regression analysis was performed. As shown in Figure 72, there 
is a clear correlation between the forskolin-induced and CFTRinh-172-sensitive Isc in 
non-CF PNECs (R2 = 0.07, p<0.0001). The negativity of this correlation arises from 
the decrease in Isc by CFTRinh-172 (i.e. a greater negative CFTRinh-172-sensitive Isc 
signifies a larger response). This relationship was not paralleled in non-CF PBECs 
(R2 = 0.49, p=0.19). In view of the relative specificity of CFTRinh-172 for CFTR 
inhibition, this suggests that in this cohort of cultures, forskolin may have a relatively 
higher specificity for CFTR activation in non-CF PNECs than PBECs. 
Figure 72: Linear regression analysis for short circuit current responses to 
forskolin and CFTRinh-172 in non-CF PNEC and PBEC cultures 
Linear regression analysis was performed to investigate the relationship between the 
forskolin-induced (DIsc forskolin) and CFTRinh-172-sensitive (DIsc CFTRinh-172) 
responses in differentiated non-CF PNECs (A) and PBECs (B). R2 is the coefficient 
of determination whereby 0.0 indicates no linear relationship and 1.0 indicates a 
perfect linear relationship. 
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4.4.10 Assessment of intra-donor variability of short circuit current responses 
to amiloride, forskolin and CFTRinh-172  
Grouped analyses in Figure 52 and Figure 65 of Isc responses to amiloride, forskolin 
and CFTRinh-172, respectively, represent the median Isc responses with the IQR for 
each group of cultures and clearly provide an impression of the inter-donor variability 
evident in each culture group. This was particularly notable in the amiloride-sensitive 
Isc in PNECs, and the forskolin-induced Isc in all non-CF cultures. However, it is 
important to also consider the extent of the intra-donor variability i.e. the variation in 
Isc responses between culture inserts obtained from the same donor. To ascertain the 
magnitude of intra-donor variability, individual responses measured in each culture 
insert per donor are shown and grouped by culture type in Figure 73 to Figure 76 
below. All Ussing chamber experiments were performed in at least 2 culture inserts 
derived from each donor. 
The intra-donor variability in response to amiloride was predominantly greater in 
PNECs derived from both non-CF and CF donors as shown in Figure 73 and Figure 
75, respectively. Amongst non-CF PNECs, the greatest variability in amiloride-
sensitive Isc was seen in cultures isolated from PWT13 (mean -25.2 µA/cm2 ± SD 
7.7). In CF PNECs, this was greatest in PCF26 PNECs (-17.9 µA/cm2 ±7.4). 
Interestingly, the intra-donor variability in amiloride-sensitive Isc did not seem to relate 
to the variability in responses to forskolin and CFTRinh-172, as best demonstrated in 
non-CF PNECs. For example, although the variability in the amiloride-sensitive Isc 
was lowest in cultures isolated from PWT4 (mean -13.1 µA/cm2 ±1.9), these cultures 
showed the largest variability in responses to forskolin and CFTRinh-172 (forskolin: 
14.3 µA/cm2 ±8.7; CFTRinh-172: -13.5 µA/cm2  ±9.7), suggesting no relationship 
between the extent of variability in ENaC versus CFTR function.  
In non-CF cultures, forskolin-induced intra-donor variability in Isc was apparent in both 
PNEC and PBECs. The greatest variability was found in PWT4 cultures as 
mentioned above. In non-CF PBECs, cultures derived from PWT11 showed the 
greatest intra-donor variability (forskolin: 11.5 µA/cm2  ±7.5; CFTRinh-172: -13.1 
µA/cm2  ±4.0). Notably, intra-donor variability in the CFTRinh-172-sensitive Isc was 
more pronounced in PNECs versus PBECs. Overall, these findings have shown that 
there is evidence of intra-donor variability in Isc responses to amiloride, forskolin and 
CFTRinh-172, and the extent of this variability is predominantly greater in PNECs 
versus PBECs.  
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Figure 73: Assessment of intra-donor variability in short circuit current 
responses to amiloride, forskolin and CFTRinh-172 in non-CF PNEC cultures  
Intra-donor variability of short circuit current responses (DIsc) to amiloride, forskolin 
and CFTRinh-172 were assessed in non-CF PNEC ALI cultures. Data is presented as 
the mean DIsc response ± SD. PWT4N: n=2 inserts; PWT8N: n=4 inserts; PWT9N: 
n=2 inserts; PWT11N: n=5 inserts; PWT13N: n=3 inserts; PWT16N: n=3 inserts; 
PWT17N: n=6 inserts.  
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Figure 74: Assessment of intra-donor variability in short circuit current 
responses to amiloride, forskolin and CFTRinh-172 in non-CF PBEC cultures 
Intra-donor variability of short circuit current responses (DIsc) to amiloride, forskolin 
and CFTRinh-172 were assessed in non-CF PBEC ALI cultures. Data is presented as 
the mean DIsc response ± SD. PWT8B: n=4 inserts; PWT9B: n=2 inserts; PWT10B: 
n=3 inserts; PWT11B: n=6 inserts; PWT17B: n=6 inserts. 
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Figure 75: Assessment of intra-donor variability in short circuit current 
responses to amiloride, forskolin and CFTRinh-172 in CF PNEC cultures 
Intra-donor variability of short circuit current responses (DIsc) to amiloride, forskolin 
and CFTRinh-172 were assessed in CF PNEC ALI cultures. Data is presented as the 
mean DIsc response ± SD. PCF10N: n=3 inserts; PCF19N: n=3 inserts; PCF23N: n=6 
inserts; PCF25N: n=3 inserts; PCF26N: n=3 inserts; PCF28N: n=2 inserts. 
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Figure 76: Assessment of intra-donor variability in short circuit current 
responses to amiloride, forskolin and CFTRinh-172 in CF PBEC cultures 
Intra-donor variability of short circuit current responses (DIsc) to amiloride, forskolin 
and CFTRinh-172 were assessed in CF PBEC ALI cultures. Data is presented as the 
mean DIsc response ± SD. PCF22B: n=2 inserts; PCF23B: n=6 inserts; PCF24B: n=3 
inserts; PCF25B: n=6 inserts.  
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4.4.11 Functional characterisation of the R751L mutation using the primary 
airway epithelial culture model  
As evident in Figure 65, CF PBEC cultures derived from the donor with the 
F508del/R751L genotype (PCF24) demonstrated larger responses to forskolin and 
CFTRinh-172 compared with cultures obtained from CF participants with more severe 
mutations. This particular participant clinically had a mild phenotype with a diagnostic 
sweat chloride at diagnosis of 83 mmol/L and features of pancreatic sufficiency. At 
present, there is no reported detailed characterisation of this genotype and reported 
Ussing chamber experiments in this PhD relating to this mutation are novel.  
Figure 77 demonstrates the mean Isc responses in 3 PBEC culture inserts derived 
from this participant. To investigate the relative magnitude of CFTR function in 
F508del/R751L, forskolin-induced Isc responses were compared with PBECs derived 
from non-CF and F508del homozygous participants (i.e. a severe clinical phenotype). 
These results are shown below in Figure 77. Although the magnitude of the forskolin-
induced Isc associated with F508del/R751L was less than the median Isc evident in 
non-CF PBECs (F508del/R751L: median 4.4 µA/cm2, IQR 4.0 to 4.4 versus 18.3 
µA/cm2, IQR 10.2 to 24.0), it is greater than that evident in PBECs isolated from 
F508del homozygous donors (0.3 µA/cm2, IQR 0 to 0.5). These findings correlate 
with the relatively mild phenotype evident in this CF donor, and the effects of R751L 
on CFTR channel function warrant further investigation. No differences were found 
with the magnitude of amiloride-sensitive Isc in the F508del/R751L cultures (-1.3 
µA/cm2, IQR -1.0 to -1.6) compared with F508del homozygous (-8.2 µA/cm2, IQR -
6.7 to -9.6) and non-CF cultures (-7.4 µA/cm2, IQR -4.4 to -9.6).   
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Figure 77: Short circuit current responses in PBEC cultures derived from a CF 
donor with the F508/R751L genotype  
PBEC culture inserts derived from the CF PCF24B (F508/R751L) were mounted in 
the Ussing chamber and bathed apically and basolaterally in 125 mM chloride Krebs. 
Resultant short circuit current (Isc) responses to amiloride, forskolin and CFTRinh-172 
are shown in A; lines represent mean with error bars for SD; n= 3 inserts.  
Changes in the forskolin-induced Isc (DIsc forskolin) were compared with responses 
seen in non-CF PBECs and CF PBECs derived from F508del/F508del donors (B). 
Each point represents the mean DIsc for each donor. Data is presented as median ± 
IQR and analysed with Kruskal-Wallis and post hoc Dunn’s multiple comparison test; 
**p<0.01; non-CF PBECs (n=5 donors, 21 inserts), F508del/R751L donor (n=1 
donor, 3 inserts), CF PBECs (n=2 donors, 8 inserts). 
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4.5 Discussion 
4.5.1 Functional expression of ENaC does not differ in CF versus non-CF 
differentiated paediatric primary nasal and bronchial epithelial cultures 
Overall, investigation of the amiloride-sensitive Isc in this cohort of paediatric cultures 
has not shown any significant changes in CF versus non-CF epithelia in both PNECs 
and PBECs. These findings are contrary to the previously reported enhancement of 
ENaC activity in CF and subsequent sodium hyperabsorption in the absence of 
functional CFTR. Nasal PD in vivo assessment has shown a greater response to 
amiloride in CF versus non-CF subjects (Knowles et al., 1983). In vitro studies have 
demonstrated greater apical sodium conductance in freshly excised nasal tissue and 
submerged confluent nasal epithelial cells, both derived from nasal polyp tissue in CF 
and non-CF donors (Boucher et al., 1986, Boucher et al., 1988, Mall et al., 1998).  
However, in addition to the results obtained in this PhD, there are also conflicting 
results from other studies, including a report which found no differences in response 
to amiloride on transepithelial conductance in primary ALI tracheal and bronchial 
cultures derived from explanted lung tissue of 261 non-CF and 74 CF donors (Itani et 
al., 2011). Furthermore, this group did not find any differences in the net rate of 
sodium absorption in CF versus non-CF epithelia. Interestingly, the amiloride-
sensitive Isc was greater in CF epithelia, but this was caused by a loss of chloride 
conductance due to dysfunctional CFTR rather than an increase in sodium 
conductance (Itani et al., 2011). In non-CF epithelia, the amiloride-induced apical 
hyperpolarisation increased the driving force for chloride secretion, resulting in a 
greater reduction in the amiloride-sensitive Isc compared with CF epithelia which lack 
functional CFTR (Itani et al., 2011). 
There have also been previous reports of anatomical variations in amiloride-
sensitivity. In vivo assessment of nasal transepithelial voltage response to amiloride 
in the newborn pig model showed greater responses in CF versus non-CF pigs  
(Chen et al., 2010). However, these findings were not reproduced in tracheal 
epithelia, where results were similar. Furthermore, in vivo investigation of PD in 
children has shown more negative transepithelial voltages in tracheal versus lower 
airways (Davies et al., 2005). Interestingly, in the same study, responses were more 
negative in CF versus non-CF adult subjects in all airway regions, suggesting that 
age and hence disease severity may affect ENaC function (Davies et al., 2005). It is 
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recognised that proteolytic ENaC activation by serine proteases such as neutrophil 
elastase increases the amiloride-sensitive current in bronchial epithelial cell lines, 
and it is possible that this could contribute to greater responses seen in older 
subjects with more severe disease (Caldwell et al., 2005). 
Clearly, the question regarding an increased ENaC function in the CF airway remains 
debateable. Variations in participant age, degree of inflammation, infection status and 
disease severity may contribute to the differences seen in this PhD and other 
previous studies. Furthermore, there are reported SNPs in ENaC that are associated 
with variations in ENaC surface expression and function (Rauh et al., 2010). 
Differences may also arise from a number of other potential causes including 
experimental variations in tissue type (i.e. nasal polyp versus turbinate, bronchial 
brushing versus explanted tissue, nasal versus bronchial epithelia), culture conditions 
(ALI versus submerged; seeding density), stages of epithelial differentiation and 
experimental conditions used for Ussing chamber experiments.  
All paediatric cultures in this study showed high levels of a-ENaC expression  
compared with the other subunits. Despite the lack of difference in the amiloride-
sensitive Isc, expression of all three subunits was increased in CF versus non-CF 
PBECs. This was different in PNECs, where only b-ENaC was increased in CF 
versus non-CF cultures. Analysis in both non-CF and CF groups suggested lower 
fold changes in PNECs versus PBECs.   
The importance of relative subunit expression for ENaC function is exemplified in a 
number of diseases. For example, mutations in b and g-ENaC have been associated 
with the autosomal dominant disease Liddle syndrome, which leads to constitutive 
ENaC activation in the distal renal epithelium causing severe hypertension (Shimkets 
et al., 1994, Prince and Welsh, 1999). The systemic form of type 1 
pseudohypoaldosteronism can be caused by mutations in each of the three ENaC 
subunits in multiple tissue sites causing renal salt wasting episodes and lower 
respiratory tract infections (Chang et al., 1996, Strautnieks et al., 1996). There have 
been 2 reported cases of b-ENaC mutations in patients with a ‘CF-like’ disease with 
pulmonary infections and elevated sweat chloride (Sheridan et al., 2005). 
Furthermore, the development of the transgenic over-expressing b-ENaC mouse is 
used as a model to investigate CF-like lung disease (Mall et al., 2004).  
Relative contribution of ENaC subunit to resultant channel function has been 
assessed by injection of each subunit isolated from rat colonic epithelia into Xenopus 
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oocytes and subsequent measurement of amiloride-sensitive currents (Canessa et 
al., 1994, Bonny et al., 1999). Presence of a-ENaC alone was sufficient to induce an 
amiloride-sensitive current, however, this response was potentiated by over 100 
times in the presence of all three subunits, which was later confirmed as equalling 2 
% of total ENaC function (Canessa et al., 1994, Bonny et al., 1999). This increased 
to 15 % when either a and b or a and g subunits were co-expressed (Bonny et al., 
1999). Both studies confirmed that b and g-ENaC  failed to produce any currents in 
isolation, which increased to 15 % when either subunit was co-expressed with a-
ENaC (Canessa et al., 1994, Bonny et al., 1999). In contrast to the study by Canessa 
et al, Bonney et al were able to demonstrate ENaC activity when b and g-ENaC 
where co-expressed to around 2 % total function. In addition to potentiating overall 
ENaC activity, a-ENaC facilitates trafficking of b and g-ENaC to the plasma 
membrane, while b and g subunits are required for plasma membrane stabilisation 
(Gaillard et al., 2010).  
The overall variation seen in ENaC-subunit mRNA expression in this PhD may 
account for lack of correlation seen with functional assessment of amiloride-sensitive 
Isc. Similar oscillations in subunit expression in individual donors have been 
previously reported in nasal epithelial cultures, however, these authors were able to 
demonstrate upregulation of all 3 subunits in CF versus non-CF nasal cultures 
isolated from nasal polyp tissue (Bangel et al., 2008). This variability may reflect 
genuine differences in ENaC assembly and composition of subunits in different 
cellular populations, therefore making it difficult to make reliable assessments of such 
correlations. Two different ENaC populations have been described at the plasma 
membrane; basally active cleaved channels and uncleaved ‘near silent’ channels 
(Caldwell et al., 2005). However, it remains to be determined as to how these 
channels are distributed within distinct cellular populations. Furthermore, post 
transcriptional modifications of ENaC are likely to limit the value and weighting of 
mRNA expression analysis. Detailed exploration of protein expression would be 
useful to help explore this area further.  
Although the numbers were small, paired analysis of PNEC/PBEC cultures isolated 
from the same donors did provide some useful information regarding variations in 
ENaC function and expression at the two culture sites. Overall, findings suggested 
that in the paired non-CF cultures, the amiloride-sensitive Isc and a-ENaC expression 
were increased in nasal versus bronchial tissue. This paralleled the grouped 
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analyses of all non-CF cultures. Investigation of anatomical variations of ENaC 
subunit expression in non-CF airways has previously been performed in non-CF 
adults (Pitkänen et al., 2001). Nasal, bronchial and peripheral lung tissue were 
isolated from volunteers undergoing lobectomy for malignancy. Using RT-PCR, these 
authors found relatively higher levels of a-ENaC in nasal tissue. However, they also 
found increasing proportions of b and g-ENaC with distal airway progression, which 
was not evident in the paediatric paired non-CF cultures (Pitkänen et al., 2001).   
Analysis in paired CF cultures revealed the reverse situation, where amiloride-
sensitive Isc  and a-ENaC expression were increased in PBECs. Unfortunately, there 
are no similar studies to compare these findings with, and this does warrant further 
investigation. Although the numbers are too small to perform any formal assessment 
of correlation in the paired cultures, there is a suggestion that a-ENaC expression 
was associated with an increase in the amiloride-sensitive Isc.  
Finally, it should be noted that although Ussing chamber experiments are widely 
employed to assess the epithelial function of ion channels such as ENaC, there are 
limitations with this technique. Under normal thin film conditions, the ASL overlying 
the airway epithelium is around 7-10 µm in height (Gaillard et al., 2010). In the 
Ussing chamber system, epithelial monolayers are mounted and bathed in 
significantly larger volumes, in this case 5 mL in each compartment. ENaC is 
subsequently proteolytically cleaved and activated in an attempt to restore ASL 
volume back to the normal height (Gaillard et al., 2010). This has been observed 
anecdotally on initial mounting of epithelia in the Ussing chamber, where the basal Isc 
showed an initial increase (see Figure 51). Since this basal Isc contributes to the 
majority of the amiloride-sensitive Isc, it is most likely caused by ongoing ENaC 
activation at the plasma membrane. However, all assessments of the amiloride-
sensitive Isc were performed after a period of 15-20 minutes, to enable basal Isc 
stabilisation prior to amiloride addition.  
4.5.2 CFTR functional expression does not differ significantly between 
differentiated paediatric primary nasal and bronchial epithelial cultures  
Investigation of CFTR-mediated chloride secretion in this cohort of paediatric cultures 
has not revealed any differences between the magnitude of both forskolin-induced 
and CFTRinh-172-sensitive Isc responses in PNECs versus PBECs. This therefore 
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demonstrates the suitability of PNECs for exploration of CFTR function using this 
experimental approach.  
As expected the responses to both reagents were greater in non-CF versus CF 
cultures. However, the lack of significance seen amongst PBECs may be in part 
explained by the relatively small sample size, which was limited by the initial 
challenges faced with PBEC culture success. The non-parametric Kruskal-Wallis test 
was used for all Ussing chamber analyses. Normality was formally tested with 
Shapiro-Wilk assessment; however, this did not show normality across all culture 
groups. In view of the need to make reliable comparisons between CF/non-CF and 
PNEC/PBEC cultures and the difficulties of accurately testing for normality in small 
sample sizes, non-parametric analyses were used to investigate relationships 
between each culture group and maintain appropriate application of statistical 
comparisons. Interestingly, application of the parametric one-way ANOVA revealed 
findings to be significantly different between non-CF and CF PBECs (forskolin-
induced Isc: p=0.003), however without reliably assessing for normality, the decision 
was made not to use this analysis.  
Forskolin has been widely employed for the in vitro assessment of CFTR secretory 
function in a range of studies including those that have investigated the role of 
potentiators and correctors in patient-derived epithelial cultures (Van Goor et al., 
2009a, Ahmadi et al., 2017, Pranke et al., 2017). This was the rationale for selecting 
forskolin to investigate CFTR-mediated chloride secretion in this PhD to enable 
comparable analyses of results. As previously mentioned, CFTR is activated by PKA-
mediated phosphorylation at multiple phosphorylation sites on the R domain (Bozoky 
et al., 2013). In vitro, this can be achieved with forskolin which acts to elevate 
cytosolic cAMP levels via direct (i.e. protein-independent)  activation of adenylate 
cyclase (Moran and Zegarra-Moran, 2008), and subsequent PKA. 
Concentrations of up to 10 µM forskolin are sufficient to activate CFTR with higher 
concentrations demonstrating non-specific responses (Moran and Zegarra-Moran, 
2008). The initial peak and plateau response has been noted and suggested to occur 
due to limited activity of the basolateral Na/K/2Cl co-transporter and subsequent 
failure to maintain cytosolic chloride (Li et al., 2004). This could be investigated 
further by permeabilising the basolateral membrane to eliminate the effects of 
channels involved in generating a chloride gradient (Li et al., 2004). Although this 
may be a potential explanation for this type of response evident in some paired 
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PBEC cultures in this study, it does not explain why this finding was not apparent in 
PNECs. It is possible that there are variations in Na/K/2Cl functional expression in 
the two culture types and does requires further investigation. The phosphodiesterase 
inhibitor, 3-isobutyl-1-methylxanthine (IBMX), can also be used in conjunction with 
forskolin to augment CFTR activation, however, addition of this reagent also affects 
the gating properties of CFTR, and so it was not selected for use in this PhD (Moran 
and Zegarra-Moran, 2008).  
The thiazolidinone CFTRinh-172 is a relatively specific and reversible CFTR inhibitor 
with a significantly greater potency than other inhibitors such as glibenclamide and 
niflumic acid (Taddei et al., 2004). It works by reducing channel open probability and 
increases the time spent in the closed state, suggesting alteration of channel gating 
by binding to NBD1 as opposed to blockage of the channel pore as is the case with 
many alternative inhibitors (Taddei et al., 2004). GlyH-101, was later identified as 
another CFTR inhibitor, but despite its favourable property of improved water 
solubility, it was found to have additional inhibitory effects on alternative chloride 
conductance pathways, including SLC26A9 and CaCC (Bertrand et al., 2009, Melis 
et al., 2014). It was therefore not utilised in this PhD due to the requirement for 
TMEM16A investigation and the potential for unintended inhibition of CaCC.  
Linear regression analysis of resultant DIsc responses to forskolin and CFTRinh-172 in 
non-CF PNECs showed that the two responses were significantly correlated. This 
suggested that in view of the relative specificity of CFTRinh-172-mediated CFTR 
inhibition, forskolin may also be relatively specific for CFTR activation. The lack of 
correlation evident in non-CF PBECs could be explained by cAMP-activation of non-
CFTR channels, such as cAMP-sensitive potassium channels as well as ion 
transporters such as the basolateral Na/K/2Cl cotransporter, the apical 
sodium/bicarbonate exchanger and the SLC26 co-transporters (Cuthbert et al., 1999, 
Haas and Forbush Iii, 2000, Frizzell and Hanrahan, 2012). Furthermore, co-
expression of wild type CFTR and an alternative chloride channel, SLC26A9, in HEK 
293 cells has shown enhanced forskolin-stimulated currents (Bertrand et al., 2009). 
Therefore, more selective activation of CFTR and knowledge of alternative chloride 
channel response and function would be beneficial in PBEC-related studies that 
require detailed exploration of CFTR activation including response to modulator 
therapies. 
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Although paired culture assessment did not show any differences between forskolin 
responses in PNEC and PBECs derived from both non-CF and CF donors, there 
were two occasions where the CFTRinh-172 responses differed. In the non-CF PWT8 
donor, the response was greater in PNECs versus PBECs. The reverse of this was 
true in the CF PCF25 cultures, where a greater response was evident in PBECs. The 
exact reason for this remains unclear and could be further investigated by assessing 
CFTR expression by Western blot or immunofluorescence to determine potential 
relationships of expression with functional CFTR. However, this is unlikely to have 
any significant implications for the application of PNECs in CF research, but is an 
important consideration.  
4.5.3 There is evidence of inter- and intra-donor variability in Ussing chamber 
responses to amiloride, forskolin and CFTRinh-172 
There was notable variability in the responses to amiloride, forskolin and CFTRinh-
172 between cultures derived from different donors. Although it is important to 
recognise that channel expression and function may be affected by the tissue culture 
process and culture quality, all cultures were subject to the same processes and 
conditions including seeding density. Therefore, this inter-donor variability is likely to 
reflect the underlying variations in amiloride and CFTR function evident in cultures 
derived from the different donors. This is further exemplified by the presence of 
CFTR-mediated chloride secretion evident in cultures derived F508del/R751L and 
the absence of response in cultures representing severe CF mutations, therefore in 
keeping with the clinical phenotype.  
It is important to recognise that cultures in the non-CF group were not isolated from 
completely healthy participants. As described in Chapter 3, the predominant reasons 
for clinical bronchoscopy in this group were to investigate recurrent LRTI, chronic 
cough and wheeze. This could potentially impact upon variations in ion transport in 
the airway, however, this study is not adequately powered to draw any sensible 
conclusions relating to this. Nevertheless, in vitro studies have recognised additional 
factors that may affect CFTR function. These include chronic exposure to b2-agonists 
(which are used clinically to treat chronic wheeze), exposure to second-hand 
cigarette smoke and additional disorders of mucostasis and subsequent ASL 
dehydration including non-allergic asthma and non-CF bronchiectasis (Brewington et 
al., 2018a, Savitski et al., 2009, Schulz and Tümmler, 2016). However, for the non-
CF cultures used in this PhD to investigate Isc responses, sweat tests were 
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performed in 5 out of 8 children and reported to be normal, suggesting normal CFTR-
mediated chloride function in these participants.  
There was also evidence of variability between different culture inserts isolated from 
individual donors. This intra-donor variability may have arisen from different baseline 
levels of CFTR activation in different culture inserts, therefore impacting upon the 
degree of cAMP-mediated activation by forskolin (Moran and Zegarra-Moran, 2008). 
Culture quality should also be considered as a potential factor; however, ALI culture 
inserts displaying adequate TEER values and epithelial characteristics as described 
in Chapter 3 were carefully selected to perform all Ussing chamber experiments. 
Importantly, this assessment of intra-donor variability is limited by failure to compare 
consistent numbers of culture inserts for each donor analysed.   
Indeed, the extent of intra and inter-donor variability of TEER in response to 
pharmacological agents such as amiloride has been comprehensively assessed in 
PNECs isolated from healthy volunteers (Tosoni et al., 2016). As with this PhD, the 
data was found to be non-parametric in nature (Tosoni et al., 2016). By varying their 
protocol with amiloride addition either before or after forskolin and CFTRinh-172, no 
differences were evident in the resultant change in amiloride-induced TEER, 
suggesting that ENaC functional expression was innate to an individual donor’s 
epithelium (Tosoni et al., 2016). Furthermore, Tosoni et al. did not find any 
correlation with the magnitude of the amiloride and forskolin responses, further 
highlighting the complexities of epithelial ion transport.   
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4.6 Conclusion 
In this cohort of paediatric cultures, no differences were seen in the amiloride-
sensitive Isc in CF versus non-CF cultures in both PNEC and PBEC groups, further 
highlighting that the relationship between ENaC and CFTR remains in question. 
Responses were significantly greater in non-CF PNECs versus PBECs. This may be 
relevant where detailed ENaC assessment is performed in PNECs and translated to 
lower airway disease. Although the numbers are small, analyses from paired cultures 
do provide some useful insights with respect to relative changes in ENaC expression 
in the two anatomical sites. However, differences were not apparent in CF cultures, 
and therefore may not have significant implications. 
No differences were evident in the assessment of Isc responses to forskolin and 
CFTRinh-172 in PNEC versus PBEC cultures, suggesting that under these 
experimental conditions, paediatric PNECs are a representative tool to investigate 
CFTR airway function.  The presence of inter-donor variability in Ussing chamber 
responses may be related to TEER variability previously reported in Chapter 3. 
However, given the consistency of culture conditions it is likely to be a true reflection 
of variability in cultures derived from different participants. 
The findings in this chapter have demonstrated the feasibility of using cultured 
paediatric airway epithelial cells to investigate ion transport profiles relating to ENaC 
and CFTR function in Ussing chamber experiments. Although adult primary bronchial 
cultures have been previously established in the current laboratory environment and 
utilised in Ussing chamber experiments, the work performed in this PhD was the first 
instance of applying this technique to paediatric ALI cultures. This has been 
exceptionally valuable, not only to facilitate the work required for this PhD but will 
establishment of this process will also be beneficial for future work involving 
paediatric CF ALI cultures.  
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5 Chapter 5: Investigating the expression and function of 
TMEM16A in differentiated paediatric primary nasal and 
bronchial epithelial cultures derived from children with and 
without cystic fibrosis 
5.1 Introduction 
Chloride secretion into the ASL is achieved through a combined effect of basolateral 
chloride entry via the Na/K/2Cl co transporter and apical channels that facilitate 
chloride transport. It has long been recognised that CFTR is co-expressed with other 
chloride channels, including CaCCs (Boucher et al., 1989). Although CFTR is the 
major contributor to maintaining ASL volume under basal conditions, acute CaCC 
stimulation can also increase ASL height, therefore potentially providing an 
alternative approach to restoring ASL volume and reducing ASL hydration in CF 
(Tarran et al., 2002).  
Having established the feasibility of utilising paediatric PNEC and PBEC cultures to 
explore their ion transport profiles, the next focus of this research was to investigate 
the presence of CaCCs and their relative contribution to chloride secretion in 
paediatric airway epithelial cultures. Furthermore, the specific presence of TMEM16A 
has not previously been assessed in paediatric PNEC or PBEC cultures. Since the 
identification of TMEM16A ten years ago, there has been a large body of work 
investigating the expression and modulation of the channel in the airway, the majority 
of which has been performed using established cell lines (HEK 293, human bronchial 
epithelial) or PBEC cultures isolated from explanted lung tissue (Jung et al., 2013, 
Scudieri et al., 2012a, Ruffin et al., 2013, Caci et al., 2015, Ousingsawat et al., 2011, 
Gorrieri et al., 2016). At the time of this PhD, there was a lack of information 
regarding both CaCC and TMEM16A in the paediatric airway, including details 
regarding expression and function.  
The work carried out in this chapter will investigate the role of CaCC in paediatric 
epithelial cultures developed in this PhD, with a view to investigating TMEM16A 
function and expression using experimental techniques described in preceding 
chapters.  
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5.2 Hypotheses 
• Differentiated paediatric PNEC and PBEC ALI cultures can be used in Ussing 
chamber experiments to explore the function of CaCC. 
• TMEM16A is expressed in differentiated paediatric PNEC and PBEC cultures. 
5.3 Aims 
The specific aims of this chapter were to: 
• Investigate the function and expression of CaCC in paediatric differentiated ALI 
cultures using Ussing chamber experiments and determine any differences 
between PNECs and PBECs derived from non-CF and CF participants 
• Investigate the function and expression of TMEM16A in these cultures. 
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5.4 Results 
5.4.1 Assessment of calcium activated chloride channel function  
To investigate CaCC-mediated chloride secretion, Ussing chamber experiments were 
performed in differentiated paediatric PNEC and PBEC ALI cultures. A Krebs solution 
containing 125 mM chloride was added to the apical and basolateral compartments 
and maintained at 5 % CO2 and 37 °C. All experiments described in this chapter 
involved the initial addition of amiloride, forskolin and CFTRinh-172 as previously 
outlined in Chapter 4 and performed from 25d to 33d ALI.  UTP (100 µM) was 
subsequently added to the apical compartment to activate CaCC (Mason et al., 
1991). The resultant Isc and TEER were measured and calculated as previously 
described in Chapter 2 section 2.5. Although CaCC-mediated chloride secretion via 
P2Y2 receptor stimulation can be stimulated  equally well with ATP and UTP, UTP 
was selected for these Ussing chamber experiments due to its additional activity on 
airway P2Y4 receptors, therefore maximising the resultant Isc response (Lazarowski 
and Boucher, 2009). Furthermore, whereas ATP hydrolysis produces adenosine 
which modulates anion secretion via cAMP-dependent CFTR regulation, the 
hydrolysis product of UTP, uridine, does not have this effect, thereby minimising 
alternative mechanisms for UTP-induced chloride secretion (Paradiso et al., 2000). 
To exemplify the nature of the response evident with UTP addition, representative 
Ussing chamber traces for Isc and TEER responses to UTP in a non-CF culture are 
shown in Figure 78. Addition of UTP caused a rapid Isc increase by 6.6 µA/cm2 due to 
calcium activated chloride secretion, but unlike CFTR, the response was transient 
with spontaneous return to baseline of 1.9 µA/cm2 without the need for 
pharmacological channel inhibition. The was accompanied by a TEER decrease of 
110 W.cm2 due to enhanced CaCC-mediated chloride conductance.  
To investigate this further in paediatric PNEC and PBEC ALI cultures isolated from 
non-CF and CF donors, Ussing chamber experiments were performed to investigate 
the effects of apical UTP addition in 7 non-CF PNEC, 5 non-CF PBEC, 5 CF PNEC 
and 1 CF PBEC (Figure 79) cultures. In addition to the peak UTP-induced Isc (DIsc), 
the area under the curve (AUC) was also calculated as a measure of total UTP-
induced Isc as previously described in Chapter 2 section 2.5. As shown in Figure 79, 
in non-CF cultures, the UTP-induced Isc in PNECs was similar to the response in 
PBECs (non-CF PNEC: median 3.3 µA/cm2, IQR 1.8 to 5.5 versus non-CF PBEC: 2.4 
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µA/cm2, IQR 1.8 to 3.4, p=0.48). No differences were found in the total UTP-induced 
Isc (non-CF PNEC: median 9.0 µA/cm2.min, IQR 5.2 to 25.1 versus non-CF PBEC: 
9.2 µA/cm2.min, IQR 5.7 to 9.8, p=0.56). Cultures isolated from one particular donor 
(PWT9) demonstrated the largest UTP-induced Isc increase (mean 12.5 µA/cm2 ± SD 
0.27) and total response (120.9 µA/cm2.min ± SD 0.14). Interestingly this was the 
same donor that had the greatest amiloride-sensitive Isc as shown in Chapter 4 Figure 
52.  
In PNECs, the median UTP-induced Isc in CF PNECs was 2.4 µA/cm2, IQR 1.0 to 6.4, 
which was not statistically different to non-CF PNECs (p=0.67). This was paralleled 
with similar changes in the total UTP-induced Isc for both groups (CF PNECs: 
9.7µA/cm2.min, IQR 3.4 to 21.2, p=0.66). Statistical comparisons could not be made 
involving CF PBECs because it was only possible to determine the peak UTP-
induced Isc in 1 CF PBEC for reasons explained below in section 5.4.3 . 
Further investigation into the UTP-induced Isc responses were investigated in paired 
PNEC/PBEC cultures isolated from 2 non-CF culture pairs. Cultures derived from the 
PWT8 donor (Figure 80) showed a 2-fold increase in the UTP-induced Isc in PNECs 
compared with PBECs, however, this was not statistically significant (PNEC median: 
4.6 µA/cm2, IQR 4.6 to 4.7 PBEC: 2.3 µA/cm2, IQR 2.3 to 2.6 versus; p=0.1). This 
was associated with a 3-fold AUC increase in PNECs, but again this was not 
statistically significant (PNEC median: 27.3 µA/cm2.min, IQR 19.2 TO 28.8 versus 
PBEC: 8.4 µA/cm2.min, IQR 8.4 to 9.6; p=0.1). Findings were similar in PWT11 
cultures (Figure 81), whereby the UTP-induced Isc was 3-fold greater in PNECs 
(PNEC median 5.5 µA/cm2, IQR 4.4 to 6.6 versus PBEC: 1.6 µA/cm2, IQR 1.3 to 2.5; 
p=0.2). The AUC was also greater in the PNECs but not statistically significant 
(PNEC median: 23.1 µA/cm2.min, IQR 17.1 to 29.1 versus PBEC: 4.7 µA/cm2.min, 
IQR 4.4 to 5.0; p=0.2).  
Overall, this assessment did not reveal any differences between paediatric PNEC 
and PBEC non-CF and CF ALI cultures. However, analysis in paired non-CF cultures 
suggested greater responses to UTP in PNECs versus PBECs. 
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Figure 78: Representative Ussing chamber traces of the UTP-induced short 
circuit current and transepithelial electrical resistance response in a non-CF 
PNEC culture 
A PNEC ALI culture insert derived from the non-CF PWT11N donor was mounted in 
the Ussing chamber and bathed apically and basolaterally in 125 mM chloride Krebs 
solution. After a 20-minute period of stabilisation, 10 µM amiloride was added to the 
apical compartment, followed by 10 µM forskolin and 20 µM CFTRinh-172 at 25 and 
30 minutes respectively. Resultant short circuit current (Isc) and transepithelial 
electrical resistance (TEER) responses were recorded as shown in A and B 
respectively.  
10 15 20 25 30 35 40 45 50 55 60
0
10
20
30
Time (min)
I sc
 (µ
A
/c
m
2 )
Amiloride
Forskolin CFTRinh-172
UTP
A
10 15 20 25 30 35 40 45 50 55 60
0
500
1000
1500
Time (min)
TE
ER
 (Ω
.cm
2 )
Amiloride Forskolin
CFTRinh-172 UTP
B
  193 
Figure 79: Assessment of the peak and total UTP-induced short circuit current 
in paediatric differentiated non-CF and CF PNEC and PBEC cultures 
The UTP-induced change in peak short circuit current (DIsc UTP peak) was assessed 
in differentiated PNEC and PBECs from 25 to 33d ALI in Ussing chamber 
experiments and shown in A. The area under the curve (AUC) was calculated for 
each response and shown in B. Each point represents the mean UTP-induced Isc or 
AUC for each donor investigated. Data is presented as median ± IQR and analysed 
with Kruskal-Wallis and post hoc Dunn’s multiple comparison test with no significant 
differences found. Non-CF PNECs (n=7 donors, 16 inserts), non-CF PBECs (n=5, 12 
inserts), CF PNECs (n=5, 10 inserts), CF PBECs (n=1, 3 inserts). CFTR mutations 
for each CF donor are colour-coded as shown in the legend. 
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Figure 80: Paired assessment of UTP-induced short circuit current in PNEC 
and PBEC cultures derived from the non-CF PWT8 donor  
Ussing chamber traces for PNEC and PBEC cultures isolated from the non-CF 
PWT8 donor are shown in A. Lines represents the mean short circuit current (Isc) with 
error bars for the SD (PNEC in black, PBEC in blue, n=3 inserts for each culture 
type). The change in peak short circuit current (DIsc) and area under the curve (AUC) 
after UTP addition were calculated and shown in B and C respectively. Data is 
presented as median ±IQR and analysed with Mann-Whitney test; p=0.1 for B and C. 
PNEC: n=3 inserts, PBEC: n=3 inserts.  
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Figure 81: Paired assessment of UTP-induced short circuit current in PNEC 
and PBEC cultures derived from the non-CF PWT 11 donor 
Ussing chamber traces for PNEC and PBEC cultures isolated from the non-CF 
PWT11 donor are shown in A. Lines represents the mean short circuit current (Isc) 
with error bars for the SD (PNEC in black, n=2 inserts, PBEC in blue, n=3 inserts). 
The change in Isc (DIsc) and area under the curve (AUC) after UTP addition were 
calculated and shown in B and C respectively. Data is presented as median ±IQR 
and analysed with Mann-Whitney test; p=0.2 for B and C. PNEC: n=2 inserts, PBEC: 
n=3 inserts.  
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5.4.2 Assessment of relative chloride transport by CFTR and CaCC 
Although CFTR is the principal channel involved in airway epithelial chloride 
secretion, it also transports bicarbonate into the ASL, with a relative permeability to 
chloride transport of 25 % (Tang et al., 2009). Investigation of relative chloride 
permeability by CaCC would be difficult to assess within the capacity of this PhD, 
however, assessment of CaCC-mediated chloride transport was assessed to 
ascertain its role in chloride secretion in paediatric airway epithelial cultures.  
To determine the relative proportion of chloride transported by CaCC, the effect of 
chloride removal from Ussing chamber solutions was compared using 125 mM 
chloride with chloride free (0 mM) Krebs solutions. The composition of these 
solutions has been previously described in Chapter 2 section 2.5. Representative 
Ussing chamber traces demonstrating the responses seen in both 125 mM and 0 mM 
chloride Krebs are shown below in Figure 82. These experiments were performed in 
PNEC and PBEC cultures isolated from the non-CF PWT8 donor. It is evident that in 
both cases, removal of chloride resulted in a reduction in responses to amiloride, 
forskolin, CFTRinh-172 and UTP.  
The effect of chloride removal was investigated in 3 PNEC and 3 PBEC non-CF 
cultures. As shown in Figure 83, responses to forskolin were significantly reduced in 
0 mM chloride (125mM chloride: 22.0 µA/cm2, IQR 12.1 to 24.9 versus 0 mM 
chloride: 1.4µA/cm2, IQR 0.9 to 2.4, p=0.002). This was also the case with the 
CFTRinh-172-sensitive Isc (125 mM chloride: -16.1 µA/cm2, IQR -9.3 to -23.7 versus 0 
mM chloride: -2.5 µA/cm2, IQR -1.2 to -3.9, p=0.002). Each response was calculated 
as a percentage response relative to 125 mM chloride (which was given a value of 
100 %).  As shown in Figure 83, the percentage forskolin-induced Isc responses in 0 
mM chloride in both PNECs and PBECs were significantly less than responses seen 
at 125 mM chloride (PNEC: 8.6 % ±4.9; p=0.03; PBEC: 10.7 % ±5.5, p=0.04). The 
percentage responses for CFTRinh-172-sensitive Isc at 0 mM chloride were also 
reduced but the findings did not reach statistical significance (PNEC: 10.6 % ±4.3, 
p=0.11; PBEC: 21.5 % ±5.3, p>0.99). 
The effects of chloride removal on the resultant UTP-induced Isc were next 
investigated in 8 cultures (non-CF PNEC, non-CF PBEC and CF PNEC). Although 
there was a reduction in the UTP-induced Isc in 0 mM chloride in all cultures as 
shown in Figure 84, the changes were not statistically significant (125 mM chloride: 
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2.4 µA/cm2, IQR 1.9 to 4.2 versus 0 mM 1.5 µA/cm2, IQR 0.8 to 2.7, p=0.1). The 
percentage UTP-induced Isc response in 0 mM chloride relative to 125 mM in all three 
culture groups were all reduced, but only statistically significant in the non-CF PNECs 
(non-CF PNEC: 49.8 % ±7.6, p=0.04; non-CF PBEC: 78.4 % ±21.5, p=0.52; CF 
PNEC: 46.6 % ±21.2, p=0.09). Notably, UTP-induced Isc responses in all 3 groups in 
0 mM chloride conditions were proportionally greater than those evident with forskolin 
and CFTRinh-172.  
Overall these results have shown that in this cohort of paediatric cultures, as 
predicted, CFTR was predominantly involved in chloride secretion. Importantly, the 
relative contribution of CaCC-mediated chloride transport was proportionately less 
than CFTR. Aside from the non-CF PNECs, there were no differences in the UTP-
induced Isc in chloride and chloride-free conditions. The large residual Isc response, 
the effect of which was greatest in non-CF PBECs, could be secondary to 
bicarbonate transport, but confirmation of this would require further detailed 
investigation.  
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Figure 82: Representative trace of UTP-induced short circuit current in 125 mM 
and 0 mM chloride Krebs in PNEC and PBEC cultures isolated from a non-CF 
donor 
PNEC and PBEC ALI culture inserts derived from the non-CF PWT8 donor were 
mounted in the Ussing chamber and bathed apically and basolaterally in 125 mM 
chloride Krebs solution. After a 20-minute period of stabilisation, 10 µM amiloride was 
added to the apical compartment, followed by 10 µM forskolin, 20 µM CFTRinh-172 
and 100 µM UTP at 25, 35 and 45 minutes respectively. This was repeated in 0 mM 
chloride Krebs solution. Resultant short circuit current (Isc) responses for the PNEC 
(A) and PBEC cultures (B) are shown above at 125 mM chloride (solid black line) and 
0 mM chloride (dashed black line); n=1 insert for each culture type. 
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Figure 83: Short circuit responses to forskolin and CFTRinh-172 in 125 mM and 
0 mM chloride Krebs in non-CF PNEC and PBEC cultures  
Resultant short circuit current responses to forskolin and CFTRinh-172 (DIsc ) are 
shown in A and B respectively at 125 mM and 0 mM chloride solutions. Each point 
represents the mean DIsc for each donor; each line represents individual donors. Data 
was analysed using the Mann-Whitney test; p=0.002 for forskolin and CFTRinh-172. 
The percentage DIsc at 0 mM relative to 125 mM chloride was calculated as shown in 
C. Bars represent mean percentage ±SD. Data is analysed using Kruskal-Wallis and 
post hoc Dunn’s multiple comparison test; non-CF PNEC 0 mM versus 125 mM 
chloride DIsc forskolin: p=0.03; non-CF PBEC 0 mM versus 125 mM chloride DIsc 
CFTRinh-172: p=0.04 for; non-CF PNECs n=3 donors (10 inserts); non-CF PBECs 
n=3 donors (9 inserts).  
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Figure 84: Short circuit current responses to UTP in 125 mM and 0 mM chloride 
Krebs in PNEC and PBEC cultures 
Resultant short circuit current responses to UTP (DIsc ) at 125 mM and 0 mM chloride 
solutions are shown in A. Each point represents the mean DIsc for each donor; each 
line represents individual donors. Data analysed using the Mann-Whitney test with no 
statistical differences found. Percentage DIsc at 0 mM chloride relative to 125 mM 
chloride was calculated as shown in B. Bars represent mean percentage ± SD. Data 
is analysed using Kruskal-Wallis and post hoc Dunn’s multiple comparison test; non-
CF PNEC 0 mM versus 125 mM: p=0.04; non-CF PBEC. 0 mM versus 125 mM: 
p=0.54, CF PBEC 0 mM versus 125 mM: p=0.09; non-CF PNECs n=3 donors (6 
inserts); non-CF PBECs n=3 donors (6 inserts); CF PNECs: n=2 donors (5 inserts).  
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5.4.3 Investigation of the atypical UTP-induced short circuit current responses  
In a cohort of ALI cultures, apical UTP addition in Ussing chamber experiments 
resulted in responses that were not characteristic of CaCC activation. This occurred 
in 3 CF PBECs, 1 non-CF PBEC and 1 CF PNEC culture. It was not possible to 
reliably calculate the UTP-mediated CaCC activation in these cultures, and although 
Isc changes were present, results from these cultures were omitted from the above 
comparisons and analyses.  
Apical UTP addition in these circumstances resulted in a downward deflection in Isc 
response, which is contrary to the characteristic upward change caused by CaCC-
mediated chloride secretion under these experimental conditions. To demonstrate 
this effect, representative Ussing chamber traces from paired PNEC/PBEC cultures 
isolated from the PCF23 CF donor are shown in Figure 85. Panel A demonstrates the 
negative Isc responses seen in both PNEC and PBECs, with a smaller response 
evident in PNECs (PNEC: -2.5 µA/cm2 ± SD 3.2 versus PBEC: -12.2 µA/cm2 ±3.9; 
mean responses derived from 2 culture inserts from each donor). Corresponding 
TEER changes are shown in panel B, where there was an associated TEER 
reduction of similar magnitudes resulting from increased channel conductance 
(PBEC: -308.8 W.cm2 ±68.4; PNEC: -312 308.8 W.cm2 ±37.0).  
Similar to the changes seen with CaCC activation, these Isc responses were 
transient, raising the possibility of an alternative UTP-mediated calcium activated 
channel. UTP-induced CaCC activation characteristically results in a positive Isc, 
resulting from the outward flux of anions i.e. chloride ion secretion. However, the 
alternative resultant negative Isc responses were likely caused by an outward flux of 
cations. This together with their transient nature led to the hypotheses that they were 
secondary to UTP-mediated activation of large conductance calcium activated 
potassium (BK) channels.  
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Figure 85: Representative Ussing chamber traces of the UTP-induced short 
circuit current and transepithelial electrical resistance response in PNEC and 
PBEC cultures derived from the PCF23 donor 
Ussing chamber short circuit current (Isc) traces for PNEC (A) and PBEC (B) cultures 
isolated from the PCF23 donor (F508del/2896delA) are shown. Corresponding  
transepithelial resistance (TEER) traces for PNECs and PBECs are shown in C and 
D respectively; n=1 culture insert for each condition.   
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5.4.4 Effects of barium chloride and BAPTA-AM on the atypical UTP-induced 
short circuit current response 
To investigate this hypothesis, barium chloride (BaCl2), a non-selective BK channel 
inhibitor, was added to the apical Ussing chamber compartment to determine its 
effects on the resultant Isc in the PCF23 PNEC/PBEC cultures (2 culture inserts were 
used for each PBEC/PNEC). As demonstrated in Figure 86, apical addition of BaCl2 
prior to UTP eliminated the negative Isc that was previously evident in the PNEC 
cultures, with a resultant positive Isc response of 2.4 µA/cm2 ±0.6 and a reduction in 
TEER decline (-77.1 W.cm2 ±68.3). In the PBECs, the UTP-induced Isc remained 
negative after BaCl2  addition, however, the magnitude of both Isc and TEER 
responses were reduced (Isc: -2.4 4 µA/cm2 ±2.2; TEER: -69.9 W.cm2 ±3.5). Of note, 
the response at the time of BaCl2 addition evident in Figure 86 was likely secondary 
to artefact and was not present in other experiments involving BaCl2 addition.  
To investigate if these negative Isc responses were calcium-mediated, cell cultures 
were pre-treated with the calcium-selective cell permeator, BAPTA-AM (50 µM), for 
60 minutes prior to performing Ussing chamber experiments to determine effects on 
UTP-induced Isc and TEER. This was performed in the PCF25 PNEC/PBEC culture 
pair. Resultant traces together with changes in Isc response are shown (Figure 87). 
Untreated PCF25 PNEC cultures demonstrated characteristic Isc responses to UTP 
albeit small (1.1 µA/cm2). In contrast, the PBEC culture showed a rapid UTP-induced 
decline in Isc of -1.2 µA/cm2 followed by an increase of 2.5 µA/cm2. This was 
consistently evident in these PBEC cultures, suggesting a combination of potassium 
conductance and chloride secretion.  
BAPTA-AM treatment in PNECs did not alter the resultant UTP-induced Isc 
(untreated: 0.6 µA/cm2 ±0.4; BAPTA-AM: 0.7 µA/cm2 ± 0.2). Notably, there was a 2-
fold reduction in the resultant negative and positive induced-Isc in PBECs (negative Isc 
untreated: -2.8 µA/cm2 ±2.2 versus BAPTA-AM: -1.3 µA/cm2 ±0.5; positive Isc 
untreated: 3.9 µA/cm2 ±2.0 versus BAPTA-AM: 1.8 µA/cm2 ±1.3). Experiments were 
performed in 2 culture inserts from each donor for each condition and therefore 
formal statistical analysis was not performed. However, these results suggested that 
calcium chelation reduced the UTP-induced responses in these PBECs, with no 
effect seen in PNECs. This could be explained by the relatively small UTP-induced Isc 
present in untreated cultures or requirement for optimisation of the protocol used for 
BAPTA-AM addition in primary cultures.  
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Figure 86: Representative Ussing chamber traces demonstrating the effects of 
barium chloride on the UTP-induced short circuit current response in PNEC 
and PBEC cultures derived from the CF PCF23 donor 
Ussing chamber short circuit current (Isc) traces for PNEC (A) and PBEC (B) cultures 
isolated from the CF PCF23 donor (F508del/2896delA) are shown. Barium chloride 
(BaCl2) was added 5 minutes prior to UTP addition. The resultant change in peak 
short circuit current (DIsc) was calculated (C). Bars represent mean ± SD; untreated: 
n=3 inserts for each culture type; BaCl2: n=2 culture inserts for each culture type 
(statistical tests not applied). 
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Figure 87: Representative Ussing chamber traces demonstrating the effects of 
BAPTA-AM pre-treatment on the UTP- induced short circuit current response in 
PNEC and PBEC cultures derived from the CF PCF25 donor 
Ussing chamber short circuit current (Isc)  traces for PNEC (A) and PBEC (B) cultures 
isolated from the CF PCF25 donor (F508del/F508del) are shown above. Cell cultures 
were treated with 50 µM BAPTA-AM for 60 minutes prior to the Ussing chamber 
experiment. The resultant change in peak UTP-induced short circuit current (DIsc) 
was calculated (C). Bars represent mean ± SD; untreated: n=2 inserts for each 
culture type; BAPTA-AM: n=2 culture inserts for each culture type (statistical tests not 
applied). 
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5.4.5 Assessment of chloride-dependence of the atypical UTP-induced short 
circuit current response 
To determine the chloride-dependent nature of this negative UTP-induced Isc 
response, Ussing chamber experiments were performed in 125 mM and 0 mM 
chloride Krebs. These experiments were carried out in paired non-CF PWT17 PNEC 
and PBEC cultures (Figure 88). Due to a limited number of available culture inserts, 1 
insert was used for each assessment. In 125 mM chloride. The resultant UTP-
induced Isc in PNECs was positive in 125 mM chloride (3.8 µA/cm2), which was 
negative in chloride free conditions (-0.9 µA/cm2). In 125 mM chloride, the response 
in PBECs was initially negative (-5.3 µA/cm2), followed by an increase by 4.7 µA/cm2 
from baseline. Chloride removal eliminated the positive Isc component and the 
resultant negative Isc predominated. This modification in Isc response was also 
evident in the CF PCF22 PBEC culture as shown in Figure 89. In all cases, there was 
an associated decrease in resistance, again suggesting an increase in conductance 
(data not shown). The results obtained for the Ussing chamber experiments 
performed in 0 mM chloride suggested that the UTP-induced negative response was 
caused by chloride-independent channel activation.  
Overall, experiments investigating the effects BaCl2 and BAPTA in conjunction with 
assessment in chloride free conditions suggested that these responses were 
secondary to the UTP-induced activation of BK channels. This was not explored 
further during this PhD but does require further investigation using inhibitors of 
specific BK channels together with the exploration of BK channel expression in 
differentiated ALI cultures.  
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Figure 88: Representative Ussing chamber traces demonstrating the UTP-
induced short circuit current in 125 mM and 0 mM chloride Krebs solutions in 
PNEC and PBEC cultures derived from the non-CF PWT17 donor 
Ussing chamber short circuit current (Isc)  traces for PNEC and PBEC cultures 
isolated from the non-CF PWT17 donor are shown above in 125 mM chloride (A and 
B) and 0 mM chloride (C and D);  n=1 culture insert for each condition.   
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Figure 89 : Representative Ussing chamber traces for the UTP-induced short 
circuit current response in 125 mM and 0 mM chloride Krebs in PBEC cultures 
derived from the CF PCF22 donor  
Ussing chamber short circuit current (Isc)  traces for PBEC cultures isolated from the 
CF PCF22B donor (F508del/F508del) are shown above in 125 mM chloride (A) and 0 
mM chloride (B);  n=1 culture insert for each condition.   
 
 
 
 
 
 
 
 
40 45 50 55 60
-6
-4
-2
0
2
4
6
Time (min)
I sc
 (µ
A
/c
m
2 )
UTP
A
125 mM chloride Krebs
40 45 50 55 60
-6
-4
-2
0
2
4
6
Time (min)
I sc
 (µ
A
/c
m
2 )
UTP
B
0 mM chloride Krebs
  209 
5.4.6 Assessment of TMEM16A activation with the small molecule activator 
Eact in paediatric primary nasal epithelial cultures 
Although purinergic agonists such as UTP are useful to determine the functional 
expression of CaCC in paediatric ALI cultures in Ussing chamber experiments, 
alternative agonists are required to enable the specific investigation of TMEM16A. In 
2011, the small molecule Eact was discovered by high throughput screening of over 
100,000 compounds as a potent putative activator of TMEM16A (Namkung et al., 
2011b). Its mechanism of action is thought to be calcium-independent, through direct 
binding to the calcium binding site on TMEM16A (Namkung et al., 2011b). The 
effects of Eact were investigated during this PhD in Ussing chamber experiments 
involving paediatric differentiated ALI cultures at 25 to 33d ALI.  
Initial evaluation was performed using conditions as previously described, with the 
application of 125 mM chloride Krebs to both Ussing chamber compartments, and 
the initial apical addition of amiloride, forskolin and CFTRinh-172 as previously 
described. The Eact-induced Isc relative to UTP was first established and investigated 
in PNEC cultures derived from a CF donor. As shown by the representative Ussing 
chamber traces in Figure 90, the Eact-induced Isc was comparatively small (Eact: 0.7 
µA/cm2; UTP: 8.1 µA/cm2).  
To determine if this Eact-induced response could be augmented, a chloride gradient 
was established using 40 mM chloride Krebs apically and 125 mM chloride Krebs 
basolaterally (as previously described in Chapter 2 section 2.5) in PNEC cultures 
derived from the PWT4 donor. Responses using this chloride gradient were 
compared with experiments performed with 125 mM and 0 mM chloride solutions. 
Representative Isc and TEER traces for each condition results are shown below in 
Figure 91 and summarised in Table 19. Due to limited culture insert availability, these 
experiments were performed only once, and therefore provide only descriptive data. 
Introduction of a chloride gradient increased the forskolin-induced Isc (26.4 µA/cm2) 
compared with 125 mM (20.4 µA/cm2) and 0 mM chloride (1.2 µA/cm2) conditions. In 
these cultures, introduction of a chloride gradient did not alter the resultant UTP-
induced Isc compared with 125 mM chloride (2.4 µA/cm2 versus 2.2 µA/cm2).  Eact 
induced-Isc responses were evident in both 125 mM chloride and with the presence of 
a chloride gradient, however the nature of response differed in the 2 conditions, as 
evident in Figure 91 and Table 19. In 125 mM chloride Krebs, there was a gradual 
increase in the Eact-induced Isc, with a peak response of 1.4 µA/cm2, occurring 5 min 
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after Eact addition, followed by a return to a baseline of 0.2 µA/cm2. With a chloride 
gradient, the Eact-induced Isc was greater at 2.3 µA/cm2, peaking 10 min after Eact 
addition. Furthermore, although the total duration of Eact response cannot be 
determined in these experiments due to the subsequent addition of UTP, the Isc 
increase was more sustained, and had reduced by only 0.4 µA/cm2 from the peak 
value at this time. The Eact-induced Isc was the lowest in 0 mM chloride of 0.3 
µA/cm2 and the total response was much shorter in duration.  
In all chloride containing Krebs solutions, Eact addition was associated with a TEER 
reduction, indicating increased chloride secretion. Although there was an initial 
decline in TEER in 0 mM chloride that could attributed to bicarbonate secretion, there 
was a subsequent complete loss of TEER and large reduction in Isc after UTP 
addition. This sudden decline was likely caused by epithelial cell damage, resulting in 
loss of tight junction integrity and subsequent leakage of ions. Experiments were well 
tolerated in other conditions.  
The effect of a chloride gradient on the Eact-induced Isc was explored further in 
differentiated PNEC cultures isolated from 3 non-CF and 5 CF donors at 25 to 33d 
ALI. PNECs derived from 1 of each non-CF and CF donors did not respond (data not 
shown). It is evident from Figure 92 that in Eact responders, there was considerable 
intra-donor variability in the peak induced Isc, and although donor numbers were 
small, this variability was greater in non-CF cultures. The peak Eact induced Isc was 
3.2-fold greater in non-CF PNECs, however this was not statistically significant (non-
CF: 1.9 µA/cm2, IQR 1.2 to 2.7 versus CF: 0.6 µA/cm2, IQR 0.5 to 1.1, p=0.13). This 
was paralleled with a suggested higher total Eact-induced Isc in the non-CF group 
(non-CF: 28.3 µA/cm2.min, IQR 24.7 to 32.0 versus CF: 6.4 µA/cm2.min, IQR 3.4 to 
22.2; p=0.27). Overall, these results suggested that treatment with Eact generated an 
Isc in these cultures and the effects were greatest in non-CF PNECs. The lack of 
statistical significance is likely due to limited culture numbers. 
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Figure 90: Representative Ussing chamber trace demonstrating short circuit 
current responses to UTP and Eact in a CF PNEC culture  
A PNEC ALI culture insert the CF PCF10N donor (F508del/F508del) was mounted in 
the Ussing chamber and bathed apically and basolaterally in 125 mM chloride Krebs. 
After the addition of amiloride, forskolin and CFTRinh-172 (not shown) either 100 µM 
UTP (grey) or 10 µM Eact (black) were added apically. Resultant short circuit current 
(Isc) responses are shown in A. The magnified Eact-induced Isc response is shown in 
B.  
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Figure 91: Representative short circuit current and transepithelial electrical 
resistance responses demonstrating the effects of chloride concentration in 
PNEC cultures derived from a non-CF donor  
PNEC culture inserts derived from the non-CF PWT4 donor were mounted in the 
Ussing chamber and bathed bilaterally in 125 mM or 0 mM chloride, or in a 40/125 
mM apical to basolateral chloride gradient. After a period of stabilisation, 10 µM 
amiloride, 10 µM forskolin, 20 µM CFTRinh-172, 10 µM Eact and 100 µM UTP were 
added apically at 30, 35, 40, 50 and 70 minutes respectively. Resultant short circuit 
current (Isc) and corresponding transepithelial electrical resistance (TEER) were 
measured as shown in A and B respectively; n=1 culture insert for each condition.  
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Measurement 0 mM chloride 125 mM 
chloride 
40/125 mM chloride 
Peak D Isc  (µA/cm2) 0.3  1.4  2.2  
AUC (µA/cm2.min) 1.4  19.0 44.6 
Duration (min) 6.5 25 > 25 
D TEER (W.cm2) -486 -134 -289 
Table 19: Ussing chamber responses to Eact in 0 mM chloride, 125 mM 
chloride and a 40mM/125mM apical to basolateral chloride gradient in PNEC 
cultures isolated from the non-CF PWT4 donor 
Abbreviations: DIsc: change in short circuit current; AUC: area under the curve; 
TEER: transepithelial resistance.  
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Figure 92: Assessment of Eact-induced short circuit current in non-CF and CF 
PNEC cultures  
The Eact-induced change in peak short circuit current (DIsc) was assessed in 
differentiated non-CF and CF PNECs in Ussing chamber experiments. Responses 
seen in each donor are shown in A, where each point represents the mean response 
± SD. Donors with no response to Eact are shown in red. Combined Eact peak DIsc 
and total (AUC) responses for non-CF and CF PNECs are shown in B and C 
respectively. Data is presented as median ± IQR and analysed with Mann Whitney 
test with no significant differences found. Non-CF PNECs (n=2 donors, 4 inserts), CF 
PNECs (n=4, 11 inserts). 
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5.4.7 Investigation of the effects of IL-4 on TMEM16 activation with Eact in 
paediatric primary nasal epithelial cultures 
It has been shown previously by other groups that treatment of primary airway 
epithelial cultures with cytokines such as IL-4 or IL-13 promote a pro-secretory profile 
due to decreases in the amiloride-sensitive Isc and increases in the forskolin and 
CaCC-induced responses (Danahay et al., 2002, Galietta et al., 2002, Gorrieri et al., 
2016).  In view of the relatively small magnitude of the Eact-induced Isc described in 
the previous section, cell cultures were treated with IL-4 to determine if these 
responses could be enhanced.  
Representative Ussing chamber traces demonstrating the comparative responses in 
vehicle control or IL-4 treated cultures for PNEC cultures derived from a non-CF and 
CF donor are shown in Figure 93 and Figure 94 respectively. As shown in Figure 93, 
the amiloride-sensitive Isc in the PWT2 PNEC was reduced from -135 to -14.9 
µA/cm2. There was no effect on the forskolin and CFTRinh-172 responses. In these 
cultures, there was no Eact-induced Isc, however, IL-4 treatment resulted in a small 
response of 0.5 µA/cm2 as shown in this figure. The UTP-induced Isc demonstrated in 
this figure increased over 3 times with IL-4 treatment from 13.6 to 44.7 µA/cm2. 
Representative Isc traces for PCF15 PNEC cultures in Figure 94 showed a similar 
picture, with a decrease in the amiloride-sensitive Isc from -11.0 to -2.5 µA/cm2 and 
an increase in the UTP-induced Isc from 6.7 to 19.8 µA/cm2. However, IL-4 treatment 
did not affect the magnitude of the Eact-induced Isc (0.5 µA/cm2). 
Responses to Eact in control and IL-4 treated cultures were assessed in PNECs 
derived from 2 non-CF and 2 CF donors as shown in Figure 95. IL-4 treatment 
increased the Eact-induced Isc in all cultures aside from PCF15. All three culture 
inserts derived from the PWT1 donor did not show an Eact response in control 
conditions, but there was a suggested increase with IL-4 treatment (IL-4: 0.5 µA/cm2, 
IQR 0.3 to 0.8, p=0.1). PWT2 PNECs showed the greatest Eact-induced Isc under 
control conditions (2.7 µA/cm2, IQR 1.8 to 3.5), which in 1 culture insert was 
increased by IL-4 treatment to 8.7 µA/cm2.  IL-4 treatment in cultures derived from 
PCF13N suggested an increase in the Eact-induced Isc  by 179 % (control: 0.43 
µA/cm2, IQR 0.4 to 0.5 versus IL-4: 1.3 µA/cm2, IQR 1.2 to 1.5 , p=0.2).  
Comparable UTP-induced Isc responses in IL-4 treated cultures (1 non-CF and 2 CF 
PNECs) are also shown in Figure 95. In all cases, IL-4 treatment demonstrated large 
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increases in the UTP-induced Isc. Notably this was also evident in the PCF15 
cultures, which had failed to show a response with Eact. For completion, the 
comparable responses to amiloride, forskolin and CFTRinh-172 are shown in Figure 
96. As expected, all cultures demonstrated reductions in the amiloride-sensitive Isc 
after IL-4 treatment. Cultures derived from PWT1 did not demonstrate an increase in 
the forskolin-induced Isc, but there was a larger response to CFTRinh-172. PWT2N did 
show enhanced CFTR activity with IL-4 treatment. Notably, it was possible to 
increase Isc responses to forskolin and CFTRinh-172 in the PCF15 PNEC cultures by 
214 % and 117 % respectively.  
These results indicate treatment with IL-4 produced expected responses in ENaC, 
CFTR and CaCC-mediated ion transport. It was possible to enhance the activity of 
Eact with IL-4 treatment, but this was not consistently possible in all cultures 
investigated. 
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Figure 93: Representative Ussing chamber traces demonstrating the effects of 
IL-4 treatment in PNEC cultures derived from a non-CF donor 
PNEC culture inserts derived from the non-CF PWT1 donor were mounted in the 
Ussing chamber and bathed bilaterally in a 40/125 mM chloride gradient. After a 
period of stabilisation, 10 µM amiloride, 10 µM forskolin and 20 µM CFTRinh-172 were 
added apically at 30, 35, and 40 minutes respectively as shown in A. 10 µM Eact was 
added at 45 minutes followed by 100 µM UTP as shown in B and C respectively. The 
representative traces shown above demonstrate Isc responses for culture inserts 
either treated with 10 ng IL-4 (grey) or vehicle control (black) for 24 hours; n=1 
culture insert for each condition. 
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Figure 94: Representative Ussing chamber traces demonstrating the effects of 
IL-4 treatment in PNEC cultures derived from a CF donor 
PNEC culture inserts derived from the CF PCF15 donor were mounted in the Ussing 
chamber and bathed bilaterally in a 40/125 mM chloride gradient. After a period of 
stabilisation, 10 µM amiloride, 10 µM forskolin and 20 µM CFTRinh-172 were added 
apically at 30, 35, and 40 minutes respectively as shown in A. 10 µM Eact was added 
at 45 minutes followed by 100 µM UTP as shown in B and C respectively. The 
representative traces shown above demonstrate Isc responses for culture inserts 
either treated with 10 ng IL-4 (black) or vehicle control (grey) for 24 hours; n=1 
culture insert for each condition. 
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Figure 95: Effects of IL-4 treatment of the peak UTP and Eact-induced short 
circuit current responses in non-CF and CF PNEC cultures 
Cultures were treated with vehicle control (black) or IL-4 (grey) for 24 hours and 
investigated in Ussing chamber experiments. The resultant Eact and UTP-induced 
change in peak short circuit current (DIsc) are shown in A and B respectively. Data is 
presented as the mean Isc response ± SD and analysed with Mann Whitney test with 
no significant differences found. Percentage increases in Isc in IL-4 treated cultures 
are included. PWT1N: n=6 inserts; PWT2N: n=3 (1 for IL-4); PCF13N: n=5; PCF15N: 
n=9. 
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Figure 96: Effects of IL-4 treatment on short circuit current responses to 
amiloride, forskolin and CFTRinh-172 in non-CF and CF PNECs  
Cultures were treated with vehicle control (black) or IL-4 (grey) for 24 hours and 
investigated in Ussing chamber experiments. The resultant short circuit responses 
(DIsc) to amiloride, forskolin and CFTRinh-172 are shown in A,B and C respectively. 
Data  presented as the mean Isc response ± SD and analysed with Mann Whitney 
test; PCF15N CFTRinh-172; p=0.02. Percentage increases in Isc in IL-4 treated 
cultures are included. PWT1N: n=6 inserts; PWT2N: n=4; PCF13N: n=5; PCF15N: 
n=9. 
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5.4.8 Investigation of Eact addition in differentiated paediatric CF primary 
bronchial epithelial cultures  
The effects of Eact in PNECs were more sustained than the typical UTP-induced Isc 
therefore supporting previous published data to suggest that Eact activates 
TMEM16A via calcium-independent mechanisms (Namkung et al., 2011b). It was 
uncertain as to how the CF PBEC cultures would respond, given their 
uncharacteristic response to UTP as previously detailed in section 5.4.3.  
To firstly ascertain the nature of Eact-induced Isc in CF PBECs and secondly 
determine any potential effects of application of both Eact and UTP in the same 
culture inserts, Ussing chamber experiments were performed in PBEC cultures 
derived from a CF donor (PCF22). Experiments were first performed using 125 mM 
chloride Krebs in both apical and basolateral compartments as previously described, 
with the initial addition of amiloride, forskolin and CFTRinh-172. UTP (100 µM) was 
next added apically, followed by Eact (10 µM) after 20 minutes; these were alternated 
in separate culture inserts for comparative assessment. Two culture inserts were 
used for each assessment and the mean Isc and TEER were assessed as shown in 
Figure 97.  
As shown in Figure 97A, apical UTP addition initially caused a downward deflection 
in the Isc by a mean of -1.9 µA/cm2 ± SD 1.6 followed by an increase from baseline of 
2.0 µA/cm2 ±0.1. This was associated with a mean TEER reduction of -146 W.cm2 ± 
SD 25 due to an increase in ion conductance (Figure 97B). As previously described, 
this was most likely secondary to a combination of BK and CaCC activation. After a 
steady baseline Isc, subsequent Eact addition resulted in a further Isc decline by -4.3 
µA/cm2 ±1.1 associated with an initial drop in TEER by -167 W.cm2  ±4.0. However, 
after this initial Isc decline, there was a disproportionate Isc increase associated with a 
decline in resistance to near 0 levels over a 20 min period. This latter finding 
suggested that the epithelial monolayer was damaged, resulting in paracellular ion 
transport. Figure 97C and Figure 97D demonstrate the effects on Isc and TEER of 
Eact addition prior to UTP. Although Eact addition caused a small initial decrease in 
Isc, there was an associated reduction in TEER by -163 W.cm2  ±53. This was 
followed by a gradual loss of TEER in conjunction with a gradual Isc increase, again 
suggesting epithelial damage. Although UTP was added as shown, there was no 
response due to the ongoing decline of monolayer integrity.   
  222 
These results revealed an atypical UTP-induced Isc response, whereby there was an 
initial downward deflection followed by an upward change, suggesting a combination 
of BK and CaCC activation. Eact had been well tolerated in PNECs, however its 
addition in these PBECs either pre or post UTP resulted in epithelial damage and 
complete loss of resistance. It was hypothesised that these detrimental effects were 
secondary to non-CaCC channel activation and in view of the previously described 
effects of UTP on probable BK channel activation, it was hypothesised that these 
channels may predominate in the CF PBEC cultures and that like UTP, Eact was 
also demonstrating a similar secondary effect. 
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Figure 97: Representative Ussing chamber traces demonstrating the UTP-and 
Eact induced short circuit current responses in 125 mM chloride in PBEC 
cultures derived from the CF PCF22 donor 
Ussing chamber short circuit current (Isc)  and transepithelial resistance (TEER) 
traces for PBEC cultures isolated from the CF PCF22B donor (F508del/F508del) are 
shown above in 125 mM chloride with the initial addition of UTP followed by Eact (A) 
with the corresponding TEER responses (B).  Isc (C)and TEER (D) responses for the 
alternative addition of Eact added prior to UTP are shown; n=2 inserts for A, B and D, 
n=1 insert for C.   
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5.4.9 Assessment of chloride-dependence of the atypical Eact-induced short 
circuit current response 
To determine the chloride-dependent nature of this atypical Eact-induced Isc 
response, Ussing chamber experiments involving PCF22 PBECs were firstly 
repeated in 0 mM chloride Krebs to determine the chloride-dependence of the Eact 
response. As shown in Figure 98A and B, initial application of UTP in 0 mM chloride 
abolished the secondary upward Isc that was evident in 125 mM chloride, and 
resultant UTP-induced Isc and TEER responses were reduced, to -8.7 µA/cm2 ±0.2 
and -333 W.cm2  ±17 respectively. Similar to 125 mM chloride conditions, the 
response was transient, with a return to a stable Isc baseline and TEER recovery. 
Eact addition showed a similar response to that seen at 125 mM chloride, however, 
the induced response was greater at -8.3 µA/cm2 ±0.1. However, once again Eact 
addition was followed by a large Isc increase and loss of TEER. As shown Figure 98C 
and D, initial Eact addition prior to UTP generated a larger negative deflection in Isc at 
0 mM compared with 125 mM chloride of -9.9 µA/cm2 ±2.2. Once again, the effects of 
UTP were not determined due to a complete loss of TEER. 
These results for the experiments performed in both 125 mM and 0 mM chloride are 
summarised in Figure 99, with detrimental effects of Eact application in these CF 
PBEC cultures apparent both pre and post UTP addition. As with UTP, the 
magnitude of the initial Eact-induced Isc was greater in 0 mM chloride conditions 
(UTP: p=0.008; Eact: p=0.05) suggesting also potential involvement of calcium 
activated BK channels.  
To determine if the above responses were consistently evident in CF PBECs, Eact 
assessment was next performed in PBEC cultures derived from a different donor, 
PCF23. These cultures had also previously shown negative UTP-induced Isc with an 
associated decrease in TEER (as previously shown in Figure 85). Like the PCF22 
PBEC cultures, Eact addition after UTP in PCF23 cultures resulted in a negative Isc 
Figure 100A). However, the resultant Isc response together with the associated TEER 
reduction was transient, showing signs of recovery, with no apparent effect on 
epithelial monolayer integrity (Figure 100B). Eact application prior to UTP resulted in 
a similar effect to that seen with PCF22B PBECs, whereby there was a decline in 
TEER demonstrating loss of epithelial resistance as evident in Figure 100C and D.  
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Figure 98: Representative Ussing chamber traces demonstrating the UTP-and 
Eact induced short circuit current responses in 0 mM chloride in PBEC 
cultures derived from the CF PCF22 donor 
Ussing chamber short circuit current (Isc)  and transepithelial resistance (TEER) 
traces for PBEC cultures isolated from the CF PCF22B donor (F508del/F508del) are 
shown above in 0 mM chloride with the initial addition of UTP followed by Eact (A) 
with the corresponding TEER responses (B).  Isc (C)and TEER (D) responses for the 
alternative addition of Eact added prior to UTP are shown; n=2 inserts for each 
condition.  
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Figure 99: Resultant short circuit current and transepithelial resistance 
responses to UTP and Eact addition in 125 mM and 0 mM chloride in PBECs 
isolated from the CF PCF22 donor 
The resultant short circuit (DIsc) and transepithelial resistance (DTEER) in 125 mM 
and 0 mM chloride Krebs are shown in A and B respectively. The effects of UTP 
followed by Eact addition are demonstrated in addition to the alternative application 
of Eact followed by UTP.  Data is presented as the mean response ± SD; n=2 inserts 
for each condition therefore statistical analysis not performed.  
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Figure 100: Representative Ussing chamber traces of short circuit current and 
transepithelial electrical resistance responses to UTP and Eact in PBEC 
cultures derived from the CF PCF23 donor  
Ussing chamber short circuit current (Isc)  and transepithelial resistance (TEER) 
traces for PBEC cultures isolated from the CF PCF23 donor (F508del/2896delA) are 
shown above with the initial addition of UTP followed by Eact (A) with the 
corresponding TEER responses (C).  Isc (C)and TEER (D) responses for the 
alternative addition of Eact added prior to UTP are shown; n=1 insert for each 
condition.  
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5.4.10 Effects of barium chloride and BAPTA-AM on the atypical Eact-induced 
short circuit current response 
It was possible that these effects were also secondary to BK channel activation and 
the effects of channel inhibition with BaCl2 were next investigated as shown in Figure 
101A and B. Furthermore, in view of the suggestion that these effects were calcium-
mediated, the calcium-selective cell permeator, BAPTA-AM was applied to the 
cultures as previously described to determine any modification in resultant Isc and 
TEER as shown in Figure 101C and D, with a summary provided in Figure 102.  
Addition of BaCl2 resulted in an overall reduction in the UTP-induced Isc. Both the 
magnitude of the UTP and Eact-induced decline in Isc and resultant TEER in these 
PBECs were reduced following the addition of BaCl2 or pre-treatment with BAPTA-
AM. Overall BaCl2 treatment reduced the UTP-induced Isc by 5-fold from -12.2 
µA/cm2  ± SD3.9 to -2.4 µA/cm2 ±3.9 with a similar reduction in TEER from -308.8 
W.cm.2 ±68.4 to 70 W.cm.2 ±3.5. The effect of BaCl2 on the Eact-induced Isc was less 
pronounced with a 3-fold reduction in both Isc and TEER from -17.9 µA/cm2 ±6.5 to -
5.5 µA/cm2 ±0.9 and -262.3 W.cm.2 ±61 to -87.0 W.cm.2 ±12.9 respectively. BAPTA-
AM pre-treatment had a smaller effect on the UTP-induced Isc and TEER to -4.1 
µA/cm2 ±2.9 and -131.1 W.cm.2 ±91 respectively. This was also the case for the Eact-
induced Isc with a resultant Isc and TEER changes of -7.6 µA/cm2 ±8.8 and -91.0 
W.cm.2 ±104.  
The effects of BaCl2 and BAPTA-AM were also investigated in PNEC cultures 
derived from the same PCF23 donor, and the results have been summarised in 
Figure 103. As previously shown in section 5.4.4, these PNECs demonstrated both 
negative and positive Isc deflections. In these cultures, addition of both BaCl2 and 
BAPTA-AM had similar effects, whereby there was complete resolution of the 
negative Isc deflection. However, responses to both reagents were less pronounced 
than in the PBECs.  
To demonstrate that the relationship between Eact and UTP was not confined to CF 
PBECs, resultant Isc traces for paired cultures obtained from the PWT8 donor are 
shown in Figure 104. Experiments were performed to assess the effect of UTP/Eact 
addition in the same culture inserts, and to ascertain any changes in chloride free 
Krebs solutions. As shown in this figure, in 125 mM chloride, UTP addition in PBEC 
and PNEC cultures was in keeping with CaCC activation when applied first. Eact did 
  229 
not cause an Isc change in PNECs. In PBECs, it caused a negative change in Isc, 
which when applied first, prevented a UTP response in PBECs, and modified the 
response in PNECs to comprise a negative component. In 0 mM chloride, Eact 
caused a negative Isc in all cases, the effect of which was greatest in PBECs. It was 
not possible to explore this further in these cultures due to limited culture insert 
availability.  
Overall these results indicate that in the PBECs investigated, the UTP and Eact-
induced Isc responses suggested activation of alternative calcium-mediated channels 
with the potential involvement of BK channels. Non-selective inhibition of these 
channels with BaCl2, and pre-treatment with the calcium chelator BAPTA-AM showed 
some evidence of reduction in the magnitude of the Isc in CF PBECs and modification 
of the response in the PCF23 PNEC investigated. However, addition of these 
reagents did not eliminate the responses completely, suggesting that other 
mechanisms may be involved or further optimisation of these protocols are required 
in primary ALI cultures. Further investigation is required to investigate the effects of 
BK channel inhibition and BAPTA-AM on the Eact-induced Isc alone. 
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Figure 101: Representative Ussing chamber traces demonstrating the effects 
of barium chloride and BAPTA-AM on the UTP and Eact-induced short circuit 
current and transepithelial resistance responses in PBEC cultures isolated 
from the CF PCF23 donor 
Ussing chamber short circuit current (Isc) and transepithelial resistance (TEER) traces 
for PBEC cultures isolated from the CF PCF23 donor (F508del/2896delA) are shown 
above. Barium chloride (BaCl2) was added 5 minutes prior to UTP addition and Eact 
was subsequently added as shown with resultant Isc (A) and TEER (B) responses.  
In a separate experiment cell culture inserts were treated with 50 µM BAPTA-AM for 
60 minutes prior to the Ussing chamber experiment. UTP and Eact were 
subsequently added as shown with resultant Isc (C) and TEER (D) responses; n=1 
insert for each culture type. 
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Figure 102: Effects of barium chloride and BAPTA-AM on short circuit current 
and transepithelial resistance measurements in PBEC cultures derived from 
the CF PCF23 donor 
The resultant changes in peak UTP and Eact-induced short circuit current (DIsc) and 
transepithelial resistance (DTEER) were determined in response to treatment with 
barium chloride (BaCl2) and BAPTA-AM as previously described in PBEC cultures 
derived from the PCF 23 donor (F508del/2896delA). Bars represent mean ± SD; n=2 
culture inserts for each condition (no statistical test applied).  
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Figure 103: Effects of barium chloride and BAPTA-AM on short circuit current 
and transepithelial resistance measurements in PNEC cultures derived from 
the CF PCF23 donor 
The resultant changes in peak UTP and Eact-induced short circuit current (DIsc) and 
transepithelial resistance (DTEER) were determined in response to treatment with 
barium chloride (BaCl2) and BAPTA-AM as previously described in PNEC cultures 
derived from the PCF 23 donor (F508del/2896delA). Bars represent mean ± SD; n=2 
culture inserts for each condition (no statistical test applied).  
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Figure 104: Representative Ussing chamber traces demonstrating the UTP-and 
Eact induced short circuit current responses in 125 mM and 0 mM chloride in 
PNEC and PBEC cultures derived from the non-CF PWT8 donor 
Ussing chamber short circuit current (Isc)  traces for PNEC and PBEC cultures 
isolated from the non-CF PWT8 donor are shown above in 125 mM (A and B) and 0 
mM chloride (C and D) conditions. Back lines represent UTP addition prior to Eact, 
green lines represent the reverse; n=2 inserts for PNECs and PBECs at 125 mM 
chloride where UTP was added first., n=1 insert for remaining conditions. 
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5.4.11 The effects of TMEM16A inhibition with small molecule inhibitors: tannic 
acid and T16inh-A01  
In view of the relatively recent identification of TMEM16A, the development of small 
molecule inhibitors has been recent, with ongoing identification of new molecules 
during the timeframe of this PhD. By measuring the kinetics of iodide efflux using 
YFP fluorescence techniques in FRT cells, tannic acid was identified as a potent 
CaCC inhibitor, with no effects on CFTR function (Namkung et al., 2010b). An 
additional compound was identified by the same group, T16inh-A01with improved 
specificity for TMEM16A inhibition (Namkung et al., 2011a). Assessment of T16inh-
A01 in airway epithelial cells revealed a small inhibition of the peak UTP-induced 
response with little effect on the total CaCC current (Namkung et al., 2011a). 
During the initial stages of this PhD, effects of both tannic acid and T16inh-A01 were 
first investigated in PNEC cultures derived from a CF donor (PCF5; Figure 105). 
Although performed only once, pre-treatment with either 100 µM tannic acid or 10 µM 
T16inh-A01 5 minutes prior to UTP addition did not alter the peak UTP-induced Isc 
response (untreated: 19.3 µA/cm2; tannic acid: 18.3 µA/cm2, T16inh-A01: 18.1 
µA/cm2), but the total response, as measured by AUC, was clearly reduced with each 
inhibitor (untreated;81.6 µA/cm2.min; tannic acid: 45 µA/cm2.min; T16inh-A01: 47.3 
µA/cm2.min). Application of tannic acid after UTP (Figure 106) caused a reduction in 
both the peak Isc (untreated: 23.1 µA/cm2; tannic acid: 16.9 µA/cm2) and the AUC 
(untreated: 95.5 cm2.min; tannic acid: 55.0 cm2.min), however, the decline in the 
UTP-induced Isc was gradual, as opposed to the immediate inhibitory effect that had 
previously been described in the literature (Namkung et al., 2010b).  
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Figure 105: The effects of tannic acid and T16inh-A01 pre-treatment on the peak 
and total UTP-induced short circuit current in PNEC cultures derived from the 
CF PCF5 donor 
Ussing chamber short circuit current (Isc)  traces for PNEC cultures isolated from the 
CF PCF5 donor (F508del/F508del) are shown above (A) for untreated (black), tannic 
acid (red) and T16inh-A01 (brown) treatment 5 minutes prior to UTP addition. 
Resultant changes in peak Isc and area under the curve (AUC) are shown in B and C 
respectively; n=1 culture insert for each condition. 
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Figure 106: The effects of tannic acid treatment on the peak and total UTP-
induced short circuit current in PNEC cultures derived from the CF PCF5 donor 
Ussing chamber short circuit current (Isc)  traces for PNEC cultures isolated from the 
CF PCF5 donor (F508del/F508del) are shown above (A) for untreated (black) and 
tannic acid (red) treatment 2 minutes after UTP addition. Resultant changes in peak 
Isc and area under the curve (AUC) are shown in B and C respectively; n=1 culture 
insert for each condition.  
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5.4.12 Inhibitory effects of the small molecule CaCCinh-A01 on TMEM16A 
Although both tannic acid and T16inh-A01 did demonstrate alterations in the UTP-
induced Isc, the activities of more potent new reagents were assessed with a view to 
enabling better characterisation of TMEM16A activity in primary cultures. This was of 
particular importance given the limitations of reliably using Eact as described above. 
The effects of an alternative TMEM16A inhibitor, CaCCinh-A01 (Namkung et al., 
2011a), were investigated in paediatric ALI PNEC cultures derived from CF donors in 
Ussing chamber experiments. Representative Isc traces taken from these 
experiments are shown in Figure 107. After the addition of amiloride, forskolin, and 
CFTRinh-172 in 125 mM chloride solutions as previously described, 10 µM CaCCinh-
A01 was added apically 5 minutes prior to 100 µM UTP. As evident from these traces 
and as summarised in Figure 108, the greatest reductions in the peak and total 
induced Isc were evident in cultures derived from PCF12 (70 % and 66 %, 
respectively). The peak UTP-induced Isc was reduced in PCF11 and PCF15N 
cultures to a lesser degree (39 % and 31 %, respectively). However, the total UTP-
induced response was greater in PCF11 and PCF15N cultures (25 % and 107 %, 
respectively), suggesting that CaCCinh-A01 had inhibited only the initial phase of the 
UTP response, with no inhibitory effect on the subsequent plateau.  
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Figure 107: Representative Ussing chamber traces  for the effects of CaCCinh-
A01 in PNEC cultures derived from 3 CF donors 
Ussing chamber short circuit current (Isc)  traces for PNEC cultures isolated from the 
CF PCF11 (A), PCF12 (B) and PCF15 (B) donors (all F508del/F508del) are shown. 
Black lines represent UTP addition in untreated conditions, green lines represent 
CaCCinh-A01 addition 5 minutes prior to UTP; n=1 inserts for each condition. 
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Figure 108: The effects of CaCCinh-A01 on the peak and total UTP-induced 
short circuit current in PNEC cultures derived from 3 CF donors 
The resultant UTP-induced change in peak short circuit current responses (DIsc  UTP 
peak) for PNECs derived from the PCF11, PCF12 and PCF15 donors (all 
F508del/F508del) are shown in A for untreated (black) and CaCCinh-A01 (green) 
treatment 5 minutes to UTP. The area under the curve (AUC) for total UTP-induced 
responses are shown in B. Data is presented as mean ± SD; n=2 inserts for each 
condition therefore statistical tests not applied.   
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5.4.13 Inhibitory effects of the small molecule Ani9 on TMEM16A 
In the search for a more potent selective inhibitor of TMEM16A, a further cell based 
screening approach again utilising FRT cells and the YFP technique was more 
recently performed by Namkung et al, and the results published during this PhD (Seo 
et al., 2016). This screen revealed an alternative compound, Ani9, to be the most 
selective inhibitor of TMEM16A to date.  
The effects of Ani9 compared with CaCCinh-A01 on the UTP-induced Isc were 
investigated in PNEC and PBEC cultures derived from the PWT17 donor. As 
previously performed, amiloride, forskolin, and CFTRinh-172 were first added to the 
Ussing chamber using 125 mM chloride solutions, after which either 10 µM CaCCinh-
A01 or 10 µM Ani9 were apically added 5 minutes prior to UTP.  
Representative Isc traces taken from these experiments together with a summary of 
the Isc changes are shown in Figure 109 and Figure 110 respectively. In PNEC 
cultures, both inhibitors reduced the peak and total UTP-induced Isc. However, the 
percentage reduction in peak and total Isc was greater with Ani9 (CaCCinh-A01: 57 % 
and 26 %, respectively, versus Ani9: 79 % and 72 %, respectively).  
PBEC cultures obtained from this donor had previously shown negative UTP-induced 
Isc responses as detailed in section 5.4.5. The effects of both inhibitors on the 
percentage reduction of peak positive UTP-induced Isc was more modest in 
comparison to PNECs (CaCCinh-A01: 26 %; Ani9: 22 %). This was also the case with 
the total positive UTP-induced Isc whereby there was a small increase of 7 % with 
CaCCinh-A01, and a reduction of 14 % with Ani9. However, as evident from the traces 
in Figure 109, addition of both inhibitors also reduced the negative responses. It is 
difficult to explain this given the activity of these inhibitors against TMEM16A and not 
BK channels, however, more comprehensive assessment of this finding was not 
possible due to limited culture insert availability.  
Overall, these results obtained with all small molecules investigated highlight the 
challenges associated with finding selective inhibitors of TMEM16A for use in Ussing 
chamber experiments involving primary ALI cultures. Although only investigated in a 
limited number of cultures, these results suggest a greater degree of inhibition with 
Ani9, however, its function in a larger group of cultures remains to be determined.  
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Figure 109: Representative Ussing chamber traces for the effects of CaCCinh-
A01 in PNEC and PBEC cultures derived from the non-CF PWT17 donor 
Ussing chamber short circuit current (Isc)  traces for PNEC (A and B) and PBEC 
cultures (C and D) isolated from the non-CF PWT17 donor are shown. Black lines 
represent UTP addition in untreated conditions, green and blue lines represent the 
addition of CaCCinh-A01 or Ani9 respectively 5 minutes prior to UTP; n=1 inserts for 
each condition. 
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Figure 110: The effects of CaCCinh-A01 and Ani9 on the peak and total UTP-
induced short circuit current in PNEC and PBEC cultures derived from the non-
CF PWT17 donor 
The resultant UTP-induced change in peak short circuit current responses (DIsc  UTP 
peak) for PNECs and PBECs derived from PWT17 donor are shown in A for 
untreated (black), CaCCinh-A01 (green) and Ani9 (blue) treatment 5 minutes to UTP. 
The area under the curve (AUC) for total UTP-induced response are shown in B. 
Data is presented as mean ± SD; n=2 inserts for each condition therefore statistical 
tests not applied.   
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5.4.14 Assessment of TMEM16A expression  
To determine the relative mRNA expression of TMEM16A in differentiated paediatric 
ALI PNEC and PBEC cultures derived from non-CF and CF donors, RT-qPCR 
analysis was performed at 28d to 33d ALI as previously described in Chapter 2 
section 2.7.  
In non-CF cultures, no differences in TMEM16A expression were apparent in PBECs 
versus PNECs as shown in Figure 111A (1.1-fold change ±1.8) and this was 
paralleled by the lack of significance in the corresponding 2-ΔCT analysis of relative 
gene expression (p=0.32; Figure 112). Although there was a small increase in 
relative TMEM16A  in CF PBECs versus CF PNECs (1.5-fold change ±0.7) as shown 
in Figure 111B, the 2-ΔCT analysis between the two groups was not statistically 
significant (p>0.99).  
Gene expression and relative fold change analysis of TMEM16A was also performed 
to investigate any differences between disease groups in nasal and bronchial 
cultures as shown in Figure 111C and D. In nasal cultures, no differences were found 
between CF versus non-CF PNECs (0.8-fold change ±0.6) and there were no 
significant differences seen in 2-ΔCT analysis of gene expression for these 
comparisons (p>0.99). Although there was a 3.1-fold increase ±1.5 in CF PBECs 
versus non-CF PBECs, again the 2-ΔCT analysis was not significant (p>0.99), 
potentially attributable to the low donor number in the CF PBEC group.  
To determine any potential relationship of TMEM16A expression with functional 
activity, correlation with the UTP-induced Isc was investigated in differentiated ALI 
cultures where both experimental techniques were performed (Figure 113). 
Spearman rank correlation assessment of all ALI cultures did not reveal any 
relationship between TMEM16A and UTP-induced Isc (r=0.24, p=0.4). Further 
subgroup analysis of each culture group did not reveal any correlations of TMEM16A 
mRNA expression with the UTP-induced Isc. 
As previously described in section 5.4.7, IL-4 treatment of ALI cultures increased the 
UTP-induced Isc, with some suggestion of enhanced Eact activity in CF PNECs. IL-4 
has previously been found to upregulateTMEM16A expression in cultured CF PBECs 
derived from explanted lung tissue (Gorrieri et al., 2016). To determine the effects of 
IL-4 treatment on TMEM16A expression in paediatric PNECs, RT-qPCR analysis 
was performed in PNEC cultures derived from 2 non-CF and 2 CF donors. As shown 
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in Figure 114, IL-4 treatment upregulated TMEM16A expression in both non-CF and 
CF PNECs. The magnitude of upregulation was similar in both groups compared with 
the controls in each group (non-CF PNECs: 115-fold ±135; CF PNECs: 102-fold 
±77). Importantly, despite this upregulation, levels of TMEM16A expression in IL-4 
treated PNECs as determined by the 2-ΔCT analysis were lower in the CF versus non-
CF cultures (non-CF PNECs IL-4: 0.13 vs CF PNECs IL-4: 0.03). Statistical analysis 
was not possible due to the presence of only two donors from each group.   
Expression and localisation of TMEM16A was also assessed using 
immunofluorescence and confocal microscopy in 8 paediatric ALI cultures which 
were fixed at 28 to 33d ALI.  The protocol used for this technique has been 
previously described in Chapter 2, section 2.3.10. In all cases, immunofluorescence 
confirmed the presence of TMEM16A, with evidence of apical TMEM16A as shown in 
Figure 115. 
The area of fluorescence intensity was calculated for each cell culture investigated as 
a measure of relative expression (Figure 116). The median area of fluorescence/cell 
was lower in non-CF cultures (non-CF: median 253.1 A.U. IQR 43.6 to 947.7 versus 
CF: 448 A.U. IQR 337.2 to 558.7). However, these findings were not significant 
(p=0.88) likely secondary to the low donor number in the CF group. Furthermore, 
there was considerable variability in the fluorescence intensity in the non-CF group. 
Immunofluorescent assessment of TMEM16A was also performed in a CF PNEC 
culture that had been treated with IL-4 (Figure 115). IL-4 increased the area of 
fluorescence intensity (control: 337.2 A.U versus IL-4 865.7 A.U), with localisation of 
TMEM16A at the apical aspect of the PNEC epithelium. This was performed in 
cultures derived from one donor and would require further investigation in more 
participants.  
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Figure 111: Relative fold change of TMEM16A in non-CF and CF cultures 
Fold change of TMEM16A expression were determined in PNECs relative to PBECs 
in non-CF (A) and CF cultures (B) as assessed by RT-qPCR. This was also 
assessed in CF cultures relative to non-CF cultures in PNECs (C) and PBECs (D) 
non-CF PNECs (n=8 donors), non-CF PBECs (n=8 donors), CF PNECs (n=7 
donors), CF PBECs (n=4 donors).  
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Figure 112: Relative gene expression of TMEM16A in non-CF and CF PNEC and 
PBEC cultures 
TMEM16A expression was assessed in differentiated cultures using RT-qPCR. 2-ΔCT 
values were calculated to determine relative gene expression and complement data 
for relative fold change. Data is displayed as the median ±IQR and analysed with 
Kruskal-Wallis and post hoc Dunn’s multiple comparison test with no statistical 
differences found; non-CF PNECs (n=8 donors), non-CF PBECs (n=8 donors); CF 
PNECs (n=7 donors), CF PBECs (n=4 donors).   
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Figure 113: Correlation of TMEM16A expression with the UTP-induced short 
circuit current in all paediatric cultures 
Spearman analysis of correlation was performed for expression of TMEM16A as 
measured by 2-ΔCT with corresponding assessment of UTP-induced short circuit 
current (Isc) in all CF and non-CF PNEC and PBEC cultures. The correlation 
coefficient (r) was calculated whereby r of 1.0 indicates perfect correlation, 0.0 is no 
correlation and -1.0 refers to perfect inverse correlation; n=14. 
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Figure 114: Effects of IL-4 treatment on TMEM16A mRNA expression in 
paediatric PNEC cultures 
TMEM16A expression was assessed in differentiated PNEC cultures treated with 
either vehicle control or IL-4 using RT-qPCR. 2-ΔCT values were calculated to 
determine relative gene expression and complement data for relative fold change; 
non-CF PNECs (n=2 donors), CF PNECs (n=2 donors); no statistical analysis was 
performed.  
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Figure 115: Detection of TMEM16A protein by immunofluorescence in 
differentiated CF PNEC cultures 
A representative confocal image of immunofluorescent TMEM16A detection (green) 
in PNEC cultures derived from the CF PCF28 donor (F508del/F508del) is shown in 
A; nuclei stained with DAPI (blue). Staining in IL-4 treated PNECs is shown in B. No 
secondary/no primary antibody (Ab) controls are shown in C and D respectively; 
scales as shown. 
A: PCF28 PNEC 
DAPI     TMEM16A 
B: PCF28 PNEC: IL-4  
 
C: No secondary antibody Ab 
 
D: No primary antibody Ab 
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Figure 116: Quantification of TMEM16A immunofluorescence in IL-4 treated 
differentiated non-CF and CF PNEC cultures  
Detection of TMEM16A by immunofluorescence and confocal microscopy was 
performed in differentiated non-CF and CF PNEC cultures as previously described. 
The area of fluorescence/cell was determined to quantify TMEM16A presence in 
non-CF and CF (A) and in IL-4 treated cultures (B). Each point represents a different 
donor and bars represent median ±IQR. A: Data analysed with Mann-Whitney test 
with no statistical differences found; n=6 non-CF donors, n=3 CF donors. B: n=2 CF 
donors for each group (no statistical test applied). 
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5.5 Discussion  
5.5.1 CaCC function and expression does not differ significantly in non-CF 
versus CF paediatric primary airway epithelial cultures 
It has been proposed that in the CF airway, CaCC is the key contributor to apical 
chloride secretion and large CaCC mediated changes in anion secretion have been 
found in CF relative to normal airway epithelial cells (Paradiso et al., 2000). As 
previously discussed in Chapter 1, section 1.6.4, CFTR has been found to inhibit 
endogenous CaCC activity and the purinergic response to CaCC is enhanced in the 
CF airway (Kunzelmann et al., 1997, Knowles  et al., 1991, Ousingsawat et al., 
2011). The results described in this chapter have not revealed any differences in the 
magnitude of the UTP-induced Isc non-CF and CF PNECs suggesting similar levels of 
function in the non-CF and CF nasal epithelium. 
However, it is important to acknowledge that the number of donors investigated in 
this PhD was small and further investigation with cultures derived from a larger 
cohort of participants is likely to be required. Nevertheless, there is limited 
assessment of CaCC function in paediatric ALI cultures in the literature to date, and 
these findings have demonstrated the feasibility of assessing CaCC expression by 
Ussing chamber experiments in paediatric differentiated ALI cultures.  
It was interesting to note that despite no differences found between the UTP-induced 
Isc in the total cohort of PNEC and PBEC cultures in the non-CF group, paired 
assessment did suggest an increased CaCC function in PNECs. However, given the 
limited number of paired cultures available for this assessment, this does require 
further investigation to determine the presence of any airway anatomical variations of 
CaCC function and expression assessed by the UTP-induced Isc. RT-qPCR 
assessment of TMEM16A mRNA expression did not reveal any suggestion of 
variations in expression in PNECs versus PBECs in both non-CF and CF groups, 
however, again this assessment included the combined cohort of differentiated 
cultures and was limited to paired assessment of PNEC/PBEC culture pairs derived 
from the same donor.  
Importantly, the relative contribution of CaCC to chloride secretion was smaller than 
that evident with CFTR, with a suggestion of greater bicarbonate transport in CF 
PNECs and non-CF cultures assessed. It is possible that the residual Isc response 
evident in these primary cultures can be attributed to the bicarbonate secretory 
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properties of CaCC. This has significant implications for the potential role of CaCC 
and TMEM16A activation in counteracting the detrimental effects of dysfunctional 
CFTR on ASL acidification and dehydration through restoration of ASL pH and 
chloride transport. However, this does require further comprehensive assessment of 
firstly the UTP-induced Isc changes in bicarbonate free conditions and secondly the 
specific inhibition of bicarbonate secretion with compounds such as acetazolamide (a 
carbonic anhydrase inhibitor) on the resultant forskolin and UTP-induced Isc 
responses. 
5.5.2 TMEM16A activation with Eact was achieved in paediatric primary nasal 
epithelial cultures  
With respect to activation of TMEM16A with the putative small molecule Eact, it was 
possible to detect Isc changes in the 6 out of 8 PNEC cultures investigated. However, 
these responses were small, ranging from 0.5 to 2.7 µA/cm2, in comparison to the 
UTP-induced Isc, which ranged from 0.6 to 12.5 µA/cm2 and importantly investigation 
of the latter was performed without enforcement of a chloride gradient. Although the 
peak Eact-induced Isc was relatively small, the total response as calculated by the 
area under the curve was larger, with a median value comparable to that seen with 
the UTP-induced Isc. The characteristic rapid Isc increase evident after apical UTP 
application occurs secondary to the activation of P2Y2, mobilisation of intracellular 
calcium stores and a rapid increase intracellular calcium concentration resulting in 
CaCC activation. The transient nature of the response is due to a combination of 
multiple effects, including rapid UTP hydrolysis, depletion of intracellular calcium 
stores and desensitisation of GPCR. This has limited the benefits of CaCC-activators 
to date as an alternative therapy for people with CF (Picher et al., 2004, Mason et al., 
1991, Clarke et al., 1999).  
Findings in this PhD suggested that Eact’s mode of action was more sustained in 
comparison to UTP, which could be explained by its calcium-independent mode of 
action (Namkung et al., 2011b). However, this was not specifically assessed in this 
PhD. Eact-induced Isc responses evident in this PhD were comparatively smaller than 
those found during the original identification and characterisation of Eact (Namkung 
et al., 2011b). Experiments performed in the latter study involved the stable 
expression of TMEM16A in FRT cells, membrane permeabilization methods and the 
investigation of Isc using a chloride gradient. Although a gradient was applied in these 
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PhD experiments, the aim was to determine the relative magnitude of Eact-induced 
Isc that could be achieved in primary airway epithelial cultures. Findings from this PhD 
revealed that TMEM16A was expressed in PNEC cultures, albeit at low levels. In 
view of the potential additional effects of UTP on calcium-activated potassium 
channels and therefore subsequent chloride secretion, it is possible that this did not 
occur with Eact, which could account for the relatively smaller magnitude of Isc 
responses seen.  
5.5.3 The activity of CaCC and TMEM16A could not be determined in 
paediatric CF primary bronchial epithelial cultures due to potential 
activation of calcium activated potassium channels 
A major challenge encountered during the work outlined in this chapter related to the 
UTP-induced Ussing chamber Isc responses that were not reflective of published 
characterisation of CaCC and occurred predominantly in CF PBECs. This prevented 
the inclusion of CF PBECs in overall UTP response analysis, and therefore hindered 
formal comparisons with the non-CF PBEC and CF PNEC culture groups. The most 
likely reason for the downward UTP response was secondary to BK channel 
activation, as suggested from the experimental work involving non-specific BK 
channel inhibition with BaCl2 and augmentation of the response in chloride free 
conditions. Cultures were also treated with BAPTA-AM to clamp intracellular calcium 
levels as an effort to determine the calcium-dependence of these responses. It was 
anticipated that the resultant UTP-induced Isc in BAPTA-AM treated cultures would 
be completely abolished. However, the response was modified, with a reduction in 
both the negative and positive Isc components, as shown in Figure 87. Although the 
literature was comprehensively reviewed to ascertain an appropriate concentration 
and treatment duration for BAPTA-AM, these findings suggest that the protocol for 
administration does require optimisation in these primary cultures, perhaps by 
increasing both factors.   
It is possible that this investigation of CaCC has generated novel data that could 
reflect the complexity of CaCC assessment and function. Many GPCRs are not 
confined solely to one G protein and it is possible that UTP is involved in the 
activation of other signalling pathways involving phosphatidylinositol phosphate 
(PIP)/PIP kinases and alternative kinases such as protein kinase B and D 
(Rosenbaum et al., 2009). This could result in the activation or inhibition of other 
channels and transporters that have an overall impact in the final Isc response.  
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Although again only investigated in a small number of cultures, application of both 
BaCl2 and BAPTA-AM modified the nature of the Eact-induced Isc responses, 
suggesting it also led to calcium activated BK channel activity. However, unlike with 
UTP, in the CF PBEC cultures Eact addition resulted in a complete loss of Isc and 
TEER suggesting epithelial damage. The exact cause of this is unknown. It is well 
recognised that high levels of intracellular calcium can cause apoptosis, and it is 
possible that this was the resultant effect of Eact in these cultures (Eggermont, 
2004). However, this contradicts the proposed calcium independent nature of Eact 
(Namkung et al., 2011b). Although entirely anecdotal, discussion at relevant 
conferences with other researchers interested in this field have queried Eact’s mode 
of TMEM16A activation and effects on intracellular calcium.  Since its identification 
there are few studies in the literature that have utilised Eact to investigate airway 
TMEM16A function, making it difficult to determine if similar problems have been 
encountered by other research groups.  
A major limitation of the results reported in relation to these UTP and Eact Ussing 
chamber responses is the descriptive nature of the data. Statistical analyses were 
not performed in circumstances where 2 or less culture inserts were used to assess 
an intervention, therefore limiting the value of the results obtained. Limited by the 
requirement of culture inserts for alternative experimental work together with 
problems encountered with culture failure, as described in Chapter 3 section 3.5.2, 
low numbers of remaining culture inserts were available to make detailed 
investigation of the underlying mechanisms involved. Furthermore, it was not 
possible to predict the occurrence of these UTP and Eact responses and they were 
only revealed in real-time during the Ussing chamber experiments. Nevertheless, it 
has been possible to propose potential involvement of BK channel activity. Had more 
culture inserts for these donors been available, further investigation would have 
involved the comprehensive investigation of calcium/potassium free Krebs solutions, 
application of reagents to modify the intracellular calcium environment including 
thapsigargin (to inhibit the uptake of intracellular calcium) and ionomycin (a calcium 
ionophore) and assessment of intracellular calcium concentrations.  
BK channels are large conductance, voltage-dependent channels that are 
ubiquitously expressed and are present in the airway epithelium (Barrett et al., 1982, 
Manzanares et al., 2011). They consist of four subunits which regulate the calcium 
and voltage dependence of channel function (Manzanares et al., 2011). As opposed 
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to the membrane depolarisation that occurs with CaCC mediated chloride secretion, 
BK activation causes membrane hyperpolarisation due to potassium ion efflux. This 
provides/maintains the electrical driving force for sustained chloride secretion and 
therefore contributes towards maintenance of ASL hydration and MCC (Manzanares 
et al., 2011). It is possible that the paediatric PBEC cultures investigated in this PhD 
had higher levels of BK channel expression, thus leading to the negative UTP and 
Eact-induced Isc responses.  
Attempts were made to investigate relative mRNA expression of the BK channel pore 
forming subunit, KCNMA1, however, it was not possible within the timeframe of this 
PhD to optimise the primers to facilitate this investigation. This work could have been 
complemented by immunofluorescence and Western blot assessment to investigate 
levels and localisation of protein expression, together with the application of a more 
selective BK blocker, paxilline, in the Ussing chamber (Zaidman et al., 2017).  
Recent published work has attributed the presence of hydrocortisone for purinergic 
BK channel activation channel in airway epithelial cultures via protein kinase C-
dependent activation (Zaidman et al., 2017). Hydrocortisone has been shown to be 
necessary for the maintenance of ion transport properties in muco-ciliated 
differentiated PBECs (Zaidman et al., 2016). All PNEC and PBEC cultures in this 
PhD were grown and differentiated using a standardised protocol of cell culture 
components, included a consistent concentration of hydrocortisone. It is therefore 
difficult to attribute the presence of hydrocortisone to the findings in this PhD. 
However, BK channels are susceptible to post-transcriptional modifications, and the 
effects of the cell culture process on CF PBEC development should be considered 
(Zaidman et al., 2017).  
5.5.4 Small molecule inhibitors demonstrated limited effects on TMEM16A 
inhibition in differentiated paediatric primary airway epithelial cultures 
In view of the challenges faced with investigating TMEM16A activation, inhibition with 
recently developed small molecules was investigated to determine any effect in 
paediatric differentiated ALI cultures. Although both CaCCinh-A01 and Ani9 
demonstrated inhibition of the UTP-induced Isc, investigation in one culture pair 
derived from PWT17, demonstrated Ani9 to have a larger inhibitory effect on the 
peak and total UTP-induced Isc compared with CaCCinh-A01.  
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Assessment in PBEC cultures was limited by suggested BK channel activity. 
However, of note, the nature of the UTP-induced Isc was modified with both inhibitors, 
suggesting potential effects on reducing intracellular calcium concentration, thereby 
inhibiting BK channel as well as TMEM16A activity. This is contradictory to recent 
published data which has shown the effects of Ani9 to be independent of intracellular 
calcium signalling (Hahn et al., 2017). Of note, Ani9 application in this study 
completely abolished the UTP-induced Isc (Hahn et al., 2017). However, these 
findings were obtained in TMEM16A transfected HEK293 cells and rat tracheal 
epithelial cells, which could account for failure of the UTP-induced Isc to be abolished 
with Ani9 in human paediatric cultures in this present study.  
Although both CaCCinh-A01 and Ani9 have previously been shown to inhibit the UTP-
induced Isc response in alternative cellular models, this was not evident in paediatric 
cultures investigated in this PhD. This finding is important and is suggestive of a 
number of possibilities: i) TMEM16A does not form a significant component of CaCC-
mediated airway chloride secretion (which has previously been suggested (Namkung 
et al., 2011a); ii) these small molecule inhibitors have a low specific potency for 
TMEM16A inhibition and iii) UTP is acting on alternative non-TMEM16A channels. 
Although all of these possibilities are feasible, the latter is an important consideration 
and is highly possible. Although UTP is employed for the purinergic activation of 
CaCC, previous investigation in primary bronchial cells has shown that UTP can 
induce CFTR-dependent chloride secretion via cAMP signalling (Namkung et al., 
2010a). UTP was consistently added after CFTR inhibition in all Ussing chamber 
experiments, however re-application of CFTRinh-172 after UTP could have helped 
determine any potential effects of UTP-mediated CFTR activation. Furthermore, it is 
also possible that the residual CaCCinh-A01/Ani9 inhibited UTP-induced Isc was the 
result of alternative non-TMEM16A CaCCs that remain to be characterised. 
5.5.5 IL-4 upregulated TMEM16A expression in differentiated paediatric 
primary airway epithelial cultures 
The effects of proinflammatory stimuli on the modification of airway epithelial ion 
transport properties has previously been recognised including the effects of IL-4 and 
IL-13 on inhibition of the amiloride-sensitive Isc, enhancement of cAMP-mediated 
CFTR activation and increased responses to UTP (Galietta et al., 2002, Danahay et 
al., 2002). Indeed one of the three methods used to identify TMEM16A as an 
essential component of CaCC utilised this knowledge, whereby global gene 
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expression analysis was performed to identify proteins that were regulated by IL-4 
(Caputo et al., 2008).  
As a Th2 cytokine, IL-4 is implicated in respiratory diseases with features of mucus 
hypersecretion and goblet cell hyperplasia such as asthma (Daher et al., 1995, 
Steinke and Borish, 2001). Although CF is characterised by mucus hypersecretion, 
there is little evidence to demonstrate the exact relevance of IL-4 in the CF airway. 
Nevertheless, there is evidence to support the role of IL-4 in upregulating TMEM16A 
expression in bronchial epithelial cell lines and PBECs derived from explanted CF 
lung tissue (Scudieri et al., 2012a, Gorrieri et al., 2016).  
This knowledge was utilised in this PhD to determine if TMEM16A expression could 
be enhanced in paediatric cultures. Treatment with IL-4 did demonstrate increases in 
both the UTP and Eact induced Isc responses in paediatric PNEC cultures, with a 
paralleled suggestion of increased TMEM16A mRNA expression in both non-CF and 
CF PNECs. Furthermore, assessment by immunofluorescence in 2 CF PNEC 
cultures complemented these findings, with evidence of localisation to the apical 
aspect of the epithelium. Of note, the immunofluorescence work was demonstrated 
using only one anti-TMEM16A antibody, and although confirmation with an additional 
antibody would have been preferable, it was not possible to achieve any reliable 
staining despite considerable measures to optimise 2 alternative commercially 
available antibodies. 
Reassuringly, the assessment of TMEM16A in IL-4 treated cultures complemented 
previously reported findings in bronchial cultures, further confirming the suitability of 
using paediatric PNECs for this work. Importantly, treatment was well tolerated by the 
cultures, with no detrimental effects on epithelial integrity as observed by TEER 
assessment. 
There is limited data regarding in vivo airway concentrations of IL-4, however, both 
published BAL data in adult patients and the assessment of IL-4 and IL-13 in 
paediatric BAL samples in this PhD (Chapter 3 section 3.6.7) have shown elevated 
levels compared with non-CF participants (Bergin et al., 2013). Notably this finding 
was not present in cell culture supernatants, with no differences in the IL-4 and IL-13 
between the CF and non-CF groups. However, it must be considered that this mode 
of investigation was utilised solely to augment channel function and it is difficult to 
translate this to the human CF airway. Furthermore, it would not be feasible to use 
this as a therapeutic strategy to increase TMEM16A function in CF, particularly given 
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the relatively large concentrations of IL-4 (in this case 10ng for 24 hours) required to 
achieve these outcomes. Although concentrations of IL-4 used to treat cell cultures 
are considerably greater than levels evident in BAL, the pro-secretory effects of such 
cytokines and impacts on ion transport are important considerations when assessing 
electrophysiological properties of the CF airway. 
5.6 Conclusion 
It has been possible to demonstrate the feasibility of using differentiated paediatric 
PNEC cultures to characterise CaCC and TMEM16A expression. No differences 
were evident in CaCC expression in PNEC cultures derived from non-CF and CF 
participants and although no differences were found between PNEC and PBEC 
cultures, paired assessment suggested increased CaCC function in PNECs derived 
from non-CF participants. 
There was evidence to suggest the activation of BK channel expression in some 
paediatric cultures, with a predominance for PBECs derived from CF donors. This 
does require further exploration and investigation as outlined. Characterisation of 
TMEM16A with the application of known activators and inhibitors in Ussing chamber 
experiments has been demonstrated, despite the limited availability of reliable small 
molecules. Application of a combination of experimental techniques to complement 
Ussing chamber experiments, including RT-qPCR and immunofluorescence, has 
provided evidence to suggest that although present at low levels in the paediatric 
cultures, TMEM16A has potential for modulation in the paediatric airway. 
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6 Chapter 6: Investigation of TMEM16A activation with the novel 
C5 activating compound 
6.1 Introduction 
The work carried out in this PhD was closely associated with the research of a CF 
Trust funded Strategic Research Centre grant entitled “Non-CFTR approaches for CF 
therapy”, led by Dr Mike Gray. As part of this SRC, research groups of project 
collaborators Professor Karl Kunzelmann (University of Regensberg, Germany) and 
Professor Margarida Amaral (University of Lisbon, Portugal) had identified novel 
TMEM16A activating compounds as described below. Of the seven identified ‘C’ 
compounds that demonstrated potential, the C5 compound was selected for further 
investigation in this PhD. These first-generation compounds had not yet been 
investigated in primary airway epithelial cultures and as a result there was very little 
known about potential effects and activity using this in vitro model. The results 
described in this chapter are primarily descriptive in nature.  
In addition to investigating any potential responses of the C5 compound in primary 
cultures using Ussing chamber experiments, the additional purpose of the work in 
this chapter was to determine the feasibility of utilising established paediatric primary 
ALI cultures to investigate newly developed molecules as a strategy for TMEM16A 
activation and CF therapy.  
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6.2 Hypotheses 
• Differentiated paediatric PNEC and PBEC ALI cultures can be used in Ussing 
chamber experiments to explore the effects of C5, a novel TMEM16A activating 
compound. 
6.3 Aims 
The specific aims of this chapter were to: 
• investigate the effects of C5 application in cultures derived from non-CF and CF 
donors using Ussing chamber experiments  
• demonstrate the feasibility of utilising paediatric differentiated airway epithelial 
cultures established in this PhD to investigate the effects of novel small molecule 
targets for therapy  
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6.4 Results 
6.4.1 Preliminary investigation of novel C5 compounds in HT29 cells 
This work was performed by the research groups of Professors Kunzelmann and 
Amaral who kindly shared the preliminary data for the purposes of compound 
investigation in this PhD. Novel candidate molecules for TMEM16A activation were 
identified by the research groups of Professors Amaral and Kunzelmann using an in-
silico approach of compounds structurally similar to Eact and investigated using the 
YFP halide assay. As detailed in Chapter 1, the YFP assay can be used as a 
measure of CaCC sensitivity. Cells expressing YFP are placed into an iodide rich 
solution and challenged with a calcium agonist. The resultant iodide flux results in 
rapid YFP fluorescence, the rate of which is proportionate to CaCC activity. In this 
case, YFP-expressing HT29 cells (human adenocarcinoma cell line) were transfected 
with TMEM16A and pre-incubated for 10 minutes with varying concentrations of the 
novel compounds. The rate of iodide quenching was assessed, revealing seven C 
compounds with significant increases in anion conductance. Compound C5 was 
selected as one of the key activating molecules and the YFP assay results are shown 
below relative to Eact (Figure 117). This preliminary investigation showed significant 
increases in iodide quenching at 10 and 50 µM C5 that were comparable to Eact.  
Figure 117: YFP iodide assay demonstrating the C5 activity in HT29 cells 
This work was performed by the research groups of Professor Amaral and the data 
presented was kindly provided for the purposes of this PhD. HT29-YFP cells were 
pre-incubated with either Eact (A) or C5 (B) at 0.1, 1, 10, 50 and 100 µM 
concentrations for 10 minutes. Iodide quenching was assessed at 37 °C as a 
measure of anion conductance. Bars represent the mean ±SEM. Data analysed with 
one-way ANOVA; *p<0.05; A: n=6-13 experiments, B: n=8-22. 
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6.4.2 Effects of acute C5 treatment in paediatric primary nasal epithelial 
cultures derived from non-CF donors 
The presence of any potential activity of C5 in paediatric primary cultures was firstly 
assessed in PNEC cultures derived from a non-CF donor, PWT11. The first priority 
was to ensure that the UTP-induced Isc was characteristic of CaCC secretion, 
therefore responses to the standard protocol utilised in this PhD were first 
investigated. Ussing chamber experiments were performed using the standard 
protocol with an initial apical addition of amiloride, forskolin and CFTRinh-172 as 
previously described in Chapter 2 section 2.5. As shown from the resultant traces 
below in Figure 118, the response to UTP was characteristic of CaCC mediated 
chloride secretion (mean UTP-induced Isc: 5.5 µA/cm2 ± SD 1.5), therefore enabling 
reliable future exploration of C5 effect on Isc response and TMEM16A activity.  
Figure 118: Short circuit current responses to amiloride, forskolin, CFTRinh-172 
and UTP in PNEC cultures derived from the non-CF PWT11 donor 
Ussing chamber experiments were performed in 125 mM chloride as previously 
described. 100 µM amiloride, 10 µM forskolin, 20 µM CFTRinh-172 and 100 µM UTP 
were added at 20, 25, 30 and 40 minutes respectively as shown. Lines represent the 
mean short circuit current (Isc) responses with error bars for the SD; n=2 culture 
inserts. 
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The effect of C5 addition alone was next explored in cultures derived from this donor. 
All experiments involving C5 addition were performed using 125 mM chloride Krebs, 
with the preceding addition of amiloride, forskolin and CFTRinh-172. Previous data 
from the Kunzelmann lab had demonstrated significant increases in iodide quenching 
in the YFP assay with 10 µM and 50 µM of C5. It was not possible to perform a 
formal dose response in primary cultures, namely due to the very limited amount of 
compound that was available for investigation. Concentrations of 10 µM and 20 µM 
C5 were therefore initially investigated. Representative Ussing chamber traces 
together with the resultant peak and total Isc responses are shown in Figure 119. 
Both concentrations demonstrated increases in the C5-induced Isc, however there 
were no significant differences found between the two concentrations (10 µM: 0.9 
µA/cm2 ± SD 0.5 versus 20 µM: 1.7 µA/cm2 ± SD 0.2; p=0.4). C5 addition at 10 µM 
produced a significantly smaller peak Isc  response than UTP (p=0.04), but no 
significant differences were found between UTP and  20 µM C5 (p=0.8). Although no 
significant differences were found in peak response with 10 µM C5, there was a 
suggestion of a greater total Isc response with C5 compared with 100 µM UTP 
(23.1µA/cm2.min ± SD 8.4), which was larger with 20 µM C5 (10µM: 32.1 µA/cm2.min 
± SD 1.9; p=0.7; 20 µM: 36.0 µA/cm2.min ± SD 3.6; p=0.1). These C5-induced Isc 
changes were not accompanied by a reduction in TEER, and although there was a 
TEER decrease with UTP addition, this was small (-58.0 W.cm2 ± SD 66.5).  
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Figure 119: Short circuit current response to C5 in PNEC cultures derived from 
the non-CF PWT11 donor 
Representative short circuit current (Isc) responses for 10 µM (green) and 20 µM (red) 
C5 addition in PWT11 PNECs. The peak-induced Isc (DIsc) and area under the curve 
(AUC) as compared with 100 µM UTP (black) are shown in B and C respectively. 
Bars represent mean ± SD. Data analysed with Kruskal Wallis and Dunn’s multiple 
comparisons tests; *p=0.04 for peak DIsc for 100 µM UTP versus 10 µM C5; n=3 
inserts for each condition.  
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6.4.3 C5 potentiation of the UTP-induced short circuit current 
The next focus of work was to determine the ability of C5 to potentiate the UTP-
induced Isc. Until now, 100 µM UTP had been used in Ussing chamber experiments to 
ensure maximal CaCC activation. However, for the investigation of UTP potentiation, 
a reduced concentration was required to prevent complete saturation of response. To 
ascertain an appropriate concentration of UTP for further assessment with C5, a 
dose response investigation was performed (Figure 120). The peak-induced Isc was 
greatest after the initial application of 1 µM (4.2 µA/cm2 ± SD 0.1) which was similar 
in magnitude to that seen at 100 µM as reported above. Increasing concentrations of 
UTP in the same culture insert resulted in a subsequent decrease in peak Isc 
suggesting that P2Y2 receptors were desensitised and calcium stores were depleted 
at concentrations above 5 µM. A UTP concentration of 1 µM was therefore selected 
for use in conjunction with C5 so as not to diminish any potential effect of C5 on Isc.  
Ussing chamber experiments were performed to assess the effects of 1 µM UTP 
addition in conjunction with either 10 µM or 20 µM C5. The effects of C5 were 
assessed after the initial application of amiloride, forskolin and CFTRinh-172 as with 
all previous experiments. The resultant peak and total Isc responses are shown in 
Figure 121. There were no differences between the peak-induced Isc between the 
UTP/C5 combinations at both C5 concentrations  (1 µM UTP/10 µM C5: 6.2 µA/cm2 ± 
SD 3.1 versus 1 µM UTP/20 µM C5: 6.6 µA/cm2 ± SD 0.9; p>0.99). Furthermore, 
neither combination of UTP/C5 addition was significantly different to the peak-
induced Isc evident with either 1 µM UTP (1 µM UTP/10 µM C5: p=0.5; 1 µM UTP/20 
µM C5: p>0.99)  or 100 µM UTP (p>0.99 for both). The total Isc for 1 µM UTP alone 
was 37.6 µA/cm2.min ± SD 18.3. This was increased by 2.5-fold with 1 µM UTP/10 
µM C5 (92.0µA/cm2 ± SD 55.6; p=0.8) and 2.6-fold with 1 µM UTP/20 µM C5 (96.2 
µA/cm2 ± SD 15.3; p=0.3), however, these findings were not statistically significant.  
These data suggest that C5 did produce small increases in Isc when applied alone. 
The greatest effect was evident with the combination of  C5 with 1 µM UTP, 
predominantly on the total induced Isc. Furthermore, there was little difference 
between 10 µM and 20 µM when used in conjunction with UTP.   
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Figure 120: Effects of increasing UTP concentration on short circuit current 
response in PNEC cultures derived from the non-CF PWT11 donor 
UTP was applied to the apical compartment of the Ussing chamber at the 
concentrations shown above in the same culture insert. Short circuit current 
responses (Isc) are shown in A; lines represent the mean response with bars for the 
SD. The peak-induced Isc (DIsc) is shown in B; bars represent mean ± SD; n=2 culture 
inserts (statistical analysis not performed). 
1 µ
M
5 µ
M
10
 µM
50
 µM
10
0 µ
M
10
0 µ
M
0
1
2
3
4
5
Δ
I sc
 P
ea
k 
U
TP
 (µ
A
/c
m
2 )
B
30 40 50 60 70 80 90 100
0
2
4
6
8
10
Time (min)
I sc
 (µ
A
/c
m
2 )
1 µM 5 µM 10 µM 50 µM 100 µM 100 µM
A
  267 
Figure 121: Effects of UTP and C5 on short circuit current response in PNEC 
cultures derived from the non-CF PWT11 donor 
Representative short circuit current (Isc) responses for 10 µM C5 (green solid line) 
and 20 µM C5 (red solid), 1 µM UTP (black), 1 µM UTP plus 10 µM C5 (green 
dashed) and 1 µM UTP plus 20 µM C5 (red dashed) addition in PNECs derived from 
the non-CF PWT11 donor. The peak-induced Isc (DIsc) and area under the curve 
(AUC) are shown in B and C respectively. Bars represent mean ± SD. Data analysed 
with Kruskal Wallis and Dunn’s multiple comparisons test with no statistical 
differences found; n=4 culture inserts for1 µM UTP, n=3 culture inserts for all other 
conditions. 
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Isc responses after acute apical addition of C5 5 minutes prior to UTP application 
were next assessed to determine any potential effects on further augmentation of the 
UTP-induced response. This was investigated in PNEC cultures derived from the 
non-CF PWT16 donor, which had demonstrated a peak UTP-induced Isc at 100 µM of 
1.8 µA/cm2 ± SD 1.1 and total response of 8.9 µA/cm2.min ± SD 2.4.  
The effects of C5 treatment alone in these cultures was firstly established to 
determine any changes in Isc as shown below in Figure 122. C5 concentration of 10 
µM was selected for investigation based on results previously reported.  Apical 
addition of C5 did increase the Isc response, with peak and total responses of 2.7 
µA/cm2 ± SD 1.7 and 88.4 µA/cm2.min ± SD 49.1, respectively, and although the total 
response was almost 10-fold greater than with UTP, this was not significant (p=0.2).  
Initial apical addition of C5 was investigated with 1, 10 and 100 µM UTP to determine 
if pre-treatment induced any changes in the subsequent UTP response. It was only 
possible to investigate this in 1 culture insert for each condition due to limited culture 
availability. As shown in Figure 123, the apical addition of UTP alone at all 3 
concentrations showed a biphasic response, with the rapid first peak demonstrating 
the largest UTP-induced Isc.  C5 addition 5 minutes prior to UTP reversed this effect 
at all 3 UTP concentrations, with a resultant larger second UTP-induced peak Isc 
increase. Although the Isc traces showed in Figure 123 show some features of 
instability, the initial resting TEER for these cultures were all in the range of 747 to 
955 W.cm2, indicating adequate tight junction integrity and suitability of these culture 
inserts for this assessment. The changes in these peak UTP-induced Isc responses 
are shown in Figure 124 whereby the largest UTP-induced Isc after C5 addition was 
evident with 100 µM UTP.  
Interestingly pre-treatment of C5 at UTP concentrations of 10 and 100 µM produced 
a CaCCinh-A01-sensitive Isc, indicating that at these concentrations, the resultant 
augmented responses involved TMEM16A activation. These responses were also 
bumetanide-sensitive, suggesting involvement of C5/UTP-mediated chloride 
secretion. Importantly, the UTP-induced Isc alone was not sensitive to CaCCinh-A01, 
suggesting minimal TMEM16A-mediated chloride secretion under these conditions. 
Of note, the TEER did not change with C5 addition in all circumstances (not shown). 
However, addition of CaCCinh-A01 with C5/UTP did show increases in TEER (10 µM 
UTP: 80 W.cm2; 100 µM UTP: 120 W.cm2) further confirming inhibition of TMEM16A-
mediated ion transport. 
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Figure 122: Short circuit current response to C5 in PNEC cultures derived from 
the non-CF PWT16 donor 
Representative short circuit current (Isc) responses for 10 µM C5 (green) and 100 µM 
UTP (black) in PNECs derived from the non-CF PWT16 donor. The peak-induced Isc 
(DIsc) and area under the curve (AUC) are shown in B and C respectively. Bars 
represent mean ± SD. Data analysed with Kruskal Wallis and Dunn’s multiple 
comparisons tests; p=0.4 for peak DIsc; p=0.2 for AUC; n=3 inserts for each condition.  
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Figure 123: Representative Ussing chamber traces for acute C5 treatment with 
varying UTP concentrations in PNEC cultures derived from the non-CF PWT16 
donor 
Representative short circuit current (Isc) responses for the addition of UTP alone 
(black line) or the 10 µM C5 added 5 minutes prior to UTP (green) at 1 µM UTP (A), 
10 µM UTP (B) and 100 µM UTP (C) addition in PNECs derived from the non-CF 
PWT16 donor; n=1 for each condition.  
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Figure 124: Effects of acute C5 treatment on the UTP-induced short circuit 
current peak response in PNEC cultures derived from the non-CF PWT16 donor 
The percentage change of the UTP-induced short circuit current (DIsc) for the second 
peak relative to the first peak was calculated for experiments where UTP was applied 
alone (black line) and where cultures were pre-treated with C5 for 5 minutes prior to 
UTP addition (green). This was calculated for 1 µM, 10 and 100 µM UTP.  
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6.4.4 Chronic C5 treatment in paediatric primary nasal epithelial cultures 
derived from non-CF donors 
The effects of chronic C5 treatment were next assessed in PNEC cultures derived 
from the PWT16 donor. Cell cultures were treated with either a vehicle control or 10 
µM C5 for 24h and 48h before performing Ussing chamber assessment of Isc 
response to 1, 10 and 100 µM UTP. Amiloride, forskolin and CFTRinh-172 were 
added prior to UTP as previously described and experiments were performed using 
125 mM chloride Krebs solutions in both Ussing chamber compartments. This was 
performed in 1 culture insert for each condition due to a limited number of cultures 
remaining for this experimental work from this donor. Therefore this data is 
descriptive. 
Responses were similar at all UTP concentrations and duration of C5 treatment; 
representative Isc and TEER Ussing chamber traces for investigation of 100 µM UTP 
at 24h are shown in Figure 125 with resultant changes in Isc at all UTP concentrations 
in Figure 126. It is difficult to ascertain the relative changes in the magnitude of 
responses with all 3 concentrations of UTP after 24h and 48h of C5 treatment 
because experiments were limited by the number of repeats. However, after both 24h 
and 48h of C5 treatment, there was clear modification of the resultant UTP-induced 
Isc, where the response was initially negative, followed by an increase. These 
changes were accompanied by a reduction in TEER. Notably, chronic C5 treatment 
at both 24h and 48h appeared to result in reductions in Isc responses to both 
amiloride, forskolin and CFTRinh-172, however these differences were only significant 
for CFTRinh-172 after 48h treatment (DMSO: -12.0 µA/cm2 ± SD versus 48h C5: -3 
µA/cm2 ± SD 1.1; p=0.04). DMSO treatment alone after 48h reduced the amiloride-
sensitive and the UTP-induced Isc on all occasions, suggesting off-target effects over 
this duration of treatment. C5 treatment for 24h was also investigated in a limited 
number of PNEC and PBEC cultures derived from the PWT17 donor, with similar 
changes seen (not shown). 
Although chronic C5 treatment was tolerated in cultures derived from both donors, 
(as determined by maintenance of TEER), it failed to augment the UTP-induced Isc , 
with additional off-target effects of modifying responses to UTP and reducing 
responses of other channels investigated.  
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Figure 125: Representative Ussing chamber short circuit current and 
transepithelial resistance responses after 24h C5 treatment in PNEC cultures 
derived from the non-CF PWT16 donor 
PNEC cultures derived from the non-CF PWT16 donor were treated with either 10 
µM C5 or vehicle control (0.1 % DMSO) for 24h before performing Ussing chamber 
experiments and addition of 100 µM UTP. Representative short circuit current (Isc) 
traces are shown in A, with expansion of the UTP-induced Isc response shown in B. 
The corresponding transepithelial resistance (TEER) measurements are shown in C; 
n=1 culture insert for each condition.  
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Figure 126: Effects of chronic C5 treatment on the short circuit current 
responses in PNEC cultures derived from the non-CF PWT16 donor 
Changes in short circuit current response (DIsc) to amiloride, forskolin and CFTRinh-
172 for 24h DMSO (black), 24h 10 µM C5 (green), 48h DMSO (grey) and 48h 10 µM 
C5 (blue) treatment in PNEC cultures derived from the non-CF PWT16 donor are 
shown in A. Bars represent mean ± SD. Data analysed with Kruskal Wallis and 
Dunn’s multiple comparisons tests; p=0.04 for CFTRinh-172 at 48h; n=3 culture 
inserts for each control and C5 condition. Resultant DIsc for varying UTP 
concentrations after chronic C5 treatment are shown in B; n=1 culture insert for each 
control and C5 condition.  
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6.4.5 Effects of IL-4 treatment on C5 response in paediatric primary nasal 
epithelial cultures derived from CF donors 
The effects of acute C5 treatment (10 µM) were assessed in cultures derived from 3 
CF donors, PCF25 (F508del/ F508del), PCF26 (F508del/G542X) and PCF28 
(F508del/F508del), all of which did not show any changes in C5-induced Isc. In view 
of the described effects of IL-4 treatment on the UTP and Eact-induced Isc, PCF28 
PNEC cultures were treated with IL-4 to investigate the effects of acute C5 treatment. 
PNEC cultures were treated with vehicle control or IL-4 (10ng) for 24 hours before 
assessing Isc responses to either 1 µM UTP, 10 µM C5 or the combination of 10 µM 
C5 5 minutes prior to 1 µM UTP apical addition. Amiloride, forskolin and CFTRinh-172 
were added prior to these reagents as previously described and experiments were 
performed using 125 mM chloride Krebs solutions in both Ussing chamber 
compartments. Each experiment was performed using 2 PNEC culture inserts and 
the resultant Isc traces together with the calculated peak and total Isc are shown in 
Figure 127 and Figure 128 respectively. Statistical analyses were not performed due 
to the limited number of culture inserts.  
In all circumstances, IL-4 treatment increased the peak Isc response (1 µM UTP 3.1 
µA/cm2 ± SD 1.5 versus 10.0 µA/cm2 ± SD 7.6; 10 µM C5: 0.2 µA/cm2 ± 0.3 versus 
1.5 µA/cm2 ± 0.3; 1 µM UTP plus 10 µM C5: 3.6 µA/cm2 ± SD 1.5 versus IL-4: 19.6 
µA/cm2 ± SD 7.6). IL-4 treatment did not increase the total Isc response for 1 µM UTP 
alone (21.8 µA/cm2.min ± SD 11.6 versus 23.4 µA/cm2.min ± 8.0). However, an 
increase was suggested for 10 µM C5 (17.1 µA/cm2.min ± 13.2 versus 30.0 
µA/cm2.min ± 7.6) and the combination of 1 µM UTP plus 10 µM C5 (43.2 
µA/cm2.min ± 20.1 versus 96.9 µA/cm2.min ± 11.6).  
These findings suggest that unlike the responses in PWT16 cultures, the C5/UTP 
combination in PCF28 PNECs did not augment the peak UTP-induced Isc response. 
However, the total UTP-induced response as assessed by AUC was increased by 2-
fold with C5/UTP, and this was further augmented by 4-fold in IL-4 treated cultures.  
Response to C5 alone was minimal (unlike mean response in PWT16 of 2.7 µA/cm2, 
as reported above), however, it was increased by 7.5-fold with IL-4 treatment. This 
finding complements the previously described increase in TMEM16A 
immunofluorescence in PCF28 PNECs (Chapter 5 section 5.4.14). Of the 7 donors 
where C5 response was assessed with Isc in conjunction with TMEM16A 
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immunofluorescence, the 2 non-CF C5-responders demonstrated the greatest 
degree of TMEM16A immunofluorescent expression and the 5 non-responders 
showed lower levels (Figure 129). These findings, together with investigation of 
TMEM16A mRNA expression (Chapter 5 section 5.4.14), suggests that C5 may be 
implicated in TMEM16A activation.  
Figure 127: Effects of IL-4 treatment on short circuit current responses to C5 
and UTP in PNECs derived from the CF PCF28 donor 
Representative short circuit current (Isc) responses to the addition of 1 µM UTP (A), 
10 µM C5 (B) and 1 µM UTP/10 µM C5 together (C) in control (black line) and IL-4 
(blue) treated PNECs derived from the CF PCF28 donor (F508del/F508del). Lines 
represent mean ± SD; n=2 culture inserts for each condition.  
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Figure 128: Effects of IL-4 treatment on the peak and total short circuit current 
responses to C5 and UTP in PNECs derived from the CF PCF28 donor  
The effects of IL-4 treatment on the peak-induced short circuit current (DIsc) and area 
under the curve (AUC) are for the addition of 1 µM UTP, 10 µM C5 and 1 µM UTP/10 
µM C5 together are shown in A and B respectively for control (black) and IL-4 treated 
(blue) PNEC cultures derived from the CF PCF28 donor (F508del/F508del). Bars 
represent mean ± SD; n=2 culture inserts for each condition (statistical analysis not 
performed).  
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Figure 129: TMEM16A immunofluorescent detection in relation to C5-induced 
short circuit current response 
Detection of TMEM16A by immunofluorescence and confocal microscopy was 
performed in differentiated non-CF and CF PNEC cultures as previously described. 
The area of fluorescence/cell was determined to quantify TMEM16A presence. Each 
point represents a different donor and bars represent median ±IQR. Data analysed 
with Mann-Whitney test with no statistical differences found; A: n=6 non-CF donors, 
n=3 CF donors. Corresponding short circuit current (Isc) responses are colour coded 
according to responders (green) and non-responders (red) to C5 addition in Ussing 
chamber experiments. Black points indicate circumstances where the effect of C5 on 
Isc was not assessed.  
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6.4.6 Effects of C5 treatment on intracellular calcium concentration in 
submerged nasal epithelial cultures 
In contrast to the characteristic transient UTP-induced Isc response, the above 
findings in differentiated PNEC ALI cultures with C5 addition could suggest either a 
sustained increase in intracellular calcium or a calcium-independent mode of action 
for C5-induced chloride secretion. To investigate this further, the effects of C5 on 
intracellular calcium concentration were assessed. This experimental work was 
performed by JinHeng Lin (PhD student, Dr Mike Gray) and assessed in submerged 
PNEC cultures derived from a non-CF (PWT19) and CF (PCF28) donor. Methods 
used were as previously described in Chapter 2, section 2.6, whereby cells were 
loaded with the ratiometric Fura-2 dye, and the changes in the ratio of 340:380 nm 
emission were proportional to changes in intracellular calcium ([Ca2+]I). Unfortunately, 
there was no corresponding Ussing chamber data for PWT19, however C5-induced 
Isc responses for PCF28 have already been described. 
C5 was first assessed after UTP addition, and this procedure was reversed to 
determine any potential relationship between the 2 reagents. In all cases, the peak 
340:380 ratios, rate of increase and rate of recovery for PWT19 (Figure 130 and 
Figure 131) and PCF28 (Figure 132 and Figure 133) were calculated. Overall, C5 
addition in PNECs derived from both PWT19 and PCF28 donors showed minimal 
increases in the [Ca2+]I when applied before (PWT19: 348/380: 0.01 ± SD 0.008; 
PCF28N: 0.006 ± SD 0.0008) and after UTP (PWT19: 348/380: 0.01 ± SD 0.008; 
PCF28N: 0.004 ± SD 0.002).  
Initial UTP application increased [Ca2+]I to similar extents in cultures derived from 
both donors (PWT19N: 0.05 ±SD 0.02; PCF28N: 0.05 ± SD 0.01). In all cultures, C5 
addition after UTP showed minimal changes in [Ca2+]I, (PWT19: 0.01 ± SD 0.008; 
PCF28N: 0.006 ±SD 0.0008). A second addition of UTP was also tested after C5 in 
PCF28N cultures to determine any potential effects of C5 on the subsequent UTP-
induced [Ca2+]I, however, no differences were found (0.06 ± SD 0.03; p>0.99). This 
investigation of a second application of UTP was likely possible due to assessment of 
[Ca2+]I  using a perfused system (in contrast to the non-perfused Ussing chamber 
used in this PhD), which allowed recovery from P2Y2 receptor desensitisation.  
C5 application prior to UTP did not affect this UTP-induced peak [Ca2+]I compared to 
responses where UTP was applied first (PWT19N: 0.09 ± SD 0.02, p>0.99; PCF28N: 
0.07 ± SD 0.04, p>0.99). Furthermore, C5 addition pre-UTP did not affect the 
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subsequent UTP-induced increase in [Ca2+]I and rate of recovery compared to the 
initial application of UTP in PWT19 PNECs (rate: p>0.99; recovery: p=0.2). Although 
there was a suggestion that C5 affected the rate of UTP-induced [Ca2+]I increase in 
PCF28 PNECs, the recovery was unchanged and findings were not significant (rate: 
p=0.4; recovery: p>0.99).  
An additional observation from this work was the relatively larger ionomycin-induced 
increase in 340:380 ratio versus the UTP response in CF cultures (Figure 132) 
compared with non-CF cultures (Figure 130), suggesting a larger UTP-induced 
[Ca2+]I increase in non-CF cultures, however, this would require further investigation 
in a larger cohort of cultures.   
Overall, these findings suggested that C5 addition did not affect [Ca2+]I, and 
application after UTP did not modify the resultant changes in [Ca2+]I kinetics. 
However, this was performed only in a limited number of culture inserts and although 
has provided some preliminary data, requires further investigation in a larger cohort 
of cultures.  
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Figure 130: Effect of C5 and UTP addition on intracellular calcium in PNEC 
cultures derived from the non-CF PWT19 donor 
Submerged PNEC cells derived from the non-CF PWT19 donor were grown to 
confluence and incubated with Fura-2 AM for 1 hour. After dye removal, cells were 
incubated with HEPES buffered solution at room temperature and mounted on a 
Nikon Fluor oil immersion microscope. Cells were alternately excited at 340 nm and 
380 nm for 0.25 s continuously. Changes in the 340:380nm emission were 
proportional to changes in intracellular calcium concentration. The effects of initial 
UTP addition, followed by C5 (A) compared with the initial application of C5 followed 
by UTP (B) were investigated. The calcium ionophore, ionomycin, was used as a 
positive control.  
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Figure 131: Kinetics of intracellular calcium changes induced by C5 and UTP in 
PNECs derived from the non-CF PWT19 donor  
The Fura-2 340nm/380nm was used to calculate the peak increase in intracellular 
calcium concentration ([Ca2+]I,) where UTP was added prior to C5, and with the 
reverse protocol of C5 addition before UTP (A). Rate of UTP-induced [Ca2+]I, increase 
(B) and rate of recovery of the UTP response (C) were calculated for each protocol.  
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Figure 132: Effect of C5 and UTP on intracellular calcium in PNEC cultures 
derived from the CF PCF28 donor 
Submerged PNEC cells derived from the CF PCF28 donor (F508del/F508del) were 
grown to confluence and incubated with Fura-2 AM for 1 hour. After dye removal, 
cells were incubated with HEPES buffered solution at room temperature and 
mounted on a Nikon Fluor oil immersion microscope. Cells were alternately excited at 
340 nm and 380 nm for 0.25s continuously. Changes in the 340:380nm emission 
were proportional to changes in intracellular calcium concentration. The effects of 
initial UTP addition, followed by C5 and UTP (A) compared with the initial application 
of C5 followed by UTP (B) were investigated. The calcium ionophore, ionomycin, was 
used as a positive control.  
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Figure 133: Kinetics of intracellular calcium changes induced by C5 and UTP 
from PNEC cultures derived from the CF PCF28 donor 
The Fura-2 340nm/380nm was used to calculate the peak increase in intracellular 
calcium concentration ([Ca2+]I,) where UTP was added prior to C5 and UTP, and with 
the reverse protocol of C5 addition to UTP (A). Rate of UTP-induced [Ca2+]I, increase 
(B) and rate of recovery of the UTP response (C) were calculated for each protocol.  
 
 
 
 
 
 
 
UTP C5 UTP Ionomycin C5 UTP Ionomycin
0.00
0.05
0.10
0.15
0.20
Fu
ra
-2
 A
M
 ra
tio
 (3
40
/3
80
)
UTP → C5 → UTP C5 → UTP
A
UTP 1 UTP 2 UTP
0.0
5.0×10-3
1.0×10-2
1.5×10-2
R
at
e 
of
 in
cr
ea
se
 (Δ
34
0:
38
0/
s)
UTP → C5 → UTP C5 → UTPB
UTP 1 UTP 2 UTP
-1×10-3
-8×10-4
-6×10-4
-4×10-4
-2×10-4
0
R
at
e 
of
 re
co
ve
ry
 (Δ
34
0:
38
0/
s)
UTP → C5 → UTP C5 → UTPC
  285 
6.5 Discussion 
The results from the experimental work detailed in this chapter has demonstrated the 
feasibility of investigating the effects of the novel compound C5 on TMEM16A activity 
in differentiated paediatric PNEC ALI cultures. Importantly, although this compound 
has been previously assessed using alternative cell lines, this is the first study in 
airway epithelial cultures derived from humans. In summary, it has been possible to 
use Ussing chamber experiments to demonstrate that in a small number of non-CF 
PNEC cultures, addition of C5 alone demonstrated small, but more sustained, 
increases in Isc response relative to UTP. Furthermore, it was possible to augment 
the UTP response by C5 pre-treatment, with enhanced peak and total Isc changes 
that were suggestive of increased TMEM16A-mediated chloride secretion. In 
contrast, assessment of chronic treatment with C5 in these cultures was not 
consistent with TMEM16A activation, and in fact off target effects included inhibition 
of ENaC, CFTR and alteration of the UTP-induced response. 
Importantly, a combination of 4 non-CF PNECs, 3 non-CF PBECs, 1 CF PNEC and 1 
CF PBEC were investigated, of which responses were evident in only 2 non-CF 
PNECs. This is potentially explained by the relatively low levels of TMEM16A that are 
expressed, as evident by both RT-qPCR and immunofluorescence work. It was 
possible to generate a C5-induced Isc after IL-4 treatment, and this could be a useful 
assessment tool for future work involving more detailed characterisation of this and 
similar compounds.  
Although C5 application either with, or before UTP increased the Isc response in the 
PWT16 cultures, further investigation did not show any changes in [Ca2+]I secondary 
to C5 addition. Therefore the effect of C5 appeared to be independent of an increase 
in cytosolic calcium. However, it should be highlighted that the [Ca2+]I experiments 
were performed in cultures derived from a different donor, PWT19. Submerged 
cultures required for [Ca2+]I assessment were prepared at the start of the culture 
process and corresponding ALI cultures were not successful. It would have been 
highly valuable to follow through a comprehensive analysis involving assessment of 
Isc, RT-qPCR, immunofluorescence and measurement of [Ca2+]I in cultures obtained 
from each individual donor, however, this was not possible. A limitation of this 
technique used to assess [Ca2+]I  was use of undifferentiated submerged cultures, in 
contrast to the differentiated ALI cultures used in Ussing chamber experiments. 
However, this method was accessible at the time of performing this PhD, and 
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alternative methods to explore the effects of C5 on [Ca2+]I  in ALI cultures would be 
required in the future.  
In view of the sustained nature of the C5 response, together with the lack of any 
substantial increase in [Ca2+]I, the augmented UTP-induced Isc with C5 could have 
occurred secondary to calcium-independent chloride secretory mechanisms. 
Although UTP can be used as a purinergic agonist for CaCC activation in Ussing 
chamber experiments, previous investigation in primary bronchial cells has shown 
that UTP can induce CFTR-dependent chloride secretion via cAMP signalling 
(Namkung et al., 2010a). It is possible that C5 mediated a similar and more sustained 
Isc increase, that was secondary to calcium-independent cAMP-mediated chloride 
secretion. This theory could be further supported by the limited C5 response in non-
CF cultures only. However, all experiments were performed after inhibition of CFTR 
with CFTRinh-172, suggesting that any cAMP-mediated chloride secretion was via 
alternative ‘non-CFTR’ channels and transporters. It was not possible to investigate 
this within the timeframe of this PhD, however, further clarification of the effects of C5 
on the UTP-induced Isc could be investigated by comparing the application of 
CFTRinh-172 versus CaCCinh-A01 or Ani9 to determine the relative contribution of 
CFTR and CaCC to the induced response. Furthermore, specific inhibitors of 
cAMP/PKA signalling such as H89, and assessment of intracellular calcium reduction 
(e.g. with BAPTA-AM) could be used to ascertain the underlying mechanisms 
involved and determine potential contributions of ‘non-CFTR’ channels. 
6.6 Conclusion 
Treatment of paediatric differentiated primary airway epithelial cultures with C5 has 
shown some evidence of changes in Isc that suggest TMEM16A activation. This 
preliminary investigation of C5 response in primary cultures has potential to help 
direct future work including investigation in a wider range of cultures and assessment 
of other related compounds. Furthermore, this compound is the first of its generation, 
and assessment in human in vitro models will help to guide subsequent development 
of next generation compounds that may be of benefit in improving the ion transport 
defects that exist in CF. 
Importantly the work carried out in this chapter has demonstrated the suitability of 
using paediatric PNEC cultures to investigate novel small molecule therapeutic 
targets.   
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7 Discussion 
7.1 Introduction 
This final discussion will summarise the key results described in this thesis together 
with the key strengths and limitations to complement previous discussions from each 
chapter. Finally, the chapter will conclude with considerations for future investigations 
that are needed to confirm and investigate the work detailed in this thesis.  
7.2 Development of differentiated primary nasal and bronchial epithelial cell 
cultures from children with and without CF 
The value of utilising patient-derived primary airway epithelial cultures for CF 
research has been validated through their recent role in the development of novel 
CFTR modulator therapies (Van Goor et al., 2009b). They have helped to provide a 
more accessible tool for research than animal models and have overcome the 
problems of karyotype instability associated with alternative immortalised cellular 
models. CF research in children remains important, namely in view of the recognised 
early onset of bronchiectasis which is progressive and life-limiting  (Adam et al., 
2013, Khan et al., 1995b, Sly et al., 2013). To facilitate the development of robust 
paediatric research models it is highly important that methods used to acquire 
research samples are minimally invasive and well tolerated. The suitability of PNECs 
as a surrogate for PBECs remains a long-standing yet pertinent question. Clearly if 
PNECs are found to be a representative research tool, they are well placed to 
facilitate paediatric research given the relative ease of nasal brushing sampling. 
However, the suitability of their role in CF remains in question, as highlighted by a 
recent review in the Journal of CF (Clancy et al., 2018).  
A key aim of this PhD was to establish the relevance of paediatric-derived PNECs as 
a suitable model for CF research and validate their role as a drug discovery tool. The 
initial focus of work was to design the research study protocol and drive the ethical 
approval processes required to enable the research to take place in the Great North 
Children’s Hospital and Newcastle University.  As a paediatric speciality trainee, I 
was well placed to acknowledge the importance of designing a protocol that enabled 
the acquisition of nasal and bronchial brushings, whilst ensuring minimal distress to 
the research participants involved. Having previously worked closely with the CF 
clinical team and patients, I was able to obtain their valuable insight into research 
design and establishment within the hospital environment. Collecting both nasal and 
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bronchial brushings at the time of clinical bronchoscopy under general anaesthetic 
ensured that research procedures were minimally invasive.  
However, the decision to sample brushings during a clinically indicated bronchoscopy 
limited the phenotype of the non-CF group to children who were being investigated 
for recurrent respiratory infections, persistent bacterial bronchitis, persistent wheeze 
and chronic cough. Although these children were comparatively healthier than those 
with CF, research findings related to BAL, cell culture inflammatory environment as 
assessed by cytokine levels should be interpreted with some caution.  
ALI cultures derived from nasal and bronchial brushings demonstrated typical 
epithelial characteristics and features of muco-ciliary differentiation as assessed by 
morphology, TEER, epithelial marker detection by immunofluorescence and RT-
qPCR and analysis of cytokine production. Despite the maintenance of consistent 
culture conditions differences in TEER measurements were found between PNECs 
and PBECs, with highest values evident in CF PNECs. The exact cause for this was 
unclear, but there have been comparable TEER values reported in the literature 
together with reductions in TEER after the application of a mucolytic to the culture 
surface (Sajjan et al., 2004). Furthermore, both intra and inter-donor variation of 
TEER measurement is a recognised finding (Tosoni et al., 2016).  
Elevated mRNA expression of Foxj1 mRNA in CF PBECs was an unanticipated 
finding. This was attributed to its role in promoting cilial differentiation and therefore a 
reflection of the role of cilia for MCT in lower airways. Furthermore, given the 
association of Foxj1 with cilial motility and increasing levels of expression evident at 
later stages of ALI, reduced levels of expression in PNECs could be accounted for by 
their later onset of ciliagenesis (Jain et al., 2010).  
Although the technique of growing adult PBECs from explanted lung tissue and 
bronchoscopic brushings was well established at the time of starting this PhD, 
paediatric cultures had not previously been developed. Considerable optimisation of 
techniques was therefore required, from sampling nasal and bronchial airways 
through to the ALI culture process, which accounted for the initial poor success rates. 
Infection rates significantly reduced and techniques for sampling and culture 
improved, but cultures did fail during the ALI process with no clear cause despite 
monitoring and assessment of controllable conditions. This highlights a key challenge 
associated with this model, however, culture success rates did improve during the 
course of the PhD. Importantly it was possible to develop paediatric PNEC and 
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PBEC culture models to investigate the aims of this PhD research and provide a 
valuable resource for future paediatric CF research in Newcastle.  
7.3 Functional characterisation of ion transport profiles  
At the time of starting this PhD, no published information was available relating to the 
ion transport profiles of paediatric ALI cultures including no direct comparisons of 
PNEC and PBEC cultures. In view of the major contributions of CFTR and ENaC to 
the maintenance of ASL hydration and composition, it was decided to compare the 
functional expression of these channels in the established PNEC and PBEC ALI 
cultures using Ussing chamber experiments.  
This present work did not find any significant differences between the functional 
expression of ENaC in non-CF versus CF cultures in both PNECs and PBECs. RT-
qPCR assessment of ENaC subunit expression showed a-ENaC to be the 
predominant subunit, which is unsurprising given the ability of this subunit to produce 
amiloride-sensitive Isc changes without the other subunits. All three subunits had 
lower levels of expression in non-CF versus CF PBECs and overall expression was 
lower in PNECs. Overall there was considerable variability in all three subunits 
between different donors.  
As described in detail in the discussion of Chapter 3, the lack of differences in Isc 
responses found in this PhD contradicts the previously reported concept of sodium 
hyperabsorption in the CF airway (Knowles et al., 1983, Boucher et al., 1988, Mall et 
al., 1998). This could be explained by the young median age of the CF participants, 
relatively mild degree of lung disease and variations in experimental techniques used 
with these previously reported studies. However, the impact of CF and dysfunctional 
CFTR on ENaC remains under debate, with conflicting results in other studies (Itani 
et al., 2011). Evidently the investigation of ENaC functional expression is complex 
with additional factors including SNPs, variations in plasma membrane ENaC 
channel activity, experimental variations and culture conditions that likely to 
contribute to the changes in channel function and expression (Azad et al., 2009, 
Caldwell et al., 2005).  
No significant differences were found with CFTR functional expression between 
PNECs and PBECs. Interestingly, the shape of the Ussing chamber Isc response was 
different. This could have arisen from differences in the basolateral NaK2Cl 
cotransporter activity, therefore limiting apical CFTR-mediated chloride secretion (Li 
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et al., 2004). The experimental protocol used in Ussing chamber experiments to 
assess CFTR activation and inhibition could have included more detailed 
characterisation of CFTR-mediated apical chloride secretion. Pharmacological 
permeabilisation of the basolateral membrane with an ionophore would have 
eliminated the effects of basolateral channels involved in generating a chloride 
gradient, enabling more specific exploration of CFTR-mediated chloride secretion (Li 
et al., 2004). However, a key consideration in the experimental design was a protocol 
that enabled the investigation of ENaC, CFTR and CaCC in the same culture insert, 
whilst minimising the duration of time spent in the Ussing chamber. Addition of an 
ionophore would have increased this time, and potentially impacted on the 
assessment of alternative channels. Nevertheless, this is an important consideration 
for experiments that require detailed characterisation of CFTR. 
The main experimental technique used in this PhD involved assessment of Isc as a 
measure of net ion transport utilising Ussing chamber experiments. A non-perfused 
system was used, whereby all reagents remained in the chambers for the duration of 
the experiment. Although the system was continuously gassed, residual reagents 
may have impacted on subsequent channel responses. Perfused systems are 
commercially available but were not accessible for this PhD.  
Alternative techniques are available to measure epithelial ion transport. For example, 
the patch clamp technique can be used to electrically isolate a small patch of 
membrane using a glass micropipette tip to measure single or multiple channel 
events (Moran and Zegarra-Moran, 2008). This method can help to overcome the 
variations in channel distribution and expression that are increasingly recognised to 
be present in epithelial monolayers and provides detailed characterisation of ion 
channels (Caldwell et al., 2005, Caputo et al., 2008). However, this technique is 
recognised to be technically challenging in primary epithelial cultures and was not 
used in this PhD. Alternative assessment of CFTR can be achieved via flux assays, 
for example the iodide flux assay that utilised CFTR’s property of iodide permeability, 
with the addition of radiolabelled or fluorescent probes or fluorescently tagged cells 
(Moran and Zegarra-Moran, 2008). However, these techniques are generally 
reserved for high throughput screening assessment.  
Ussing chamber assessment of Isc is a widely adopted tool for the investigation of 
channel-mediated ion transport in CF research. It was deemed appropriate for 
application in this PhD in view of existing expertise within the lab environment and its 
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suitability for application with primary airway epithelial cultures. Importantly, this work 
demonstrated the feasibility of using paediatric PNECs for Ussing chamber 
experiments. 
7.4 Investigating the expression and function of TMEM16A   
Overall assessment of CaCC functional expression in differentiated paediatric 
cultures did not show any differences between PNEC and PBEC cultures in the non-
CF group. Furthermore, no differences were found between non-CF and CF PNECs. 
CF PBECs demonstrated features of BK channel activation. Unfortunately, it was not 
possible to include these cultures in the CaCC and TMEM16A analyses and this was 
a significant limitation of this work performed.  
The lack of reliable activators and inhibitors of TMEM16A limited the ability to 
perform detailed characterisation of TMEM16A-mediated ion transport using Ussing 
chamber experiments. Despite these challenges, it was possible to provide some 
evidence of Eact-induced increases in chloride secretion in addition to TMEM16A 
inhibition with the small molecules CaCCinh-A01 and Ani9. These molecules did not 
completely eliminate the UTP-induced Isc, and this does require further investigation 
as previously discussed.  
Alternative methods were employed to assess the functional expression of 
TMEM16A including immunofluorescence and RT-qPCR. Both of these techniques 
revealed low levels of TMEM16A expression under basal conditions, which is 
consistent with the literature (Scudieri et al., 2012a, Gorrieri et al., 2016). This was an 
obstacle to detection of TMEM16A by immunofluorescence and the current protocol 
used in this PhD was developed after considerable optimisation. It was possible to 
upregulate TMEM16A expression with IL-4 and this was used as a tool to facilitate 
more detailed characterisation and verify expression in the paediatric airway. This 
was consistent with the literature relating to PBECs isolated from explanted CF 
lungs, thereby further validating the role of paediatric PNECs for this area of research 
(Scudieri et al., 2012b, Gorrieri et al., 2016).  
Suggested UTP-induced BK channels activation in CF PBECs was an unanticipated 
finding. Although noted in one of each non-CF PBEC and PNEC culture type, this 
finding was relatively specific for CF PBECs. Of note, PBEC cultures derived from 
the CF participant with the less severe R751L/F508del mutation demonstrated a 
UTP-induced Isc response characteristic of CaCC activation. It was possible to 
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investigate the hypotheses related to BK channel activation by inhibiting channels 
and reducing intracellular calcium levels. However, this analysis was significantly 
limited by the number of culture inserts available for comprehensive investigation and 
was predominantly descriptive.  
Investigation of TMEM16A functional expression in paediatric PNEC ALI cultures has 
not previously been performed and this work has provided preliminary data which will 
help guide and facilitate future directions of work.  
7.5 Investigation of TMEM16A activation with the novel C5 activating 
compound  
The activity of a novel TMEM16A activator, C5, was investigated in the differentiated 
PNEC and PBEC ALI cultures using Ussing chamber experiments. A sustained C5-
induced Isc response was evident in PNEC cultures derived from 2 non-CF donors. 
This suggested C5-mediated chloride secretion with additional augmentation of the 
UTP-induced Isc. Cultures did not respond to chronic C5 treatment, with a reduction 
in both ENaC and CFTR functional expression. The effects of C5 were calcium 
independent, suggesting either a similar mechanism of action to that proposed for 
Eact with direct binding to TMEM16A’s calcium binding site or alternative activation 
of non-CaCC channels. Assessment of C5 was not possible in CF PBECs due to the 
difficulties mentioned previously.  
This investigation of C5 was very preliminary and novel, performed for the first time in 
primary airway epithelial cultures. Further investigation was not possible due to time 
constraints, however, the work carried out in this PhD has provided some useful 
information to help guide future experiments and assessment of additional C 
compounds. Furthermore, it has validated the role of paediatric PNEC cultures 
developed in this PhD for their suitability in investigating responses to novel 
therapeutic targets.  
7.6 Reflection: the application of differentiated paediatric primary nasal and 
bronchial epithelial cultures as an experimental model  
The aims of this PhD were to establish paediatric PNEC and PBEC cultures isolated 
from non-CF and CF donors and utilise these to characterise epithelial and ion 
transport properties. This was with the objective of investigating the role of 
TMEM16A in the paediatric airway and responses to novel small molecule TMEM16A 
activators. The strategy employed in this PhD was to recruit multiple non-CF and CF 
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participants, with the objective of using the described experimental techniques to 
characterise cultures. The final numbers available for these analyses were limited by 
culture success rates and comprehensive analysis was limited by the number of 
culture inserts available. This was improved to some extent by moving from 6-well to 
12-well plates and was facilitated by the upgrade of an Ussing chamber system in 
2017 that was compatible for use with these smaller culture inserts.  
There are recognised techniques for cell culture expansion, including the use of 
fibroblastic feeders or Rho-associated protein kinase (ROCK) inhibitors (Horani et al., 
2013, Martinovich et al., 2017). In hindsight, the research focus at the start of my 
PhD could have been to optimise these expansion methods after establishing the 
paediatric culture models. This would have facilitated more detailed analyses of the 
key findings (e.g. variations in ENaC expression, BK channel characterisation, C5 
compound investigation). However, this would have involved a huge body of work, 
particularly in view of my limited cell culture experience at the start of this PhD. In 
view of the time required for cell culture in addition to the experimental work, these 
investigations would have only been possible in a cultures derived from a small 
number of donors.  
Detailed assessment of TMEM16A function has been performed by other research 
groups using cell lines and siRNA to overexpress TMEM16A and this approach could 
have been adopted for this PhD (Scudieri et al., 2012a). Preliminary work was 
performed at the start of this PhD with the bronchial epithelial CFBE41d- cell line, 
however, these did not produce reliable results in Ussing chamber experiments. 
Patient-derived primary cultures are recognised to be more representative of the in 
vivo airway environment and it was important to establish if TMEM16A was present 
in the paediatric airway. Furthermore, the degree of intra-donor variability evident 
with ENaC and CFTR functional expression in primary cultures would have not have 
been appreciated. 
This thesis has demonstrated that ion channel functional in airway epithelial ALI 
cultures is complex. However, the work has provided some valuable information 
regarding the characterisation and comparisons of paediatric differentiated PNEC 
and PBEC ALI cultures that will help guide future research.  
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7.7 Future work 
7.7.1 Functional characterisation of differentiated paediatric primary nasal and 
bronchial epithelial cultures  
Paired assessment of ENaC and CaCC functional expression in PNEC and PBECs 
derived from the same donor did suggest that there could be differences in ENaC 
and CaCC, but analysis was limited by the number of repeated assessments in these 
cultures. Culture success rates have improved since then, including the ability to 
successfully establish paired cultures. To investigate these differences further, paired 
cultures would be expanded using the above-mentioned ROCK inhibitor technique. 
This method has since been optimised for use with paediatric PNEC and PBEC 
cultures by other members of the research group and would facilitate detailed 
assessment of Ussing chamber responses.  
Detailed investigation of the functional expression of BK channels in paediatric CF 
PBECs is required.  Future work would start with detailed BK channel 
characterisation using Ussing chamber experiments together with assessment of 
mRNA and protein expression for KCNMA1, the pore-forming structure of the 
channel. This investigation would be required in all culture types to determine 
selectivity for CF cultures. Importantly, the effects of different culture media on the 
expression of CaCC and KCNMA1 would also provide useful information relating to 
the contribution of culture conditions to BK channel expression.  
In addition to assessing morphology and epithelial characterisation, the work is this 
thesis has predominantly focussed on the ion transport profiles of established 
cultures. To help determine any differences between paediatric PNEC and PBEC 
cultures harvested from both non-CF and CF donors, detailed analysis of the 
transcriptomic profile could be performed using techniques such as RNAseq, and 
data collection for this for paired non-CF and CF cultures is underway.  
Assessment of ASL parameters including ASL height and pH would be highly 
valuable to determine any variations between PNECs and PBECs and ascertain how 
these relate to ion transport profiles. Techniques to enable the dynamic assessment 
of pH in ALI cultures has been carefully optimised by a member of the research 
group and assessment in paediatric cultures would help contribute to the growing 
body of literature around this area.  
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7.7.2 Assessment of TMEM16A in differentiated paediatric primary nasal and 
bronchial epithelial cultures  
To complement the RT-qPCR analysis of channel mRNA expression, future work 
would involve techniques such as Western blot to investigate TMEM16A protein 
expression in paediatric CF cultures and further elucidate any differences between 
PNECs versus PBECs. These techniques are described in the literature and could be 
consulted to help optimise protocols in paediatric cultures (Gorrieri et al., 2016). In 
view of the relative low levels of TMEM16A under basal conditions, it would be useful 
to determine how much is expressed relative to CFTR in paediatric cultures.  
Detailed assessment of TMEM16A localisation is required in paediatric cultures, with 
particular reference to co-localisation with CFTR and epithelial cell types. TMEM16A 
overexpression has been associated with goblet cell hyperplasia and this requires 
comparable investigation in paediatric cultures (Scudieri et al., 2012a).  
Immunostaining of TMEM16A has previously been performed in adult bronchial 
tissue (Ousingsawat et al., 2009). Assessment in paediatric-derived airway tissue 
would help to determine any variations with age and disease severity. However,  
bronchial tissue is relatively difficult to acquire due to the relative infrequency of 
paediatric lung transplantation and mucosal biopsy. Alternatively, nasal polyp tissue 
could be an alternative model, and although this would be achievable in CF, may 
prove more difficult with control tissue.  
7.7.3 Investigation of novel TMEM16A activators and their role as a potential 
CF therapeutic avenue 
Comprehensive characterisation of C5-induced Isc responses is required in expanded 
cell cultures that responded to C5. This would involve application of current 
TMEM16A inhibitors and modification of the Ussing chamber solutions to permit 
investigation of chloride and calcium dependence of responses.  
If C5 is determined to have consistent benefits and characteristics of TMEM16A 
activation, the clinical relevance of these compounds for CF therapy could be 
investigated by assessing impact on ASL height, pH, airway inflammation and 
mucociliary clearance. At least 2 further C compounds demonstrated potential 
benefits for TMEM16A in preliminary work performed by Professor Amaral’s lab in 
HT29 cells and these would require investigation using above-mentioned methods.  
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A higher throughput assay based on the forskolin-induced assay currently utilised in 
organoid cultures could be developed to investigate the effects of a panel of C 
compounds on improving ASL volume (Dekkers et al., 2013).   
7.7.4 Clinical relevance of the paediatric primary air liquid interface epithelial 
culture model 
Having demonstrated the value of paediatric PNEC ALI cultures, the comparisons 
made in this PhD could be further validated by PNECs derived from completely 
healthy children. This would be achievable given the minimally invasive nature of 
nasal brushing and would further increase the variety of CF patients by enabling 
sampling from a range of disease severities.  
The inter-donor variability in ion transport profiles and channel expression 
demonstrated in this PhD has emphasised the need for future work to focus on 
comprehensively characterising responses in individual donors, rather than grouping 
data together from different donors, to facilitate personalised assessment of channel 
function and response to novel therapeutic targets. In this PhD, this has been 
exemplified by the findings relating to the CF donor with the R751L/F508del 
mutation, and the residual CFTR functional expression that was found with Ussing 
chamber experiments. This novel and exciting finding was selected as an oral 
presentation at the European CF Society conference this year and has facilitated 
collaborations with other CF research groups that will assist with detailed 
characterisation of this mutation. Further understanding of the phosphorylation or 
gating mechanisms affected with this mutation, and potential responses to small 
molecule CFTR modulators may have clinical implications for patients with this 
specific mutation.  
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7.8 Concluding remarks 
This present work has described the establishment of a research programme to 
facilitate the sampling of nasal and bronchial brushings to develop differentiated 
paediatric PNEC and PBEC ALI cultures. The ion transport profiles have been 
characterised in these cultures, including the assessment of TMEM16A functional 
expression and response to novel activating compounds. Furthermore, the work has 
demonstrated that paediatric PNECs do provide a representative CF research model 
and are a valuable resource to facilitate a personalised approach to investigating ion 
transport profiles and responses to novel therapeutic targets.   
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Appendix A: Ethical approval, consent forms and parent and 
participant information literature 
 
 
 
 
A Research Ethics Committee established by the Health Research Authority 
 
 
NRES Committee North East - Newcastle & North Tyneside 1 
Jarrow Business Centre 
Room 001 
Viking Industrial Park 
Rolling Mill Road 
Jarrow 
NE32 3DT 
 
Telephone: 0191 428 3384 
 
 
08 September 2015 
 
Dr Malcolm Brodlie 
Great North Children's Hospital 
Old Children's Outpatients Department 
Newcastle upon Tyne 
NE1 4LP 
 
Dear Dr Brodlie  
 
Study title: Functional characterisation of the airway epithelium in 
children  
REC reference: 15/NE/0215 
Protocol number: 7494 
IRAS project ID: 178672 
 
Thank you for your letter of 19th August 2015, responding to the Committee’s request for further 
information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair. 
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the 
date of this favourable opinion letter.  The expectation is that this information will be published 
for all studies that receive an ethical opinion but should you wish to provide a substitute 
contact point, wish to make a request to defer, or require further information, please contact 
the REC Assistant, Sarah Prothero, 
nrescommittee.northeast-newcastleandnorthtyneside1@nhs.net. Under very limited 
circumstances (e.g. for student research which has received an unfavourable opinion), it may 
be possible to grant an exemption to the publication of the study.  
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
as revised, subject to the conditions specified below. 
 
 
  299 
 
 
 
 
 
 
Consent	Form	Version	2.0	
29.07.2015	
Please	initial	box	
Participant	Identification	Number:	
CONSENT	FORM	
(For	parent/person	with	parental	responsibility)	
Title	of	Study:		 Characterisation	of	the	Airway	Epithelium	in	Children	
	Researcher:	 Dr	Malcolm	Brodlie	
Consultant	in	Paediatric	Respiratory	Medicine	
 
	 	 	 	 	 	 	 	 	
1. I	confirm	that	I	have	read	and	understand	the	information	sheet	dated	……………………	
version	……………	for	the	above	study	and	have	had	the	opportunity	to	ask	questions.	
2. I	understand	participation	is	voluntary	and	that	I	am	free	to	withdraw	at	any	time,	
without	giving	any	reason	and	without	my	child’s	medical	care	or	legal	rights	being	
affected.	
3. I	understand	that	relevant	sections	of	my	child’s	medical	notes	and	data	collected	
during	the	study	may	be	looked	at	by	responsible	individuals	from	the	NHS	Trust	or	
from	regulatory	authorities,	where	it	is	relevant	to	my	child	taking	part	in	this	
research.	I	give	permission	for	these	individuals	to	have	access	to	my	child’s	records.		
4. I	agree	to	my	child	taking	part	in	the	above	study	including	the	taking	and	storing	of	
blood,	nasal	and	lower	airway	brushings	and	broncho-alveolar	lavage	samples	as	
described	in	the	patient	information	sheet.		
       
--------------------------------------------------	
Name	of	Patient	 	 	 	 		
	
-------------------------------------	 	 ------------------	 	 --------------------------------	
Name	of	Parent		 	 	 Date	 	 	 Signature	
	
	
--------------------------------------	 	 -------------------	 	 --------------------------------	
Name	of	Person	taking	consent	 	 Date	 	 	 Signature	
(if	different	from	researcher)	 	 	
	
-------------------------------------	 	 -------------------	 	 --------------------------------	
Researcher	 	 	 	 Date	 	 	 Signature	
	
Affix	patient	sticker	here:	
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Assent	Form	Version	2.0	
29.07.2015	
Yes	
Yes	
Yes	
Yes	
Yes	
Yes	
No	
No	
No	
No	
No	
No	
Yes	 No	
Affix	patient	sticker	here:	Participant	Identification	Number:		
ASSENT	FORM	
(To	be	completed	by	child	with	their	parent/guardian)	
Title	of	Study:		 Characterisation	of	the	Airway	Epithelium	in	Children	
Researcher:	 Dr	Malcolm	Brodlie	
	 	 Consultant	in	Paediatric	Respiratory	Medicine	
	
 
	 	 	 	 	 	 	 	 	 	
1. Have	you	read	(or	had	read	to	you)	the	information	sheet	about	this	project?	
2. Has	somebody	else	explained	what	this	project	is	about?	
3. Do	you	understand	what	this	project	is	about?	
4. Have	you	been	given	the	chance	to	ask	questions	about	this	project?	
5. Have	you	understood	the	answers	that	you	have	been	given	to	your	questions?	
6. Do	you	understand	that	you	can	stop	taking	part	in	this	project	at	any	time?		
7. Are	you	happy	to	take	part?		
	
If	any	answers	are	‘no’,	or	you	don’t	want	to	take	part,	don’t	sign	your	name!	
If	you	do	want	to	take	part,	you	can	write	your	name	below	
       
	
-------------------------------------	 	 ------------------	 	 	
Your	name	 	 	 	 Date	 	 	 	
	
The	doctor	who	explained	this	project	needs	to	sign	their	name	too:	
	
-------------------------------------	 	 -------------------	 	 --------------------------------	
Print	Name	 	 	 	 Date	 	 	 Signature	
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Parent	Information	Leaflet	(non-CF)	Version	2.0	
29.07.2015	 	 	
1	
“Characterisation	of	the	Airway	Epithelium	in	Children”	
This	information	sheet	is	for:	
Parents/Guardians	of	children	without	CF	who	are	having	a	bronchoscopy	
Investigators:		Dr	Malcolm	Brodlie,	Consultant	in	Paediatric	Respiratory	Medicine,	
Great	North	Children’s	Hospital	
	 	 Dr	Iram	Haq,	Clinical	Research	Fellow,	Great	North	Children’s	Hospital	
We	would	like	to	invite	your	child	to	take	part	in	our	research	study.	Before	you	decide	
whether	or	not	you	would	like	to	take	part,	we	would	like	to	explain	why	the	research	
is	being	done,	and	what	it	will	involve	for	your	child.	Please	the	take	the	time	to	read	
the	following	information	carefully.	One	of	our	team	can	go	through	this	information	
with	you	and	answer	any	questions	you	may	have.		
What	is	the	study	about?	
Cystic	fibrosis	(CF)	is	the	most	common	inherited	condition	in	the	UK.	In	CF,	the	body	
makes	very	thick	mucus.	This	mainly	affects	the	lungs	and	digestive	system.	In	the	
lungs	this	mucus	is	very	difficult	to	clear,	causing	infections	and	severe	lung	damage.	
Children	with	CF	need	intensive	treatment	regimes	to	help	manage	their	symptoms.	
Despite	this,	CF	is	life	shortening.	Research	is	important	to	help	us	understand	more	
about	CF	and	develop	new	treatments	so	people	with	CF	can	live	longer	and	healthier	
lives.		
Research	scientists	can	learn	more	about	CF	and	investigate	new	treatments	by	
studying	cells	that	come	directly	from	the	lining	of	the	lower	airways.	These	cells	are	
collected	using	a	brush	during	a	bronchoscopy	and	grown	in	a	laboratory	for	research.		
Collecting	nasal	cells,	cells	from	the	nose,	may	also	give	us	the	same	information	about	
CF	as	the	lower	airways.	Nasal	cells	can	be	collected	from	a	person	when	they	are	
awake.		This	is	a	more	simple	procedure	that	can	be	done	without	an	anaesthetic.		
In	our	study,	we	would	like	to	compare	nasal	cells	with	lower	airway	cells.	We	will	look	
at	these	cells	in	a	research	laboratory	and	measure	different	properties	that	are	
important	in	CF.	We	will	look	at	how	these	compare	with	children	that	do	not	have	CF.	
If	we	find	that	nasal	cells	are	similar	to	lower	airway	cells,	this	will	provide	us	and	other	
researchers	with	valuable	information	about	using	nasal	cells	in	future	CF	research.	
Given	how	simple	it	is	to	collect	nasal	cells,	large	numbers	could	be	collected.	This	
could	bring	researchers	closer	to	finding	more	treatments	for	CF.	Our	study	will	help	us	
find	out	more	about	how	children	with	CF	are	different.	Studying	these	cells	will	also	
help	researchers	learn	more	about	other	airways	diseases	in	children.	
Why	has	my	child	been	invited?	
Your	child	has	been	invited	to	take	part	in	this	study	because	they	are	attending	
hospital	for	a	bronchoscopy.	During	the	anaesthetic,	we	would	like	to	collect	some	
samples	that	would	not	otherwise	be	possible.	Your	child	does	not	have	CF,	and	so	we	
will	be	able	to	compare	their	samples	with	children	that	have	CF.	
  302 
 
 
 
	
Parent	Information	Leaflet	(non-CF)	Version	2.0	
29.07.2015	 	 	
2	
Does	my	child	have	to	take	part?	
No.	It	is	up	to	you	and	your	child	(where	possible)	to	decide	if	you	want	to	take	part.		If	
you	do	decide	to	take	part,	you	are	both	free	to	withdraw	from	the	study	at	any	time	
without	giving	a	reason.	Your	decisions	will	not	affect	your	child’s	standard	of	care.		
What	will	happen	if	I	agree	for	my	child	to	take	part?	
• If	you	agree	to	take	part,	we	will	ask	you	to	sign	a	consent	form.	If	your	child	is	old	
enough	and	able	to	understand	the	research,	they	can	write	their	name	on	the	
assent	form.	
• With	your	permission,	we	will	collect	information	about	your	child’s	health	and	
medical	information	from	their	medical	records.		
• Your	child	will	attend	for	a	bronchoscopy	as	planned	by	their	clinical	team.	
What	samples	will	be	collected	during	the	bronchoscopy?		
• Collection	of	blood	
As	is	normal	before	the	bronchoscopy,	a	drip	(cannula)	will	be	inserted	into	your	
child.	Blood	will	be	taken	from	this	drip	for	the	study.	No	extra	needles	will	be	
needed.	The	blood	will	be	tested	for	glucose	levels	and	the	rest	of	the	blood	will	be	
kept	for	the	study	to	look	at	other	tests	that	are	important	in	CF.		
• Collection	of	airway	brushings		
A	soft	brush	will	be	used	to	brush	some	cells	from	the	surface	of	the	airways	inside	
each	nostril,	and	from	the	lower	airways.	These	cells	will	be	grown	in	the	research	
laboratory	to	look	at	factors	that	are	important	in	CF.	Your	child	will	not	feel	
anything	whilst	these	samples	are	collected	because	they	will	be	asleep.	
	
	
	
	
	
	
	
• Collection	of	a	broncho-alveolar	lavage	(washing	from	the	lower	airway)	and	
lower	airway	secretions	
During	the	bronchoscopy,	the	lungs	can	be	washed	with	a	small	amount	of	salt-
water.	This	is	called	a	broncho-alveolar	lavage,	and	is	usually	taken	to	look	for	
infection	inside	the	lungs.	We	will	collect	some	of	this	for	the	study.	It	isn’t	always	
performed,	and	may	be	collected	specifically	for	our	study.	We	will	also	try	and	
collect	some	of	the	suctioned	secretions	that	would	normally	be	discarded	during	
the	bronchoscopy.	
Location of airway brushings 
The bronchoscope (flexible telescope) 
will be passed down the nose, into the 
windpipe, down the bronchus (large 
airway) and into the lower airways.  
 
Nasal brushings will be taken from 
inside the nose. 
Lower airway brushings will be taken 
from the lower airways (from below the 
vocal cords and the lower smaller 
airways).  
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Are	there	any	disadvantages	to	my	child	taking	part	in	this	study?	
Collection	of	the	research	samples	will	add	around	10	minutes	onto	the	procedure.	
This	should	not	cause	any	significant	problems	with	your	child	or	change	their	recovery	
after	the	bronchoscopy.		
We	have	performed	many	brushings	in	children	in	Newcastle.	Very	occasionally,	there	
can	be	mild	bleeding	from	inside	the	nose.	This	is	very	short-lived	and	does	not	need	
any	additional	treatment.		
Sometimes	children	can	have	a	high	temperature	after	a	washing	is	taken	from	the	
airway.	Again,	this	is	usually	short-lived.		
Are	there	any	benefits	to	my	child	taking	part	in	this	study?	
There	are	no	direct	benefits	to	your	child	taking	part	in	this	study.	However,	your	child	
will	be	part	of	research	that	will	help	us	understand	more	about	CF	in	children	and	find	
treatments	for	CF	in	the	future.		
Will	information	about	my	child	be	kept	confidential	and	how?	
Yes.	All	personal	information	on	your	child	will	be	kept	confidential.	Only	people	
involved	in	the	study	will	have	access	to	this	information.	All	samples	used	in	the	study	
will	be	anonymised	with	a	code.	We	will	follow	ethical	and	legal	practice	to	make	sure	
that	all	personal	information	about	your	child	will	be	kept	secure	and	confidential.		
Has	anyone	reviewed	this	study?	
All	research	carried	out	in	the	NHS	is	looked	at	by	an	independent	group	of	people	
called	a	Research	Ethics	Committee.	This	is	to	protect	you	and	your	child’s	safety,	
rights,	dignity	and	respect.	The	Newcastle	and	North	Tyneside	1	Research	Ethics	
Committee	have	reviewed	this	study.	
The	study	has	also	been	independently	scientifically	reviewed	by	an	expert	in	this	field.	
How	is	the	study	being	funded?	
This	study	is	being	funded	by	Newcastle	University.	The	money	from	this	funding	is	
being	used	to	pay	for	one	of	the	clinical	researcher’s	salary.	It	is	also	being	used	to	pay	
for	the	collection	and	testing	of	the	samples	that	will	be	looked	at	in	the	study.	None	
of	the	doctors	or	nurses	asking	you	to	help	with	the	study	will	make	any	extra	money	if	
you	agree	to	take	part.		
What	will	happen	to	the	results	of	the	study?	
This	study	is	part	of	an	educational	research	project.	Findings	from	the	study	will	be	
written	in	a	research	project,	and	may	be	published	in	medical	journals.	However,	
personal	information	about	you	or	your	child	will	not	be	available	from	what	is	written.	
Will	I	learn	the	results	of	the	study?	
If	you	and	your	child	are	interested,	we	can	give	you	a	copy	of	the	results	after	the	
study	has	finished.		
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What	will	happen	to	the	samples	that	have	been	collected?	
Samples	collected	for	the	study	will	be	stored	in	the	research	laboratory	until	the	study	
is	finished.	
The	airway	cells	that	are	grown	will	be	stored	in	an	appropriate	research	laboratory	so	
that	they	can	be	used	in	future	research	looking	at	lung	diseases	in	children.	Your	
child’s	personal	information	will	be	kept	confidential.		
Where	can	I	get	more	information?	
If	you	require	any	further	information	regarding	the	study,	you	can	contact	the	
investigators	who	are	based	at	the	Great	North	Children’s	Hospital.		
If	you	wish	to	speak	to	one	of	the	doctors	working	in	the	Respiratory	Department,	you	
can	speak	to	Dr	Christopher	O’Brien,	Consultant	in	Paediatric	Respiratory	Medicine.		
What	if	there	are	any	problems?	
If	you	have	any	concerns	about	any	aspect	of	the	study,	you	can	speak	to	any	of	the	
researchers.	If	there	is	still	a	problem	and	you	wish	to	make	a	formal	complaint,	you	
can	contact	the	Patient	Advice	and	Liaison	Service.	
Contacts	
Research	Contact:	 	 	 	 	 Patient	Advice	and	Liaison	Service:	
Dr	Malcolm	Brodlie	 	 	 	 	 Freepost:	RLTC-SGHH-EGXJ	
Great	North	Children’s	Hospital	 	 	 North	of	Tyne	PALS	
Queen	Victoria	Road		 	 	 	 	 The	Old	Stables	 	
Newcastle	upon	Tyne		 	 	 	 Grey’s	Yard	
NE1	4LP	 	 	 	 	 	 Morpeth	
	 	 	 	 	 	 NE61	1QD	
What	now?	
If	you	and	your	child	have	decided	that	you	would	like	to	take	part,	please	let	the	
doctors	and	nurses	know	when	you	come	to	hospital,	and	someone	from	the	study	
team	will	come	and	speak	to	you.		
CF	can	have	a	significant	impact	on	the	lives	of	affected	children,	adults	and	their	
families.	If	you	agree	to	take	part	in	the	study,	you	will	be	providing	us	with	some	very	
important	information	that	will	help	us	understand	more	about	CF	in	children	and	how	
we	may	treat	CF	in	the	future.	We	are	very	grateful	for	this,	and	would	like	to	thank	
you	and	your	child	for	helping	us	with	this	study.	
If	you	decide	not	to	take	part,	we	appreciate	very	much	the	time	you	have	taken	to	
read	this,	and	would	like	to	thank	you	for	doing	this.	
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“Characterisation	of	the	Airway	Epithelium	in	Children”	
This	information	sheet	is	intended	for:	
Parents/Guardians	of	children	with	Cystic	Fibrosis	who	are	having	a	bronchoscopy	
Investigators:		Dr	Malcolm	Brodlie,	Consultant	in	Paediatric	Respiratory	Medicine,	
Great	North	Children’s	Hospital	
	 	 Dr	Iram	Haq,	Clinical	Research	Fellow,	Great	North	Children’s	Hospital	
We	would	like	to	invite	your	child	to	take	part	in	our	research	study.	Before	you	decide	
whether	or	not	you	would	like	to	take	part,	we	would	like	to	explain	why	the	research	
is	being	done,	and	what	it	will	involve	for	your	child.	Please	the	take	the	time	to	read	
the	following	information	carefully.	One	of	our	team	can	go	through	this	information	
with	you	and	answer	any	questions	you	may	have.		
What	is	the	study	about?	
Cystic	fibrosis	(CF)	is	the	most	common	inherited	condition	in	the	UK.	In	CF,	the	body	
makes	very	thick	mucus.	This	mainly	affects	the	lungs	and	digestive	system.	In	the	
lungs,	this	mucus	is	very	difficult	to	clear,	causing	infections	and	severe	lung	damage.	
Children	with	CF	need	intensive	treatment	regimes	to	help	manage	their	symptoms.	
Despite	this,	CF	is	life	shortening.	Research	is	important	to	help	us	understand	more	
about	CF	and	develop	new	treatments	so	people	with	CF	can	live	longer	and	healthier	
lives.	
Research	scientists	can	learn	more	about	CF	and	investigate	new	treatments	by	
studying	cells	that	come	directly	from	the	lining	of	the	lower	airways.	These	cells	are	
collected	using	a	brush	during	a	bronchoscopy	and	grown	in	a	laboratory	for	research.		
Collecting	nasal	cells,	cells	from	the	nose,	may	also	give	us	the	same	information	about	
CF	as	the	lower	airways.	Nasal	cells	can	be	collected	from	a	person	when	they	are	
awake.		This	is	a	more	simple	procedure	that	can	be	done	without	an	anaesthetic.		
In	our	study,	we	would	like	to	compare	nasal	cells	with	lower	airway	cells.	We	will	look	
at	these	cells	in	a	research	laboratory	and	measure	different	properties	that	are	
important	in	CF.	We	will	look	at	how	these	compare	with	children	that	do	not	have	CF.	
If	we	find	that	nasal	cells	are	similar	to	lower	airway	cells,	this	will	provide	us	and	other	
researchers	with	valuable	information	about	using	nasal	cells	in	future	CF	research.	
Given	how	simple	it	is	to	collect	nasal	cells,	large	numbers	could	be	collected.	This	
could	bring	researchers	closer	to	finding	more	treatments	for	CF.	Our	study	will	help	us	
find	out	more	about	how	children	with	CF	are	different.	Studying	these	cells	will	also	
help	researchers	learn	more	about	other	airways	diseases	in	children.	
Why	has	my	child	been	invited?	
Your	child	has	been	invited	to	take	part	in	this	study	because	they	are	attending	
hospital	for	a	bronchoscopy.	During	the	anaesthetic,	we	would	like	to	collect	some	
samples	that	would	not	otherwise	be	possible.	Your	child	has	CF,	and	we	will	compare	
their	samples	with	those	collected	from	children	that	don’t	have	CF.	
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Does	my	child	have	to	take	part?	
No.	It	is	up	to	you	and	your	child	(where	possible)	to	decide	if	you	want	to	take	part.		If	
you	do	decide	to	take	part,	you	are	both	free	to	withdraw	from	the	study	at	any	time	
without	giving	a	reason.	Your	decisions	will	not	affect	your	child’s	standard	of	care.		
What	will	happen	if	I	agree	for	my	child	to	take	part?	
• If	you	agree	to	take	part,	we	will	ask	you	to	sign	a	consent	form.	If	your	child	is	old	
enough	and	able	to	understand	the	research,	they	can	write	their	name	on	the	
assent	form.	
• With	your	permission,	we	will	collect	information	about	your	child’s	health	and	
medical	information	from	their	medical	records.		
• Your	child	will	attend	for	a	bronchoscopy	as	planned	by	their	clinical	team.	
What	samples	will	be	collected	during	the	bronchoscopy?		
• Collection	of	blood	
As	is	normal	before	the	bronchoscopy,	a	drip	(cannula)	will	be	inserted	into	your	
child.	Blood	will	be	taken	from	this	drip	for	the	study.	No	extra	needles	will	be	
needed.	The	blood	will	be	tested	for	glucose	levels	and	the	rest	of	the	blood	will	be	
kept	for	the	study	to	look	other	tests	that	are	important	in	CF.	
• Collection	of	airway	brushings		
A	soft	brush	will	be	used	to	brush	some	cells	from	the	surface	of	the	airways	inside	
each	nostril,	and	from	the	lower	airways.	These	cells	will	be	grown	in	the	research	
laboratory	to	look	at	important	factors	that	are	important	in	CF.	Your	child	will	not	
feel	anything	whilst	these	samples	are	collected	because	they	will	be	asleep.	
	
	
	
	
	
	
	
• Collection	of	a	broncho-alveolar	lavage	(washing	from	the	lower	airway)	and	
lower	airway	secretions	
During	the	bronchoscopy,	the	lungs	can	be	washed	with	a	small	amount	of	salt-
water.	This	is	called	a	broncho-alveolar	lavage,	and	is	usually	taken	to	look	for	
infection.	This	often	applies	to	children	with	CF,	and	we	will	collect	some	of	this	for	
the	study.	It	isn’t	always	performed,	and	may	be	collected	specifically	for	our	study.	
Location of airway brushings 
The bronchoscope (flexible telescope) 
will be passed down the nose, into the 
windpipe, down the bronchus (large 
airway) and into the lower airways.  
 
Nasal brushings will be taken from 
inside the nose. 
Lower airway brushings will be taken 
from the lower airways (from below the 
vocal cords and the lower smaller 
airways).   
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We	will	also	try	and	collect	some	of	the	suctioned	secretions	that	would	normally	
be	discarded	during	the	bronchoscopy.	
Are	there	any	disadvantages	to	my	child	taking	part	in	this	study?	
Collection	of	the	research	samples	will	add	around	10	minutes	onto	the	procedure.	
This	should	not	cause	any	significant	problems	with	your	child	or	change	their	recovery	
after	the	bronchoscopy.		
We	have	performed	many	brushings	in	children	in	Newcastle.	Very	occasionally,	there	
can	be	mild	bleeding	from	inside	the	nose.	This	is	very	short-lived	and	does	not	need	
any	additional	treatment.		
Sometimes	children	can	have	a	high	temperature	after	a	washing	is	taken	from	the	
airway.	Again,	this	is	usually	short-lived.		
Are	there	any	benefits	to	my	child	taking	part	in	this	study?	
There	are	no	direct	benefits	to	your	child	taking	part	in	this	study.	However,	your	child	
will	be	part	of	research	that	will	help	us	understand	more	about	CF	in	children	and	find	
treatments	for	CF	in	the	future.		
Will	information	about	my	child	be	kept	confidential	and	how?	
Yes.	All	personal	information	on	your	child	will	be	kept	confidential.	Only	people	
involved	in	the	study	will	have	access	to	this	information.	All	samples	used	in	the	study	
will	be	anonymised	with	a	code.	We	will	follow	ethical	and	legal	practice	to	make	sure	
that	all	personal	information	about	your	child	will	be	kept	secure	and	confidential.	
Has	anyone	reviewed	this	study?	
All	research	carried	out	in	the	NHS	is	looked	at	by	an	independent	group	of	people	
called	a	Research	Ethics	Committee.	This	is	to	protect	you	and	your	child’s	safety,	
rights,	dignity	and	respect.	The	Newcastle	and	North	Tyneside	1	Research	Ethics	
Committee	have	reviewed	this	study.	
The	study	has	also	been	independently	scientifically	reviewed	by	an	expert	in	this	field.	
How	is	the	study	being	funded?	
This	study	is	being	funded	by	Newcastle	University.	The	money	from	this	funding	is	
being	used	to	pay	for	one	of	the	clinical	researcher’s	salary.	It	is	also	being	used	to	pay	
for	the	collection	and	testing	of	the	samples	that	will	be	looked	at	in	the	study.	None	
of	the	doctors	or	nurses	asking	you	to	help	with	the	study	will	make	any	extra	money	if	
you	agree	to	take	part.		
What	will	happen	to	the	results	of	the	study?	
This	study	is	part	of	an	educational	research	project.	Findings	from	the	study	will	be	
written	in	a	research	project,	and	may	also	be	published	in	medical	journals.	However,	
personal	information	about	you	or	your	child	will	not	be	available	from	what	is	written.	
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Will	I	learn	the	results	of	the	study?	
If	you	and	your	child	are	interested,	we	can	give	you	a	copy	of	the	results	after	the	
study	has	finished.		
What	will	happen	to	the	samples	that	have	been	collected?	
Samples	collected	for	the	study	will	be	stored	in	the	research	laboratory	until	the	study	
is	finished.	
The	airway	cells	that	are	grown	will	be	stored	in	an	appropriate	research	laboratory	so	
that	they	can	be	used	in	future	research	looking	at	lung	diseases	in	children.	Your	
child’s	personal	information	will	be	kept	confidential.		
Where	can	I	get	more	information?	
If	you	require	any	further	information	regarding	the	study,	you	can	contact	the	
investigators	who	are	based	at	the	Great	North	Children’s	Hospital.		
If	you	wish	to	speak	to	one	of	the	doctors	working	in	the	Respiratory	Department,	you	
can	speak	to	Dr	Christopher	O’Brien,	Consultant	in	Paediatric	Respiratory	Medicine.		
What	if	there	are	any	problems?	
If	you	have	any	concerns	about	any	aspect	of	the	study,	you	can	speak	to	any	of	the	
researchers.	If	there	is	still	a	problem	and	you	wish	to	make	a	formal	complaint,	you	
can	contact	the	Patient	Advice	and	Liaison	Service.	
Contacts	
Research	Contact:	 	 	 	 	 Patient	Advice	and	Liaison	Service		
Dr	Malcolm	Brodlie	 	 	 	 	 Freepost:	RLTC-SGHH-EGXJ	
Great	North	Children’s	Hospital	 	 	 North	of	Tyne	PALS	
Queen	Victoria	Road		 	 	 	 	 The	Old	Stables,		
Newcastle	upon	Tyne		 	 	 	 Grey’s	Yard		
NE1	4LP	 	 	 	 	 	 Morpeth		
NE61	1QD	 	 	
	 	 	
What	now?	
If	you	and	your	child	have	decided	that	you	would	like	to	take	part,	please	let	the	
doctors	and	nurses	know	when	you	come	to	hospital,	and	someone	from	the	study	
team	will	come	and	speak	to	you.		
CF	can	have	a	significant	impact	on	the	lives	of	affected	children,	adults	and	their	
families.	If	you	agree	to	take	part	in	the	study,	you	will	be	providing	us	with	some	very	
important	information	that	will	help	us	understand	more	about	CF	in	children	and	how	
we	may	treat	CF	in	the	future.	We	are	very	grateful	for	this,	and	would	like	to	thank	
you	and	your	child	for	helping	us	with	this	study.	
If	you	decide	not	to	take	part,	we	appreciate	very	much	the	time	you	have	taken	to	
read	this,	and	would	like	to	thank	you	for	doing	this.	
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	“Characterisation	of	the	Airway	Epithelium	in	Children”	
	This	leaflet	is	for:	
Children	aged	11	to	15	years	without	Cystic	Fibrosis	who	are	having	a	bronchoscopy	
Investigators:		Dr	Malcolm	Brodlie,	Consultant	in	Paediatric	Respiratory	Medicine,	
Great	North	Children’s	Hospital	
	 	 Dr	Iram	Haq,	Clinical	Research	Fellow,	Great	North	Children’s	Hospital	
We	are	inviting	you	to	take	part	in	our	research	study.	Before	you	decide	if	you	want	to	
join	in,	it’s	important	you	understand	why	it	is	being	done	and	what	it	will	involve	for	
you.	Please	read	this	leaflet	carefully.	Talk	to	your	family,	friends,	doctors	or	nurses	if	
you	want	to	and	ask	us	if	you	have	any	questions.		
What is the study all about? 
Cystic	fibrosis	(CF)	is	a	disease	that	affects	the	lungs.	The	body	makes	very	thick	mucus,	
which	is	very	hard	to	get	rid	of	and	causes	lung	infections.	People	with	CF	need	to	take	
lots	of	medicines	every	day	and	do	regular	physiotherapy	to	help	get	rid	of	this	mucus.	
The	lungs	can	still	be	badly	damaged	making	people	with	CF	very	unwell.	Research	is	
important	to	help	us	learn	more	about	why	CF	happens,	and	how	we	can	help	people	
with	CF	live	longer.	
Scientists	can	learn	about	new	CF	treatments	by	studying	cells	that	come	from	the	
lower	airways	of	the	body’s	breathing	system.	These	are	collected	using	a	brush	when	
a	person	has	a	bronchoscopy	and	grown	in	a	laboratory	for	scientific	experiments.		
Collecting	cells	from	inside	the	nose	(nasal	cells)	may	also	tell	us	important	information	
about	CF.	These	are	collected	easily	without	an	anesthetic	when	someone	is	awake.		
In	our	study,	we	would	like	to	compare	nasal	cells	to	lower	airway	cells.	We	will	grow	
them	in	a	research	laboratory,	and	measure	things	that	are	important	in	CF.	We	will	
compare	these	with	cells	from	children	that	don’t	have	CF.	If	nasal	cells	are	similar	to	
lower	airway	cells,	they	could	be	used	more	in	CF	research.	Lots	of	cells	could	be	used	
because	they	are	easier	to	collect.	This	would	help	scientists	perform	more	research	
experiments	to	help	find	treatments	for	CF.		
Our	study	will	help	us	to	find	out	if	we	can	use	nasal	cells	in	CF	research,	and	more	
about	how	children	with	CF	are	different.	Studying	nasal	and	lower	airway	cells	will	
also	help	researchers	find	out	more	about	other	lung	diseases	in	children.		
Why have I been invited?  
You	have	been	invited	to	take	part	because	you	are	coming	to	hospital	
for	a	bronchoscopy.	We	will	collect	some	samples	during	the	
bronchoscopy	that	will	help	with	our	research.	You	don’t	have	CF,	and	so	
we	will	be	able	to	compare	your	samples	with	children	that	have	CF.		
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Do I have to take part?  
No.	If	you	decide	not	to	take	part,	it	will	not	affect	how	your	doctors	and	nurses	look	
after	you.		
What happens if I want to take part?  
• We	will	ask	you	to	sign	a	form	giving	your	assent	if	you	are	able	to	do	this.		
• We	will	give	you	a	copy	of	this	information	for	you	to	keep.	
• You	can	stop	taking	part	in	the	study	at	any	time	during	the	research.	You	won’t	
have	to	give	us	a	reason	for	deciding	to	stop.		
What will I have to do? 
We	will	collect	some	samples	from	you	when	you	have	the	bronchoscopy.	
• Blood	sample	
Before	starting	the	bronchoscopy,	a	drip	(cannula)	is	normally	put	
into	by	doctors	in	the	theatre	room.	We	will	collect	some	blood	
from	this	drip	for	our	study.	No	extra	needles	will	be	needed.	
• Brushing	samples	
A	soft	brush	will	be	used	to	pick	up	some	cells	from	inside	your	nose	and	lower	
down	the	airways.	You	will	not	feel	anything	because	you	will	be	asleep.	These	cells	
will	be	studied	in	the	research	laboratory.		
	
	
	
	
	
	
	
	
• Washings	and	secretions	from	the	lower	airways		
During	the	bronchoscopy,	a	washing	can	be	taken	from	the	lungs	using	salty	water,	
to	look	for	infections	inside	the	lungs.	We	will	collect	some	of	this	for	our	study.	This	
isn’t	always	done	and	we	may	collect	it	especially	for	our	study.	We	will	look	for	
bugs	and	other	important	factors	in	CF.	We	will	also	try	and	collect	any	suctioned	
secretions	that	would	have	normally	been	thrown	away.	
Location of airway brushings 
The bronchoscope (flexible telescope) 
will be passed down the nose, into the 
windpipe, down the bronchus (large 
airway) and into the lower airways.  
 
Nasal brushings will be taken from 
inside the nose. 
Lower airway brushings will be taken 
from the lower airways (from below the 
vocal cords and the lower smaller 
airways).   
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Is there anything I should worry about? 
It	will	take	around	10	minutes	to	take	these	samples.	You	will	be	asleep	when	you	have	
the	bronchoscopy,	and	so	you	won’t	feel	anything.		
Brushings	are	taken	in	Newcastle	without	any	problems.	Sometimes	there	can	be	a	
very	small	bleed	from	the	area	that	is	brushed,	but	this	stops	by	itself	very	quickly.		
Many	washings	are	taken	in	Newcastle.	You	may	have	a	mild	temperature	later	that	
day.	This	usually	is	for	a	very	short	time	and	gets	better	by	itself.		
What are the benefits in taking part? 
You	will	not	directly	benefit	from	taking	part.	However,	you	will	be	helping	us	learn	
more	about	CF,	and	how	we	may	treat	it	in	the	future.		
Will information collected about me be kept confidential? 
Yes.	Your	information	will	be	kept	confidential	and	safe.	We	will	only	tell	people	who	
have	a	right	to	know	that	you	are	taking	part	in	the	study.		
This	study	is	part	of	an	educational	project,	which	will	be	written	up	as	a	research	
project.	We	may	also	write	up	this	study	in	a	medical	journal,	but	you	and	your	
parents/guardian	won’t	be	identifiable	from	what	is	written.	If	you	want	to	find	out	
the	study	results,	we	give	you	a	copy	of	the	results	after	the	study	has	finished.	
Has anyone reviewed this study? 
All	research	in	the	NHS	is	looked	at	by	an	independent	group	of	people	called	the	
Research	Ethics	Committee.	This	makes	sure	that	the	research	is	fair.	The	Newcastle	
and	North	Tyneside	1	Research	Ethics	Committee	has	checked	our	study.	An	expert	
doctor	for	lung	problems	in	children	has	also	checked	the	study.	
How is the study being funded? 
This	study	is	being	funded	by	Newcastle	University.	The	money	from	this	funding	is	
being	used	to	pay	for	one	of	the	research	doctor’s	salary.	It	is	also	being	used	to	pay	
for	the	collection	and	testing	of	the	samples	that	will	be	looked	at	in	the	study.	None	
of	the	doctors	or	nurses	asking	you	to	help	with	the	study	will	make	any	extra	money	if	
you	agree	to	take	part.		
What will happen to my samples when the study has finished? 
Samples	collected	for	the	study	will	be	stored	in	the	research	laboratory	until	the	study	
is	over.	
The	airway	cells	that	are	grown	will	be	stored	so	that	they	can	be	used	in	future	
research	looking	at	lung	diseases	in	children.	Your	personal	information	will	be	kept	
confidential.		
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Where can I get more information? 
If	you	want	any	more	information	about	the	study,	you	can	speak	to	us	or	your	doctors	
and	nurses	at	the	Great	North	Children’s	Hospital.		
If	you	have	any	questions	or	are	unhappy	about	anything,	speak	to	your	parents.	Either	
they	or	you	can	ask	to	speak	to	one	of	the	researchers,	who	will	do	their	best	to	help	
you.		
Research	Contact:		
Dr	Malcolm	Brodlie,	Consultant	in	Paediatric	Respiratory	Medicine,	GNCH	0191	
2336161,	extension	25089	
What now? 
Please	have	a	think	about	if	you	want	to	take	part	and	talk	to	your	family,	doctors	and	
nurses	about	the	study	if	you	want	to.		
If	you	and	your	parents	agree,	let	the	doctors	and	nurses	know,	and	someone	from	the	
study	team	will	come	and	speak	to	you.		
Your	doctors	and	nurses	will	look	after	you	in	the	same	way	whether	or	not	you	take	
part.		
Whatever	you	decide,	we	thank	you	for	reading	this,	and	hope	your	stay	in	hospital	
goes	well.		
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“Characterisation	of	the	Airway	Epithelium	in	Children”	
This	leaflet	is	for:	
Children	aged	11	to	15	years	with	Cystic	Fibrosis	who	are	having	a	bronchoscopy	
Investigators:		Dr	Malcolm	Brodlie,	Consultant	in	Paediatric	Respiratory	Medicine,	
Great	North	Children’s	Hospital	
	 	 Dr	Iram	Haq,	Clinical	Research	Fellow,	Great	North	Children’s	Hospital	
We	are	inviting	you	to	take	part	in	our	research	study.	Before	you	decide	if	you	want	to	
join	in,	it’s	important	you	understand	why	it	is	being	done	and	what	it	will	involve	for	
you.	Please	read	this	leaflet	carefully.	Talk	to	your	family,	friends,	doctors	or	nurses	if	
you	want	to	and	ask	us	if	you	have	any	questions.		
What is the study all about?  
As	you	know,	cystic	fibrosis	(CF)	is	a	disease	that	affects	the	lungs.	The	body	makes	
very	thick	mucus,	which	is	very	hard	to	get	rid	of	and	causes	lung	infections.	People	
with	CF	need	to	take	lots	of	medicines	every	day	and	do	regular	physiotherapy	to	help	
get	rid	of	this	mucus.	The	lungs	can	still	be	badly	damaged	making	people	with	CF	very	
unwell.	Research	is	important	to	help	us	learn	more	about	why	CF	happens,	and	how	
we	can	help	people	with	CF	live	longer.	
Scientists	can	learn	about	new	CF	treatments	by	studying	cells	that	come	from	the	
lower	airways	in	the	body’s	breathing	system.	These	are	collected	using	a	brush	when	
a	person	has	a	bronchoscopy	and	are	grown	in	a	laboratory	for	scientific	experiments.		
Collecting	cells	from	inside	the	nose	(nasal	cells)	may	also	tell	us	important	information	
about	CF.	These	are	collected	easily	without	an	anesthetic	when	someone	is	awake.		
In	our	study,	we	would	like	to	compare	nasal	cells	to	lower	airway	cells.	We	will	grow	
them	in	a	research	laboratory,	and	measure	things	that	important	in	CF.	We	will	
compare	these	with	cells	from	children	that	don’t	have	CF.	If	nasal	cells	are	similar	to	
lower	airway	cells,	they	could	be	used	more	in	CF	research.	Lots	of	cells	could	be	used	
because	they	are	easier	to	collect.	This	would	help	scientists	perform	more	research	
experiments	to	help	find	treatments	for	CF.		
Our	study	will	help	us	to	find	out	if	we	can	use	nasal	cells	in	CF	research,	and	more	
about	how	children	with	CF	are	different.	Studying	nasal	and	lower	airway	cells	will	
also	help	researchers	find	out	more	about	other	lung	diseases	in	children.		
Why have I been invited?  
You	have	been	invited	to	take	part	because	you	are	coming	to	hospital	for	a	
bronchoscopy.	We	will	collect	some	samples	during	the	bronchoscopy	that	will	help	
with	our	research.	We	will	compare	your	samples	with	children	that	don’t	have	CF.	
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Do I have to take part?  
No.	If	you	decide	not	to	take	part,	it	will	not	affect	how	your	doctors	and	nurses	look	
after	you.		
What happens if I want to take part?   
• We	will	ask	you	to	sign	a	form	giving	your	assent	if	you	are	able	to	do	this.		
• We	will	give	you	a	copy	of	this	information	for	you	to	keep.	
• You	can	stop	taking	part	in	the	study	at	any	time	during	the	research.	You	won’t	
have	to	give	us	a	reason	for	deciding	to	stop.		
What will I have to do? 
We	will	collect	some	samples	from	you	when	you	have	the	bronchoscopy.		
• Blood	sample	
Before	starting	the	bronchoscopy,	a	drip	(cannula)	is	normally	put	
into	by	doctors	in	the	theatre	room.	We	will	collect	some	blood	
from	this	drip	for	our	study.	No	extra	needles	will	be	needed.	
• Brushing	samples	
A	soft	brush	will	be	used	to	pick	up	some	cells	from	inside	your	nose	and	lower	
down	the	airways.	You	will	not	feel	anything	because	you	will	be	asleep.	These	cells	
will	be	studied	in	the	research	laboratory.		
	
	
	
	
	
	
	
	
• Washings	and	secretions	from	the	lower	airways		
During	the	bronchoscopy,	a	washing	can	be	taken	from	the	lungs	using	salty	water,	
to	look	for	infections	inside	the	lungs.	We	will	collect	some	of	this	for	our	study.	
This	is	usually	done	in	children	with	CF,	but	we	may	collect	it	especially	for	our	
study.	We	will	look	for	bugs	and	other	important	factors	in	CF.	We	will	also	try	and	
collect	any	suctioned	secretions	that	would	have	normally	been	thrown	away.		
Location of airway brushings 
The bronchoscope (flexible telescope) 
will be passed down the nose, into the 
windpipe, down the bronchus (large 
airway) and into the lower airways.  
 
Nasal brushings will be taken from 
inside the nose. 
Lower airway brushings will be taken 
from the lower airways (from below the 
vocal cords and the lower smaller 
airways).   
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Is there anything I should worry about? 
It	will	take	around	10	minutes	to	take	these	samples.	You	will	be	asleep	when	you	have	
the	bronchoscopy,	and	so	you	won’t	feel	anything.	
Brushings	are	taken	in	Newcastle	without	any	problems.	Sometimes	there	can	be	a	
very	small	bleed	from	the	area	that	is	brushed,	but	this	stops	by	itself	very	quickly.		
Many	washings	are	taken	in	Newcastle.	You	may	have	a	mild	temperature	later	that	
day.	This	usually	is	for	a	very	short	time	and	gets	better	by	itself.		
What are the benefits in taking part? 
You	will	not	directly	benefit	from	taking	part.	However,	you	will	be	helping	us	learn	
more	about	CF,	and	how	we	may	treat	it	in	the	future.		
Will information collected about me be kept confidential? 
Yes.	Your	information	will	be	kept	confidential	and	safe.	We	will	only	tell	people	who	
have	a	right	to	know	that	you	are	taking	part	in	the	study.		
This	study	is	part	of	an	educational	project,	which	will	be	written	up	as	a	research	
project.	We	may	also	write	up	this	study	in	a	medical	journal,	but	you	and	your	
parents/guardian	won’t	be	identifiable	from	what	is	written.	If	you	want	to	find	out	
the	study	results,	we	give	you	a	copy	of	the	results	after	the	study	has	finished.	
Has anyone reviewed this study? 
All	research	in	the	NHS	is	looked	at	by	an	independent	group	of	people	called	the	
Research	Ethics	Committee.	This	makes	sure	that	the	research	is	fair.	A	Research	Ethics	
Committee	has	checked	our	study.	An	expert	doctor	for	lung	problems	in	children	has	
also	checked	the	study.	
How is the study being funded? 
This	study	is	being	funded	by	Newcastle	University.	The	money	from	this	funding	is	
being	used	to	pay	for	one	of	the	research	doctor’s	salary.	It	is	also	being	used	to	pay	
for	the	collection	and	testing	of	the	samples	that	will	be	looked	at	in	the	study.	None	
of	the	doctors	or	nurses	asking	you	to	help	with	the	study	will	make	any	extra	money	if	
you	agree	to	take	part.		
What will happen to my samples when the study has finished? 
Samples	collected	for	the	study	will	be	stored	in	the	research	laboratory	until	the	study	
is	over.	
The	airway	cells	that	are	grown	will	be	stored	so	that	they	can	be	used	in	future	
research	looking	at	lung	diseases	in	children.	Your	personal	information	will	be	kept	
confidential.		
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Where can I get more information? 
If	you	want	any	more	information	about	the	study,	you	can	speak	to	us	or	your	doctors	
and	nurses	at	the	Great	North	Children’s	Hospital.		
If	you	have	any	questions	or	are	unhappy	about	anything,	speak	to	your	parents.	Either	
they	or	you	can	ask	to	speak	to	one	of	the	researchers,	who	will	do	their	best	to	help	
you.		
	
Research	Contact:		
Dr	Malcolm	Brodlie,	Consultant	in	Paediatric	Respiratory	Medicine,	GNCH	0191	
2336161,	extension	25089	
What now? 
Please	have	a	think	about	if	you	want	to	take	part	and	talk	to	your	family,	doctors	and	
nurses	about	the	study	if	you	want	to.		
If	you	and	your	parents	agree,	let	the	doctors	and	nurses	know,	and	someone	from	the	
study	team	will	come	and	speak	to	you.		
Your	doctors	and	nurses	will	look	after	you	in	the	same	way	whether	or	not	you	take	
part.		
Whatever	you	decide,	we	thank	you	for	reading	this,	and	hope	your	stay	in	hospital	
goes	well.				
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“Characterisation	of	the	Airway	Epithelium	in	Children”	
This	leaflet	is	for:	
Children	aged	6	to	10	years	without	Cystic	Fibrosis	
who	are	having	a	bronchoscopy	
Investigators:		Dr	Malcolm	Brodlie,	Consultant	in	Paediatric	Respiratory	Medicine,	
Great	North	Children’s	Hospital	
	 	 Dr	Iram	Haq,	Clinical	Research	Fellow,	Great	North	Children’s	Hospital	
What is the study all about? 
We	are	asking	you	if	you	would	like	to	join	in	a	research	study	about	cystic	fibrosis,	or	
CF.	People	with	CF	get	lots	of	chest	infections	and	breathing	problems.	We	would	like	
to	learn	more	about	children	with	and	without	CF	so	that	we	can	try	and	help	treat	it.	
Why am I being asked to take part?  
You	are	coming	to	hospital	to	have	a	special	camera	test	called	a	
bronchoscopy	to	have	a	look	inside	your	chest.	You	don’t	have	
CF,	but	we	would	like	to	collect	some	samples	from	you.	This	will	
help	us	learn	more	about	how	children	with	CF	are	different.	
Do I have to take part?  
No.	You	don’t	have	take	part	if	you	don’t	want	to.		
If	you	take	part	and	want	to	stop	any	time,	you	can	tell	your	parents,	doctors	or	
nurses.	They	won’t	be	cross	with	you.	
What will I have to do? 
When	you	come	to	hospital	for	your	bronchoscopy,	we	will	
collect	some	samples	from	you	while	you	are	asleep.	
	 	
	
• Before	starting	the	bronchoscopy,	a	drip	(plastic	tube)	is	put	into	
your	arm	by	the	doctors.	You	will	be	asleep	at	this	time.	We	will	
collect	some	blood	from	this	drip	for	our	study.	There	won’t	be	any	
extra	needles.		
	
• While	you	are	asleep,	we	will	wash	and	take	some	fluid	from	your	chest.	We	will	
also	use	a	very	small	brush	to	brush	some	cells	from	inside	your	nose	and	your	
chest.	You	won’t	feel	any	of	these	things	happening.		
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 Is there anything that might upset me? 
You	will	be	asleep	when	we	take	these	samples	and	so	you	won’t	feel	anything.		
Sometimes	you	can	feel	hot	later	on	after	the	washing	is	taken,	but	this	gets	better	
very	quickly.	Lots	of	these	samples	are	taken	at	this	hospital	and	there	aren’t	usually	
any	problems.		
 Will joining in help me?  
Joining	in	won’t	help	you,	but	what	we	learn	from	the	study	may	help	us	know	more	
about	CF	and	how	to	help	children	that	have	it.			
 Will anyone else know I am doing this? 
We	will	keep	your	details	private.	We	will	only	tell	people	who	have	a	right	to	know.	
We	will	write	up	this	study	as	a	project	and	in	medical	journals,	but	we	won’t	write	
anything	about	your	private	details.		
 Did anyone else check that this study is OK to do? 
Before	any	research	can	happen,	it	has	to	be	looked	at	by	a	group	of	people	from	a	
Research	Ethics	Committee.	They	make	sure	that	the	research	is	fair.	This	study	has	
been	looked	at	by	the	Research	Ethics	Committee	and	an	expert	doctor	for	children’s	
lung	problems.	
 What if there are any problems?  
If	you	have	any	questions	or	problems	during	the	study,	speak	to	your	parents,	or	
doctors	and	nurses	who	will	be	able	to	help	you.		
What now? 
Please	think	about	if	you	want	to	join	in	and	talk	to	your	mum	and	dad.	You	can	talk	to	
the	doctors	and	nurses	that	look	after	you	if	you	want	to.		
If	you	and	your	parents	agree,	let	the	doctors	and	nurses	know,	and	someone	from	the	
study	team	will	come	and	speak	to	you.		
Your	doctors	and	nurses	will	look	after	you	just	the	same	whether	or	not	you	join	in.		
	
Thank	you	for	reading	this.	We	hope	your	stay	in	hospital	goes	well.			
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	“Characterisation	of	the	Airway	Epithelium	in	Children”	
This	leaflet	is	for:	
Children	aged	6	to	10	years	with	Cystic	Fibrosis	
who	are	having	a	bronchoscopy	
Investigators:		Dr	Malcolm	Brodlie,	Consultant	in	Paediatric	Respiratory	Medicine,	
Great	North	Children’s	Hospital	
	 	 Dr	Iram	Haq,	Clinical	Research	Fellow,	Great	North	Children’s	Hospital	
What is the study all about? 
We	are	asking	you	if	you	would	like	to	join	in	a	research	study	about	cystic	fibrosis,	or	
CF.	People	with	CF	get	lots	of	chest	infections	and	breathing	problems.	We	would	like	
to	learn	more	about	children	with	and	without	CF	so	we	can	try	and	help	treat	it.	
Why am I being asked to take part?  
You	have	CF	and	are	coming	to	hospital	to	have	a	special	camera	
test	called	a	bronchoscopy	to	have	a	look	inside	your	chest.	We	
would	like	to	collect	some	samples	from	you	when	you	have	
this.		
Do I have to take part?  
No.	You	don’t	have	take	part	if	you	don’t	want	to.		
If	you	take	part	and	want	to	stop	any	time,	you	can	tell	your	parents,	doctors	or	
nurses.	They	won’t	be	cross	with	you.	
What will I have to do?  
	
When	you	come	to	hospital	for	your	bronchoscopy,	we	will	
collect	some	samples	from	you	while	you	are	asleep.	
	
	
• Before	starting	the	bronchoscopy,	a	drip	(plastic	tube)	is	put	into	
your	arm	by	the	doctors.	You	will	be	asleep	at	this	time.	We	will	
collect	some	blood	from	this	drip	for	our	study.	There	won’t	be	any	
extra	needles.		
	
• While	you	are	asleep,	we	will	wash	and	take	some	fluid	from	your	chest.	We	will	
also	use	a	very	small	brush	to	brush	some	cells	from	inside	your	nose	and	your	
chest.	You	won’t	feel	any	of	these	things	happening.		
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 Is there anything that might upset me? 
You	will	be	asleep	when	we	take	these	samples	and	so	you	won’t	feel	anything.		
Sometimes	you	can	feel	hot	later	on	after	the	washing	is	taken,	but	this	gets	better	
very	quickly.	Lots	of	these	samples	are	taken	at	this	hospital	and	there	aren’t	usually	
any	problems.		
 Will joining in help me?  
Joining	in	won’t	help	you,	but	what	we	learn	from	the	study	may	help	know	more	
about	CF	and	how	to	help	children	that	have	it.			
 Will anyone else know I am doing this? 
We	will	keep	your	details	private.	We	will	only	tell	people	who	have	a	right	to	know.	
We	will	write	up	this	study	as	a	project	and	in	medical	journals,	but	we	won’t	write	
anything	about	your	private	details.		
 Did anyone else check that this study is OK to do? 
Before	any	research	can	happen,	it	has	to	be	looked	at	by	a	group	of	people	from	a	
Research	Ethics	Committee.	They	make	sure	that	the	research	is	fair.	This	study	has	
been	looked	at	by	a	Research	Ethics	Committee	and	an	expert	doctor	for	children’s	
lung	problems.		
 What if there are any problems?  
If	you	have	any	questions	or	problems	during	the	study,	speak	to	your	parents,	or	
doctors	and	nurses	who	will	be	able	to	help	you.		
What now? 
Please	think	about	if	you	want	to	join	in	and	talk	to	your	mum	and	dad.	You	can	talk	to	
the	doctors	and	nurses	that	look	after	you	if	you	want	to.		
If	you	and	your	parents	agree,	let	the	doctors	and	nurses	know,	and	someone	from	the	
study	team	will	come	and	speak	to	you.		
Your	doctors	and	nurses	will	look	after	you	just	the	same	whether	or	not	you	join	in.		
	
Thank	you	for	reading	this.	We	hope	your	stay	in	hospital	goes	well.	
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Appendix B: Academic achievements during this PhD 
 
Funding 
Wellcome Trust Clinical Research Training Fellowship, July 2016 
Publications 
Haq IJ, Harris C, Taylor J, McKean MC, Brodlie M. Should we use Montelukast in 
wheezy children? Arch Dis Child. 2017 Nov;102(11):997-998. 
doi:10.1136/archdischild-2017-312655. 
Zainal Abidin N, Haq IJ, Gardner AI, Brodlie M. Ataluren in cystic fibrosis: 
development, clinical studies and where are we now? Expert Opin Pharmacother. 
2017 Sep;18(13):1363-1371. doi: 10.1080/14656566.2017.1359255. 
Ibrahim SH, Turner MJ, Saint-Criq V, Garnett J, Haq IJ, Brodlie M, Ward C, Borgo C, 
Salvi M, Venerando A, Gray MA. CK2 is a key regulator of SLC4A2-mediated Cl-
/HCO3- exchange in human airway epithelia. Pflugers Arch. 2017 Apr 28. doi: 
10.1007/s00424-017-1981-3. 
Haq IJ, Battersby AC, Eastham K, McKean M. Community acquired pneumonia in 
children. BMJ. 2017 Mar 2;356:j686. doi: 10.1136/bmj.j686.  
Haq IJ, Gardner A, Brodlie M. A multifunctional bispecific antibody against 
Pseudomonas aeruginosa as a potential therapeutic strategy. Ann Trans Med. 2016 
Jan;4(1):12. doi: 10.3978/j.issn.2305-5839.2015.10.10. 
Haq IJ, Gray MA, Garnett JP, Ward C, Brodlie M. Airway surface liquid homeostasis 
in cystic fibrosis: pathophysiology and therapeutic targets. Thorax. 2015; 
10.1136/thoraxjnl-2015-207588. 
Brodlie M, Haq IJ, Roberts K, Elborn JS. Targeted therapies to improve CFTR 
function in cystic fibrosis. Genome Medicine 2015; doi: 10.1186/s13073-015-0223-6. 
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Oral presentations 
‘Using the nose to investigate novel therapeutic avenues in cystic fibrosis’, invited 
speaker at the Clinical Academic Training Pathway Scientific Meeting September 
2018, Newcastle University, Newcastle upon Tyne.   
‘First functional characterisation of the R751L CFTR mutation using an ex vivo 
primary airway epithelial cell culture model’, European Cystic Fibrosis Conference 
June 2018, Belgrade, Serbia. 
‘Functional characterisation of the airway epithelium in children with cystic fibrosis’, 
Annual Northern Cystic Fibrosis Meeting February 2018, Centre for Life, Newcastle 
upon Tyne. 
‘Use of primary airway epithelial cells from children with cystic fibrosis to investigate 
novel anoctamin 1 activators’, Newcastle, Edinburgh, Cambridge and Sheffield 
Scientific Collaborative Meeting November 2017, Sheffield. 
‘A case of lobar lung transplantation in a boy with cystic fibrosis’, Northern Paediatric 
Respiratory Spring Meeting March 2016, Newcastle upon Tyne. 
‘Asthma: getting the diagnosis right’, educational session for primary care physicians 
March 2016, Newcastle University. 
‘My experience of paediatric training in the Northern Deanery’, invited speaker at the 
MBBS careers day June 2016, Newcastle University. 
‘Research in paediatrics: a trainee’s perspective’, invited speaker at the Great North 
Children’s Hospital Research Community Meeting February 2016, Newcastle upon 
Tyne. 
‘Lung research for children at the Great North Children’s Hospital’, Invited speaker at 
the North-East Young People’s Advisory Group for Research September 2015, Sir 
James Spence Institute, Royal Victoria Infirmary, Newcastle upon Tyne 
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Poster presentations 
‘Use of ex vivo paediatric primary nasal epithelial cultures to investigate TMEM16A 
as a potential therapeutic target in children with cystic fibrosis’, European Cystic 
Fibrosis Conference June 2018, Belgrade, Serbia. 
‘Characterisation of primary paediatric nasal epithelial cells as a model system to 
investigate TMEM16A as a therapeutic avenue in CF, European Cystic Fibrosis 
Basic Science Conference April 2018, Loutraki, Greece. 
‘A paediatric primary nasal epithelial cell culture model to investigate bypass 
channels as a therapeutic target in cystic fibrosis’, European Cystic Fibrosis Basic 
Science Conference April 2017, Albufeira, Portugal.  
‘A paediatric primary nasal epithelial cell culture model to investigate bypass 
channels as a therapeutic target in cystic fibrosis’, Institute of Cellular Medicine 
Directors Day June 2017, (poster prize awarded), Newcastle University, Newcastle 
upon Tyne 
‘A paediatric primary nasal epithelial cell culture model to investigate bypass 
channels as a therapeutic target in cystic fibrosis’, Great North Children’s Research 
Community Conference March 2017, The Sage, Gateshead. 
‘Airway epithelial cells from children with cystic fibrosis to investigate novel 
anoctamin 1 activators’, Newcastle Academic Health Partners Research Day June 
2016, Newcastle University, Newcastle upon Tyne. 
‘Airway epithelial cells from children with cystic fibrosis to investigate novel 
anoctamin 1 activators’, Young Person’s Advisory Group North East Research 
Conference December 2016, The Hancock Museum, Newcastle upon Tyne. 
Additional academic activities 
Editorial board member for ‘Beat Asthma’ – online resource for children and young 
people with asthma, September 2017.  
Invited interview with the BMJ for review on community acquired pneumonia in 
children doi: 10.1136/bmj.j686, February 2017 (available online). 
Invited reviewer for the BMJ, BMJ Paediatrics Open and BMC Pulmonary Medicine. 
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